

Sasso, L. (2015) In vitro uptake studies of cell targeting agents and nanoparticles. PhD thesis, University of Nottingham.

Access from the University of Nottingham repository:

http://eprints.nottingham.ac.uk/28529/1/e-thesis%20Luana%20Sasso.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

- Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners.
- To the extent reasonable and practicable the material made available in Nottingham ePrints has been checked for eligibility before being made available.
- Copies of full items can be used for personal research or study, educational, or notfor-profit purposes without prior permission or charge provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
- · Quotations or similar reproductions must be sufficiently acknowledged.

Please see our full end user licence at: <u>http://eprints.nottingham.ac.uk/end_user_agreement.pdf</u>

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk



Division of Drug Delivery and Tissue Engineering

School of Pharmacy

In vitro uptake studies of cell targeting agents and

nanoparticles

Luana Sasso Bsc. Hons

Thesis submitted at the University of Nottingham for the degree of

Doctor of Philosophy

September 2014

Abstract

Recent progress in synthetic chemistry has enabled the preparation of new highlydefined polymers that exhibit changes in their structure in response to environmental changes. These responsive nanomaterials may be desirable as carriers of drugs to deliver at the cellular and sub-cellular level. However, the endocytic pathways used by these nanoparticles to access cells must be defined.

Carboxylated polystyrene beads (C-PB) of 50 and 100 nm size were chosen as 'model' nanomedicines and their route of uptake into cells characterised and compared to thermoresponsive PLGA-*b*-(PEGMA-co-PPGMA) and PLA-*b*-(DEGMA-*co*-OEGMA) block copolymers of 50-150 nm ('candidate' drug delivery systems) uptake. A number of protocols were optimised for endocytosis inhibition studies.

Results reported that the inhibition of clathrin mediated endocytosis (CME) with chlorpromazine (CPZ) was cell- and time-dependent. After the maximal effect of the inhibitor, the endocytosis of human transferrin (Htf), a marker of CME, recovered up to uninhibited levels in 3T3 and HCT116 cells. Furthermore, high passage number and ageing of cells showed a resistance towards the inhibition of the uptake of Htf with CPZ.

Both PLGA-*b*-(PEGMA-*co*-PPGMA) and PLA-*co*-(DEGMA-*co*-OEGMA) thermoresponsive block copolymers presented colloidal instability and aggregation that impeded further endocytic pathway internalization experiments. However, the results reported in this thesis question some of the interpretation in the literature of the susceptibility of cells to CPZ in the internalization of nanomaterials. New experimental settings for CPZ inhibition studies should be considered and protocols optimised in order to avoid incorrect and potentially misleading outcomes.

Ш

Oral presentation

Gordon Research Seminar 'Lysosomes and Endocytosis', Andover, USA, 2014.

'In vitro uptake studies of cell targeting agents and nanoparticles'

Poster presentations

Gordon Research Seminar and Conference 'Lysosomes and Endocytosis', Andover, USA, 2014

'In vitro uptake studies of cell targeting agents and nanoparticles'

UKICRS Workshop and Symposium - Drug Delivery Uncorked, Cork, Ireland, 2014

'In vitro uptake studies of cell targeting agents and nanoparticles'

EMBO Conference 'Sistems Dynamics in Endocytosis', Villars, Switzerland, 2013

'Optimization studies on the inhibition of endocytic pathways to investigate nanoengineered particles for drug delivery and their preferred route of uptake'

Papers in preparation

- Gallon, E., Sasso, L. et al. 'Delivery of nucleic acids and gene knockdown by responsive polymers'. To be submitted in October 2014.
- Sasso L. et al. 'Effects of endocytosis inhibitors on selected cell lines in vitro'.
- Sasso L. et al. 'Uptake, transport and intracellular processing of carboxylated polystyrene nanoparticles in selected cell lines'.

Acknowledgements

I would like to express my outmost gratitude to my supervisors Professor Cameron Alexander and Dr Anna Grabowska for their support during these 4 years of my PhD. Thanks for being always present at any time, day, night, weekends and whenever your support was needed. Thanks for sharing your views and guiding me in many crucial aspects of my work. I would also like to acknowledge Lee Moir, Nora Francini and Teresa Matini for providing polymers for my research and the EPSRC for supporting the studies described in this thesis.

I would like to recognise Professor David Bates for improving the organisation of the Cancer Biology laboratory in ways that boosted my research. I was also fortunate to work with Dr David Onion, who has been like a mentor in the early part of my studies. I would like to thank all the staff and colleagues of the Cancer Biology and Polymers Therapeutics groups, my laboratories, and especially Pam Collier for sharing her positive outlook on daily challenges in the lab, Dr Roya Babaei-Jadidi, Dr Maria Machado, Delyan Ivanov, Hiteshri Makwana, Xi Ye, Federica Lorenzi, Makhliyo Normatova, and Emenike Onyido for their kindness and outgoing way of being. My gratitude goes to Jane Wrigley and Dr Simon Jiang from Precos for repeatedly sharing equipment with me and to my former colleagues Dr Fernandes Trillo Francisco (Paco) and Dr Gokcen Yasayan for always sparing some of their time to discuss my scientific questions. Thanks to Amy Nairn, Sandra Lever, Carol Turrill, Gail Atkinson and Julia Crouch for their kind help with orders, meetings and conferences.

A special thanks goes to the cardiovascular unit of the QMC and flow cytometry facility. In particular to Jackie Glenn, Ann White, Jane May, Dr Sue Fox and Andrew Johnson for having been so kind and welcoming. From day one I never felt like a

۷

stranger in your department. I wish to extend my thanks to Pete Stevens for his help with orders and early morning chats on sport, holidays and weather and to Seema Rajani, Professor Steve Atkinson, Tim Self and Denise Christie for their competent assistance with confocal microscopy and TEM.

It was an absolute pleasure to work with Musah-Eroje Ahmed and Tatiana Jamillo Forcada, they made the long hours in the lab light-hearted and cheery. I would like to acknowledge the staff of the Greenfield Medical Library and Hallward Library for the support with papers from around the world; in particular to the endless assistance of Sue Bingham at the interlibrary loans. I would also take the chance to thank two wonderful couples: Francesca Saini and Marco Muleri, and Federica Riu and Daniele Avitabile, you have made me feel at home during this chapter of my life in Nottingham.

I would finally express my sincere gratitude to the teachers and professors that I encountered during my academic studies and that have supported me through the years. Without Professors Mariella Giganti, Domenico D'Auria, Luciana Guazzoni and Jatinder Ahluwalia I would not be here.

Dulcis in fundo, as the Romans would say...My warmest and heartfelt love goes to my wonderful husband, Matteo. It is honestly impossible to express in words the infinite practical and emotional ways you have contributed to this achievement. I wish to thank you for just being you and may we always be this unique and exclusive thing that we are now.

My deepest love goes to my family: to my mum for her warm, protective and caring way of being a brilliant mum and to my lovely dad from whom I have taken the attitude of being a dreamer. My dearest love goes to the rest of my family and my extended family, in particular to my sister Loredana and to my grandma 'Nonna Maria'

VI

for the wonderful memories that will always be with me. I feel blessed to have you both in my life.

Table of Contents

ABSTRACT	III
LIST OF POSTER/PRESENTATIONS	IV
PAPERS IN PREPARATION	IV
ACKNOWLEDGEMENTS	V
TABLE OF CONTENTS	VIII
LIST OF FIGURES	XIV
LIST OF TABLES	XVIII
LIST OF ABBREVIATIONS	XIX
LIST OF CELL LINES	XXII
1- CHAPTER 1	23
1.1 Barriers to drug delivery	24
1.2 Strategies for drug delivery	25
1.2.1 Nanomaterials in drug and gene delivery	25
1.3 Routes of cellular uptake	35
1.3.1 Endocytic compartments	36
1.3.2 Membrane domains	

1.3.3 Phagocytosis	40
1.3.4 Clathrin-mediated endocytosis	42
1.3.5 Caveolae-dependent endocytosis	51
1.3.6 Non-clathrin, non-caveolae-mediated endocytosis	55
1.4 The biological environment and nanomaterials	58
1.4.1 Nanoparticles in the bloodstream	59
1.4.2 Extravasation of nanoparticles	62
1.4.3 Nanocarriers passage into body tissues and organs	63
1.4.4 Nanoparticles uptake into cells	63
1.5 Nanoparticles in the literature	67
1.5.1 Colloidal Gold Nanoparticles	67
1.5.2 Quantum dots (QDs)	68
1.5.3 Iron oxide nanoparticles	69
1.5.4 Polystyrene nanoparticles	69
1.6 Aims and thesis outline	73
1.7 Experimental Approach	75
2- CHAPTER 2	88
2.1 General Materials	89
2.1.1 Cell lines	89
2.1.2 Cell culture materials	89
2.1.3 Polymers studied	91

2.1.4 Materials for inhibition studies	92
2.2 General methods	93
2.2.1 General cell maintenance procedures	93
2.2.2 Dynamic Light Scattering (DLS)	95
2.2.3 Transmission Electron Microscopy (TEM) of C-PB	96
2.2.4 Zeta potential of C-PB	96
2.2.5 Toxicity Tests	97
2.2.6 Htf and LacCer Wash Efficiency Studies	102
2.2.7 Inhibition of Htf uptake with CPZ	106
2.2.8 Inhibition of Htf uptake with Pitstop 2	106
2.2.9 Inhibition of LacCer uptake with MBCD	107
2.2.10 Endocytosis inhibition in the presence of C-PB	108
2.2.11 Procedures for sterilization of coverslips for microscopy	108
2.2.12 Confocal microscopy live imaging methods	108
2.2.13 Immunofluorescence of clathrin and caveolin-1	109
3- CHAPTER 3	112
3.1 Introduction	113
3.2 Methods	114
3.2.1 C-PB size and charge characterization	114
3.2.2 Cell viability studies of C-PB, MBCD and CPZ	115

3.2.3 Immunofluorescence of clathrin heavy chain isoform α (CHC $\alpha)$ and
caveolin-1 (cav-1) in 3T3, HCT116 and MGLVA-111
3.2.4 Wash efficiency studies for the removal of markers of endocytosis 12
3.3 Results
3.3.1 Size and Charge Characterization of 50 nm C-PB12
3.3.2 Size and Charge Characterization of 100 nm C-PB12
3.3.3 Cell viability studies of C-PB, CPZ and MBCD12
3.3.4 C-PB cell viability studies12
3.3.5 Characterization of the viability of cells treated with MBCD
3.3.6 Characterization of the effects on cells of CPZ13
3.3.7 Clathrin and caveolin immunocytochemistry studies
3.3.8 Wash efficiency studies of endocytosis markers13
3.4 Discussion13
3.5 Conclusions14
4- CHAPTER 4
4.1 Introduction15
4.2 Methods15
4.2.1 Optimization of the inhibition of Htf uptake15
4.2.2 Optimization of the inhibition of LacCer uptake with MBCD15
4.2.3 Inhibition of endocytosis of C-PB with CPZ and MBCD15
4.2.4 Confocal microscopy live imaging15

4.3 Results	155
4.3.1 Optimization of the inhibition of Htf uptake	155
4.3.2 Inhibition of the endocytosis of C-PB with CPZ and MBCD	
4.3.3 Confocal microscopy live imaging studies	167
4.4 Discussion	189
4.5 Conclusions	201
5- CHAPTER 5	206
5.1 Introduction	207
5.2 Materials used for the studies	208
5.3 Methods	215
For a schematics of all the experiments carried out with polymers formula	ations 1-9,
cell lines used, and aggregation state please refer to Table 5-3.	215
5.3.1 Cell viability studies	215
5.3.2 Cell uptake studies	216
5.3.3 Assessment of the uptake of polymer micelle-like nanoparticles 5	218
5.3.4 Assessment of the kinetics of endocytosis of formulation 6	218
5.3.5 Uptake studies for nanoparticle formulations 6 and 7	219
5.3.6 Uptake studies of the internalization of micelle 8	219
5.3.7 Uptake studies of the internalization of micelle-like nanoparticles 9)220
5.4 Results	221
5.4.1 Acute cell viability studies	221

5.4.2 Internalization studies of micelle-like structures from polymer 5	224
5.4.3 Micelle 6 and 7 live imaging studies	227
5.4.4 Live cell imaging of nanoparticles 8	234
5.4.5 Micelles 9 live imaging	247
5.5 Discussion	251
5.1 Conclusions	262
6- CHAPTER 6	
7- APPENDIX I	279
8- APPENDIX II	
9- APPENDIX III	289
10- APPENDIX IV	

List of Figures

Figure 1-1 Different geometries in polymer structures
Figure 1-2 Schematic representation of the hydration state changes in thermoresponsive polymers above a LCST
Figure 1-3 Schematic representation of micelles and vesicles with their typical loads
Figure 1-4 Visual description of packing parameter, mean curvature and Gaussian curvature described in equation 1
Figure 1-5 Diagram for PEO-PBO block copolymers in relation to their concentration in water and their molecular weight
Figure 1-6 Diagram showing the theoretical (a) and observed (b) shapes of PB-PEO block copolymers
Figure 1-7 Phagocytosis internalises different materials by different mechanisms of engulfment at the plasma membrane41
Figure 1-8 Mechanisms of endocytosis43
Figure 1-9 Schematic representation of the AP adaptor proteins46
Figure 1-10 Schematic representation of the AP2 protein in its open state46
Figure 2-1 Poly(lactide- <i>co</i> -glycolide)- <i>block</i> -poly(poly(ethylene glycol methyl ether methacrylate)- <i>co</i> -poly(propylene glycol methacrylate)) (PLGA- <i>b</i> -(PPGMA- <i>co</i> -PEGMA)) thermoresponsive polymers
Figure 2-2 Polylactide- <i>block</i> - poly(poly(diethylene glycol methacrylate)- <i>co</i> -poly(oligoethylene glycol methacrylate)) (PLA- <i>b</i> -(DEGMA- <i>co</i> -OEGMA)) thermoresponsive polymers
Figure 3-1 DLS characterization of 50 and 100 nm C-PB122
Figure 3-2 TEM's plot of Feret's diameter for 50 and 100 nm C-PB123
Figure 3-3 Double Gaussian distribution for 100 nm C-PB123
Figure 3-4 TEM images of 50 nm (A) and 100 nm (B) C-PB124
Figure 3-5 Titration curves of 3T3, HCT116 and MGLVA-1 cells at 4.5 h in HBSS/HEPES 20 mM with MTT (left) and Cell Titer Glo (right) at 4.5 h126
Figure 3-6 MTT titration curves with 3T3, HCT116 and MGLVA-1 cells at 24 and 48 h127
Figure 3-7 Biocompatibility studies of 50 and 100 nm C-PB at 4 h in 3T3, HCT116 and MGLVA-1 cells
Figure 3-8 MTT toxicity assay of 50 nm C-PB at 24 and 48 h incubation130
Figure 3-9 MBCD (left) and CPZ (right) toxicity studies at 4.5 h with MTT (black lines and squares), Cell Titer Glo (red lines and circles) and Apo I caspase 3/7 (green lines and diamonds) in 3T3, HCT116 and MGLVA-1 cells
Figure 3-10 CHC α and cav-1 flow cytometry immunofluorescence experiments133
Figure 3-11 Immunocytochemistry confocal microscopy experiments of 3T3, MRC-5, HCT116 and MGLVA-1 for CHCα

Figure 3-12 Immunocytochemistry confocal microscopy images of the staining of Figure 3-13 Histograms of the fluorescence intensity for Clathin mAb X22 and Caveolin-1 mAb clone 2297 immunolabelling135 Figure 3-14 Flow cytometry results of 3 replicates experiments on the different efficiency of the removal of Htf and LacCer endocytic markers from the plasma membrane of cells for washes carried out on adherent cells (in T25 flasks) or in cell Figure 4-1 Flow cytometric analysis of the inhibition of the uptake of Htf with 80 µM CPZ or 1.25 mM MBCD at 1,2,3 or 4 h in 3T3, HCT116 and MGLVA-1 cells......157 Figure 4-2 Flow cytometry histograms on the inhibition of Htf uptake with 80 µM CPZ at different time points and cell lines. The X axes show the fluorescence intensity of Htf, the Y axes show the number of cells. The dark shadows show Htf uptake at basal, uninhibited levels while the light shadows show Htf uptake in the presence of Figure 4-3 Effect of lower concentrations of CPZ on the inhibition of Htf uptake in Figure 4-4 Flow cytometry experiments incubated with different concentrations of CPZ in 3T3 and HCT116 cells in the absence of Ca²⁺ and Mg²⁺......161 Figure 4-5 The effect of passage number and ageing of cells on the inhibition of CME with Htf 6.7 µg/ml and 80 µM CPZ at 1 and 2 h in 3T3 and HCT116 cells....163 Figure 4-6 Htf inhibition of endocytosis with Pitstop 2 at 12.5, 18.75 and 25 µM in Figure 4-8 Inhibition of the uptake of 50 nm and 100 nm C-PB with 80 µM CPZ and Figure 4-9 Confocal live imaging studies of 3T3 cells treated with 50 µg/ml 100 nm C-PB for a period of 60 min169 Figure 4-10 Orthogonal projection of a 3D image of 3T3 cells treated with 50 µg/ml Figure 4-11 3T3 fibroblasts treated with 100 nm C-PB171 Figure 4-12 Zoom images of live experiments of 3T3 cells treated with 100 nm C-PB 50 µg/ml for a period of 60 minutes172 Figure 4-13 Analysis of the fluorescence of 3T3 cells treated with 50 µg/ml 100 nm Figure 4-14 Merge of fluorescence live images for HCT116 cells incubated with 50 Figure 4-15 Orthogonal projection of a 3D image obtained with HCT116 incubated with 50 nm C-PB177 Figure 4-16 Images of the redistribution of the red CellMask membrane staining at 4 Figure 4-17 Details of the live imaging experiments of HCT116 cells incubated with

Figure 4-18 A. Spindle-like structures of HCT116 membrane of cells incubated for 4 minutes with 50 nm C-PB, demonstrating an intense activity of the membrane. B. Analysis of the green fluorescence of HCT116 cells incubated with 50 nm C-PB. 179 Figure 4-19 Confocal live studies of MGLVA-1 cells treated with 50 µg/ml 50 nm C-Figure 4-20 Orthogonal projection of a 3D image taken from MGLVA-1 cells treated Figure 4-21 MGLVA-1 cells treated with 50 µg/ml 50 nm C-PB for 60 minutes 183 Figure 4-22 Details of the live images studies of MGLVA-1 cells treated with 50 Figure 4-23 Analysis of the fluorescence of MGLVA-1 cells treated with 50 nm C-PB Figure 4-24 MGLVA-1 gastric cancer cells treated with 100 nm C-PB for a period of Figure 4-25 Orthogonal projection of a 3D image obtained from MGLVA-1 cells treated with 100 nm C-PB......186 Figure 4-26 Redistribution of the C-PB (Green) and CellMask membrane staining (Red) over time for MGLVA-1 cells treated with 50 µg/ml of 50 nm C-PB187 Figure 4-27. A. Details of live images studies of the endocytosis of 100 nm C-PB in MGLVA-1 cells for a period of 60 minutes. B. Magnification of the regions enclosed Figure 4-28 Analysis of the fluorescence of MGLVA-1 cells treated with 100 nm C-Figure 5-1 Poly(lactide-co-glycolide)-block-poly(poly(ethylene glycol methyl ether methacrylate)-co-poly(propylene glycol methacrylate)) (PLGA-b-(PPGMA-co-Figure 5-2 Polylactide- block- poly(poly(diethylene glycol methacrylate)-coglycol methacrylate)) (PLA-b-(DEGMA-co-OEGMA)) poly(oligoethylene Figure 5-3 Manual method for the formation of micelle-like nanoparticles from Figure 5-4 Schematic representation of the mixing apparatus used for the production of polymer formulation 8 and 9217 Figure 5-5 Assessment of cell activity interference of micelle-like formulation 1 (A), 2 (B), 3 (C) 4 (D) following incubation in 3T3, HCT116 and MGLVA-1 cells with an MTT acute test at 4 h......222 Figure 5-6 Assessment of cell activity of polymer micelles 6 on 3T3, HCT116 and Figure 5-7 Micelle-like structures 5 incubated at 42 ℃ (above TTT) for 8 h......226 Figure 5-8 Confocal live studies of the kinetics of uptake of micelle-like formulation 6 Figure 5-9 Comparison of the fluorescence intensity of 3T3 cells before and after 1 h

Figure 5-10 3T3 cells treated with micelle-like formulation 6 for 2 h232
Figure 5-11 3T3 cells treated with micelle-like nanoparticles 7 preincubated for 30 minutes at 37 $^{\circ}$ C before application on cells for 2 h
Figure 5-12 Micelle-like nanoparticles 7 preincubated at $37 ^\circ C$ for 30 minutes prior to the application on 3T3 cells for 2 h233
Figure 5-13 Micelle-like formulation 6 preincubated at 37 °C for 30 minutes and consequently applied to 3T3 cells for 17 h233
Figure 5-14 Mann-Whitney t test of the fluorescence for the negative untreated cells and positive control cells treated with formulation 6
Figure 5-15 3T3, HCT116 and MGLVA-1 cells treated with different concentrations of formulation 8 for 24 h at 37° C237
Figure 5-16 3T3, HCT116 and MGLVA-1 cells treated with 1000 $\mu g/ml$ of formulation 8 for 24 h at 37 $^{\circ}\!C$
Figure 5-17 3T3, HCT116 and MGLVA-1 cells treated with 500 $\mu g/ml$ of formulation 8 for 24 h at 37 $^{\circ}\!C$
Figure 5-18 3T3, HCT116 and MGLVA-1 cells treated with 250 $\mu g/ml$ of formulation 8 for 24 h at 37 $^{\circ}\!C$
Figure 5-19 3T3, HCT116 and MGLVA-1 cells treated with 62.5 $\mu g/ml$ of formulation 8 for 24 h at 37 $^{\circ}\!C$ 241
Figure 5-20 3T3, HCT116 and MGLVA-1 cells treated with 31.25 $\mu g/ml$ of formulation 8 for 24 h at 37 °C242
Figure 5-21 Evidence of aggregation over time of formulation 8 upon storage at - 20℃
Figure 5-22 Flasks with or without HCT116 cells treated with formulation 8 at room temperature for 1 h, at 37 °C overnight and before and after rinse
Figure 5-23 Formulation 9 incubated with HCT116 cells in different conditions249
Figure 5-24 Internalization of 250 $\mu\text{g/ml}$ of micelle suspension 9 after overnight incubation at 37 $^{\circ}\text{C}$
Figure 5-25 Orthogonal projection of a 3D image acquired on 3T3 (left) HCT116

Figure 5-25 Orthogonal projection of a 3D image acquired on 3T3 (left) HCT116 cells (right) treated with 250 μ g/ml of micelle suspension 9 overnight at 37 °C 250

List of Tables

Table 1-1 Correlation between rearrangement of polymers in aqueous solutionsand v, a, I, H and K parameters
Table 1-2 Summary of nanomedicines that have reached clinical trials or themarket
Table 2-1 A summary of the cells lines used
Table 3-1 Statistical analysis of the Z factor and Signal Window at 4 h127
Table 3-2 Statistical analysis for MTT assays at 24 and 48 h
Table 3-3 Reference values for Z factor and Signal Window provided according to ²⁵ (*) and ²⁶ (**)
Table 3-4 Summary of the IC_{50} and 95% confidence intervals obtained in the tested cell lines with MTT and Cell Titer Glo at 4 h -24 and 48 h incubation of 50 nm C-PB
Table 3-5 IC ₅₀ and 95% conficence intervals of MTT, Cell Titer Glo and Apo I caspase 3/7 activity
Table 4-1 Two-Way ANOVA statistical analysis of the inhibition of Htf uptake inthe presence of CPZ and MBCD.159
Table 4-2 Chlorpromazine (CPZ) chemical structure, chemical nomenclature andmolecular weight.189
Table 4-3 Pitstop chemical structure, nomenclature and molecular weight196
Table 5-1 Summary of the characteristics of the PLGA-b-(PPGMA-co-PEGMA)thermoresponsive polymers and micelle-like nanoparticles used for the study. 212
Table 5-2 Summary of the characteristics of PLA-b-(DEGMA-co-OEGMA)thermoresponsive micelle-like nanoparticles used in the study

List of Abbreviations

AAK1	Adaptor Associated Kinase 1		
ANOVA	Analysis of Variance	DMSO	Dimethylsulphoxide
AP1	Assembly Polypeptide 1	EDH2	EPS15 Homology Domain-containing protein 2
AP2	Assembly Polypeptide 2	EDTA	Ethylene Diamine Tetracetic Acid
AP3	Assembly Polypeptide 3	EE	Early Endosomes
AP4	Assembly Polypeptide 4	EEA-1	Early Endosome Antigen 1
AP5	Assembly Polypeptide 5	EGF	Epithelial Growth Factor
APC	Allophycocyanin	eNOS	Endothelial Nitric Oxide Synthase
Аро I	Caspase 3/7 Apoptosis Assay	EPR	Enhanced Permeability and Retention
Apo-Htf	Apo-transferrin	EPS15	Epithelial Growth Factor Receptor
APP	Amyloid Precursor Protein		Pathway Substrate 15
ATCC	American Type Culture Collection	ErbB2	Epidermal Growth Factor (EGF) Receptor (EGFR) Tyrosine Kinases Family of
A.U.	Arbitrary Units		Receptors
AuNP	Gold Nanoparticles	ESCRT	Endosomal Sorting Complex Required for Transport
BAR	Bin/amphiphysin/Rvs protein	FAK	Focal Adhesion Kinase
BSA	Bovine Serum Albumin	F-BAR	Fer-CIP4 homology- Bin/amphiphysin/Rvs
Cav-1	Caveolin-1	1 5/11	Protein
CD2AP	CD2 adaptor protein	FBS	Foetal Bovine Serum
cdc42	Cell division control protein 42	FCHo1/2	Fer/Cip4 homology domain-only (FCHo)
CDE	Caveolae-Dependent Endocytosis	504	protein 1 and 2
CHCα	Clathrin Heavy Chain α	FDA	Food and Drug Administration
CIE	Clathrin-Independent Endocytosis	FI	Fluorescence Intensity
CI-MPR	Cation-Independent Mannose 6- Phopshate Receptor	FITC GFP	Fluorescein Isothiocyanate Green Fluorescent Protein
CLIC-GEEC	Clathrin-Independent Carrier	GI tract	Gastrointestinal tract
	Glycosylphosphatidylinositol-Anchored	GLUT4	Glucose Transporter 4
	Proteins Enriched Endocytic Compartment	GMA	Glycidyl Methacrylate
CMC	Critical Micellar Concentration	GPC	Given and the state of the stat
CME	Clathrin-Mediated Endocytosis	GPI-APs	
C-PB	Carboxylated Polystyrene Beads	UFI-AF3	Glycosylphosphatidylinositol-Anchored Proteins
CPP CPZ	Cell Penetrating Peptide Chlorpromazine	GRAF-1	Focal Adhesion Kinase-1
CV	Coefficient of Variance	GULP	Engulfment Adaptor Protein
Ð	Polydispersity	HBSS	Hank's Balanced Salt Solution
DAB2	Disabled Adaptor-2	HDAC6	Histone Deacetylase 6
DAPI	4',6-Diamino-2-Phenylindole,	HEPES	2-[4-(2-hydroxyethyl)piperazin-1- yl]ethanesulfonic acid
	Dyhydrochloride	HIP1R	Huntingtin-binding Protein 1 Related
dBSA	Defatted Bovine Serum Albumin	HIV-1	Human Immunodeficiency Virus Type 1
DEGMA	poly((diethylene glycol)methacrylate)	HMEM	Hank's Minimum Essential Medium
DLS	Dynamic Light Scattering	Holo-Htf	Holo-transferrin
DMEM	Dulbecco Modified Eagle Medium	Hsc70	Heat shock cognate protein 70

HSP70	Heat Shock Protein 70 Family	PBS	Phosphate Buffered Saline
Hsp90	Heat shock protein 90	PDGF	Platelet-Derived Growth Factor
Htf	Human Transferrin	PEG	Polyethylene glycol
HUVEC	Human Umbilical Vascular Endotelium	PEGMA	Poly((ethylene glycol) methacrylate)
HOVEC	Cells	PEI	Polyethylenimine
IC ₅₀	Inhibitory Concentration (50%)	PFA	Paraformaldehyde
ICOS	Interdisciplinary Computing and Complex	PH domain	Pleckstrin Homology domain
	Biosystems	PI(4,5)P2	Phosphatidylinositol 4,5 Bisphosphate
lgG	Immunoglobulin G	PI3K	Phosphatidyl Inositol 3 Kinase
IL2Rβ	Interleleukin 2 Receptor β	PI3P	Phosphatidylinositol 3 Phosphate
JACoP	Just Another Colocalization Plugin	PIC	Polyions Complexes
K _d	Apparent Dissociation Constant	PICsomes	Polyion Complexes Vesicles
LacCer	Lactosyl ceramide	ΡΚΝβ	Protein Kinase N-construct β
LAMP1/2	Lysosomes Associated Membrane Proteins 1 and 2	PLA	Poly(lactic acid)
LC	Light Chain	PLGA	Poly(lactic- <i>co</i> -glycolic acid)
LCST	- Lower Critical Transition Temperature	PPGMA	Poly((propyleneglycol)methacrylate)
LDL	Low-Density Lipoproteins	PSMA	Prostate Specific Membrane Antigen
LE	Late Endosomes	QD	Quantum Dots
LSM	Laser Scanning Microscope	Rabs	Ras-like Small G Proteins
mAb	Monoclonal Antibody	Rac1	Ras-related C3 Botulinum Toxin Substrate
MARCKS	Myristoylated Alanine-Rich C-Kinase		1
MBCD	Substrate protein Methyl-β-cyclodextrin	RAFT	Reversible Addition-Fragmentation Chain Transfer
MEM	Minimum Essential Medium Eagle	Rho	Ras homolog oncogene
MHC1	Histocompatibility Complex 1	ROS	Radical Oxygen Species
Mn	Molecular Weight	RPMI	Roswell Park Memorial Institute
MPRs	Mannose Phosphate Receptors	RT-PCR	Real Time Polymerase Chain Reaction
Mr	Relative Molecular Weight	SAR	Structure-Activity Relationship
MRI	Magnetic Resonance Imaging	SH3 domain	SRC- Sarcoma Oncogene Homology 3
MSN	Mesoporous Silica Nanoparticles	SNAP	Domain Synaptosome-Associated Protein
MTT	(3-(4,5-Dimethylthiazol-2-yl)-2,5- Diphenyl-Tetrazomium Bromide)	SNAF	Soluble N-ethylmaleimide-Sensitive Factor
MVB	Multivesicular Bodies	CDION	Attachment Protein Receptors
M _w	Weight Average Molecular Weight	SPION	Superparamagnetic Iron Oxide Nanoparticles
NEAA	Non-Essential Animo acids	SV40	Simian Virus 40
NLS	Nuclear Localization Sequence	TAT	HIV Tat-Protein Transduction Domain
ns	Non Significant	TEM	Transmission Electron Microscopy
OEGMA	Poly((oligoethylene glycol)methacrylate)	TR1	Transferrin receptor 1
PAA	Poly(acrylic acid)	TR2	Transferrin receptor 2
PAK 1 and 2	p21-Activated Kinase 1 and 2	t-SNARES	Target-bound Soluble N-ethylmaleimide-
PAR1	Protease-Activated Receptor 1		sensitive factor Attachment Protein Receptors
РВ	Polystyrene Beads	TTT	Thermal Transition Temperature
PB-PEO	Poly-Butadiene – Poly Ethylene Oxide	UCST	Upper Critical Solution Temperature
		0.001	

UV	Ultra Violet	v-SNARES	Vesicle-bound Soluble N-ethylmaleimide-	
VAMP2	Vesicle-associated Membrane Protein 2		sensitive factor Attachment Protein Receptors	
V-ATPases	vacuolar ATPases Membrane Proton Pumps	YO	Yellow-Orange	
		$\lambda_{\text{max, em}}$	Maximal wavelength of emission	
		$\lambda_{max, ex}$	Maximal wavelength of excitation	

List of Cell lines

3Т3	Mouse Swiss Albino Embryo Fibroblasts
A549	Human Lung Carcinoma Cells
B16	Non-phagocytic Murine Melanoma Cells
ECV304	Endothelial Cell Line Derived from Human Bladder Cell Line T24
HCT116	Human Colon Cancer Cells
HeLa	Human Cervical Adenocarcinoma Cells
Hepa1-6	Murine Hepatoma
HepG2	Human Hepatocellular Carcinoma
KLN205	Murine Lung Squamous Cell Carcinoma
MGLVA-1	Human Ascites Gastric Cancer Cells
MKN45	Human Gastric Adenocarcinoma Cells
MKN45G	Human Gastrin Producing Gastric Cancer Cells
MRC-5	Human Foetal Lung Fibroblasts
THP1	Human Acute Monocytic Leukaemia Cell Line

1-Chapter 1

Nanomaterials and Endocytosis

1.1 Barriers to drug delivery

Many powerful drugs fail to reach the market because of delivery-related issues. Problems such as lack of absorption, poor solubility, poor biodistribution, metabolic modification with either rapid loss of therapeutic effect or increased toxicity, and undesirable clearance kinetics are all reasons why drugs fail to progress through clinical trials^{1,2}.

Physiological barriers to drug delivery depend on the route of administration and on the compartmentalization of the target organ³. For example, in oral administration, the low pH in the stomach and consequent adsorption through the gut are important barriers to overcome. Other examples of barriers to drug delivery are the blood brain barrier for central nervous system delivery of drugs, skin penetration for topical and transdermal applications, and mucus penetration for aerosol, gastric, ocular or vaginal administration⁴.

Drug delivery systems constitute a strategy for overcoming many of these barriers and are being actively studied in order to develop and optimise therapy with new drug compounds⁵⁻⁸. Amongst the classes of drug delivery systems are those classed as 'nanomedicines'. Materials with at least one dimension ranging between 1 and 100 nm have been defined as nanomaterials by the National Technology Initiative, the Food and Drug Administration (FDA) and American Society for Testing and Materials⁹. The advantages and applications of carrier systems with size ranges in the 'nanomaterial region' are numerous. Firstly, they can be easily internalised in cells with an inverse relationship between size and absorption; secondly they have a high surface to volume ratio that makes the surface chemistry of these materials highly represented and hence important for cell/nanoparticle interactions. Finally, the use of nanocarriers of drugs could make possible the delivery of nucleic acids for gene therapy which are otherwise

challenged by ubiquitous nucleases^{10,11}; they could be loaded with anticancer drugs and reduce their side effects and systemic exposure to the drug and toxicity. Moreover, they could be employed to increase the solubility of many drugs that are highly effective but their application is limited by their poor solubility by loading them in hydrophobic compartments of the carrier. Finally, not only therapy, but also diagnostics and probe technology, can benefit from these materials¹²⁻¹⁴. Examples are nanocarriermediated delivery of aptamers (small RNA, single stranded sequences of DNA or peptides with high affinity for one molecule or protein due to their specific 3D rearrangement)²¹⁰⁻²¹² for the diagnosis of cancer or gold nanoparticles for increased sensitivity in the detection of HIV-1 antigen^{15,16}.

1.2 Strategies for drug delivery

1.2.1 Nanomaterials in drug and gene delivery

A great variety of nanomaterials have been designed for use in drug delivery. Many of the investigated nanomaterials are based on polymers, usually with monomer components to confer surfactant or amphiphilic properties, i.e. with a hydrophobic region to interact with a hydrophobic drug compound and a hydrophilic component to enable dispersion in aqueous media or the bloodstream. To date, many combinations of different polymers have been investigated for drug and gene delivery¹⁷⁻¹⁹.

1.2.1.1 Block copolymers

When polymers are formed by two different monomers they are called copolymers; the two monomer constituents can be present randomly in the structure and in this case they are defined as statistical copolymers (Figure 1-1). When monomers of one type are grouped together and monomers of a second type are also attached to each other the resultant structure is defined as a block co-polymer. Depending on how many different monomer sequences and polymers are present, and consequently, how many

regions of the polymers can be distinguished, they are named diblock copolymers, triblock-copolymers and so on. Triblock copolymers can be classified as A+B+A or A+B+C depending on how many different polymers are included in the structure and how they are arranged with respect to each other²⁰. Hence, monomers can be covalently linked to each other²¹ and can be formed by homopolymer or more polymers with different characteristics and different patterns of assembly. Polymers can be linear, branched, or hyperbranched (grafted copolymers, dendrimers) and examples of branched and hyperbranched polymers can be viewed in Figure 1-1²¹.

Polymers can also be bound through electrostatic interactions. Examples are polyion complexes (PIC) which are formed by the interaction of two polymers with opposite charges or nucleic acid and a cationic polymer for gene delivery²².




Figure 1-1 Examples of block copolymers. In this picture are shown the rearrangement of a linear homopolymer, a diblock, an A+B+A and A+B+C triblock copolymers, a random or statistical copolymer and a dendrimer. Polymers blocks with different polarities are shown in different colours.

Block copolymers can self-assemble into superstructures under certain conditions. The assembly can be spontaneous and irreversible or it can be triggered by a reversible stimulus.

1.2.1.2 Stimuli-responsive polymers

Many approaches have been investigated in order to obtain 'intelligent' or 'smart' materials that are able to release a loaded drug to a given target. Common examples are pH-sensitive, thermo-responsive, redox, light, ion, magnetic, ultrasound, enzymes-sensitive polymers and so on²²⁻²⁸.

Thermo-responsive polymers were the first 'intelligent systems' investigated and poly(N) isopropyl acrylamide was the first thermoresponsive polymer studied. Thermoresponsive polymers can be classified into two groups: polymers that present a Lower Critical Solution Temperature (LCST) and polymers that present an Upper Critical Solution Temperature (UCST). Thermoresponsive polymers below the LCST are soluble in appropriate solutions while above the LCST they lose their solubility (Figure 1-2). This effect is driven by the entropy of the system. Above a given temperature the most energetically convenient rearrangement of the polymer is out of solution. This is caused by the release of the water from the hydrophilic chains of the polymer that reduce the solubility of the polymer but also produces an increase of entropy which is energetically favourable. This effect is ruled by the Gibbs-Helmholtz equation²⁹:

$$\Delta G = H - T \Delta S$$

Where:


 ΔG = free energy


H= enthalpy

T= temperature in Kelvin

$\Delta S = entropy$

UCST polymers behave in an opposite way and are not solubilised below a given temperature while the solution results clear and homogeneous above an UCST. This effect is driven by the enthalpy of the system. Thermoresponsive carriers of drugs have been investigated for applications in inflammation sites where often a mild temperature gradient is present reaching a maximum temperature of 42 °C or in conjunction with the external administration of mild hyperthermia by near infrared irradiation, ultrasound probes or microwave irradiation of the target body region.





pH-responsive systems are among the most studied and well-characterised polymers. Their solubility, volume, configuration or conformation can be reversibly manipulated by pH changes³⁰. Methacrylic acid and related co-polymers are examples of pH-responsive polymers. They are hydrophobic at low pHs and are deprotonated and hydrophilic with the increase of pH. Their use has been suggested in the gastrointestinal (GI) tract where a pH gradient is present within the stomach (pH ranges between 1 and 3) and the jejunum and ileum (pH between 6 and 7) where the pH

Introduction – Nanomaterials and Endocytosis


gradient can trigger the release of the loaded drug. Other applications are in cancerous tissues as they are acidic (pH ranges from 6 to 7.2) and at the subcellular level where the pH for endolysosome compartments has been reported between 4.5 and 6³¹.

Other stimuli-responsive systems are sensitive to the naturally reducing environment inside the cell (*redox polymers*). Disulfide groups are often used in these systems as, when they reach the inner cellular environment, they are easily targeted by glutathione activity and cleaved (Kim et al., 2010 as reported by³²). *Ion-sensitive polymers* have also been studied addressing the *salting in* and *salting out* properties of *chaotrope* (water structure breaker) and *kosmotrope* (water structure maker) ions²⁵. Many other smart polymers have been reported in the literature but a detailed overview of such systems is beyond the scope of this thesis.

Following stimulation, smart polymers produce a sharp conformational change that, in some cases, can be used to rapidly release the loaded drug. A recent new approach describes stimuli-responsive vesicles where only the permeability of such structures is increased instead of the arrangement being completely lost³³.

1.2.1.3 Micelles and vesicles

Covalently bound block copolymers can self assemble and produce micelles, which are formed by a hydrophilic shell and a hydrophobic core, or vesicles (also called polymersomes) with the creation of a hollow compartment surrounded by three layers: hydrophilic, hydrophobic and hydrophilic again, as depicted in Figure 1-3²⁰. Also non covalently bound electro-statically associated polyion complexes can produce micelles and vesicles (PICsomes)³⁴.



Amphyphilic block-copolymers

Figure 1-3 Schematic representation of micelles and vesicles with their typical loads. Hydrophobic regions are represented in orange, hydrophilic regions are represented in blue. Hydrophobic drugs are usually loaded in the hydrophobic core of micelles or in the hydrophobic layer of polymersomes while hydrophilic drugs are usually encapsulated into the hydrophilic hollow compartment of polymersomes. Drugs can also be covalently linked to polymers. If the drug retains its activity when bound to the polymer the structure can be termed a polymer-drug. Here the drug can be directly bound to the polymer or can also be bound through a spacer. More often the drug must be released by the polymer to be active; in this case, the polymer-drug conjugate is called a macromolecular pro-drug. In macromolecular pro-drugs the spacer must be cleaved by hydrolytic, oxidative or enzymatic activity and, ideally, becoming susceptible to cleavage only when it has reached the target.

1.2.1.4 Formulation of copolymers into micelles, vesicles and nanoparticles

Single block copolymers formed by a hydrophobic block and a hydrophilic block are surfactants. In other terms they are surface active materials and rearrange at the solvent-air surface to reduce the contact of the water insoluble block of the polymer with an aqueous solvent. In this way they also reduce the surface tension of the solvent at the interphase. Amphiphilic block copolymers can self-assemble in aqueous solution

Introduction – Nanomaterials and Endocytosis

and produce micelles. This process occurs above a critical micellar concentration (CMC) that is dependent upon the temperature of the solution and the length of the carbon chain of the polymer. Above the CMC the polymers produce aggregates by a process called micellarization³⁶. These micelles can be spherical, rod-like (also called worms) or rearrange in flat membranes³⁷. However, for all the above-mentioned rearrangements, the hydrophobic portion of polymers reorganize orienting their structures so that they do not come into contact with the aqueous solution³⁸. The hydrophilic region of the polymer produces a corona around the hydrophobic region of the micelles minimising the contact area of the hydrophobic core with the incompatible solvent³⁹. The micellarization process is reversible and single block copolymers can be freed in solution below the CMC of the polymer and this aspect is important in drug delivery where the dilution of the micelles in the blood stream below the CMC might cause the micelles to disassemble before reaching the target⁴⁰.

Vesicles are formed in a two step self-assembly process:

- 1) The formation of a membrane;
- 2) The closure of the membrane into a vesicle⁴¹.

In the classical description, the shape of the vesicle is determined by equation 1^{23} (Figure 1-4):

Equation
$$1 = p = \frac{v}{al} = 1 - Hl + \frac{Kl^2}{3}$$

Where:

p = surfactant packing parameter (Israeleachvili's parameter);

- v = volume of the hydrophobic portion;
- a = interfacial area;
- I = the chain length normal to the interface of the hydrophobic portion;
- H = mean curvature;
- K = Gaussian curvature.




Figure 1-4 Visual description of packing parameter, mean curvature and Gaussian curvature described in equation 1.

When the interfacial area increases in proportion to the hydrophilic block length, a reduction of the hydrophobic/hydrophilic ratio produces the shift from spherical to cylindrical micelles, to membranes and finally to vesicles (Table 1-1).

Introduction – Nanomaterials and Endocytosis

К
1/R ²
0
0

Table 1-1 Correlation between rearrangement of polymers in aqueous solutions and v, a, l, H and K parameters.

Other important parameters to consider are the entropy of the system or how stiff the block copolymer chain is, its degree of freedom and the level of interfacial energy. If the polymer is stiff, with low degree of freedom and entropy, membranes and vesicles are more probable. If the interfacial energy is high and the entropy loss is low, association thermodynamics are dominated by interfacial area energy minimization arrangements. Discher and Eisenberg suggested that a hydrophilic weight fraction of 35% ±10% is necessary in coil-coil block copolymers for vesicles formation^{23,42}. Stiffness of a block copolymer can be enhanced by complementarities within the block copolymer such as secondary interactions (H bonds, Van der Waals, electrostatic, π interactions and so on).

Vesicles easily form when the elasticity of the membrane is low and the surface tension is high. The surface tension increases when the concentration of block copolymers is low. When the concentration is high instead, the membrane chooses different rearrangements such as sheet-like micelles (Figure 1-5)^{24,41}.




Figure 1-5 Diagram for PEO-PBO block copolymers rearrangements in solution in relation to their concentration in water and their molecular weight. (Diagram from²⁴).Reproduced by permission of the Royal Society of Chemistry.

Also ΔA , which is the difference between internal and external area of the polymer ($\Delta A = A_{in} - A_{ext}$) is another key parameter. A is proportional to the volume to area ratio v=6 $\pi^{1/2}$ VA^{-3/2} where V is the volume of the polymer. The following image describes the theoretical (a) and observed (b) changes in shape of poly-butadiene - polyethylene-oxide (PB-PEO) vesicles (Figure 1-6)⁴¹.




Figure 1-6 Diagram showing the theoretical (a) and observed (b) shapes of PB-PEO block copolymers in solution. (Diagram from⁴¹). Reproduced by permission of the Royal Society of Chemistry.

1.3 Routes of cellular uptake

The knowledge of the pathway used by nanocarriers to access cells is an important starting point to design efficient transporters of drugs and it is being intensely investigated for this purpose. For this reason the current state of understanding in cell uptake pathways, essential protein machinery and compartmentalization are considered below.

Eukaryotic cells use many different endocytotic mechanisms, some of which are still poorly understood. Endocytosis is an essential pathway for the uptake of nutrients and communication, and it is also used by toxins and viruses to enter cells⁴³. It can be divided into two main subgroups: phagocytosis and pinocytosis. The classic definitions of phagocytosis and pinocytosis are now widely accepted. Phagocytosis is the internalization of solid materials and it is usually carried out by specialised phagocytic cells such as macrophages, neutrophils, monocytes and dendritic cells⁴³. Pinocytosis is an ubiquitous process by which cells engulf liquids. Once internalised, cargoes undergo sorting towards different compartments and this often happens with the help of Ras-like small G proteins (Rabs). Rabs GTPases are the most prominent group of Rabs⁴⁴, they are a group of about 63 membrane proteins and control many processes such as endocytosis, trafficking, endosomes-membrane fusion and exocytosis^{45,46}. Examples of compartmentalization involving Rabs include endocytic vesicles and early endosomes (Rab5), late endosomes (Rab7), recycling endosomes (Rab4), the movement of vesicles from the trans-Golgi network to the plasma membrane (Rab11), endosomes directed to the Golgi (Rab9) and endoplasmic reticulum (Rab1 and 2)^{45,47}.

SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) are another important category of proteins. They are involved in membrane fusion of intracellular compartments and hence are a key class of proteins for endocytic compartment maturation and in traffic⁴⁸. They bind SNAP (synaptosome-associated protein) receptors on the target membrane and can be localised in vesicles, and they are defined as v-SNAREs, or on the target (t-SNAREs). Their hallmark is a SNARE motif which is constituted by a sequence of 60-70 amino acids that is formed by a series of 7 amino acid repeat units (heptad repeat). Monomeric SNAREs are not organised in a defined structure, but, upon assembly organise in helices of high stability and produce a hydrophobic core where strongly conserved hydrophilic amino acids reside. Each SNARE bears one of these amino acids so that three SNARE proteins consist of glutamines (Q) and one of arginine (R). The respective SNAREs proteins are named Qa,Qb, Qc and R-SNAREs^{46,49}.

1.3.1 Endocytic compartments

Upon endocytosis, the endocytic vesicle is directed towards the first cellular compartment: the Early Endosome (EE). EE is composed of a thin tubular extension of about 60nm and vesicular regions of about 400nm that present a multivesicular structure of an immature multivesicular body (MVB). These two morphologies of different regions of the same EE are believed to be essential for the subsequent processing and compartmentalization of the endocytosed cargo where, for example, recycling cargoes cluster around tubular membranes with a local pH of 6.5, while cargoes undergoing a degradative pathway cluster around MVB structures of the same compartment in which the pH of the lumen is more acidic (ranging between 6.2 and 5.5)⁵⁰. The acidification process occurs through vacuolar type H⁺ ATPases (V-ATPases) membrane proton pumps. EE are enriched in Rab5, in phosphatidylinositol 3 phosphate (PI3P), early endosome antigen 1 (EEA-1) and they interact with actin and microtubules tracts that confer motility to the compartment ^{51,52}.

Another well-characterised subcellular compartment is the late endosome (LE). It is believed to be generated by maturation of EE where it becomes gradually enriched in

Rab7 and other proteins. This organelle is a pre-lysosomal compartment of about 100-600nm that the endocytosed cargo access roughly after 4-30 min from endocytosis in mammalian cells. It is more spherical with respect to EE and is formed by MVBs that are the hallmark of this compartment. LEs can in fact also be referred to as MVBs or multivesicular endosomes. They have intraluminar vesicles with an average size of about 50 nm and are formed by the action of endosomal sorting complex required for transport (ESCRT). The ESCRTs are a relatively recently discovered class of proteins required for the inward invagination of the endosomal membrane to produce intraluminal vesicles⁵³. LE are distinguished from the EE because they are more acidic (pH 5-5.5) and enriched in markers proteins such Rab7, and from the lysosomal compartments because they present mannose phosphate receptors (MPRs) that transport newly synthesised lysosomal protein from the Golgi complex. MVBs can mature to lysosomes or fuse to the plasma membrane and release intraluminar vesicles in the extracellular compartment in the form of exosomes^{49,54,55}.

Lysosomes are another compartment that endocytosed cargoes can be directed to. They are degradative compartments of less than 1µm in non specialised cells but can become larger in macrophages. They are enriched in hydrolases, and it is accepted that molecules smaller than 200Da can diffuse freely though their membrane. Lysosomes present about 20 different membrane transporters but to date only 3 have been fully characterised. They also present V-ATPases that acidify the pH of the lumen of the organelle to around 4.5. Lysosomes are defined as MPR negative and are positive for lysosomes can present multilamellar structures in their lumen. However, these compartments are unrelated to multivesicular bodies (MVB). Lysosomal degradation products can be directed to the trans-Golgi-network or exocytosed⁵⁷.

Autophagosomes are other characteristic compartments that a cargo can be directed to by a process called autophagy that occurs during amino acid and nutrient starvation, oxidative stress and radical oxygen species production (ROS)⁵⁸. Autophagy is dependent on lysosomes and is used by cells for the degradation and recycling of intracellular components. There are 4 different categories of autophagy in mammalians, classified as macroautophagy, microautophagy, chaperone-mediated autophagy and piecemeal microautophagy⁵⁹. Macroautophagy relies on the use of specialised vesicles localised in the cytosol that engulf a cytoplasmic components and that ultimately fuse with a lysosomes. Microautophagy relies on the production of invaginations directly on the membrane of the lysosomes that envelops parts of the cytoplasm that are for degradation; chaperone-mediated autophagy uses chaperones that unfold proteins that are then translocated into the lysosomes⁵⁹; piecemeal microautophagy has been observed in yeast and occurs by degradation of portions of the nucleus that are carried into a vacuole, where the vacuole is the yeast equivalent of lysosomes. The most common and best characterised process of autophagy is macroautophagy. It happens with a phagophore, also known as an isolation membrane, which has been suggested to originate from the point of contact of the endoplasmic reticulum and the mitochondria⁶⁰. This membrane elongates and envelopes around the cytoplasmic components that are intended for degradation and produces a compartment called autophagosome with a double membrane. This structure is then fused with different compartments of the endocytic process. An autophagosome shares the same machinery that is used for endocytosis and fuses with an EE, subsequently with a LE and finally a lysosome and produces a autolysosome, this process is called maturation of the autophagosome^{61,62}.

1.3.2 Membrane domains

Eukaryotic membranes possess a high variability in lipid composition and are formed by hundreds of different lipids. The membrane bilayer has evolved the ability to segregate its constituents laterally by dynamics of liquid-liquid lipids immiscibility. Different regions have been recognised on the plasma membrane, and can be seen as a mosaic of organised microdomains enriched in a few lipids that associate and are supplemented with specific plasma membrane proteins⁶³. This organization defines specialised subcompartments on the membrane that are used for endocytosis, signalling and trafficking. Lipid rafts are one of these domains. Lipid rafts are membrane microdomains of about 50 nm in diameter, with a membrane composition that differs from the adjacent areas and these are enriched in cholesterol, glycolsphingo-lipids, sphingo-myelin, long and unsaturated phospholipids, proteins bound to glycosyl-phosphatidyl-inositol as well as some membrane spanning proteins^{64,65,66}. These structures are present as a metastable state that can be activated by specific lipid-lipid, lipid-protein and protein-protein interactions⁶⁶.

Another of the defined domains involved in endocytosis consists of clathrin-enriched large patches that have been described in both adherent and non adherent adipocytes. They present little lateral mobility and are also enriched with phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2), cholesterol and receptors that are endocytosed by this pathway⁶⁷⁻⁷⁰. This structure also defines a membrane ruffling region where ruffling can be triggered by an unconventional myosin 1c expression. Ruffles are regions on the plasma membrane that arise when exocytosis is activated and actin polymerization pushes outward the membrane⁷¹. Myosin 1c expression is also responsible for exocytosis of GLUT4 (glucose transporter 4) vesicles in adipocytes and for E-cadherin-mediated cell-cell adhesion, both processes also rely on PI(4,5)P2 presence in the plasma membrane and also actin-enriched membrane projections⁷²⁻⁷⁵.

1.3.3 Phagocytosis

Phagocytosis (Figure 1-7) is carried out primarily by specialised phagocytes such as macrophages, monocytes, neutrophils and dendritic cells and it is a highly efficient process. Fibroblasts, epithelial cells and endothelial cells are also known as non-professional or paraprofessional phagocytes and can uptake particles via phagocytic mechanisms but to a lower extent with respect to phagocytic professional cells. Also many other cells have phagocytic capacities, for example thyroid and bladder cells phagocytose erythrocytes *in vivo* and other cells have been induced to phagocytose *in vitro*⁷⁶. The major differences between professional and non professional phagocytes are in the numbers of phagocytic receptors on their membrane; these receptors both speed up the process and allow a wider range of particles to be recognised and phagocytosed⁷⁶.

Even if every specialised cell has different fine tuning events in the phagocytic process three general steps can be distinguished:

a. *Opsonisation of the particle*. This usually occurs in the bloodstream and consists of tagging the target element with opsonins such as antibodies (especially IgG and IgM), complement elements C3, C4 and C5 (by complement activation via the classical, alternative or lectin pathway) and blood serum proteins such as laminin, fibronectin, C-reactive protein and type-I collagen and many others which opsonise foreign hydrophobic particles⁷⁷⁻⁷⁹.

b. Recognition of the opsonised particle by the phagocytic cell. Opsonised particles are recognised by specific receptors on the phagocytic cell such as Fc receptor for antibodies and complement receptors. Mannose/fructose and scravenger receptors can also be involved in phagocytic mechanisms while many other receptors (i.e. CD44 receptors) are still being discovered.

c. Engulfment of the particle – Phagosome formation. Opsoninphagocytic cell interaction activates a transduction cascade via the Ras homolog oncogene (Rho) – family small GTPase that induces actin polymerization and activates the phagocytic process. The engulfment occurs via the formation of cytoplasmic protrusions or sinking for complement receptors-mediated endocytosis that finally enwrap the opsonised particle and translocate it into the cytoplasm (Figure 1-7)⁸⁰. During phagosome formation the actin filaments depolymerise and make the phagosome accessible by early endosomes that finally mature to late endosome and lysosomes and produce a phagolysosome. The compartment is acidified by proton pump ATPases located on the membrane and enriched with digestive enzymes such as esterases and cathepsins as well as chemical factors such as superoxides and hydrogen peroxide to degrade the phagocytic load.




Figure 1-7 Phagocytosis internalises different materials by different mechanisms of engulfment at the plasma membrane.

1.3.4 Clathrin-mediated endocytosis

Clathrin-mediated endocytosis (CME, Figure 1-8) takes place for many essential events and well-studied examples are: low density lipoproteins (LDL) and transferrin receptor (TR) uptake. Other examples of receptor-mediated endocytosis though a clathrin-mediated mechanism are protease-activated receptor 1 (PAR1), the cation-independent mannose 6-phosphate receptor (CI-MPR). Also amyloid precursor protein (APP) and epithelial growth factor (EGF) access cells thorough CME. CME also has a key role in intracellular signalling and regulation of the expression of cell membrane receptors and ion channels, the movement of receptors in other compartments of the cell, synaptic transmission as well as uptake of toxins and viruses. It is also clathrin-mediated the 'zippering' of bacteria where the latter process is used by pathogens that express proteins on their plasma membrane that interact with host receptors and trigger internalization⁸¹⁻⁹⁰.

CME is the best-characterized endocytic process. The unravelling of its mechanism of action has taken place over the past 30 years. Crystal structures of components of the CME such as clathrin, adaptor proteins and the combination of these proteins in the presence and the absence of their substrates has provided evidence at the molecular level of the mechanisms of CME. The best characterized process in CME is the formation of the clathrin lattice at the plasma membrane. This paragraph, although not exhaustive of all the evidence present in the literature, gives an overview of the CME and it reveals the complexity of this endocytic process. This complexity is most likely to be applied to other endocytic pathways that are far less characterized at the present.




Figure 1-8 Mechanisms of endocytosis. In the schematics are shown macropinocytosis, phagocytosis, clathrin- and caveolin-mediated endocytosis and clathrin-independent carrier glycosylphosphatidylinositol anchored protein enriched endocytic compartments (CLIC-GEEC) endocytosis. The dotted lines show pathways that are not fully confirmed in the literature.

1.3.4.1 Clathrin, a brief introduction

Clathrin is a protein formed by three heavy chains of about 192kDa, each of which is bound to one of the two 30-kDa isoforms of the light chains: LCa and LCb. The 3 heavy chains produce a structure that is called triskelion or trimer. The heavy chain has an amino terminal β propeller domain and 7 WD40 β -sheet repeats followed by 42 α -helical zig-zags of about 30 amino acids, a longer final α -helix of 45 amino acids and a more flexible structure at the C-terminus of the protein⁹¹. The C-terminus contains a domain that is recognised by the heat shock protein family 70 (HSP70). This region is necessary for the disassembly of the clathrin cage after endocytosis and becomes accessible only upon assembly of the clathrin cage. The α -helix domain produces a

curved structure that is called 'leg'. From the vertex where all the 3 legs of clathrin converge, a single α -helix of clathrin light chain departs and connects on one heavy chain^{92,93}. The presence of the clathrin light chain does not seem to be necessary for the CME, however it has been suggested that this α -helical structure confers rigidity to the clathrin helping the CME process.

1.3.4.2 Assembly Peptide (AP) proteins family

Other essential components of the forming clathrin pit are the assembly polypeptides (APs). At the present 5 AP proteins are known, AP1, AP2, AP3, AP4 and AP5. Their schematic structure is shown in Figure 1-9. They are formed by 2 large L-shaped opposing regions that together form a squared 'bowl' structure⁹⁴. These two regions are called γ and β 1 in AP1, α and β_2 in AP2, δ and β_3 in AP3, ϵ and β_3 in AP4, ζ and β_5 in AP5. On the same AP protein also two small domains are present. They are called σ and μ and numbered from 1 to 5 depending on what AP protein they belong to; the σ regions interact with the two L shaped large regions at one point of contact while the μ domain is positioned over the angle of the L shaped β region (Figure 1-9)⁹⁵⁻⁹⁷. At the other point of contact of the large L shaped proteins two flexible domains called hinges are present, each one propelling from one of the L shaped regions, and each hinge connects to a small globular region forming a structure resembling antennae. In AP5 the described antennae region is not present. AP proteins are present in two conformations: 'open' and 'closed'. AP2 is responsible for the CME and it anchors the forming clathrin pit to the plasma membrane because clathrin itself does not contain any motifs for membrane binding (Figure 1-10). The other AP proteins are localised in different compartments of the cell and are responsible for clathrin-dependent cargo sorting to different intracellular compartments⁹⁷. When AP2 is in the closed conformation the protein is localised in the cytoplasm and the cargo binding sites are not accessible. When the AP2 changes conformation to an 'open' form (most probably

subsequently to phosphorylation by a AAK1, a kinase of the Prk/Ark serine/threonine kinase adaptor associated kinase family⁹⁵) its cargo binding site present on the μ_2 subunit becomes accessible and can recognise the Yxx motif on the cytoplasmic region of trans-membrane proteins that can be endocytosis by CME⁸³ (Figure 1-9 and 1-10). The YxxΦ motif is a linear sequence of amino acids that is widely used by cells in cargo sorting. It is a tyrosine-based sorting signal and the amino acid sequence is arranged as follows: Y is a tyrosine, x is any amino acid and Φ is a bulky hydrophobic amino acid (e.g. leucine, isoleucine, methionine, valine or phenylalanine)⁹⁸. The μ_2 subunit is also responsible for the binding of PI(4,5)P2 on the C-terminal domain producing a bridge between the plasma membrane and the forming clathrin lattice⁹⁵. On the α subunit, another common sorting motif recognition site becomes accessible in the 'open' conformation upon phosphorylation and it is the dileucine-based sequence [DE]xxx[LI], were D represents an aspartic acid, E is a glutamic acid, L is a leucine and I is an isoleucine and x is any amino acid. The latter motif binds the nascent clathrin lattice interacting with EPS15 (epithelial growth factor receptor pathway substrate 15), amphiphysin and dynamin adaptor proteins. The hinge box of the β_2 subunit express a recognition site for clathrin called clathrin box that express an amino acid sequence as follows: $L\Phi x\Phi D/E$ where x is any amino acid and Φ is a bulky hydrophobic amino acid and L is a leucine, D an aspartic acid and E a glutamic acid^{95,44,99-104}.




Figure 1-9 Schematic representation of the AP adaptor proteins. A. Schematic representation of all the AP proteins known in their close configuration. **B.** AP2 protein in its close (left) and open (right) configuration.(Readapted from⁹⁷).




Figure 1-10 Schematic representation of the AP2 protein in its open state. The regions of the 'ear' (also called appendage from some authors) known interactions are described in this Figure. (Readapted from⁹⁵).

1.3.4.3 Clathrin nucleation at the plasma membrane and lattice assembly

There are at least two distinct mechanisms of endocytosis called canonical and noncanonical clathrin-mediated endocytosis. The canonical pathway is shared by LDL, EGF, transferrin and asialoorosomucoid and it is based on the evidence that all four clathrin-coated pits produced by the internalization of the above mentioned cargoes are identical. The non-canonical pathway is used by pathogens; requires clathrin and actin and follows a pathway and relies on accessory proteins that can differ from the canonical pathway^{88,93}.

1.3.4.4 The canonical clathrin pathway

Upon receptor binding, one clathrin triskelion arrives at the clathrin pit. Only one clathrin triskelion arrives in 70% of the cases; less frequently, there are 2 or 3 triskelions arriving at the same time. The clathrin triskelion arrives already bound to two AP2 proteins⁹⁹. AP2 has been proposed to work as a hub where clathrin and other adaptor proteins that are specific for one internalising receptor are associated. These adaptor proteins have binding motifs for the receptor and also bending activity. This implies the formation of specific clathrin pits depending on the membrane protein endocytosed and the sorting of the specific cargo starts already at the assembly of the coated pit¹⁰⁵. The F-BAR protein (Fer-CIP4 homology Bin/amphiphysin/Rvs protein) containing family FCHo1/2 (Fer/Cip4 homology domain-only (FCHo) protein 1 and 2) are not essential for the coated pit formation and have been suggested as part of a complex that stabilises the coated pit as 70% of the forming coated pits are not completing their process of endocytosis^{99,106}. The FCHo1/2 proteins bind to the coated pit at low curvatures of the membrane and enhance the curvature by a bending activity¹⁰⁵. Other members of this stabilising complex for the clathrin coated pit progression are epsin 1-2 and 3, EPS15, and intersectin^{99,107}. In these conditions the clathrin triskelion starts assembling in a process that is called nucleation; the

progression of the assembly of the clathrin lattice then occurs at increasingly accelerated rates. A mean of 4 legs from different clathrin triskelions overlap and produce a cage-like structure that is formed mainly by hexagons but also by heptagons and pentagons¹⁰⁸. Pentagons are essential to produce a curved cage where otherwise hexagons would produce a flat cage. The centre of the triskelion produces a tripod-like structure that is formed by the long terminal α -helix of 45 amino acids followed by the C-terminal domain. This region stabilises the forming clathrin cage interacting with distal clathrins⁹³. Actin involvement of CME has been guestioned as the inhibition of actin polymerization does not reduce the levels of CME. However, microscopy has provided evidence of actin branched polymers at the endocytic site and around the neck of the forming endosomes^{109,110}. Kirchhausen and co-workers showed that the inhibition of actin polymerization did not inhibit the growth and un-coating of a clathrin pit but it interfered with the formation of new clathrin pits and large clusters of clathrin and AP2 proteins were observed¹¹¹. It has been proposed that actin is essential only when there is high membrane tension for example in adherent cells and when the cargo is unconventional and bulky (e.g. vesicular stomatitis virus, see also noncanonical clathrin pathway)⁸⁸. The last step of CME is the detachment of the clathrin vesicle from the plasma membrane. This process, also called membrane pinching, occurs through a large (100kDa) GTPase called dynamin¹¹². This protein exists as a tetramer and upon contact with a lipid bilayer can produce rings, spirals and helical tubes structures. It is believed to constrict the neck of the forming clathrin vesicle and it has been recently demonstrated that the numbers of dynamins bound to the neck of the clathrin vesicles vary between 26 (20% of pits), 26-52 (55%) and 52-70 (20%). Once the clathrin pit has pinched off the endocytic vesicle the clathrin cage starts a process of destabilization and uncoating that is rapid and leaves promptly the emerging endocytic vesicle. Upon detachment of the clathrin vesicle from the plasma membrane,

auxilin is recruited and arrives at the clathrin lattice. Auxilin binds by J-domains at the C-terminal domain of the clathrin at the vertex of the tripod structure described above. One auxilin binds to each clathrin, bringing up to 3 J-domains at the tripod, enlarging the funnel-like structure of the tripod and making it accessible to Hsc70 (heat shock cognate protein 70)¹¹³. The latter protein belongs to the HSP70 family and bears a ATPase domain which, upon contact of the Hsc70 with the J-domain of auxilin, hydrolyses the ATP and changes the conformation of the Hsc70 to a closed state where interacts with a HSP70 binding motif on the clathrin tripod at the C-terminal. This interaction deforms the clathrin and it has been proposed that the more these deformed conformations are present at the clathrin tripods of the clathrin lattice, the more the

Vesicles are then sorted towards two different kinds of endosomes, fast maturing and slow maturing endosomes. Fast maturing endosomes are targeted with Rab5 and acquire Rab7 within 30 seconds; slow maturing endosomes present only Rab5 on their membrane and do not acquire Rab7 after 100 seconds but acquire Rab11, which is a target for a recycling pathway. LDL, influenza virus and EGF are targeted towards fast maturing and high mobility early endosomes that are also Rab5 and 7 positive or become Rab7 positive within 30 seconds, while transferrin can be targeted towards both sorts of fast or slow maturing early endosomes¹⁰¹.

1.3.4.5 The non-canonical clathrin pathway

Some pathogens have refined their machinery for host invasion and use the clathrin endocytic proteins that are hijacked for their invasion purposes. An example is the enteropathogenic *Escherichia coli*, a bacterium that adheres to the membrane of host cells but is not internalised. It recruits clathrin which is used as a signalling molecule and triggers actin polymerization, does not require AP2 but uses an alternative endocytic protein disabled adaptor-2 (DAB2) that has a PI(4,5)P2 binding motif and it

has been suggested to require PI(4,5)P2 for endocytosis¹¹⁴. However, as for clathrin endocytosis it also requires epsin 1, dynamin and EPS15. In this way the bacterium produces a sort of pedestal that is used to bind on the membrane of host cells⁸⁸. Another mechanism that is used by pathogens is the zippering which involves CME. Some pathogens, (e.g. *Listeria monocytogenes*, a bacterium that causes Listeria fever that can complicate to meningitis in immunodeficient subjects) express surface proteins that bind host cellular receptors and trigger clathrin-dependent internalization that only partially involves the machinery used in canonical clathrin endocytosis. As in the case of enteropathogenic *Escherichia coli, Listeria monocytogenes* needs clathrin, dynamin and DAB2 together with EPS15, cortactin and cortactin-interacting protein CD2AP (CD2 adaptor protein) and Huntingtin-binding protein 1 related (HIP1R). The latter protein is also involved in the binding of actin and clathrin at the endocytic clathrin pit. Neither pathogens require AP2 for exploiting their pathogenic action while phosphorylation of clathrin heavy chain also stabilises clathrin beneath the bacterium⁸⁸.

1.3.4.6 The endocytosis of transferrin

Transferrin endocytosis occurs through a receptor-mediated endocytosis of the transferrin receptor 1 that is localised on clathrin coated pits. When the transferrin receptor binds holo-transferrin, which is a form of transferrin binding 2 ions of iron, the CME is triggered and the internalization of the transferrin-receptor complex occurs. The endocytic vesicle soon fuses with sorting or early endosomes. The pH of the endocytic vesicle is acidified and the iron load is released. However, the transferrin stays tightly bound to the transferrin receptor until the complex is recycled on the plasma membrane where the neutral pH of the extracellular compartment releases the transferrin from the receptor¹¹⁵. The transferrin receptor has been monitored with real time fluorescent Rab cell imaging. This method has allowed the recognition of two populations of endosomes, one fast maturing that is tagged with Rab5 and within 30

seconds also conjugates with Rab7, and a slow maturing population of endosomes that does not conjugates with Rab7 after 100 seconds from the internalization of the transferrin¹¹⁶. The transferrin receptor and transferrin complex can both undergo quick recycling on the plasma membrane (this process occurs in about 4 minutes from the internalization) or can be directed towards a late endosomes and recycling compartment delaying the recycling of the receptor on the plasma membrane to 24 minutes⁴⁷. This process occurs with the association of the transferrin-receptor complex with Rab5 and EEA1 for early endosome localization. Then the vesicles become enriched with Rabenosin and Rab22a and these proteins are believed to define the fate of the transferrin-receptor complex towards a recycling fate¹¹⁷⁻¹¹⁹.

1.3.4.7 Involvement of clathrin with phagocytosis

Clathrin has been recently found to be involved in phagocytosis. A recent paper using micro RNAs shows that CHCα is involved in phagocytosis processes in shrimp hemocytes and murine macrophages RAW264.7¹²⁰. The same CHC has also been found involved in phagocytosis of apoptotic bodies by non-professional gliar cells during neuron differentiation and development. The paper showed a mechanism involving GULP, an adaptor protein involved in phagocytosis, associated with Jedi-1, a mammalian engulfment receptor also involved in phagocytosis. The phagocytic process was inhibited by the loss of interaction of a tyrosine phophorylated form of CHC and GULP¹²¹.

1.3.5 Caveolae-dependent endocytosis

Caveolae-dependent endocytosis (CDE) is one of the best known uptake pathways after CME (Figure 1-8). Caveolae are flask-shaped invaginations of the cytoplasmic membrane that range between 50 and 100 nm in size in the wider part of the flask (typical values are 50-80nm). These invaginations are present in lipid rafts rich in caveolins, a family of cholesterol binding proteins and a membrane integral protein of

21kDa¹²², as well as cholesterol and glycolipids^{123,124}. They are highly stable and are produced spontaneously when caveolin-1 interacts with glycolipids of the membrane raft domains and disappear upon cholesterol depletion^{122,125}. Their stability is given by the interaction with the underlying actin cytoskeleton and only upon specific signals they are internalised in endocytic vesicles.

Endothelial cells are rich in caveolae that can constitute up to 10-20% of the cytoplasmic membrane. Abundance in caveolae has also been reported in smooth muscle cells, fibroblasts, skeletal muscle cells and adipocytes. The composition, function and appearance depend on the cell type. Caveolae in the endothelial cells are usually more narrowed at the neck of the flask shaped invagination and may have a diaphragm that reduces diffusion processes. Muscle cells present caveolae clusters of linear rows that produce the T-tubes while caveolae in epithelial tissues do not contain a diaphragm and are generally smaller¹²². Caveolae are formed by caveolin proteins, caveolin-1, caveolin-2, 3 and 4. Caveolin-1 and 2 are ubiguitous while caveolin-3 and 4 are present in the striated muscle of cells⁴³; caveolin-1 is essential for the formation of caveolae, together with cavin-1. Caveolin-1 is also present in bacteria where it triggers vesicles formation without cavin-1. However, in mammalian cells cavin-1 is essential for the formation of endocytic vesicles, while caveolin-1 is unstable and is quickly degraded in the absence of cavin-1¹²⁶. Caveolae components can be isolated as a single 80S complex and the stoichiometry of the proteins components of this complex appear to be 12 caveolin-1, 3 cavin-1 and 1 caveolin-2 or 3 implying that cavin-1 can form trimers¹²⁶. In the past two years two other proteins taking part in the caveolaedependent endocytosis have been discovered. They are Pacsin 2 (also known as Sindapin 2) that presents a BAR sensing/binding motif that induces membrane curvature and is involved in caveolae morphogenesis and partially colocalize with caveolae¹²⁷⁻¹²⁹. The other protein is EPS15 homology domain-containing protein 2

(EDH2). It is an ATPase present in caveolae and its action is involved in actin binding and caveolae stabilization. Immuno-electron microscopy studies show that the protein is also localised at the neck of the caveolae^{127,130,131}. Caveolins have a specific orientation within the membrane as both the N and the C termini lie into the cytoplasm and are connected by a hydrophobic domain that is buried but does not span the membrane¹²². Furthermore, caveolins bind to palmitoyl acid on the C-terminus, to cholesterol and can be phosphorylated on tyrosine residues and aggregate and produce dimers or oligomers¹²². Cavins also are important coating proteins taking part in caveolae-mediated endocytosis. These proteins chaperone the formation of the membrane curvature but detailed mechanistic information on how these interact with caveolin and other caveolae components are not yet available¹³². Other components that play a role in the caveosome's subsequent fusion with the target compartment are vesicle associated membrane protein (VAMP2) and synaptosome associated protein (SNAP). Particles internalised by caveolae slide along the cell membrane until they reach a caveolae invagination⁷⁸. The particles are anchored to the membrane during the caveolae-mediated uptake, which has been reported as a slower process than the clathrin-mediated uptake. This event could occur via receptor-ligand interactions. The closure of the vesicle occurs via the dynamin GTPase action. The resulting vesicle has typical values of 60-70nm and does not have any specific enzymatic content or low pH environment although some authors have reported that unassembled caveloin can be directed towards degratative lysosomal compartments by ubiquitination and the help of ESCRT proteins¹³³.

Caveolae appear to be formed into the Golgi complex where they are associated with cholesterol, undergo partial oligomerization of caveolin-1 and become detergent resistant.

Often caveolae cargoes overlap with clathrin-independent carriers and a study has shown that caveolin-1 specifically binds to a guanine nucleotide dissociation inhibitor attached to cdc42 (cell division control protein 42) protein which is implicated in clathrin-independent carriers (GPI) – glycosylphosphatidylinositol anchored proteins enriched endocytic compartments (CLIC/GEEC) endocytosis¹³⁴. Furthermore, depletion in caveolin-1 has been reported to increase cdc42 activation at the plasma membrane.

The multi-functionality of caveolin-1 is also demonstrated by its interaction with endothelial nitric oxide synthase (eNOS). The binding of these two elements inhibits the enzymatic activity of eNOS while the disaggregation of the complex causes activation and production of nitric oxide and vessel dilation *in vivo*.

Other evidence suggests that caveolae-dependent and non-caveolar raft endocytosis may be connected⁶⁴. Nichols *et al* suggested that caveolin-mediated uptake may be effective in endothelial cells that express high rates of caveolins and caveolae while other mechanisms⁶⁴ could be activated in cells with lower concentrations of both caveolins and caveolae⁶⁴.

Caveolin has also been implicated in the down-regulation of platelet derived growth factor (PDGF) and EGF via the inhibition of their receptors that are present on caveolae. Over-expression of caveolin-1 inhibits such receptors. Na⁺/K⁺ATPase are also present in caveolae and appear to exert a regulatory function¹³⁵.

Caveolae-mediated receptor endocytosis has been reported for folic acid, albumin and cholesterol internalization as well as for viruses (SV40, virus-Simian Virus 40, and polyoma virus) and the prion protein. Also this pathway is sensitive to cholesterol depletion^{78,136} and, upon *cholesterol* depletion or oxidation, caveolae relocate to endosomes, Golgi complex or endoplasmic reticulum¹²².

1.3.6 Non-clathrin, non-caveolae-mediated endocytosis

Non-clathrin and non-caveolae-mediated endocytosis have not been extensively studied because of the lack of known specific cargoes that are endocytosed by one of these pathways. However, recently some markers of clathrin- and caveolin-independent endocytosis have been recognised. They are the major histocompatibility complex 1 (MHC1), interleleukin 2 receptor β (IL2R β) and glycosylphosphatidylinositol-anchored proteins (GPI-APs) and some more information have started to emerge¹³⁷. However, data on these pathways are still fragmentary. For example, MHC I dependent endocytosis was found to necessitate of dynamin, tyrosine kinase and ubiquitin for correct endocytosis. IL2R β relies on actin though the regulation of PAK 1 and 2 (p21-activated kinase 1 and 2), Ras-related C3 botulinum toxin substrate 1 (Rac1), dynamin and phosphatidyl inositol 3 kinase, (PI3K) that are also essential in macropinocytosis but a clear understanding of the mechanism is still not known¹³⁸⁻¹⁴⁰.

1.3.6.1 CLIC-GEEC endocytic pathway

The Clathrin-independent carrier/GPI-AP-enriched early endosomal compartments (CLIC-GEEC) pathway is an important uptake route of bulk fluid uptake in fibroblasts¹³⁷. The endocytic cargoes internalised by this pathway have a peculiar ring or tubular morphology¹⁴¹. The CD44 membrane glycoprotein receptor is internalised by this route and it has been used as marker of the pathway. The CD44 receptor is responsible for the uptake of hyaluronic acid and it is involved in cell-cell interaction, adhesion and migration. It localises with lipid rafts but upon stimulation and binding of its ligand ezrin, CD44 translocates to a different membrane region and partially colocalises with the transferrin receptor¹⁴². CLIC-GEEC endocytosis is regulated by the protein GTPase regulator associated with focal adhesion kinase-1 (GRAF-1) that possesses GAP activity and inhibits the activity of small GTPases by accelerating the hydrolysis of GTP to GDP¹⁴³. It has been shown to display such activity on the small GTPases RhoA, that

also displays actin cytoskeleton activity, and cdc42 through the interaction of FAK (focal adhesion kinase) and PKN β kinases (protein kinase N construct β)^{144,145}. GRAF-1 also presents a BAR domain for the membrane deformation activity necessary to form endocytic vesicles, a PH domain (Pleckstrin Homology domain, involved in cell signalling and trafficking) and a SH3 domain (SRC- sarcoma oncogene homology 3 domain) and a prolin rich region that is a SH3 binding domain as well¹⁴⁶. GRAF-1 BAR and PH appear to be important for the formation of tubular endocytic structures and the protein showed affinity for PI(4,5)P2 suggesting a PI(4,5)P2 mechanism for the anchoring of the protein to the plasma membrane. GRAF-1 needs dynamin for endocytosis, appears to colocalize with caveolin-rich domain of the plasma membrane but does not colocalize with clathrin¹⁴³.

1.3.6.2 Macropinocytosis

Macropinocytosis was the first endocytic process indentified by Lewis in 1931 as for¹⁴⁷. However, the lack of specific ligands that are internalized selectively by this mechanism makes the distinction of the macropinocytic pathway challenging with respect to other pathways. Macropinocytosis is a quiescent process that is constitutively activated only in some cell lines such as immature dendritic cells, macrophages and transformed cells¹⁴⁷. When not constitutively activated, it can be transiently triggered (5-10 min) by growth factors and tumour inducing factors such as Sonic hedgehog in neurons and epidermal growth factor in ephythelial cells^{148,149}. Many studies have associated macropinocytosis with the formation of actin rich extensions of the plasma membrane referred as planar and circular membrane ruffles but the formation of such structures does not appear necessary for macropinocytosis occurs at lipid rafts membrane subdomains, involves an actin-mediated membrane protrusions formation which than collapse and fuse back into the membrane or on themselves and generate large

pinocytic vesicles (~0.5-1 μ m) although vesicles of diameter up to 5 μ m have been reported with the involvement of dynamin-2¹⁵¹. Once in the cytoplasm the vesicles usually acidify and shrink but the destiny of these compartments depends upon the cell type: examples of different fate for macropinocytosis include fusion with a lysosome or recycling of their load on the cellular surface. No specific coatings have been associated with this uptake pathway but it is often involved in nanocarrier uptake, the clearance of apoptotic bodies as well as some viruses (i.e. adenoviruses)^{78,136,152}.

Cholesterol, actin and PAK1 are essential for macropinocytosis. The latter kinase binds to Rho family GTP-binding protein rac1 and activates it. Also, PI3K, ras (another small GTPase family member), src protein tyrosine kinase, histone deacetylase 6 (HDAC6), heat shock protein 90 (hsp90) are involved in this uptake pathway but the extent and mechanisms are poorly understood. Macropinocytosis is involved in the internalization of viruses and bacteria as well as in the clearance of apoptotic bodies. This pathway has been reported as cholesterol-dependent. Virtually all cells can undergo macropinocytosis but some authors report that macrophages and micro-vessel endothelial cells do not adopt this pathway while others state that macrophages can also perform macropinocytosis. Macropinocytosis is considered a dynamin independent process although some specific types of macropinocytosis appear to be dynamin dependent. This specific way of internalization is called non-canonical macropinocytosis and it has been demonstrated to be involved with the uptake of the Ebola virus and quantum dots (QD)¹⁵³⁻¹⁵⁵.

1.3.6.3 Flotillin-mediated endocytosis

Flotillins are membrane bound proteins that are found almost ubiquitously in mammalian tissues. Flotillin microdomains are present in lipid rafts and are characterised by puncta on the plasma membrane. They are rich in flotillin which is formed by the oligomerization of flotillin 1 and 2¹⁵⁶ and possess membrane lateral

mobility that make them float and from this characteristic they derive their name. Although they do not share any homology with caveolin-1 they present some topology similarity such as the presence of both the N and C terminus in the cytoplasm and membrane domains that do not span the membrane¹⁵⁷. Flotillins are involved with endocytosis, membrane trafficking and signalling but it is not clear at the present if they constitute a separate endocytic pathway or if they induce endocytosis when the clathrin- and caveolin-dependent endocytosis is inhibited. Also, their endocytic machinery has not been defined at the present.

1.4 The biological environment and nanomaterials

Formulating new polymers for drug delivery is challenging as many different parameters such as particle charge, shape and size can affect the biodistribution and uptake of the delivery system. As bacteria, viruses and protozoa have hydrophobic surfaces, the human body has strategies to opsonise hydrophobic particulates, including synthetic hydrophobic nanoparticles^{77,79}. This occurs via interactions with serum proteins such as antibodies, complement factors (common examples are C3, C4 and C5) and blood serum proteins such as laminin, fibronectin, C-reactive protein, type I collagen and many others⁷⁷. These serum components facilitate the binding of nanoparticles with phagocytic cells such as macrophages, neutrophils, monocytes and dendritic cells that have a scavenger role⁷⁹. For this reason, hydrophobic polymers alone are not effective in drug delivery by intravenous routes. A well-known method to overcome such problems is the addition of a hydrophilic, protein-repelling polymer such as polyethylene glycol (PEG) to the drug delivery system. (please see below for a more extensive description of the process). On the other hand, positively charged polymers have shown higher toxicity profiles *in vitro*.

1.4.1 Nanoparticles in the bloodstream

Nanocarriers do not pass the intestinal epithelium¹⁵⁸ and only a slow absorption has been shown through Peyer's paches in the gut¹²; hence, they are often administered intravenously or subcutaneously, by inhalation through the lungs¹⁵⁹ or by intranasal adsorption¹⁶⁰.

Interaction of nanoparticles with blood components is an important aspect to take into account as it can change the biodistribution of the injected materials. Nanoparticles are known to bind serum proteins and molecules constituents. They can form a shield around the nanoparticles called corona within 30s¹⁶¹. The Dawson's group has introduced the concept of hard and soft corona^{162,163}. According to their description, the hard corona strongly interacts with the nanoparticles by electrostatic, Van Der Waals and hydrogen weak bonds and constitutes a hardly modifiable shield. A second layer that is bound less tightly to the hard corona is constituted by proteins and serum molecules that restore the original polarity of the nanoparticles, this compartment is more dynamic and interchanges more frequently with components of blood and constitutes the soft corona. The combination of soft and hard corona increases the overall size of the material. This idea of corona formation around the nanoparticles is not fully accepted and some authors question the existence of such distinct compartments around the nanoparticles and more generally refer to a unique corona of blood components that interchanges dynamically with blood constituents over time¹⁶⁴. Interactions of the nanocarriers with blood molecules can lead to formation of aggregates, might produce adducts with sizes bigger than capillaries and cause ischemia and blood clotting, which is potentially life-threatening. McGuinness and coworkers pointed out that amine and carboxyl derivatization of polystyrene and silica nanoparticles could produce aggregation of nanoparticles with platelets in vitro^{164,165}. Furthermore, the surface of blood vessels is negatively charged and it has been

reported that an ideal nanoparticle should have a neutral or slightly negative charge to avoid interaction with the vessel walls¹⁶⁶. However, it has also been proposed that negative charges reduce the extent of interactions of nanoparticles with cells membrane phospholipids that are negatively charged and, consequently, their access to intracellular compartments.

1.4.1.1 Opsonisation

One important aspect to evaluate in nanocarrier drug-delivery systems is the level of opsonisation of the particle in the bloodstream. Opsonisation reduces the concentration of particles in minutes with loss of their therapeutic effects. It occurs *in vivo* and it is carried out by the mononuclear phagocytic system, also known as reticulo-endothelial system⁷⁷. This process (described in §1.3.3) is the way the body scavenges foreign particles that are bigger than the renal threshold (typically around a molecular weight of 5,000 for linear polymers but up to 100,000 for branched or compacted polymers⁷⁷). Phagocytosed particles are readily accumulated into the spleen and liver, the main scavenger organs and, depending on the nature of the particle, can be either digested (biodegradable particles) or accumulated (non biodegradable particles) with high risk of toxicity⁷⁷.

The polarity of the surface of nanocarriers is an important aspect to evaluate when designing new drug delivery devices. As mentioned before, since bacteria, viruses and protozoa have hydrophobic surfaces, the human body has strategies to efficiently opsonise hydrophobic particulates^{77,79}. Hydrophobic particles are targets for serum proteins that adhere to the particles and tag them for rapid phagocytes recognition^{77,78}. On the other hand, nanoparticles with dense surface charge have also shown a high rate of opsonisation and scavenge rate including opsonisation by complement elements^{77,78}.

The process of adhesion of serum proteins to nanoparticles that produces a corona can give important information about both opsonisation and immunogenic reactions¹⁶⁷. Gold nanoparticle coronas coated with poly(acrylic acid) (PAA), for example, activate a cascade signal that leads to production of cytokines in human acute monocytic cell line THP1¹⁶⁸.

One strategy to reduce or block opsonisation consists of shielding the carrier with long hydrophilic but uncharged compounds that reduce non-specific protein binding such as polyethylene glycol⁷⁸. However, various shielding devices have been used for such a purpose: dextrans, alginates, cyclodextrins, hyaluronic acid, trehalose, polyacrylamide, poly-vinylalcohol, poly N vinyl pyrrolidone, poloxamines, and polysorbates ^{77,169-171}.

1.4.1.2 Polyethylene glycol coating of nanocarriers

Among the above-listed shielding strategies, one of the most efficient is PEGylation. It can be carried out by surface adsorption but a clear drawback is represented by the easy desorption of the PEG which can lead to gaps in the shield and consequent opsonisation. Harper, Bazile and co-workers have shown that PEG covalent binding is more efficient with respect to surface adsorption^{172,173}. A classic view suggests that PEG chains of 2000Da or longer have reduced binging protein ability and hence are suggested for cargo shielding of drugs¹⁷⁴⁻¹⁷⁶. However, more recently it was shown that PEG chains of 400Da had reduced unfolding properties when incubated with bovine serum albumin (BSA) and lysozyme as measured by fluorescence spectroscopy emission of tryptophan. In the same study, longer chains were more disruptive on these proteins inducing a partial unfolding of the 3D structure¹⁷⁷. Also the unfolding ability towards proteins of a nanocarrier is an important parameter to take into consideration when evaluating its biocompatibility as this process can cause the exposure of antigenic domains to the immune system that can be buried in the 3D structure of a protein. Other important parameters for PEG coating are the surface

conformation of PEG and density. It has been reported that optimal PEG coating is obtained when PEG assumes a 'mushroom' conformation where PEG chains are both more flexible and generally closer to the carrier surface. However, a minimum concentration of PEG must be assured as low PEG concentration is not sufficient for an efficient coverage of the carrier. Also a too high concentration of the polymer is not desirable as it produces a PEG conformation denoted as semi-linear or 'brush' configuration which leads to a loss in flexibility and hindrance volume of the PEG chain and increased opsonisation. PEGylated particles are known to accumulate in the spleen upon opsonisation. Even if PEGylation is a key tool in reducing opsonisation, it has been often reported that PEG coated carriers show a reduced cell uptake, a phenomenon known as the PEG dilemma¹⁷⁸.

1.4.2 Extravasation of nanoparticles

Nanoparticles in the bloodstream must overcome the endothelial barrier in order to reach tissues and organs. The endothelium is typically formed by endothelial cells adhering to the each other through tight junctions and lying on a basement membrane. Tight junction gaps between cells have typical diameters of about 2nm; they are even smaller in the blood-brain barrier while the underlying basal membrane does not allow passage of materials bigger than 13-15nm⁷⁹. Some organs and tissues, depending on their physiological functions, allow the passage of larger particulates. For example, the liver has a fenestrated endothelium which increases the upper size limit to 100 nm while the discontinuous endothelium present in the spleen is even more accessible. However, in pathologic conditions such as inflammation and some kinds of cancers, the endothelium becomes leaky and allows the passage of particles of larger size. It has been reported that inflammation and tumors can cause an increase of fenestrae size up to 700nm in some capillaries¹⁷⁹. Inflammation is common in many pathologic events and, in cancer inflammation, is often associated with the loss of lymphatic

vessels that increases the retention of particulates in such tissues⁷⁹. The increased permeability of tumor sites is often referred as enhanced permeability and retention (EPR) effect¹⁸⁰. It is nevertheless true that the oncotic pressure is increased in extracellular compartments of cancerous tissues and the efficiency of drug delivery by this means is still a matter of debate.

1.4.3 Nanocarriers passage into body tissues and organs

Nanoparticles that overcome the endothelial barrier reach the extracellular matrix. The latter is composed by an aqueous solution of proteins (i.e. collagen), polysaccharides (i.e. hyaluronic acid) and glycoproteins (i.e. chondroitin sulphate). This environment impedes nanoparticle diffusion but the presence of aqueous channels makes this compartment still accessible^{12,181}.

1.4.4 Nanoparticles uptake into cells

Many efforts are being made to characterize the way that nanocarriers enter cells and draw some generalizations in order to understand further the process of uptake. However, at present, just a few concepts are clear^{182,183}.

1.4.4.1 Size, shape and charge of nanocarriers and endocytosis

1.4.4.1.1 Phagocytosis of nanomaterials

The size of nanocarriers, in the absence of any other changes in chemistry or surface properties, influences phagocytosis. Moghimi¹⁷⁹ reported that particles with size greater than 200nm were more promptly cleared from the bloodstream. Champion *et al* on the other hand, showed that the shape of the particle at the point of contact with macrophages determines the kinetics of uptake. In this study, polystyrene spheres were internalised promptly when in contact with alveolar macrophages while flat sides of rod-like polystyrene particles were internalised more slowly. A critical angle of 45^o between the particle and the phagocytic membrane surface was calculated as the limit

for efficient phagocytosis where efficient uptake was obtained with lower angle values. This effect could be ascribed to the more complex actin structure to be realised in order to achieve phagocytosis. Surface charged nanoparticles are more readily taken up by macrophages.

1.4.4.1.2 Pinocytosis of nanomaterials and biodistribution

The characteristics of specific nanoparticles influence uptake by mechanisms other than phagocytosis in a more complicated and less evident way and it is thought that the degree of influence for such characteristics is dependent on to the cell type tested. Size, for instance, can limit internalization in some cells (i.e. Hepa 1-6 hepatoma, HepG2 and KLN 205) while it is reported not to influence uptake in HUVEC endothelial cells, ECV 304 bladder carcinoma cells and squamous carcinoma cell lines. Size can also influence the specific pathway of endocytosis⁷⁸. In melanoma B16 cells for instance small particles (<200nm) were taken up by a clathrin-mediated endocytic pathway while bigger particles showed a caveolae-mediated endocytic pathway. Other studies on HeLa cells reported that polystyrene particles of 40nm were internalised by clathrin-mediated endocytosis but particles smaller than 25nm were internalised by a non-clathrin-, non-caveolae-mediated endocytosis. Macropinocytosis, on the other hand, does not show size dependency and it has been reported to often occur together with other uptake pathways. Minchin studied the uptake of AuNP encapsulated in dendrimers of different charges and sizes and reported that distribution in some organs was dependent upon these properties. Studies of biodistribution in mice showed that small (5 nm) positive dendrimers were accumulated into the kidneys for days and mainly excreted through the urine; 5 nm neutral and negative particles were accumulated in spleen and liver. When the size of positive nanoparticles was increased to 22 nm they were not excreted by the kidneys but accumulated in lungs, liver and spleen¹⁸⁴.

Charged carriers can also influence cellular uptake. It has been reported that positively charged nanocarriers are promptly internalised by cells. This could be due, as reported before, to electrostatic interactions with the negatively-charged cell surface. Positively-charged nanoparticles have also been reported to produce defects on cell membrane in cell membrane models. Experiments on dendrimers and other amine containing polymers have been reported to strongly interact with lipid bilayers of membrane models^{9,185}. Such carriers produce membrane thinning at low concentrations and holes at higher concentrations⁹. Charged carriers have been classified in three categories:

- Charged particles that adhere closely to already present membrane defects but that cannot enhance these defects;
- b. Charged particles that cannot induce membrane defects but can increase them;
- c. Charged particles that can both start or increase membrane defects.

However, the membranes used to carry out these studies are not natural membranes. They are usually formed by a mixture of natural lipids that are often present in membranes but lack superficial and intercalating proteins and glycoproteins that can represent up to 50% of natural mammalian membranes and this should be taken into account when extrapolating to *in vivo* studies¹⁸⁶.

In the attempt to increase the efficiency of nanomedicines, and to enhance their uptake, nanoparticles have been conjugated with cell penetrating peptides (CPP). These peptides are short sequences that often resemble peptides that have been used by pathogens to access cells. They are rich in arginine and lysin that makes them positively charged or amphiphilic. Examples of CPP are TAT (HIV tat protein transduction domain) and penetratin (*Drosophila* antennapedia homeodomain)¹⁸⁷. Some of these materials have reached the market for topic applications.

Shape of nanoparticles in endocytosis has not been thoroughly investigated but it is known that some viruses (i.e. some strains of Ebola and H5N1) have filamentous shapes. When producing rod-like nanoparticles for drug delivery also the stability of the shape must be taken into consideration as it has been reported that rod-like micelles formed with PEG-p-PLA block copolymers were unstable and eventually shortened and produced spherical micelles¹⁸⁸. Other observations focusing on the increased penetration of worm-like micelles in gels suggested that rod-like micelles could have an enhanced penetration in tissues and organs which could be interesting to investigate to enhance oral adsorption of nanoparticles¹⁶⁶. However, depending on the length of nanoparticles, a rod-like shape might induce toxicity and inflammation and ROS production caused by phagocytic cells frustrated internalization as shown by asbestos and more recently by carbon nanotubes research¹⁸⁹.

From this brief overview it is possible to understand the complexity of the field. It is not trivial designing a new nanoparticle for drug or gene delivery and one approach can be a success or failure depending on the target.

However, some generalizations are possible. For example, the size and surface properties of nanoparticles size must be carefully controlled to avoid aggregation in the bloodstream, opsonization and reduced access in target cells. The ideal size range of drug delivery systems is likely to be similar of that of viruses, i.e. between 10 and 100 nm. The nanoparticle should not be strongly negatively or positively charged in order to prevent opsonisation, and respectively: low uptake or disruption of the plasma membrane of cells with consequent toxicity. Hence, the nanoparticle should ideally have a surface which is hydrophilic but not charged. The coating of drug delivery nanoparticles is intensely debated despite more than 30 years' literature on the subject. PEGylation of nanoparticles appears to delay the opsonisation but reduce the access

of the nanoparticle into cells and other coating materials are being investigated. Finally, rod like shape would be preferred as it increases the penetration of the nanoparticle into tissues and organs. However, possible side effects such as inflammation caused by a frustrated phagocytosis can also be triggered with detrimental effects for patients.

1.5 Nanoparticles in the literature

Nanoparticles such as polystyrene beads (PB), QD superparamagnetic iron oxide nanoparticles (SPION) and gold nanoparticles (AuNP) can be synthesised with a narrow size distribution and a controlled surface chemistry. For this reasons they are a useful tool in research, in diagnostics and in endocytosis studies and they have also been extensively used to understand the safety of nanomaterials¹⁹⁰⁻¹⁹³.

1.5.1 Colloidal Gold Nanoparticles

Nanoparticles derived from colloidal gold were the first colloidal nanoparticles synthesised. They present physiochemical characteristics that differ from metallic gold and are ruled by the Laws of Quantum Physics¹⁹⁴. The resulting nanoparticles in the range of 1-10nm present characteristics that are strictly dependent upon their size and do not resemble bulk metal or molecular characteristics of gold. They have a plasmon resonance band at around 530nm. The precise wavelength of that band depends on nanoparticle size and shape, and medium properties, and has found application in diagnostics¹⁹⁵. AuNP can be used in conjugation to polymers or proteins for drug delivery purposes¹⁹⁶. The gold core of such conjugates stabilises the geometry of the shell-like region around the nanoparticles and can be tailored to suit the most disparate applications. Sulphur-polymers anchored to AuNP for an easy release of the drug conjugate is an example, or polyethyleneimine (PEI) with a cyclodextrin-derivatised terminal co-polymers to enhance the hydrophobicity of the polymer terminal part for an enhanced DNA delivery¹⁹⁷. Furthermore, also their physical characteristics can be

exploited for therapeutic purposes. When the nanoparticles are hit by a light radiation in the range of 800-1200 nm they produce heating of the region and could be used in hyperthermia applications or, if conjugated with a thermoresponsive polymer could release the drug-load specifically at the intended target. From a recent review by Oh *et al.* it emerges that unconjugated AuNP of 50 nm were the most easily internalised nanoparticles while PEG coating reduced drastically internalization. Endocytosis of AuNP conjugated with cell penetrating peptide TAT and NLS (nuclear localization sequence) were enhanced. Unexpectedly, rod-like AuNP were more actively phagocytosed by macrophages than spherical nanoparticles^{183,198}.

1.5.2 Quantum dots (QDs)

QDs can be produced from many materials. Graphene, silica and hybrid CdSe or Zs-S are the most common examples of such structures. They are semiconductors nanocrystals formed by a colloidal core and one or more layers to increase their water solubility¹⁹⁹. They are exceptionally bright with an intense and extremely stable fluorescence that finds many applications, from research in cell penetration studies, to cell imaging and cancer targeting. Uncoated CdSe core and CdS or ZnS coated QDs have been shown to access HEK (primary neonatal human epidermal keratinocytes). QD of 20 nm coated with COOH groups promptly accessed HEK cells with a caveolae-mediated internalization mechanism¹⁹⁹. It has been shown that the more the QDs are charged (both positive and negative charges) the more they are internalised by cells. Also 100 nm negatively charged nanoparticles are taken up more promptly than QDs of 28nm with the same charge according to Kelf *et al*²⁰⁰. The same group also points out that the literature suggests a higher level of internalization with a clathrin-mediated mechanism of endocytosis for QDs of 50 nm.

1.5.3 Iron oxide nanoparticles

In the last decade iron oxide nanoparticles (especially maghemite, Fe₂O₃, and magnetite, Fe_3O_4) have been studied for many applications. They are particularly interesting because of their biocompatibility and they have been approved by the FDA^{192,201}. As for AuNP, nanosized iron oxide nanoparticles present unique superparamagnetic and magnetic properties that do not resemble the atomic or the bulk material. They can produce hyperthermia in an alternating magnetic field and can be directed towards a specific tissue with a magnetic field²⁰². Unmodified SPIONs can precipitate in solution as they do not show water solubility and they must be coated to enhance their water compatibility for biological applications. Their most studied applications include cell labelling for cell separation, magnetic resonance imaging (MRI) and hyperthermia therapy. Recently, EGF-conjugated SPIONS have been tested in C6 glioma cells for the detection of early stage of cancer and so substitute gadolinium contrast agents²⁰³. Although SPION nanoparticles are not normally produced for internalization and many studies have shown that the nanoparticles are safe at concentrations up to 100 µg/ml, local accumulation of SPIONs can lead to toxicity²⁰². Colloidal iron can easily oxidise leading to the Fenton reaction that is extremely toxic for cells and it destabilises membranes, proteins and DNA. Their application is oriented towards the recognition of a specific tissue for diagnosis and therapy in conjunction with other therapeutics (e.i. thermoresponsive drug-carriers conjugates).

1.5.4 Polystyrene nanoparticles

There are many protocols to synthesise polystyrene beads (PB). One of the most common is with a dispersion polymerization method but other protocols are available in the literature (i.e. macro-raft agents and other techniques)²⁰⁴⁻²⁰⁷. The advantage in using polystyrene beads is that these materials can be easily synthesised in a relatively

economical way and produce materials with narrow distribution of sizes conveniently customized from the range of microns to about 20-25 nm. Furthermore, PB can easily be labelled with fluorescent or luminescent dyes for a detection with an array of techniques; they are visible in TEM without any labelling and can be readily modified to change the polarity of their surface or for derivatization with receptor proteins or vitamins²⁰⁸. For all these reasons they are a useful tool in research, in endocytosis studies and they have also been extensively used to understand the safety of nanomaterials¹⁹⁰. Many studies have been carried out on PB of the range of 50-100 nm. It has been shown that there is usually a good correlation between PB uptake and other nanomaterials despite differences in surface chemistry and composition²⁰⁹. However it appears that the pathway of internalization is strongly influenced by the cell lines used for the study and the same material can be susceptible to different inhibitors of endocytosis depending on the cell lines adopted for the study¹⁸².

In an attempt to enhance internalization of nanoparticles and specificity towards a target organ, many strategies have been adopted. For example, nanoparticles have been associated with cell targeting ligands such as proteins specific for cells membrane receptors, with antibodies and aptamers. Nanoparticles have been tagged with specific proteins to enhance their ability to accumulate in specific tissues. An example is prostate-specific membrane antigen (PSMA) that target prostate cancer cells and virtually all solid tumour neo-vasculature²¹³. Recently, nanoparticles composed of polylactic acid or polylactic-*co*-polyglycolic acid-PEG and tagged with PSMA were used to chemically entrap tamoxifen. This anticancer drug, has been approved for the treatment of many cancers including prostate, gastric, breast, lung, and head and neck, and has entered Phase I clinical trials with the identity name of BIND 014^{210,214} (Table 1-2). Transferrin protein is also commonly conjugated to

nanoparticles (Table 1-2). Transferrin binds to the transferrin receptor that is ubiquitously expressed in functional cells but it is modestly expressed in quiescent cells such as some endothelial, endocrine pancreas, breast, kidneys and liver cells¹¹⁶. The expression of transferrin receptor is dependent on the level of proliferation the cell is undergoing. For example, transferrin receptor is expressed in foetal cells and the extent of its expression can be modulated by the presence of iron in the diet. Transferrin receptor has also been found over-expressed in many cancers such as colon, pancreas, bladder and lung and for this reason has been used conjugated to nanoparticles in order to enhance specificity of the delivery of anticancer drugs. Another common strategy applies folate targeting to nanocarriers to enhance specificity towards a pathologic region. The concept behind this approach is that often folate receptors are over-expressed in ovarian, cervical, breast, brain, and lung cancer. Again, as for transferrin receptor, it is also expressed in healthy tissues such as lungs, kidneys and placenta. Folate is needed for DNA replication and many other cell functions and it acts binding to the folate receptor that is internalised by caveolae. This localization has made the functionalization of nanoparticles with this receptor highly appealing as there is little evidence in the literature that has observed caveolaeinternalized materials being directed towards lysosomes and acidic degradation. The possibility of bypassing the lysosome compartment is a highly attractive feature in drug delivery. However, folate tagged nanomedicines have failed clinical trials so far and the latest example is Vintafolide, a vinblastine-folic acid conjugate that reached Phase III clinical trials for the treatment of platinum resistant ovarian cancers (the same compound is in Phase II trial for non-small cell lung cancer). Although there is increasing evidence of the efficacy of receptor protein conjugation approaches in vitro and in animal models, drugs that use these means to enhance specificity have failed in clinical trials to demonstrate the efficacy of such ligands. Furthermore, in vitro studies

Introduction – Nanomaterials and Endocytosis

show that the ligand internalization pathway is influenced by the presence of the conjugated nanoparticles. For example, CPP can be endocytosed by different machineries depending on the specific sequence and in the presence and absence of the intended cargo²¹⁵. Also, transferrin-conjugated nanoparticles studies suggest that transferrin-conjugated QDs are not internalised by the same route as transferrin alone¹⁵⁴. The same has also been confirmed for ricin and Shiga toxin-conjugated QDs and vitamin B12-conjugated polystyrene nanoparticles²⁰⁸. Also, it has been shown that using the same ligand protein (herceptin) specific for a membrane receptor (ErbB2) herceptin-conjugated AuNPs of 40 and 50 nm had the ability to change the internalization outcome, to modulate the expression of the receptor as well as inducing caspases and induce apoptosis with respect to the same nanoparticles of smaller or bigger sizes (size range 2-100 nm)²¹⁶. Finally it is known in the literature that nanocarriers in the blood stream can lose their specificity towards the target when in serum due to the formation of a corona of proteins enveloping the nanocarrier and shielding its functional molecules on their surface²¹⁷. There is a clear need for a better understanding of the nanoparticle characteristics that make cells activate a specific pathway. A recent publication has found a correlation between the specific serum proteins that bind the nanoparticles and the pathway of internalization which may provide a route forward for understanding this complex area²¹⁸.

Commercial name	Company	Formulation	Drug incorporated	Target	Pathology	Status
		Nanomedicine	s without targeting li	gands		
DaunoXome	Galen	Liposomes	Daunorubicin		Kaposi's sarcoma	Market
Miocet	Enzon	Liposomes	Doxorubicin		Combination therapy for, recurrent breast and ovarian cancers,	Market
Onco TCS	Inex Pharmaceuticals Corporation	Liposomes	vicristine		relapsed aggressive non-Hodgkin's lymphoma	Market
Depo-Cyt	Sigma-Tau	Liposomes	Cytarabine		Meningitis, leukaemia, glioblastoma	Market
Ambisome	Gilead	Liposomes	Amphotericin B		Fungal infection, cryptococcal meningitis	Market
Doxil-Caelyx	Janssen	PEG-Liposomes	doxorubicin		refractory Kaposi's sarcoma recurrent breast and ovarian cancers	Market
Lipoplatin	Regulon	PEG-Liposomes	Cisplatin		Various malignancies	Phase III
Thermodox	Celsion Corporation	Heat inactivated PEG-Liposomes	Doxorubicin		Hepatocellular carcinoma, recurrent chest wall breast cancer	Phase III
Abraxane	Astellas	Albumin bound- nanoparticle	Paclitaxel		Breast cancer	Market
Oncaspar	Sigma-Tau	PEG conjugated drug	L-asparaginase		Acute lymphoblastic leukemia	Market
Genexol-PM	Samyang	PLA-PEG micelles	paxlitaxel		metastatic breast cancer	Market
Abelcet	Sigma-Tau	Lipid-drug complex	Amphotericin B		Antimicrobial	Market
QD 800	Invitrogen	Streptavidin covalently bound QD			Imaging diagnostics detection of proteins and nucleic acids	Market
Resovist	Schering	SPION coated with carboxydextran			Hepatocellular carcinoma	Market
Feridex	AMAG Pharmaceuticals	Iron nanoparicles			Detection of liver lesions	Market
		Nanomedicir	nes with targeting liga	inds		
CALAA-01		Cyclodextrin- containing polymeric nanoparticles	siRNA	Transferrin	Solid tumors	Phase I
MBP-426		Liposome	Oxaliplatin	Transferrin	Gastric, oesophageal, gastric- oesophageal adenocarcinoma	Phase Ib/II
MCC-465		Liposome	Doxorubicin	F(ab)2 fragment of human antibody Ab GAH	Metastatic stomach cancer	Phase I (discontinu ed)
BIND-014		PLGA-PEG nanoparticles	Doxetaxel	PSMA peptide	Solid tumors	Phase I
SGT53-01		Liposome	P53 gene	Transferrin receptor specific-scAb	Solid tumors	Phase I

Table 1-2 Summary of nanomedicines that have reached clinical trials or the market(^{219,210}).

1.6 Aims and thesis outline

Despite numerous attempts to trigger the desired endocytic machinery for the uptake of nanomaterials, literature suggests that nanoparticles conjugated to a ligand specific for

Introduction – Nanomaterials and Endocytosis

a membrane receptor are internalised according to their physical characteristics rather than the conjugation ligand. Information on how these characteristics guide the internalization of nanoparticles through one pathway or the other is still limited, fragmentary and sometime contradictory. Also, results in the literature are challenged by the numerous variables that constitute the experimental environment of the *in vitro* studies and complicate the recognition of similarities and patterns of behaviour. However, this information is essential in order to develop nanocarriers of drugs with a desired internalization and hence, a more sophisticated control of nanomaterial interaction with cells.

The aim of this study was to investigate the pathway of internalization employed by carboxylated polystyrene nanoparticles of 50 and 100 nm as model particles to access a panel of both epithelial and fibroblastic cells. Firstly, the focus of the study revolved around understanding if there were any differences in the pathway involved in the uptake of carboxylated polystyrene nanoparticles based on differences in size. Secondly, an investigation was carried out on how different cell lines, such as fibroblasts and epithelial cancer cells could employ different mechanisms of internalization for the same material. The aim was to compare and contrast these findings with the uptake of thermoresponsive negatively charged PLGA-b-(PEGMA-co-PPGMA) and PLA-b-(DEGMA-co-OEGMA) polymeric micelles. These concepts are schematically summarised in Fig. 1-11. To pursue these objectives, inhibitors of endocytosis were employed to investigate the possible route of uptake of these materials. An assessment of the toxicity of both polystyrene nanoparticles, and inhibitors of endocytosis was carried out as well as optimization of the experimental settings for the endocytosis inhibition studies. These results are summarised in Chapter 3. Flow cytometry was used to investigate the inhibition of uptake of carboxylated polystyrene nanoparticles in the presence of inhibitors of endocytosis

while their internalization was detected by confocal live studies (Chapter 4). Finally, the results on the biocompatibility and internalization ability of thermoresponsive polymers are summarised in the last chapter of results (Chapter 5). Results are further commented on in a discussion chapter and some conclusions drawn (Chapter 6).

1.7 Experimental Approach

Two types of nanomaterials were used to study cellular uptake of nanoparticles. Carboxylated polystyrene nanoparticles, with sizes of 50 and 100nm, and a hydrophobic core and a hydrophilic coat were considered a valid model resembling research grade thermoresponsive polymers with the same size range and polarity distribution and were included in these studies. In addition, thermoresponsive PLGA-*b*-(PEGMA-co-PPGMA) and PLA-*b*-(DEGMA-*co*-OEGMA) block copolymers were used.

The investigation of different routes of uptake in different cell lines was carried out with human transferrin (Htf) and lactosylceramide (LacCer). These two molecules are routinely used and widely accepted markers of clathrin-dependent and -independent endocytosis. Chlorpromazine (CPZ) and methyl beta cyclodextrin (MBCD) have been extensively used as pharmacological inhibitors of clathrin-dependent and -independent endocytosis in the past 20 years. However, the lack of specificity of both CPZ and MBCD towards only one specific endocytic pathway is well documented in the literature and these experimental limitations were taken into account when drawing conclusions from results.

The choice of the cell lines for the study was based on evidence that many pathologies affect epithelial cells and for this reason are relevant for pharmaceutical investigations. Furthermore, increasingly significant data in the literature report of a role of mesenchymal cells in the instigation and progression of pathologies such as cancer and for this reason fibroblasts were included in the study. Immortalized cells were

Introduction – Nanomaterials and Endocytosis

preferred over primary cells because of the inherent genetic differences within primary cells from different patients. However, the limitations of this choice such as known differences between immortalized and normal cells, genetic instability are important and experimental limitations that should be devalued before drawing more general conclusions from the experimental results.

Further limitations in the above-mentioned experimental approach was due to the choice of *in vitro* settings over 3D or *in vivo* experiments that are known to resemble more closely the body environment and hence are physiologically more relevant. However, it is important to stress that much of the research field of endocytosis in mammalian cells at the moment is limited to more or less sophisticated 2D *in vitro* studies. The reason for such limitations is that 3D culture approaches are challenged by the level of perfusion of the more internal compartments of the 3D scaffolds. Another important limitation is provided by the level of detection of optical fluorescence techniques currently available and the level of penetration in thick specimens for the detection of fluorophores.




Figure 1-11 Flow chart showing the aims and experimental plans of this thesis.

References

- 1 Gaspar, R. & Duncan, R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev **61**, 1220-1231 (2009).
- 2 Duncan, R. & Gaspar, R. Nanomedicine(s) under the Microscope. Molecular Pharmaceutics **8**, 2101-2141 (2011).
- 3 Alonso, M. J. Nanomedicines for overcoming biological barriers. Biomed Pharmacother **58**, 168-172, doi:10.1016/j.biopha.2004.01.007 (2004).
- 4 Schneider, M. et al. Crossing biological barriers for advanced drug delivery. European Journal of Pharmaceutics and Biopharmaceutics **84**, 239-241 (2013).
- 5 Thomsen, T. B., Li, L. & Howard, K. A. Mucus barrier-triggered disassembly of siRNA nanocarriers. Nanoscale (2014).
- 6 Lai, S. K., Wang Yy Fau Hanes, J. & Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Advanced Drug Delivery Reviews **61**, 158-171 (2009).
- 7 Groo, A. C. & Lagarce, F. Mucus models to evaluate nanomedicines for diffusion. Drug Discov Today 19, 1097-1108 (2014).
- 8 Bramini, M. et al. Imaging Approach to Mechanistic Study of Nanoparticle Interactions with the Blood–Brain Barrier. ACS Nano **8**, 4304-4312 (2014).
- 9 Leroueil, P. R. et al. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Letters **8**, 420-424 (2008).
- 10 Yingyuad, P. et al. Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA. Journal of RNAi and Gene Silencing **28**, 490-499 (2014).
- 11 Cui, X. et al. Cationic Poly-L-Lysine-Fe2O3/SiO2 nanoparticles loaded with small interference RNA: Application to silencing gene expression in primary rat neurons. J Nanosci Nanotechnol 14, 2810-2815 (2014).
- 12 Wang, B., Siahaan, T. & Soltero, R. A. Drug delivery Principles and applications. 1st edition edn, (John Wiley&Sons, 2005).
- 13 Lin, K. Y., Kwong, G. A., Warren, A. D., Wood, D. K. & Bhatia, S. N. Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. ACS Nano 7, 9001-9009, doi:10.1021/nn403550c (2013).
- 14 Lu, W. et al. Facile synthesis and characterization of polyethylenimine-coated Fe(3)O(4) superparamagnetic nanoparticles for cancer cell separation. Molecular Medicine Reports **9**, 1080-1084 (2014).
- 15 Song, Y. et al. Point-of-care technologies for molecular diagnostics using a drop of blood. Trends in Biotechnology **32**, 132-139 (2014).
- 16 Xing, H., Hwang, K., Li, J., Torabi, S.-F. & Lu, Y. DNA aptamer technology for personalized medicine. Current Opinion in Chemical Engineering **4**, 79-87 (2014).
- 17 Zhou, Z., Li, L., Yang, Y., Xu, X. & Huang, Y. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles. Biomaterials 35, 6622-6635 (2014).
- 18 MacEwan, S. R. & Chilkoti, A. Applications of elastin-like polypeptides in drug delivery. Journal of Controlled Release 190, 314-330 (2014).
- 19 Potta, T. et al. Discovery of antibiotics-derived polymers for gene delivery using combinatorial synthesis and cheminformatics modeling. Biomaterials **35**, 1977-1988 (2014).
- 20 Qiu, L. Y. & Bae, Y. H. Polymer architecture and drug delivery. Pharmaceutical Research 23, 1-30 (2006).
- van Nostrum, C. F. Covalently cross-linked amphiphilic block copolymer micelles. Soft Matter 7, 3246-3259 (2011).

- 22 Kanayama, N. et al. A PEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells. ChemMedChem **1**, 439-444 (2006).
- 23 Le Meins, J. F., Sandre, O. & Lecommandoux, S. Recent trends in the tuning of polymersomes' membrane properties. European Physical Journal E 34 (2011).
- 24 LoPresti, C., Lomas, H., Massignani, M., Smart, T. & Battaglia, G. Polymersomes: nature inspired nanometer sized compartments. Journal of Materials Chemistry **19**, 3576-3590 (2009).
- 25 Magnusson, J. P. et al. Ion-sensitive "isothermal" responsive polymers prepared in water. Journal of the American Chemical Society **130**, 10852-10853 (2008).
- 26 Howard, K. A. et al. Nanocarrier stimuli-activated gene delivery. Small **3**, 54-57 (2007).
- 27 Thevenot, J., Oliveira, H., Sandre, O. & Lecommandoux, S. Magnetic responsive polymer composite materials. Chemical Society Reviews **42**, 7099-7116 (2013).
- 28 Huo, M., Yuan, J., Tao, L. & Wei, Y. Redox-responsive polymers for drug delivery: from molecular design to applications. Polymer Chemistry 5, 1519-1528, doi:10.1039/c3py01192e (2014).
- 29 Ward, M. A. & Georgiou, T. K. Thermoresponsive Polymers for Biomedical Applications. Polymers 3, 1215-1242 (2011).
- 30 Dai, S., Ravi, P. & Tam, K. C. Ph responsive polymers: synthesis, properties and applications. Soft Matter 4, 435-449 (2008).
- 31 Gao, W. W., Chan, J. M. & Farokhzad, O. C. pH-responsive nanoparticles for drug delivery. Molecular Pharmaceutics 7, 1913-1920 (2010).
- 32 Luo, Z. et al. Mesoporous Silica Nanoparticles End-Capped with Collagen: Redox-Responsive Nanoreservoirs for Targeted Drug Delivery. Angewandte Chemie **50**, 640-643 (2011).
- 33 Tamber H, Johansen P, Merkle H.P & B, G. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Advanced Drug Delivery Reviews **57**, 357-376 (2005).
- 34 Harada, A. & Kataoka, K. Formation of stable and monodispersive polyion complex micelles in aqueous medium from poly(L-lysine) and poly(ethylene glycol)-poly(aspartic acid) block copolymer. Journal of Macromolecular Science **34**, 21119-21133 (1997).
- 35 Branco, M. C. & Schneider, J. P. Self-assembling materials for therapeutic delivery. Acta Biomaterialia 5, 817-831 (2009).
- 36 Holmberg, K., Jonsson, B., Kronberg, B. & Lindman, B. (John Wiley & Sons, Chirchester ,UK, 2002).
- 37 Warren, N. J. & Armes, S. P. Polymerization-Induced Self-Assembly of Block Copolymer Nano-objects via RAFT Aqueous Dispersion Polymerization. Journal of the American Chemical Society 136, 10174-10185, doi:1 (2014).
- 38 Kabanov, A. V., Batrakova, E. V. & Alakhov, V. Y. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. Journal of Controlled Release 82, 189-212 (2002).
- 39 Tyrrell, Z. L., Shen, Y. & Radosz, M. Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Progress in Polymer Science **35**, 1128-1143 (2010).
- 40 Letchford, K. & Burt, H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. European Journal of Pharmaceutics and Biopharmaceutics **65**, 259-269 (2007).
- 41 Antonietti, M. & Forster, S. Vesicles and liposomes: A self-assembly principle beyond lipids. Advanced Materials **15**, 1323-1333 (2003).
- 42 Discher, D. E. & Eisenberg, A. Polymer vesicles. Science 297, 967-973 (2002).

- 43 Sahay, G., Alakhova, D. Y. & Kabanov, A. V. Endocytosis of nanomedicines. Journal of Controlled Release 145, 182-195 (2010).
- 44 Zerial, M. & McBride, H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2, 107-117 (2001).
- 45 Seachrist, J. L. & Ferguson, S. S. G. Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sciences **74**, 225-235 (2003).
- 46 Rab GTPases and Membrane Trafficking. (Bentham Science Publishers, 2012).
- 47 Maxfield, F. R. & McGraw, T. E. Endocytic recycling. Nat Rev Mol Cell Biol 5, 121 132 (2004).
- 48 Ungar, D. & Hughson, F. M. SNARE protein structure and function. Annu Rev Cell Dev Biol **19**, 493-517 (2003).
- 49 Piper, R. C. & Luzio, J. P. Late Endosomes: Sorting and Partitioning in Multivesicular Bodies. Traffic **2**, 612-621, doi:10.1034/j.1600-0854.2001.20904.x (2001).
- 50 Jovic, M., Sharma, M., Rahajeng, J. & Caplan, S. The early endosome: a busy sorting station for proteins at the crossroads. Histol Histopathol **25**, 99-112 (2010).
- 51 Bonifacino, J. S. Vesicular transport earns a Nobel. Trends in Cell Biology 24, 3-5 (2014).
- 52 Recchi, C. & Chavrier, P. V-ATPase: a potential pH sensor. Nat Cell Biol 8, 107-109 (2006).
- 53 Henne, W. M., Buchkovich, N. J. & Emr, S. D. The ESCRT pathway. Dev Cell **21**, 77-91, doi:10.1016/j.devcel.2011.05.015 (2011).
- 54 Killisch, I. et al. Characterization of early and late endocytic compartments of the transferrin cycle. Transferrin receptor antibody blocks erythroid differentiation by trapping the receptor in the early endosome. J Cell Sci **103** (**Pt 1**), 211-232 (1992).
- 55 Hanson, P. I. & Cashikar, A. Multivesicular body morphogenesis. Annu Rev Cell Dev Biol **28**, 337-362, doi:10.1146/annurev-cellbio-092910-154152 (2012).
- 56 Saftig, P. (ed Springer Science) (Landes Bioscience, New York, 2005).
- 57 Samie, M. A. & Xu, H. Lysosomal exocytosis and lipid storage disorders. J Lipid Res 55, 995-1009 (2014).
- 58 Lamb, C. A., Dooley, H. C. & Tooze, S. A. Endocytosis and autophagy: Shared machinery for degradation. Bioessays 35, 34-45 (2013).
- 59 Kunz, J. B., Schwarz, H. & Mayer, A. Determination of four sequential stages during microautophagy in vitro. J Biol Chem **279**, 9987-9996, doi:10.1074/jbc.M307905200 (2004).
- 60 Hamasaki, M. et al. Autophagosomes form at ER-mitochondria contact sites. Nature **495**, 389-393 (2013).
- 61 Xie, Z. & Klionsky, D. J. Autophagosome formation: core machinery and adaptations. Nat Cell Biol **9**, 1102-1109, doi:10.1038/ncb1007-1102 (2007).
- 62 Tooze, S. A. & Razi, M. The essential role of early endosomes in autophagy is revealed by loss of COPI function. Autophagy **5**, 874-875 (2009).
- 63 Edidin, M. Lipid microdomains in cell surface membranes. Current Opinion in Structural Biology **7**, 528-532 (1997).
- 64 Nichols, B. Caveosomes and endocytosis of lipid rafts. Journal of Cell Science **116**, 4707-4714 (2003).
- 65 Jacobson, K., Mouritsen, O. G. & Anderson, R. G. W. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 9, 7-14 (2007).
- 66 Simons, K. & Sampaio, J. L. Membrane Organization and Lipid Rafts. Cold Spring Harbor Perspectives in Biology **3** (2011).

- 67 Bellve, K. D. et al. Plasma Membrane Domains Specialized for Clathrin-mediated Endocytosis in Primary Cells. Journal of Biological Chemistry **281**, 16139-16146, doi:10.1074/jbc.M511370200 (2006).
- 68 Huang, S. et al. Phosphatidylinositol-4,5-bisphosphate-rich plasma membrane patches organize active zones of endocytosis and ruffling in cultured adipocytes. Mol Cell Biol **24**, 9102-9123 (2004).
- 69 Zhao, H. & Vaananen, H. K. Pharmacological sequestration of intracellular cholesterol in late endosomes disrupts ruffled border formation in osteoclasts. J Bone Miner Res **21**, 456-465 (2006).
- 70 Bose, A. et al. Unconventional myosin Myo1c promotes membrane fusion in a regulated exocytic pathway. Mol Cell Biol **24**, 5447-5458 (2004).
- 71 Bretscher, M. S. & Aguado-Velasco, C. EGF induces recycling membrane to form ruffles. Current Biology **8**, 721-S724 (1998).
- 72 Komaba, S. & Coluccio, L. M. Localization of myosin 1b to actin protrusions requires phosphoinositide binding. J Biol Chem **285**, 27686-27693 (2010).
- 73 Bose, A. et al. Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Nature **420**, 821-824 (2002).
- 74 Tokuo, H. & Coluccio, L. M. Myosin-1c regulates the dynamic stability of E-cadherin-based cell-cell contacts in polarized Madin-Darby canine kidney cells. Mol Biol Cell **24**, 2820-2833 (2013).
- 75 Cocucci, E. & Meldolesi, J. (ed Landes Bioscience) (Madame Curie Bioscience Database Austin (TX), 2000).
- 76 Aderem, A. & Underhill, D. M. Mechanisms of phagocytosis in macrophages. Annual Review of Immunology 17, 593-623 (1999).
- 77 Owens, D. E. & Peppas, N. A. Opsonisation, biodistribution and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics **307**, 93-102 (2006).
- 78 Hillaireau, H. & Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cellular and Molecular Life Sciences **66**, 2873-2896 (2009).
- 79 Garnett, M. C. & Kallinteri, P. Nanomedicines and nanotoxicology: some physiological principles. Occupational Medicine-Oxford 56, 307-311 (2006).
- 80 Underhill, D. M. & Goodridge, H. S. Information processing during phagocytosis. Nat Rev Immunol **12**, 492-502 (2012).
- 81 Kibbey, R. G., Rizo, J., Gierasch, L. M. & Anderson, R. G. The LDL receptor clustering motif interacts with the clathrin terminal domain in a reverse turn conformation. J Cell Biol **142**, 59-67 (1998).
- 82 Traub, L. M. Sorting it out: AP-2 and alternate clathrin adaptors in endocytic cargo selection. J Cell Biol 163, 203-208, doi:10.1083/jcb.200309175 (2003).
- 83 Traub, L. M. & Bonifacino, J. S. Cargo Recognition in Clathrin-Mediated Endocytosis. Cold Spring Harbor Perspectives in Biology 5 (2013).
- Le Roy, C. & Wrana, J. L. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol **6**, 112-126 (2005).
- 85 Zhang, Y. & Whittaker, G. R. Influenza entry pathways in polarized MDCK cells. Biochem Biophys Res Commun (2014).
- 86 Cossec, J. C. et al. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochimica and Biophysica Acta **1801**, 846-852 (2010).

- 87 Bhattacharyya, S., Ruthel, G., Bavari, S., Aman, M. J. & Hope, T. J. Ebola virus uses clathrinmediated endocytosis as an entry pathway. Virology **401**, 18-28 (2010).
- 88 Humphries, A. C. & Way, M. The non-canonical roles of clathrin and actin in pathogen internalization, egress and spread. Nat Rev Micro **11**, 551-560 (2013).
- 89 Royle, S. J. et al. Non-canonical YXXGPhi endocytic motifs: recognition by AP2 and preferential utilization in P2X4 receptors. J Cell Sci **118**, 3073-3080 (2005).
- 90 Flores-Otero, J. et al. Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. Nat Commun **5** (2014).
- 91 Xu, C. & Min, J. Structure and function of WD40 domain proteins.
- 92 Schmid, S. L. Clathrin-coated vesicle formation and protein sorting: An integrated process. Annual Review of Biochemistry **66**, 511-548 (1997).
- 93 Kirchhausen, T., Owen, D. & Harrison, S. C. Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. Cold Spring Harb Perspect Biol **6**, a016725 (2014).
- ⁹⁴ Jackson, L. P. et al. A Large-Scale Conformational Change Couples Membrane Recruitment to Cargo Binding in the AP2 Clathrin Adaptor Complex. Cell **141**, 1220-1229 (2010).
- 95 Ohno, H. Clathrin-associated adaptor protein complexes. J Cell Sci **119**, 3719-3721 (2006).
- 96 Owen, D. J., Collins, B. M. & Evans, P. R. Adaptors for clathrin coats: structure and function. Annu Rev Cell Dev Biol **20**, 153-191 (2004).
- 97 Park, S. Y. & Guo, X. Adaptor Protein Complexes and Intracellular Transport. Biosci Rep (2014).
- 98 Owen, D. J. & Evans, P. R. A structural explanation for the recognition of tyrosine-based endocytotic signals. Science **282**, 1327-1332 (1998).
- 99 Cocucci, E., Aguet, F., Boulant, S. & Kirchhausen, T. The First Five Seconds in the Life of a Clathrin-Coated Pit. Cell **150**, 495-507 (2012).
- 100 Kelly, B. T. et al. AP2 controls clathrin polymerization with a membrane-activated switch. Science **345**, 459-463 (2014).
- 101 Lakadamyali, M., Rust, M. J. & Zhuang, X. Ligands for Clathrin-Mediated Endocytosis Are Differentially Sorted into Distinct Populations of Early Endosomes. Cell **124**, 997-1009 (2006).
- 102 Vanlandingham, P. A. & Ceresa, B. P. Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J Biol Chem **284**, 12110-12124 (2009).
- 103 Engedal, N. & Mills, I. G. in Methods in Enzymology Vol. 535 179-200 (2014).
- 104 Larson, B. T., Sochacki, K. A., Kindem, J. M. & Taraska, J. W. Systematic spatial mapping of proteins at exocytic and endocytic structures. Mol Biol Cell **25**, 2084-2093 (2014).
- 105 McMahon, H. T. & Boucrot, E. Molecular mechanism and physiological functions of clathrinmediated endocytosis. Nat Rev Mol Cell Biol 12, 517-533 (2011).
- 106 Henne, W. M. et al. FCHo Proteins Are Nucleators of Clathrin-Mediated Endocytosis. Science 328, 1281-1284 (2010).
- 107 Kirchhausen, T., Owen, D. & Harrison, S. C. Molecular Structure, Function, and Dynamics of Clathrin-Mediated Membrane Traffic. Cold Spring Harbor Perspectives in Biology **6** (2014).
- Bocking, T. et al. Key interactions for clathrin coat stability. Structure 22, 819-829 (2014).
- 109 Taylor, M. J., Perrais, D. & Merrifield, C. J. A high precision survey of the molecular dynamics of mammalian clathrin-mediated endocytosis. PLoS Biol **9**, e1000604 (2011).
- 110 Collins, A., Warrington, A., Taylor, K. A. & Svitkina, T. Structural organization of the actin cytoskeleton at sites of clathrin-mediated endocytosis. Curr Biol **21**, 1167-1175 (2011).

- 111 Boucrot, E., Saffarian, S., Massol, R., Kirchhausen, T. & Ehrlich, M. Role of lipids and actin in the formation of clathrin-coated pits. Experimental Cell Research **312**, 4036-4048 (2006).
- 112 Hinshaw, J. in Annual Reviews Collection (Bethesda (MD), 2002).
- 113 Böcking, T., Aguet, F., Harrison, S. C. & Kirchhausen, T. Single-molecule analysis of a molecular disassemblase reveals the mechanism of Hsc70-driven clathrin uncoating. Nat Struct Mol Biol **18**, 295-301 (2011).
- 114 Maurer, M. E. & Cooper, J. A. The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH. Journal of Cell Science **119**, 4235-4246 (2006).
- 115 Klauser, R. D., Ashwell, G., Van Renswoude, J., Harford, J. B. & Bridges, K. R. Binding of apotransferrin to K562 cells: Explanation of the transferrin cycle. Proc Natl Acad Sci USA **80**, 2263-2266 (1983).
- 116 Tortorella, S. & Karagiannis, T. C. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. The Journal of Membrane Biology **247**, 291-307 (2014).
- 117 van Dam, E. M., ten Broeke, T., Jansen, K., Spijkers, P. & Stoorvogel, W. Endocytosed Transferrin Receptors Recycle via Distinct Dynamin and Phosphatidylinositol 3-Kinasedependent Pathways. Journal of Biological Chemistry 277, 48876-48883 (2002).
- 118 Navaroli, D. M. et al. Rabenosyn-5 defines the fate of the transferrin receptor following clathrinmediated endocytosis. Proc Natl Acad Sci U S A **109**, E471-480 (2012).
- 119 Magadan, J. G., Barbieri, M. A., Mesa, R., Stahl, P. D. & Mayorga, L. S. Rab22a regulates the sorting of transferrin to recycling endosomes. Mol Cell Biol **26**, 2595-2614 (2006).
- 120 Liu, C., Wang, J. & Zhang, X. The Involvement of MiR-1-Clathrin Pathway in the Regulation of Phagocytosis. Plos One **9**, e98747 (2014).
- 121 Sullivan, C. S. et al. The adaptor protein GULP promotes Jedi-1-mediated phagocytosis through a clathrin-dependent mechanism. Molecular Biology of the Cell (2014).
- 122 Pelkmans, L. & Helenius, A. Endocytosis via caveolae. Traffic **3**, 311-320 (2002).
- 123 Doherty, G. J. & McMahon, H. T. Mechanisms of endocytosis. Annual Review of Biochemistry 78, 857-902 (2009).
- 124 Nichols, B. J. & Lippincott-Schwartz, J. Endocytosis without clathrin coats. Trends in Cell Biology **11**, 406-412 (2001).
- 125 Fra, A. M., Williamson, E., Simons, K. & Parton, R. G. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci U S A **92**, 8655-8659 (1995).
- 126 Shvets, E., Ludwig, A. & Nichols, B. J. News from the caves: update on the structure and function of caveolae. Current Opinion in Cell Biology **29**, 99-106 (2014).
- 127 Hansen, C. G., Howard, G. & Nichols, B. J. Pacsin 2 is recruited to caveolae and functions in caveolar biogenesis. Journal of Cell Science **124**, 2777-2785 (2011).
- 128 Senju, Y., Itoh, Y., Takano, K., Hamada, S. & Suetsugu, S. Essential role of PACSIN2/syndapin-II in caveolae membrane sculpting. Journal of Cell Science **124**, 2032-2040 (2011).
- 129 Koch, D., Westermann, M., Kessels, M. M. & Qualmann, B. Ultrastructural freeze-fracture immunolabeling identifies plasma membrane-localized syndapin II as a crucial factor in shaping caveolae. Histochemistry and Cell Biology **138**, 215-230 (2012).
- 130 Moren, B. et al. EHD2 regulates caveolar dynamics via ATP-driven targeting and oligomerization. Mol Biol Cell **23**, 1316-1329, doi:10.1091/mbc.E11-09-0787 (2012).
- 131 Stoeber, M. et al. Oligomers of the ATPase EHD2 confine caveolae to the plasma membrane through association with actin. EMBO Journal **31**, 2350-2364 (2012).

- 132 Howes, M. T., Mayor, S. & Parton, R. G. Molecules, mechanisms, and cellular roles of clathrinindependent endocytosis. Current Opinion in Cell Biology 22, 519-527, doi:10.1016/j.ceb.2010.04.001 (2010).
- 133 Hayer, A. et al. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol **191**, 615-629 (2010).
- 134 Nevins, A. K. & Thurmond, D. C. Caveolin-1 functions as a novel Cdc42 guanine nucleotide dissociation inhibitor (GDI) in pancreatic beta cells. Journal of Biological Chemistry **281**, 18961-18972 (2006).
- 135 Xie, Z. J. & Askari, A. Na+/K+-ATPase as a signal transducer. European Journal of Biochemistry **269**, 2434-2439 (2002).
- 136 Belting, M., Sandgren, S. & Wittrup, A. Nuclear delivery of macromolecules: barriers and carriers. Adv Drug Deliv Rev **57**, 505-527 (2005).
- 137 Chaudhary, N. et al. Endocytic crosstalk: cavins, caveolins, and caveolae regulate clathrinindependent endocytosis. PLoS Biol **12**, e1001832 (2014).
- 138 Basquin, C. et al. The signalling factor PI3K is a specific regulator of the clathrin-independent dynamin-dependent endocytosis of IL-2 receptors. J Cell Sci **126**, 1099-1108 (2013).
- 139 Huang, T., Lehmann, M. J., Said, A., Ma, G. & Osterrieder, N. MHC class I downregulation induced by equine herpesvirus type 1 (EHV-1) pUL56 is through dynamin-dependent endocytosis. J Virol (2014).
- 140 Grassart, A., Dujeancourt, A., Lazarow, P. B., Dautry-Varsat, A. & Sauvonnet, N. Clathrinindependent endocytosis used by the IL-2 receptor is regulated by Rac1, Pak1 and Pak2. EMBO Rep 9, 356-362 (2008).
- 141 Howes, M. T. et al. Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells. J Cell Biol **190**, 675-691, doi:10.1083/jcb.201002119 (2010).
- 142 Donatello, S. et al. Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. Am J Pathol **181**, 2172-2187 (2012).
- 143 Lundmark, R. et al. The GTPase-activating protein GRAF1 regulates the CLIC/GEEC endocytic pathway. Curr Biol **18**, 1802-1808 (2008).
- 144 Shibata, H. et al. PKNbeta interacts with the SH3 domains of Graf and a novel Graf related protein, Graf2, which are GTPase activating proteins for Rho family. J Biochem **130**, 23-31 (2001).
- 145 Taylor, J. M., Macklem, M. M. & Parsons, J. T. Cytoskeletal changes induced by GRAF, the GTPase regulator associated with focal adhesion kinase, are mediated by Rho. J Cell Sci **112** (**Pt 2**), 231-242 (1999).
- 146 Alexandropoulos, K., Cheng, G. & Baltimore, D. Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc Natl Acad Sci U S A **92**, 3110-3114 (1995).
- 147 Amyere, M. et al. Origin, originality, functions, subversions and molecular signalling of macropinocytosis. International Journal of Medical Microbiology **291**, 487-494 (2001).
- 148 BoseDasgupta, S. & Pieters, J. How to clear a pathogen during inflammation: Switching from phagocytosis to macropinocytosis through coronin 1 phosphorylation. Inflammation & Cell Signaling 1, 177-181 (2014).
- 149 Kolpak, A. L. et al. Negative guidance factor-induced macropinocytosis in the growth cone plays a critical role in repulsive axon turning. J Neurosci **29**, 10488-10498 (2009).
- 150 Kerr, M. C. & Teasdale, R. D. Defining macropinocytosis. Traffic **10**, 364-371 (2009).

- 151 Cao, H., Chen, J., Awoniyi, M., Henley, J. R. & McNiven, M. A. Dynamin 2 mediates fluidphase micropinocytosis in epithelial cells. J Cell Sci 120, 4167-4177 (2007).
- 152 Mercer, J. & Helenius, A. Virus entry by macropinocytosis. Nat Cell Biol 11, 510-520 (2009).
- 153 Mulherkar, N., Raaben, M., de la Torre, J. C., Whelan, S. P. & Chandran, K. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology **419**, 72-83 (2011).
- 154 Tekle, C., Deurs, B. v., Sandvig, K. & Iversen, T.-G. Cellular Trafficking of Quantum Dot-Ligand Bioconjugates and Their Induction of Changes in Normal Routing of Unconjugated Ligands. Nano Letters **8**, 1858-1865, doi:10.1021/nl0803848 (2008).
- 155 Iversen, T. G., Frerker, N. & Sandvig, K. Uptake of ricinB-quantum dot nanoparticles by a macropinocytosis-like mechanism. J Nanobiotechnology **10**, 33 (2012).
- 156 Howes, P. & Green, M. Colloidal and optical stability of PEG-capped and phospholipidencapsulated semiconducting polymer nanospheres in different aqueous media. Photochemical & Photobiological Sciences **9**, 1159-1166 (2010).
- 157 Otto, G. P. & Nichols, B. J. The roles of flotillin microdomains--endocytosis and beyond. J Cell Sci **124**, 3933-3940 (2011).
- 158 Rausch, K., Reuter, A., Fisher, K. & Schmidt, M. Evaluation of nanoparticles aggregation in human blood serum Biomacromolecules **11**, 2836-2839 (2010).
- 159 Chen, L. et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension (Baltimore) **57**, 343 (2011).
- 160 Xu, J. H. et al. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A protects mice against nasopharyngeal colonization by streptococcus pneumoniae. Clinical and Vaccine Immunology **18**, 75-81 (2011).
- 161 Lundqvist, M. Nanoparticles: Tracking protein corona over time. Nat Nano 8, 701-702 (2013).
- 162 Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proceedings of the National Academy of Sciences 105, 14265-14270 (2008).
- 163 Milani, S., Baldelli Bombelli, F., Pitek, A. S., Dawson, K. A. & R\u00e4dler, J. Reversible versus Irreversible Binding of Transferrin to Polystyrene Nanoparticles: Soft and Hard Corona. ACS Nano 6, 2532-2541 (2012).
- 164 Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nano **8**, 772-781 (2013).
- 165 McGuinnes, C. et al. Surface derivatization state of polystyrene latex nanoparticles determines both their potency and their mechanism of causing human platelet aggregation in vitro. Toxicological Sciences **119**, 359-368 (2011).
- 166 Cabral, H. & Kataoka, K. Multifunctional nanoassemblies of block copolymers for future cancer therapy. Science and Technology of Advanced Materials **11** (2010).
- 167 Monopoli, M. P., Bombelli, F. B. & Dawson, K. A. Nanobiotechnology: Nanoparticle coronas take shape. Nature Nanotechnology **6**, 11-12 (2011).
- 168 Deng, Z. J., Liang, M. T., Monteiro, M., Toth, I. & Minchin, R. F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nature Nanotechnology **6**, 39-44 (2011).
- 169 Li, J. Self assembled supramolecular hydrogels based on polymer-cyclodextrin inclusion complexes for drug delivery. Nature Asia-Pacific –Asia Materials **2**, 112-118 (2010).
- 170 Dubruel, P. & Schacht, E. Vinyl polymers as non-viral gene delivery carriers: current status and prospects. Macromolecular Bioscience **6**, 789-810 (2006).

- 171 Wong, S. Y., Pelet, J. M. & Putnam, D. Polymer systems for gene delivery-past, present, and future. Progress in Polymer Science **32**, 799-837 (2007).
- 172 Harper, G. R. et al. Steric stabilization of microspheres with grafted polyethylene oxide reduces phagocytosis by rat Kupffer cell-in vitro. Biomaterials **12**, 695-700 (1991).
- 173 Bazile, D. et al. PEG-PLA nanoaprticles avoid uptake by the mononuclear phagocytes system. Journal of Pharmaceutical Science **84**, 493-498 (1995).
- 174 Gref, R. et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces **18**, 301 313 (2000).
- 175 Peracchia, M. T. et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release **60**, 121-128 (1999).
- 176 Pozzi, D. et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale **6**, 2782-2792 (2014).
- 177 Wu, J. et al. Binding characteristics between polyethylene glycol (PEG) and proteins in aqueous solution. Journal of Materials Chemistry B **2**, 2983-2992 (2014).
- 178 Lai, T. C., Bae, Y., Yoshida, T., Kataoka, K. & Kwon, G. S. pH-sensitive multi-PEGylated block copolymer as a bioresponsive pDNA delivery vector. Pharmaceutical Research **27**, 2260-2273 (2010).
- 179 Moghimi, S. M., Hedeman, H., Muir, I. S., Illum, L. & Davis, S. S. An Investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochimica Et Biophysica Acta **1157**, 233-240 (1993).
- 180 Kobayashi, H., Watanabe, R. & Choyke, P. L. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics **4**, 81-89, doi:10.7150/thno.7193 (2013).
- 181 Pegoraro, C. et al. Translocation of flexible polymersomes across pores at the nanoscale. Biomaterials Science **2**, 680-692 (2014).
- 182 dos Santos, T., Varela, J., Lynch, I., Salvati, A. & Dawson, K. A. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. Plos One 6, e24438 (2011).
- 183 Oh, N. & Park, J. H. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine 9 Suppl 1, 51-63 (2014).
- 184 Minchin, R. Sizing up targets with nanoparticles. Nature Nanotechnology **3**, 12-13 (2008).
- 185 Hong, S. P. et al. Interaction of polycationic polymers with supported lipid bilayers and cells: Nanoscale hole formation and enhanced membrane permeability. Bioconjugate Chemistry 17, 728-734 (2006).
- 186 Mercke, A. et al. Lipid bilayer disruption by polycation polymers: the roles of size and chemical functional groups. Langmuir **21**, 10348-10354 (2005).
- 187 Zorko, M. & Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Advanced Drug Delivery Reviews **57**, 529-545, doi:10.1016/j.addr.2004.10.010 (2005).
- 188 Geng, Y. & Discher, E. D. Hydrolytic degradation of poly(ethylene oxide)blockpolycaprolactone worm micelles. Journal of American Chemical Society **127**, 12780-12781 (2005).
- 189 Foldbjerg, R. et al. The toxic effects of single-walled carbon nanotubes are linked to the phagocytic ability of cells. Toxicology Research **3**, 228-241 (2014).

- Johnston, H. J. et al. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol **242**, 66-78 (2010).
- 191 Pellach, M., Grinberg, I. & Margel, S. Near IR fluorescent polystyrene/albumin core/shell nanoparticles for specific targeting of colonic neoplasms. Macromol Biosci **12**, 1472-1479 (2012).
- 192 Gupta, A. K. & Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials **26**, 3995-4021 (2005).
- 193 Iversen, T.-G., Frerker, N. & Sandvig, K. Quantum dot bioconjugates: uptake into cells and induction of changes in normal cellular transport. Proc. SPIE **7189** (2009).
- 194 Daniel, M. C. & Astruc, D. Gold nanoparticles: assembly, supramolecular chemistry, quantumsize-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev **104**, 293-346 (2004).
- 195 Alkilany, A. M. & Murphy, C. J. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res **12**, 2313-2333 (2010).
- 196 Aubin-Tam, M. E. Conjugation of nanoparticles to proteins. Methods Mol Biol **1025**, 19-27 (2013).
- 197 Ghosh, P., Han, G., De, M., Kim, C. K. & Rotello, V. M. Gold nanoparticles in delivery applications. Advanced Drug Delivery Reviews **60**, 1307-1315 (2008).
- 198 Chithrani, D. B. et al. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res **173**, 719-728 (2010).
- 199 Zhang, L. W. & Monteiro-Riviere, N. A. Mechanisms of Quantum Dot Nanoparticle Cellular Uptake. Toxicological Sciences 110, 138-155 (2009).
- 200 Kelf, T. A. et al. Non-specific cellular uptake of surface-functionalized quantum dots. Nanotechnology **21**, 285105 (2010).
- 201 Khandhar, A. P., Ferguson, R. M. & Krishnan, K. M. Monodispersed magnetite nanoparticles optimized for magnetic fluid hyperthermia: Implications in biological systems. J Appl Phys 109, 7B310-317B3103 (2011).
- 202 Singh, N., Jenkins, G. J., Asadi, R. & Doak, S. H. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev 1 (2010).
- 203 Shevtsov, M. A. et al. Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int J Nanomedicine **9**, 273-287 (2014).
- 204 Yeole, N., Hundiwale, D. & Jana, T. Synthesis of core-shell polystyrene nanoparticles by surfactant free emulsion polymerization using macro-RAFT agent. J Colloid Interface Sci **354**, 506-510 (2011).
- 205 Milošević, I. et al. Synthesis and size control of polystyrene nanoparticles via "liquid crystalline" nanoemulsion. Microporous and Mesoporous Materials **120**, 7-11 (2009).
- 206 Jinhua, L. & Guangyuan, Z. Polystyrene Microbeads by Dispersion Polymerization: Effect of Solvent on Particle Morphology. Vol. 2014 (2014).
- 207 Im, S. H. et al. Synthesis of polystyrene beads loaded with dual luminophors for self-referenced oxygen sensing. Talanta 67, 492-497 (2005).
- 208 Fowler, R. et al. Nanoparticle Transport in Epithelial Cells: Pathway Switching Through Bioconjugation. Small, n/a-n/a (2013).
- 209 Zauner, W., Farrow, N. A. & Haines, A. M. R. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. Journal of Controlled Release **71**, 39-51 (2001).
- 210 Yeo, Y. Nanoparticulate Drug Delivery : Systems Strategies, Technologies, and Applications. (John Wiley & Sons, 2013).

- 211 Leśniewska, K., Warbrick, E. & Ohkura, H. Peptide aptamers define distinct EB1- and EB3binding motifs and interfere with microtubule dynamics. Molecular Biology of the Cell **25**, 1025-1036 (2014).
- 212 Pei, X., Zhang, J. & Liu, J. Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol **2**, 341-348 (2014).
- 213 Hrkach, J. et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. Science Translational Medicine **4**, 128ra139 (2012).
- 214 Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41, 2971-3010 (2012).
- 215 Johnson, R., Harrison, S. & Maclean, D. in Cell-Penetrating Peptides Vol. 683 Methods in Molecular Biology (ed Ülo Langel) Ch. 38, 535-551 (Humana Press, 2011).
- 216 Jiang, W., KimBetty, Y. S., Rutka, J. T. & ChanWarren, C. W. Nanoparticle-mediated cellular response is size-dependent. Nat Nano **3**, 145-150 (2008).
- 217 Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol **8**, 137-143 (2013).
- 218 Walkey, C. D. et al. Protein Corona Fingerprinting Predicts the Cellular Interaction of Gold and Silver Nanoparticles. ACS Nano **8**, 2439-2455 (2014).
- 219 Yu, M. K., Park, J. & Jon, S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics **2**, 3-44 (2012).

2-Chapter 2

General Materials and Methods

2.1 General Materials

2.1.1 Cell lines

HCT116 human colon cancer cells¹, MGLVA-1 *ascites* gastric cancer cells² - *ascites* of a variant of MKN45 human gastric adenocarcinoma cells³, gastrin producing (MKN45G) generated in our laboratories -, 3T3-Swiss albino mouse embryo fibroblasts⁴ and MRC-5 human foetal lung fibroblasts⁵ were purchased from the American Type Culture Collection (ATCC) and LGC Standards, Teddington, UK and from the Health Science Research Resource Bank, (Osaka, Japan). Cells were harvested in Roswell Park Memorial Institute (RPMI) medium or Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% v/v heath inactivated Foetal Bovine Serum (FBS), 2 mM L-glutamine (Sigma-Aldrich, Dorset, UK) and in minimum essential medium Eagle (MEM) 10% v/v FBS, 2 mM L-glutamine, 1% v/v non essential amino acids (NEAA) according to ATCC and Cell Bank specifications. HCT116 cells were grown from passage 4 to 50, MGLVA-1 for passage 5 to 50, 3T3 from passage 21 to 60, MRC-5 from passage 34 to passage 50. All the cell lines used were adherent. A summary of the characteristics of the cells can be viewed in Table 2-1.

2.1.2 Cell culture materials

Trypan blue (0.4% w/v), porcine trypsin (0.5 g/l)/Ethylenediaminetetracetic acid (EDTA, 0.2 g/l) and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich, Dorset, UK. Phosphate buffered saline (PBS) was purchased from Oxoid (Thermo Scientific, Basingstoke, UK), 96 wells clear bottom and clear or black wall plates, clear 24 and 6 well plates, 75 and 25cm² tissue culture vented flasks, 2 ml cryovials, 0.6-1.7 ml Eppendorf tubes were obtained from Corning Life Sciences (Amsterdam, The Netherlands; Tultidan, Mexico). 10 and 1000 μl pipettes tips from Starlab, Milton

Keynes, UK; 200 µl tips from Sarstedt, Leicester, UK; Minisart filters for tissue culture 0.1 and 0.2 µm pore size were purchased from Sartorius, Stonehouse, UK. Needles 0.8x40 mm were purchased from BD Microlance, siringes from BD Plastipactm, Oxford, UK.

Cell lines	3T3	HCT116	MGLVA-1	MRC-5
Description	3T3-Swiss albino mouse	HCT116 human colon cancer	MGLVA-1 human gastric cancer ascites	MRC-5 human foetal lung fibroblasts
Media	DMEM 10% FBS 1% L-Glutamine	RPMI 10% FBS 1% L-Glutamine	RPMI 10% FBS 1% L-Glutamine	MEM 10% FBS 1% L Glutamine 1% NEAA
Tissue or origin	Embryo / normal	Colonrectal carcinoma	MKN45G gastric adenocarcinoma cells ascites – gastrin producing	14 weeks foetus lungs/ normal
Species	Mus Musculus	Homo Sapiens	Homo Sapiens	Homo Sapiens
Genetic modifications	Hypertriploid, modal chromosome number = 68 (30%) Polyploids (2.4%)	mutation in codon 13 of the ras proto- oncogene – diploid, modal number = 45 (62%), polyploids (6.8%)	Diploid modal number = 40- 44(50%)	Normal diploid (monal number = 46 (70%), XY karyotype – polyploids (3.6%) normal X and Y chromosomes
Туре	Fibroblasts	Epithelial	Epithelial	Fibroblasts
Immortalization procedure	Spontaneous	Spontaneous	Already established	SV40

Table 2-1 A summary of the cells lines used in this study with their most important characteristics such as tissue of origin, species, genetic modifications and immortalization procedure as well as the growth media employed. All the cell lines employed in these studies were adherent.






Figure 2-1 Poly(lactide-*co*-glycolide)-*block*-poly(poly(ethylene glycol methyl ether methacrylate)-*co*-poly(propylene glycol methacrylate)) (PLGA-*b*-(PPGMA-*co*-PEGMA)) thermoresponsive polymers.




Figure 2-2 Polylactide- *block*- poly(poly(diethylene glycol methacrylate)-*co*-poly(oligoethylene glycol methacrylate)) (PLA-*b*-(DEGMA-*co*-OEGMA)) thermoresponsive polymers.

Thermoresponsive polymers used in these studies were based on previous work form Abulateefeh *et al* and they were synthesised by Lee Moir (School of Pharmacy, University of Nottingham, UK)⁶. Their chemical names are poly(lactide-*co*-glycolide)*block*-poly(poly(ethylene glycol methyl ether methacrylate)-*co*-poly(propylene glycol methacrylate)) and its abbreviation is PLGA-*b*-(PPGMA-*co*-PEGMA) (Figure 2-1) and polylactide- *block*- poly(poly(diethylene glycol methacrylate)-*co*-poly(oligoethylene glycol methacrylate)) and its abbreviation is PLA-*b*-(DEGMA-*co*-OEGMA). (Figure 2-2). In these polymers the PLGA/PLA region formed the hydrophobic solid core of the micelle while the PPGMA/PEGMA or DEGMA/OEGMA formed the hydrophilic region of the polymer.

2.1.3.1 Polystyrene nanoparticles

Polystyrene Fluoresbrite Yellow-Orange carboxylated polystyrene beads (C-PB) of 50 nm (catalogue number 19775) and 100 nm (catalogue number 18791), $\lambda_{max ex}$ 529nm – $\lambda_{max em}$ 546nm, were purchased from Polysciences, Heppelheim, Germany.

2.1.4 Materials for inhibition studies

LacCer complexed with Bovine Serum Albumin (BSA), transferrin from human serum, conjugated with Alexafluor 633 (Htf), and 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) buffer were purchased from Fisher Scientific, Loughborough, UK. Chlorpromazine (CPZ), methyl-β-cyclodextrin (MBCD) and any other material not specified in this list was purchased from Sigma (Sigma-Aldrich, Dorset, UK). Methanol free paraformalehyde (PFA) was purchased from Electron Microscopy Science, Sunnyvale, CA, Alexafluor 488 and 594 secondary antibodies were purchased from Molecular Probes, Paisley, UK, anti-clathrin heavy chain monoclonal antibody (mAb) (clone X22) was purchased from Merk Biosciences, Feltham, UK and anti-caveolin-1 mAb (clone 2297) from BD Transduction

Laboratories, Lexington, KY, defatted albumin (dBSA) was purchased from Sigma-Aldrich, Dorset, UK.

2.2 General methods

2.2.1 General cell maintenance procedures

2.2.1.1 Routine tissue culture procedures

Cells were routinely grown in 75cm² vented cap flasks in tissue culture incubators at controlled CO₂ atmosphere (5% v/v), 37°C and 95% v/v humidity. Routine cell maintenance was carried out 3 times per week. Cells were checked under a reverse microscope to verify health, lack of contamination and confluence. For cell splitting procedures, cells were grown to reach 80% confluence. EDTA and trypsin/EDTA were pre-warmed to 37 °C in a tissue culture water bath before use. After checking cells at the microscope they were treated as follows: MGLVA-1, and MRC-5 were washed with 5 ml EDTA before applying trypsin/EDTA 8ml (MGLVA-1) and 4ml respectively (MRC-5). HCT116 and 3T3 cells were treated with 4ml trypsin/EDTA only. Upon detachment of cells, cell suspensions were collected in a sterile vial and the culture flask rinsed with 6 or 12ml of the appropriate cell culture media. Cell suspensions were centrifuged at 200g for 5 minutes, the supernatant was removed by aspiration and cells were re-suspended in 10 ml appropriate media. Cells were seeded depending on the desired numbers for setting up purposes or 1/10 of cell suspension re-cultured in a 75cm² sterile flask for cell line routine maintenance according to ATCC and Japanese Cell Bank protocols. For MRC-5 only the splitting ratio was kept to 1/3.

2.2.1.2 General procedures for cell counting and experiments setup

Cells detached as described above and re-suspended in their own media were mixed with the aid of a vortex (3T3, MRC-5) or passed through a 0.8 mm needle to get rid of

clamps of cells and to ease the counting process (HCT116 and MGLVA-1). Subsequently, four aliquots of 50 μl of cells were added to 50 μl trypan blue and cells counted on a Neubauer haemocytometer counting chamber (Hawksley, Cambridge, UK) with a manual counter (ENM, Chicago, USA). The count averaged according to the following formula:

$$\left[\frac{(\operatorname{count} 1) + (\operatorname{count} 2) + (\operatorname{count} 3) + (\operatorname{count} 4)}{4}\right] x 2x 10^4 = numbers of cells/ml$$

The number of dead cells was also annotated on a lab-book and experiments were not set up if the number of dead/trypan blue positive cells was more than 5% for each count. MGLVA-1 and HCT116 cells prepared for experiments were passed through a needle as described above before an aliquot of the appropriate volume of cells was diluted to the appropriate number of cells/ml for experiments setup.

2.2.1.3 Preparation of frozen stocks of cells

Confluent cells were detached from cell culture flasks with trypsin/EDTA as described above and centrifuged at 200 g for 5 minutes. Supernatant was aspirated off and the pellet re-suspended with the aid of a vortex. Fresh culture media supplemented with 10% v/v dimethyl sulfoxide (DMSO, Sigma-Aldrich, Dorset, UK) suitable for cell culture was applied to re-suspended cells and the mixture quickly transferred to a sterile labelled cryovial where the cell line, passage number, date and name of the owner was annotated for future reference. The cryovial was placed in a Mr Frosty (Thermo Scientific, Loughborough, UK) at -80 °C for 24 h and to a storage box in a -80 °C freezer for up to 6 months or to a -150 °C freezer for long storage and maintenance of cells stocks.

General Materials and Methods

2.2.1.4 Cell revival from -150 °C freezer

Prior to defrosting the desired cell line, a 75 cm² flask containing 15 ml of the appropriate media was prepared and left to equilibrate in a tissue culture incubator at $37 \,^{\circ}$ C and 5% CO₂ 95% humidity for 30 minutes. Cryovials of the desired cell lines were removed from the freezer, moved quickly to $37 \,^{\circ}$ C water-bath and swirled until defrosted. Subsequently, the cryovial content was moved with the aid of sterile 5 ml pipette into the pre-warmed flask and cells left to recover for 24 h or until completely adherent to the bottom of the flask. Finally, the media was replaced with fresh warm media to remove the DMSO present in the freezing media. A buffer period of 7-10 days was applied before using the defrosted cells for experiments.

2.2.2 Dynamic Light Scattering (DLS)

DLS is a technique used to measure the hydrodynamic radius of particles in solution. During the measurement, the solution is irradiated by coherent laser light, and a detector measures the scattered light from the particles. Fluctuations in scattering intensities are fitted to a correlation function to determine the diffusion of particles in solution. From the estimated diffusion coefficient, the hydrodynamic radius of the nanoparticles is derived by the Stoke- Einstein equation:

$$R_H = \frac{kT}{6\pi\eta D}$$

where R_H is the hydrodynamic radius, k is the Boltzmann constant, T the absolute temperature and η is the viscosity of the solvent and D is the translational diffusion (also known as Brownian motion) coefficient. The particles are assumed spherical and non-interacting. A Malvern Instruments Viscotek802 DLS (Malvern, UK) was used for all the measurements. The light source for the instrument is a diode laser, 830nm wavelength, 50 mW internal laser, 90° angle of detection. All measurements were carried out at 20°C.

50 nm C-PB were diluted in PBS buffer at a concentration of 200 µg/ml and 100 nm C-PB were prepared at a concentration of 50 µg/ml according to Malvern support suggestions. The solution was diluted to the desired concentration in PBS filtered with a 0.2 µm filter and vortexed for 1 minute to remove any C-PB aggregates before each measurement. Each reading was the result of averages of 10 readings carried out for 10 s each. 3 readings for each polystyrene bead were made and the 3 readings were averaged and data plotted in GraphPad Prism.

2.2.3 Transmission Electron Microscopy (TEM) of C-PB

TEM images were obtained with a Tecnai G12 Bio Twin Digital Transmission Electron Microscope System.

Stock solutions of 50 and 100 nm C-PB were diluted to 25 and 26.5 µg/ml in filtered PBS as described above, the prepared solution was mixed with a vortex for one minute to get rid of any aggregates and applied on a Formvar/Carbon support film 300 mesh copper grids and allowed to dry overnight. A minimum of 12 images for each size of polystyrene nanoparticles were taken for a minimum count of 250 particles for each size of C-PB. Images were analysed with ImageJ software and the Feret diameter (the larger diameter of a particle not assumed to be spherical) plotted in GraphPad Prism.

2.2.4 Zeta potential of C-PB

Electrokinetic potential or zeta potential is the description of the charge of particles in suspension. Particle suspensions are loaded onto a special chamber that is provided with two electrodes. The electrophoretic mobility of the particles is measured and the measurement converted to zeta potential through the following equation:

$$\zeta = 1.328x \left[\frac{\eta \, \mu_E}{\varepsilon_r \, f(K_a)} \right]$$

where η is the viscosity of the solution, μ_E is the measured electrophoretic mobility, ϵ_r is the solution dielectric constant and $f(K_a)$ is a constant calculated on the basis of experiments conditions such as ionic strength and temperature.

Zetasizer measurements were acquired with a Malvern Zetasizer Nano, Malvern, UK. The particles suspensions were prepared in HEPES buffer 1 mM, Ph 7.4 at a concentration of 200 μ g/ml. The values obtained were the result of 12 measurement replicates. All measurements were carried out at 20 °C.

2.2.5 Toxicity Tests

2.2.5.1 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazomium bromide) assay

The MTT assay is a colorimetric assay used to determine metabolic activity of cells. Upon application of the yellow MTT solution, the MTT is converted by the functional mitochondrial and cytoplasmic succinate dehydrogenase activity of viable cells to a purple, water insoluble formazan. The absorbance of the solubilised purple formazan can be quantified at a wavelength of 550 nm by a spectrophotometer.

The optimal concentration of cells for toxicity tests was verified by a titration curve prior the test of drugs/nanoparticles. The titration curve was obtained by serial 1 to 2 dilutions of cells from a maximum of 312000 to the limit of the detection of cells for the assay. 100 μ l of cells dilutions were seeded in triplicates in the middle wells of a clear 96 well plate and extra triplicate wells for media only were left for the blank. The edges of the wells used for the titration curve were filled with 200 μ l media to avoid excessive evaporation of media from assay wells.

For toxicity assays, 100 μ l of cells were seeded into the middle 60 wells of a clear 96 well plate at a density of 31200 cells/cm², allowed to attach to the well overnight and successively treated for 4.5 h with chemical inhibitors of endocytic pathways or for 4-

24 and 48 h with nanoparticles. Each inhibitor was applied in triplicates and both inhibitors, C-PB and polymers were prepared in HBSS supplemented with HEPES buffer 20 mM. Serial dilutions were prepared at a 1/2 ratio for CPZ, MBCD and thermoresponsive polymers or 1/10 for C-PB. CPZ and MBCD toxicity were tested every time a new stock solution was prepared to avoid weighing errors. Both CPZ, MBCD and nanoparticle toxicity tests were carried out with a reference positive and negative control consisting of PEI 0.5 mg/ml and HBSS/HEPES 20 mM respectively. A blank consisting of the same C-PB serial dilutions triplicates used in toxicity tests applied to wells without cells was also analysed in C-PB toxicity studies and the absorbance values of the blank subtracted accordingly. Upon completion of the incubation time at 37 °C and 5% CO₂, MTT (50 μl of 1 mg/ml solution) was applied and cells supplemented with MTT incubated for further 4 h. Upon completion of the MTT incubation time the solution was aspirated and 75 µl of DMSO applied to solubilise the purple water-insoluble crystals formed by the functional mitochondrial and cytoplasmic succinate dehydrogenase activity of viable cells. Blanks plates of C-PB were processed as the other tested samples (same time of incubation, same volume of MTT added, same incubation time of MTT, MTT aspirated off and DMSO applied). Absorbance readings were recorded at 550 nm on a MRX revelation microplate reader, Thermo Lab Systems, Altrincham, UK. The results were plotted in GraphPad Prism and normalised against the untreated controls.

2.2.5.2 Apo I (caspase 3/7) apoptosis assay

Caspase 3 and 7 are members of cysteine aspartic acid-specific protease (caspase) family and they are synthesized during apoptosis. Apo I caspase 3/7 detection kit (Promega, Southampton, UK) consists of profluorescent substrate formed by a peptidic region conjugated to a fluorescent dye (Rhodamine 110). In the presence of caspase 3/7 the peptidic region of the substrate is specifically cleaved by caspases 3

General Materials and Methods

and 7 and releases the fluorescent dye that is detected at 535nm. The fluorescence detected is therefore proportional to the number of apoptotic cells.

25 µl of HCT116, MGLVA-1 and 3T3 cell suspensions were seeded into the middle 240 wells of a 384 clear bottom black well plate at a density of 31200 cells/cm² in full growth media and left to attach to the bottom of the wells overnight. Two rows of wells at the edges of the 384 wells plate were filled with 50 μ I of growth media to provide moisture and help to avoid excessive evaporation of media from the wells overnight. The day after, the medium was carefully aspirated off with a pipette tip and replaced with 25 µl of HBSS/HEPES 20 mM for negative control, PEI 0.5 mg/ml and CPZ dilutions of 320-240-160-80 and 40 µM obtained in HBSS/HEPES 20 mM. Quintuplicate wells devoid of cells were replaced with HBSS/HEPES 20 mM for a blank reading. CPZ and control wells were applied in guintuplicate and 3 independent experiments repeated for each cell line. CPZ was incubated for 4.5 h. When the incubation time was over 25 µl of Apo I reagents mix was prepared according to manufacturer specifications and added to each well. Briefly, Apo I reagents were thawed and equilibrated to room temperature and Apo I substrate diluted 1/100 with Apo I buffer and added to assay wells to lysate the cells and start the conversion of the substrate to the fluorescent product by caspase 3 and 7 enzymatic activity of apoptotic cells. The plate was placed on an orbital plate shaker for 30 minutes and plate read on a spectrofluorometer (Flex Station II 384 microplate reader, Molecular Devices, Wokingham, UK). The excitation was set at 485nm, emission at 535 nm, 495 nm cutoff.

2.2.5.3 Cell Titer Glo viability assay

Cell Titer Glo viability assay is based on the activity of ultra glo recombinant luciferase, a mono-oxygenase enzyme that converts luciferin substrates to oxyluciferin. Oxyluciferin emits a luminescence signal and the quantity of oxyluciferin produced is dependent on ATP that is provided by the cells in the tested sample. Hence, the amount of conversion and luminescence signal is directly proportional to the ATP content in the tested sample and the ATP levels are directly proportional to the metabolic activity and numbers of cells. The luciferase reaction is shown below:



The luminescence signal can be quantified by a luminometer.

The optimal concentration of cells for toxicity tests was verified by a titration curve prior to the testing of drugs and nanoparticles. The titration curve was obtained in HBSS/HEPES 20 mM by 10 serial 1 to 2 dilutions of cells from a maximum of 312000 to a minimum of 635 cells/cm². 100 μ l of cells dilutions were seeded in triplicates in the middle 36 wells of a 96 well plates and extra triplicate wells for media only were left for the blank. The edges of the wells used for the titration curve were filled with 200 μ l media to avoid excessive evaporation of assay media.

For the Cell Titer Glo assay, cells at a density 31200 cells/cm² were seeded in the middle 60 wells of a clear bottom, black well plate and allowed to attach to the bottom of the wells overnight. The day after, the media of cells was aspirated off and 100 μ l of the material of interest was applied in HBSS/HEPES 20 mM in triplicates. Two or three independent experiments were carried out. C-PB of 50 and 100 nm were tested at concentrations ranging between 1000 μ g/ml and 1 and dilutions of 1/10. CPZ tested concentrations ranged between 320 and 10 μ M with dilutions 1/2. For each experiment a positive and negative control were also used consisting of PEI 0.5

General Materials and Methods

mg/ml and HBSS/HEPES 20 mM respectively and a blank consisting of HBSS/HEPES 20 mM without cells. C-PB were incubated at 37 °C and 5% CO₂ for 4 h. Endocytosis inhibitors were incubated 4.5 h. 15 minutes before the incubation time was over, the cells were removed from the incubator and left to equilibrate to room temperature according to manufacturer specification. Subsequently, Cell Titer Glo mix 100 μ l was applied and plates loaded on an orbital mixer for 2 minutes to allow cell lysis. The plate was further incubated at room temperature for 10 minutes to allow the luminiescence signal to stabilize. For C-PB toxicity studies only, prior to the application of the Cell Titer Glo mix, the wells content was removed with a pipette tip and 100 μ l of HBSS/HEPES 20 mM applied. This procedure was carried out to prevent or reduce the interaction of the nanoparticles with the Cell Titer Glo recombinant proteic enzyme and potentially reduce its activity. The luminescence signal was read for 1 second per well according to manufacturer specifications and recorded with a FluoStar Optima microplate reader (BMG LABTECH GmbH, Ortenberg, Germany).

2.2.5.4 Statistical Analysis

For all toxicity tests the Z factor and Signal Window were calculated according to the formulas below:

$$Z Factor = 1 - \left(\frac{(3xSDp.c. + 3xSDn.c.)}{|Mp.c. - Mn.c.|}\right)$$

⁽⁷)

$$Signal Window = \left(\frac{[Mn.c. - Mp.c. - 3x(SDp.c. + SDn.c.)]}{SDn.c.}\right)$$

(⁸)

Where:

SDp.c = Standard Deviation of the positive control

SDn.c = Standard Deviation of the negative control

Mp.c = Mean of the positive control

Mn.c. = Mean of the negative control

These two parameters were calculated to confirm that there was sufficient separation of the signals obtained from the negative and positive control at the chosen concentration of cells for cell activity studies and hence the studies carried out were producing good quality and reliable cell activity data.

2.2.6 Htf and LacCer Wash Efficiency Studies

Detection methods such as flow cytometry or plate reading of the signal of fluorescent markers of endocytosis cannot distinguish between the fluorescence signal from the membrane or internalised markers of endocytosis. For this reason, both Htf and LacCer washes are routine procedures for efficient removal of the endocytic marker from the plasma membrane in endocytosis inhibition studies. The following procedures were carried out to verify the efficiency of the wash of Htf and LacCer from the membrane of cells. In these experiments the buffers of the washes suggested from the literature were not altered. However, two different procedures were attempted:

- Cells treated with markers of endocytosis were washed in flasks with standard buffers before being removed with trypsin and fixed for flow cytometry.
- Cells treated with markers of endocytosis were removed from flasks with trypsin, collected in Eppendorf tubes and cells washed with standard buffers on cells suspensions. Each wash step was followed by a centrifugation step at 2000 g for 5 minutes at 4°C.

2.2.6.1 Htf and LacCer removal from the cell membrane with washes on cells suspensions

Cells were seeded at a density of 31200 cells/cm² in 25 cm² flasks and allowed to attach to the bottom of the flask overnight. Subsequently, cells were detached from flasks with trypsin, collected in Eppendorf tubes and centrifuged at 2000 g for 5 min at 4 °C. The supernatant was aspirated off with a pipette tip and Eppendorf tubes placed on ice and left to equilibrate for one minute. Subsequently, cells were resuspended in ice cold HBSS /HEPES 20 mM (negative control) or ice cold Htf 6.7 μ g/ml in HBSS/HEPES 20 mM in or LacCer 0.81 μ M in HBSS/HEPES 20 mM in duplicate Eppendorf tubes. The 2 Eppendorf tubes treated with Htf 6.7 μ g/ml or LacCer 0.81 μ M in HBSS/HEPES 20 mM consisted of one positive control not treated with consequent washing steps and used as a reference control of the membrane bound marker of endocytosis, and one positive control treated with washes on cells suspensions. The Eppendorf tubes were incubated for 5 minutes on ice to allow the binding of the marker of endocytosis on the cell membrane without internalization. Hence, cells were washed with the buffers and procedures described below.

The buffers used to remove membrane bound Htf consisted of 2 rinses with ice cold HMEM-G+I, on ice (Hank's Minimum Essential Medium (HMEM) without glucose - Gibco, Paisley, UK - supplemented with 10 mM HEPES and 5 mM sodium azide, NaN₃, to inhibit metabolic activity) followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl buffer pH 4.6⁹. The acidic wash was then rinsed on ice with 2 cold washes of HMEM-G+I.

The buffers used to remove membrane bound LacCer consisted of two ice cold washes with HMEM-G+I followed by 6 rinses (10 minutes each, on ice) of HMEM-G+I supplemented with 5% w/v dBSA (back exchange method)¹⁰.

The washes described above were carried out on cell suspensions and each wash was followed by 5 minutes centrifugation at 2000 g at 4 °C. The last wash step was then followed by centrifugation at 2000 g for 5 minutes at 4 °C and cells re-suspended in PFA 4% v/v PBS and fluorescence of cells analysed by flow cytometry with a Becton-Dickinson (BD) LSR II flow cytometer, Oxford, UK and detected with optical filters (FITC 530/30 bandpass filter for LacCer detection or an APC channel, 660/20 optical bandpass filter for the detection of Htf). Data were analysed with Weasel software, normalised against the positive and negative controls assumed being 100% and 0% uptake of the markers of endocytosis and plotted in GraphPad Prism.

2.2.6.2 Htf and LacCer removal from the cell membrane with washes on adherent cells

Cells were seeded at a density of 31200 cells/cm² in 25 cm² flasks and allowed to attach to the bottom of the flask overnight. The day after, cells were placed on ice and left to equilibrate for 10 minutes. Subsequently, full growth media was aspirated off and cells treated with ice cold HBSS/HEPES 20 mM for the negative control or ice cold Htf 6.7 μ g/ml or LacCer 0.81 μ M in HBSS/HEPES 20 mM in duplicate flasks. The 2 additional flasks for each marker of endocytosis consisted of one positive control not treated with consequent washing steps and used as a reference control of the membrane bound marker of endocytosis, and a positive control subsequently treated with flask washes. The flasks were incubated for 5 minutes on ice to allow the binding of the Htf or LacCer on the cell membrane without internalization. Hence, cells were washed on ice with the buffers and procedures described below.

The buffers used to remove membrane bound Htf consisted of 2 rinses with ice cold HMEM-G+I, on ice followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl buffer pH 4.6⁹. The acidic wash was then followed by 2 cold washes of

HMEM-G+I on ice, cells were trypsinised, centrifuged at 2000 g for 5 minutes at 4 ℃ and fixed in PFA 4% v/v PBS.

The buffers used to remove membrane bound LacCer consisted of two ice cold washes with HMEM-G+I followed by 6 rinses (10 minutes each, on ice) of HMEM-G+I supplemented with 5% w/v dBSA (back exchange method)¹⁰. Cells were then trypsinised, centrifuged at 2000 g for 5 minutes at 4°C and fixed in PFA 4% v/v PBS and analysed by flow cytometry with a Becton-Dickinson (BD) LSR II flow cytometer, Oxford, UK and detected with optical filters (FITC 530/30 bandpass filter for LacCer detection or an APC channel, 660/20 optical bandpass filter for the detection of Htf). Data were analysed with Weasel software, normalised against the positive and negative controls that were assumed being 100% and 0% uptake of the endocytosis markers and plotted in GraphPad Prism.

Inhibitors of endocytosis	Mechanism of action	Pathways' interference	
CPZ	Direct binding to calmodulin leading to plasma membrane depletion of free phosphatidyl-inositol 4,5 bisphosphate	 Clathrin mediated endocytosis Phagocytosis Macropinocytosis 	
Pitstop 2	Direct antagonist of Clathrin mediated endocytosis	•Clathrin mediated endocytosis •Phagocytosis	
MBCD	Plasma membrane depletion of cholesterol	 Caveolae mediated endocytosis Clathrin mediated endocytosis Non caveolae non clathrin mediated endocytosis 	

Table 2-2 Summary of the inhibitors of endocytosis used in this study

2.2.7 Inhibition of Htf uptake with CPZ

Cells were seeded in 25 cm² vented caps flasks at a density of 31200 cells/cm² and allowed to attach to the bottom of the flasks overnight. Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without chemical inhibitors of endocytic pathways for 30 minutes and then replaced with HBSS/HEPES 20 mM with or without LacCer 0.81 µM or Htf 6.7 µg/ml and chemical inhibitors. Chemical inhibitors working concentrations were selected as 1.25 mM MBCD and 40, 60 and 80 μM CPZ (Table 2-2). Upon completion of the incubation time, cells were washed as described above, detached from flasks with trypsin-EDTA or EDTA alone, centrifuged at 2000 g for 5 minutes and re-suspended in a fixation buffer consisting of PFA 4% v/v in PBS. Cells were then analysed with a BD LSR II flow cytometer (APC 660/20 bandpass filter). Briefly, Htf acidic wash consisted of two cold washes with HMEM-G+I followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl buffer⁹. The acidic wash was then rinsed out with 2 cold washes of HMEM-G+I. The Htf washes were carried out in 25 cm² flasks. A variant of this protocol included the used of HBSS devoid of Ca²⁺ and Mg²⁺ supplemented with 20 mM HEPES instead of standard HBSS. This protocol was aiming at depleting cells of Ca²⁺ and consequently of ATP and overall energy.

2.2.8 Inhibition of Htf uptake with Pitstop 2

Cells were seeded at a density of 31200 cells/cm² in 25 cm² vented cap flasks and allowed to attach to the bottom of the flask overnight. Subsequently, full media was replaced with HBSS supplemented with HEPES 20 mM with or without Pitstop 2 (abCam, Cambridge, UK, Table 2-2) for 15 minutes and then replaced with HBSS/HEPES 20 mM with or without Htf 6.7 μ g/ml and chemical inhibitor. Working concentrations of Pitstop 2 were selected as 12.5, 18.75 and 25 μ M and incubation times set at 1 or 2 h. Upon completion of the incubation time, cells were washed as

described above, detached from flasks with trypsin-EDTA or EDTA alone, centrifuged at 2000 g for 5 minutes and re-suspended in a fixation buffer consisting of PFA 4% in PBS. Cells were then analysed with a BD LSR II flow cytometer (APC 660/20 bandpass filter). Briefly, Htf acidic wash consisted of two cold washes with HMEM-G+I followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl buffer⁹. The acidic wash was then rinsed with 2 cold washes of HMEM-G+I. The acidic washes were carried out in flasks.

2.2.9 Inhibition of LacCer uptake with MBCD

Cells were seeded at a density of 31200 cells/cm² and allowed to attach to the 25 cm² flasks overnight. Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without chemical inhibitors of endocytosis for 30 minutes and subsequently replaced with HBSS/HEPES 20 mM alone (negative control), LacCer 0.81 µM (positive controls) or with LacCer 0.81 µM in the presence of 80 µM CPZ or 1.25 mM MBCD (Table 2-2). The incubation times were 1-2-3 and 4 h for all cell lines. Chemical inhibitors working concentrations were selected as the lowest affective inhibiting concentration of the chemical inhibitors. Upon completion of the incubation time cells were washed as described above and subsequently detached from flasks with trypsin-EDTA. Detached cells were centrifuged at 2000 g for 5 minutes and re-suspended in a fixation buffer consisting of PFA 4% v/v in PBS. Cells were then analysed with a BD LSR II flow cytometer and detected with optical filters (FITC 530/30 bandpass filter).

Briefly, LacCer wash consisted of two ice cold washes with HMEM-G+I followed by 6 rinses (10 minutes each) of HMEM-G+I supplemented with 5% w/v dBSA (back exchange method)¹⁰.

2.2.10 Endocytosis inhibition in the presence of C-PB

Cells were seeded at a density of 31200 cells/cm² and allowed to attach to the 25 cm² flasks overnight. Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without chemical inhibitors of endocytosis for 30 minutes. The buffer was subsequently replaced with HBSS/HEPES 20 mM alone (negative control), 50 nm C-PB 100 µg/ml or 100 nm C-PB 100 µg/ml (positive controls), or with 50 or 100 nm C-PB 100 µg/ml in the presence of 80 µM CPZ or 1.25 mM MBCD. C-PB and inhibitors were further incubated for 1-2 or 4 h. Subsequently, cells were washed twice with HBSS/HEPES 20 mM and EDTA, detached from flasks with trypsin/EDTA, centrifuged at 2000 g for 5 minutes and re-suspended in PFA 4% v/v PBS. Cells were then analysed with a BD LSR II flow cytometer and detected with optical filters (FITC 530/30 bandpass filter).

2.2.11 Procedures for sterilization of coverslips for microscopy

Round 22x1.5 mm glass coverslips (SLS, Nottingham, UK) were handled in a Class II cabinet. They were picked up with autoclaved tweezers and immerged in absolute ethanol (Sigma, Dorset, UK) for 5 minute. The coverslips were then removed from ethanol and left to dry to the air of the class II cabinet in a sterile six well plate before use.

2.2.12 Confocal microscopy live imaging methods

Cells were seeded in full media to a final density of 31200 cells/cm² in 6 well plates in the presence of sterile rounded 22x1.5 mm glass coverslips (SLS, Nottingham, UK). Cells were left to attach to the glass coverslips overnight. On the next day the cells were stained with Hoechst 33342 (Thermo Scientific, Rockford, USA) 1 μ g/ml and Cell Mask deep red cell membrane stain 1 μ g/ml for 30 minutes (Molecular Probes, Paisley, UK). The media was then replaced with HBSS/HEPES 20 mM for live imaging. Confocal equipment consisted of a Zeiss Laser Scanning Microscope (LSM)

710, Jena, Germany. This was supplied with a heated chamber at 37 °C that was switched on and equilibrated to temperature overnight. Glass rounded coverslips were mounted on a coverslip holder that had been previously sterilised and equilibrated at 37 °C overnight. Images of stained cells in buffer were taken prior to the exposure of cells to C-PB. The C-PB solution was then added to the buffer solution at a ratio 1:1 to obtain a final concentration of C-PB of 50 μ g/ml. Images of the 4 regions of interests were acquired at 4-10-20-30-40-50 and 60 minutes on a 40x water objective.

2.2.13 Immunofluorescence of clathrin and caveolin-1

Cells were seeded at a density of 31200 cells/cm² and allowed to attach to squared 22x22x1.5 mm glass coverslips (SLS, Nottingham, UK) or 25 cm² flasks overnight. The day after cells were washed and fixed for 30 minutes at room temperature with PFA 4% v/v for immunofluorescence or trypsinized and pelleted at 2000 g for 5 minutes before fixation for flow cytometry. Cells on coverslips were washed 3 times for 5 minutes in PBS while trypsinized cells suspensions for flow cytometry were washed in PBS once for 5 minutes on a rocker. Subsequently, PBS, 0.3% v/v Triton X-100, 5% v/v goat serum blocking buffer was applied for 1.5 h. When the incubation time was over, the blocking buffer was gently removed with a pipette tip and the chosen antibody applied according to manufacturer specifications. Anti-clathrin heavy chain mouse IgG1mAb (clone X22) prepared in PBS, 1% w/v BSA, 0.3% v/v Triton X-100 was used at a concentrations of 0.12 µg/ml and anti-caveolin-1 mouse lgG1mAb (clone 2297), prepared in PBS, 1% w/v BSA, 0.3% v/v Triton X-100, was applied at a concentration of 0.83 µg/ml for all cell lines. Mouse lgG1 was utilised as a negative control at concentrations of 0.12 µg/ml for clathrin lgG1 negative control and 0.83 µg/ml for caveolin-1 lgG1 negative control. An additional negative control consisting in cells treated with secondary antibody were incubated with PBS, 1% w/v BSA, 0.3%

General Materials and Methods

v/v Triton X-100. All cells were incubated for 1.5h; subsequently, cells on coverslips were washed 3 times for 5 minutes in PBS while cell suspensions were washed once on a rocker for 5 minutes, and goat anti-mouse (H+L) IgG1 AlexaFluor 488 nm or 594 nm secondary antibody (Molecular Probes, Paisley, UK) in PBS, 1% w/v BSA and 0.3% v/v Triton X-100 was applied overnight at 4℃. The secondary antibody was diluted to 5 µg/ml for both clathrin and caveolin staining. The following day, the secondary antibody was aspirated off and cells washed 3 times for 5 minutes with PBS. Cells prepared for microscopy were removed from the wells with the aid of a needle and tweezers, further stained with Prolong Gold Antifade DAPI mounting media (Invitrogen, Paisley, UK) applied on glass slides and left to dry at room temperature in the dark overnight. The following day, coverslips edges were sealed with nail polish to the glass slides and stored at 4℃ until used on a Zeiss LSM700 confocal microscope, Jena, Germany. Cells prepared for flow cytometry were resuspended in PBS. Flow cytometry data were acquired with a BD LSR II flow cytometer (FITC 530/30 bandpass filter for AlexaFluor488 secondary antibody) and analysed with Weasel software.

References

- 1 Brattain, M. G. et al. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Research **41**, 1751-1756 (1981).
- 2 Watson, S. A., Durrant, L.G., Morris, D.L. The effect of the E2 prostaglandine enprostil, and the somatostatin analogues SMS 201 995, on the growth of a human gastric cell line, MKN45G. International Journal of Cancer **45**, 90-94 (1990).
- 3 Hojo, J. Establishment of cultured cell lines of human stomach cancerorigin and their morphological characteristics. Niigata Igakukai Zasshi **91**, 737 (1977).
- 4 Todaro, G. J. & Green, H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol **17**, 299-313 (1963).
- 5 Jacobs, J. P., Jones, C. M. & Baille, J. P. Characteristics of a human diploid cell designated MRC-5. Nature **227**, 168-170 (1970).
- 6 Abulateefeh, S. R. et al. Facile synthesis of responsive nanoparticles with reversible, tunable and rapid thermal transitions from biocompatible constituents. Chemical Communications, 6068-6070 (2009).

- 7 Zhang, J. H., Chung, T. D. F. A. U. O. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of Biomolecular Screening **4**, 67-73 (1999).
- 8 Iversen, P. W., B.J., E., Sittampalam, G. S. & Cox, K. L. A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. Journal of Biomolecular Screening **11**, 247-252 (2006).
- 9 van Renswoude, J., Bridges, K. R., Harford, J. B. & Klausner, R. D. Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proceedings of the National Academy of Sciences **79**, 6186-6190 (1982).
- 10 Pagano, O. C. M. a. R. E. Internalization and sorting of a fluorescent analogue of glucosylceramide to the Golgi apparatus of human skin fibroblasts: utilization of endocytic and nonendocytic transport mechanisms. J Cell Biol **125**, 769-781 (1994).

3-Chapter 3

Characterisation of Materials

and Cell Lines

3.1 Introduction

Synthetic and natural polymers are being extensively studied as carriers of drugs^{1,2}. The ability of some polymers to self-assemble, creating protected compartments for the transport of drugs, together with the possibility to respond to external stimuli by conformational rearrangement and release of the drug load, are appealing characteristics for biomedical use. However, chemical and physical characteristics of these polymers such as size and superficial charge can modulate the extent of their internalization in cells as well as influencing their pathway of uptake³⁻⁶. A better understanding of how these characteristics can change cellular processing of these materials in different cell lines will help the design of more reliable carriers of drugs. For this reason, commercially available Polysciences Carboxylated Yellow-Orange Polystyrene Beads (C-PB) of well defined size charge and shape were used as a model for polymeric nanomaterials with a hydrophobic bulk and slightly negative surface charge. The C-PBs were characterized in the intended buffer for the endocytosis experiments by ζ potential measurements and their sizes determined by both DLS and TEM. The effects of these materials on cell viability were also characterized by MTT and Cell Titer Glo ATPase assays.

The choice of the cell lines for the study was made on the basis of evidence that many pathologies affect epithelial cells⁷⁻⁹. However, literature reports an increasing role of mesenchymal cells in the instigation and progression of pathologies such as cancer. Here, myofibroblasts are heavily involved in the production and preservation of the tumor microenvironment; the so called 'niche' or stroma where myofibroblasts and epithelial cell signalling and cross-talk promotes changes in epithelial cells towards more aggressive cancers^{10,11}. Moreover, fibroblasts are also involved in other pathologies such as fibrosis, inflammation and arthritis which make their activity also

a potential target for new therapeutics. For all these reasons, two epithelial cancer cells, HCT116 and MGLVA-1 and one fibroblastic cell line, Swiss Albino 3T3 fibroblasts, were chosen for the study and characterized for the presence of clathrin and caveolin that are involved in the two best characterized endocytic pathways.

In this chapter a series of experiments were carried out to define the experimental settings for the studies of endocytosis inhibition. The investigation of different routes of uptake in different cell lines was carried out with human transferrin (Htf) and lactosylceramide (LacCer). These two molecules are widely accepted markers of clathrin-dependent and -independent endocytosis¹². Chlorpromazine (CPZ) and methyl beta cyclodextrin (MBCD) have been widely used as pharmacological inhibitors of clathrin-dependent and -independent endocytosis^{13,14}. As the specificity of both CPZ and MBCD have been questioned in the past, the inhibition experiments with each marker of endocytosis were carried out in the presence of both pharmacological inhibitors to spot any non-specific inhibition of endocytosis¹³⁻¹⁵. The extent of inhibition was measured by flow cytometry as this technique gives a better snapshot of the rate of internalization of markers of endocytosis at the single cell level and can detect also small shifts in inhibition of endocytosis in a statistically robust way. Finally, as both CPZ and MBCD have been reported as cytotoxic, a thorough characterization of their cell activity was carried out¹⁶⁻²⁴. The effects of MBCD on cell activity was tested with both MTT and Cell Titer Glo while CPZ was investigated with MTT, Cell Titer Glo and Apo I assays.

3.2 Methods

3.2.1 C-PB size and charge characterization

Detailed information on the DLS and TEM methods used to characterize 50 and 100 nm C-PB can be found in the materials and methods §§ 2.2.2 and 2.2.3. Briefly, for

DLS studies, 50 and 100 nm C-PB were diluted to 200 µg/ml and 50 µg/ml in filtered PBS buffer, vortexed for 1 minute to remove aggregates of nanoparticles and 10 µl of the nanoparticles suspension loaded into a quartz micro-cuvette in a DLS reader previously equilibrated to 20 °C. The DLS equation settings were updated for the PBS buffer, and the mean size of nanoparticles was given by 10 replicates measurements. These measurements were repeated 3 times, averaged and plotted in GraphPad Prism.

For TEM, the nanoparticles were diluted to 25 or 26.5 µg/ml in PBS, loaded on a copper grid and allowed to dry overnight. The day after, a minimum of 12 TEM images were collected for a minimum of 250 nanoparticles counts. Nanoparticle sizes were measured from images with ImageJ software and data plotted in GraphPad Prism. The coefficient of variance for the TEM and DLS measured size was calculated as follows:

$$CV\% = \left(\frac{\sigma}{M}\right) \cdot 100$$

Were CV% = coefficient of variance %

 $\sigma = STDEV$

M = mean size of the nanoparticles

 ζ potential measurements were carried out in HEPES buffer 1 mM, Ph 7.4 at 20 °C at concentrations of C-PB of 200 µg/ml. The results are reported as the mean of 12 measurement replicates.

3.2.2 Cell viability studies of C-PB, MBCD and CPZ

3.2.2.1 Cell viability assays titration curves and statistical analysis

The seeding density of cells to obtain a linear relationship between numbers of cells and viability signal was investigated by a titration curve for MTT and Cell Titer Glo

prior to toxicity tests. Different titration curves were run for different time of incubations. For a more detailed description of the procedures used to obtain the titration curves please refer to §§ 2.2.5.1 and 2.2.5.3. Briefly, cells were counted and seeded at densities ranging from 312000 to 1985 cells/cm² and incubated overnight. The day after, the media was aspirated off and HBSS/HEPES 20 mM added to cells for the desired time-length. Upon completion of the incubation time, the cells were treated according to the standard assay protocol and colorimetric or luminescence signals recorded.

For all toxicity tests the Z factor and Signal Window were calculated according to the formulae below:

$$Z Factor = 1 - \left(\frac{(3xSDp.c. + 3xSDn.c.)}{|Mp.c. - Mn.c.|}\right)$$

(25)

Signal Window =
$$\left(\frac{[Mn.c. - Mp.c. - 3x(SDp.c. + SDn.c.)]}{SDn.c.}\right)$$

(²⁶)

Where:

SD_{p.c} = Standard Deviation of the positive control

SD_{n.c} = Standard Deviation of the negative control

 $M_{p.c}$ = Mean of the positive control

 $M_{n.c.}$ = Mean of the negative control

These two parameters were calculated to confirm that there was sufficient separation from the signal between negative and positive control at the chosen concentration of

cells for cell viability studies and hence the studies carried out were producing good quality and reliable cell viability data.

3.2.2.2 Metabolic activity (viability) of cells in the presence of C-PB

Studies at 4 h of C-PB of 50 and 100 nm in cells were carried out in triplicate wells in 3 independent experiments. Effects of C-PB were investigated by MTT and Cell Titer Glo assays. Only one replicate for MTT viability tests at 24 and 48 h were carried out with 50 nm C-PB in triplicate wells. For a thorough description of the methods used please refer to §§ 2.2.5.1 and 2.2.5.3. Briefly cells at a density of 31200 cells/cm² were seeded in a 96 well plate and allowed to attach to the wells overnight. The day after the media was replaced with serial dilutions of C-PB in HBSS/HEPES 20 mM, for C-PB concentrations ranging from 1 to 1000 µg/ml and a negative control consisting of assay media (HBSS/HEPES 20 mM) or PEI 0.5 mg/ml positive control, in triplicate wells. The same serial dilutions were placed on 96 well plates without cells for a blank reading for both the MTT and the Cell Titer Glo assays and blank values subtracted from the absorbance/luminescence readings on the C-PB with cells. C-PB of 50 and 100 nm were incubated for 4 h, 50 nm C-PB were also tested with an MTT at 24 and 48 h. Upon completion of the incubation time MTT or Cell Titer Glo were applied according to standard protocols. Acquired absorbance and luminescence measurements were normalised against the negative control that was assumed being the 100% viability of cells.

3.2.2.3 Studies on the effects of MBCD on cell viability

The effects of MBCD on cells were carried out in triplicate wells for a minimum 3 independent experiments using the MTT and Cell Titer Glo assays. For a more complete description of the methods used refer to §§ 2.2.5.1 and 2.2.5.3. Briefly, cells at a density of 31200 cells/cm² were seeded in a 96 well plate and allowed to attach

to the wells overnight. The day after the media was replaced with serial dilutions of MBCD in HBSS/HEPES 20 mM, for concentrations ranging from 0.33 to 10 mM. Each assay presented also a positive control consisting of PEI 0.5 mg/ml, a negative control of cells in HBSS/HEPES 20 mM only and a blank reading in HBSS/HEPES 20 mM assay media devoid of cells. MBCD was incubated for 4.5 h and upon completion of the incubation time MTT or Cell Titer Glo were applied according to manufacturer protocols. Acquired colorimetric and luminescence measurements were normalised against the negative control that was assumed being the 100% viability of cells.

3.2.2.4 Effects of CPZ on cell viability

A thorough investigation of the effects of CPZ was carried out using MTT, Cell Titer Glo and Apo I caspase 3/7 viability assays. Studies using CPZ were carried out in triplicate wells in 3 independent experiments. Cells were seeded in 96 well plates for MTT and Cell Titer Glo and on 384 well plate for Apo I caspase 3/7 assay. For a thorough description of the methods used please refer to § 2.2.5.1 for the MTT, § 2.2.5.3 for Cell Titer Glo and § 2.2.5.2 for Apo I. Briefly cells at a density of 31200 cells/cm² were allowed to attach to the wells overnight. The day after the media was replaced with serial dilutions of CPZ in HBSS/HEPES 20 mM, for concentrations ranging from 10 to 457 μ M and incubated for 4.5 h. Upon completion of the incubation time, MTT, Cell Titer Glo and Apo I caspase 3/7 were applied according to standard protocols.

3.2.3 Immunofluorescence of clathrin heavy chain isoform α (CHCα) and caveolin-1 (cav-1) in 3T3, HCT116 and MGLVA-1

A more extensive description of these methods can be found at § 2.2.13. Here, 3T3 mouse fibroblasts, MRC-5 human fibroblasts, HCT116 human colon cancer and MGLVA-1 human gastric cancer cells were seeded at a density of 31200 cells/cm² and allowed to attach to glass coverslips or 25 cm² flasks overnight. The day after,

cells were washed and fixed for 30 min at room temperature with PFA 4% v/v for confocal microscopy or trypsinized and pelleted at 2000 g for 5 min before fixation for flow cytometry. Rinsed cells were treated with PBS, 0.3% v/v Triton, 5% v/v goat serum blocking buffer for 1.5h. Subsequently, the blocking buffer was gently removed with a pipette tip, and anti-CHCa mouse IgG1mAb (Immunoglobulin G1 monoclonal antibody, clone X22) 0.12 µg/ml and anti-caveolin-1 isoform a mouse IgG1mAb (clone 2297) 0.83 µg/ml incubated for further 1.5 h. Mouse IgG1 was utilised as a negative control at concentrations of 0.12 µg/ml for clathrin IgG1 negative control and 0.83 µg/ml for cav-1 lgG1 negative control. An additional negative control consisting of cells treated only with secondary antibody were incubated with PBS, 1% w/v BSA, 0.3% v/v Triton. Upon completion of the incubation time, cells were rinsed and treated with goat anti-mouse (H+L) IgG1 AlexaFluor 488 nm or 594 secondary antibody overnight at 4 °C. The following day, the secondary antibody was removed and cells washed with PBS. Cells prepared for microscopy were removed from the wells with the aid of a needle and tweezers, further stained with Prolong Gold Antifade DAPI mounting media, applied on glass slides and left to dry at room temperature in the dark overnight. The following day, coverslips edges were sealed to the glass slides with nail polish and stored at 4 ℃ until use on a Zeiss LSM 700 confocal microscope. Cells prepared for flow cytometry were resuspended in PBS. Flow cytometry data were acquired with a BD LSR II flow cytometer with a FITC 530/30 bandpass optical filter and analysed with Weasel software and plotted in GraphPad Prism.

To verify that the binding affinity of the mAb was comparable between human and murine proteins, CHCα and cav-1 protein 3D rearrangement were compared to the human sequences with ICOS protein 3D simulator software, where a score ranging between 0 and 4 was given for the amino acids (aa) more or less exposed to the surface of the protein and external environment.

3.2.4 Wash efficiency studies for the removal of markers of endocytosis

A detailed description of the methods carried out in these experiments can be found in the general materials and methods section at § 2.2.6.

Briefly, two wash procedures were attempted to verify the removal of membrane bound endocytic markers: one with adherent cells in 25 cm² flasks and another in Eppendorf tubes and cell suspensions. The wash solutions used for both Htf and LacCer removal were the traditional buffers reported in the literature^{27,28}. The buffer wash procedures used to remove membrane bound Htf consisted of 2 rinses with ice cold HMEM-G+I, on ice (HMEM without glucose supplemented with 10 mM HEPES and 5 mM sodium azide to inhibit metabolic activity) followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl buffer pH 4.6²⁷. The acidic wash was then followed by 2 cold washes of HMEM-G/HEPES/NaN₃ on ice.

The buffer wash methods for removal of membrane bound LacCer consisted of two ice cold washes with HMEM-G+I followed by 6 rinses (10 minutes each, on ice) of HMEM-G+I supplemented with 5% w/v BSA (back exchange method)²⁸.

3.3 Results

3.3.1 Size and Charge Characterization of 50 nm C-PB

Polysciences described C-PB as in the size range of 50 nm \pm 15% coefficient of variance. DLS studies of the 50 nm C-PB showed that the measured sizes of the materials were in general agreement with the sizes stated by the manufacturer (Figure 3-1A). DLS intensity, mass and number distribution ranges of the diameter of the nanoparticles reported a mean size of 57 nm. However, the coefficient of variance for intensity, mass and number distributions were higher than those stated and equal to \pm 39.7%. TEM measurements (Figure 3-2A) indicated a mean diameter of 30 nm

and a coefficient of variance of $\pm 29\%$. Figure 3-4A shows a TEM picture of 50 nm C-PB. From TEM data the diameters of C-PB ranging between 20 and 40nm accounts for 286 events while the edges of the Gaussian distribution (from 5 -19 to 41 – 70 nm) account for 51 events.

Z potential measurements revealed a charge of -37.7 mV.




Figure 3-1 DLS characterization of 50 and 100 nm C-PB shown as intensity, mass and number plots (A and B). 100 nm CPB intensity peak is broad and the data fit a double Gaussian distribution. 50 and 100 nm C-PB were diluted to 200 µg/ml and 50 µg/ml in filtered PBS buffer, vortexed for 1 minute and loaded into a quartz micro-couvette in a Malvern Instruments Viscotek 802 DLS reader previously equilibrated to 20°C. The DLS equation settings were updated for the PBS buffer, and the mean size of nanoparticles was given by 10 replicates measurements. This procedure was repeated 3 times and data plotted in GrapPad Prism. Intensity, mass and number distributions of the 50 nm C-PB report a peak diameter of 57nm. Intensity measurements for 100 nm C-PB shows a broader peak that corresponds to a double population of nanoparticles. Peak diameter is at 108 nm for intensity, 71 nm for mass and 67 nm for number distributions.





Figure 3-2 TEM's plot of Feret's diameter measurements confirming the presence of a second population of smaller nanoparticles for 100 nm C-PB. The measurements were obtained from 12 images and a minimum of 250 nanoparticles for 50 and 100 nm C-PB. C-PB were diluted to 25 μ g/ml and 26.5 μ g/ml in PBS, loaded on a copper grid and allowed to dry overnight. The day after, a minimum of 12 TEM images were collected for a minimum of 250 nanoparticles counts. Nanoparticle sizes were measured with ImageJ software and data plotted in GraphPad Prism. TEM data confirm the DLS findings: 50 nm C-PB present a single but slightly broad size distribution with a maximal peak at 30 nm while 100 nm C-PB showed two main populations at 20 and 100 nm.



3.3.2 Size and Charge Characterization of 100 nm C-PB

Figure 3-3 Intensity DLS data for 100 nm C-PB fit a double Gaussian distribution. The double Gaussian distribution was calculated by GraphPad Prism. Here, two sizes of nanoparticles are measured with peak diameters at 75 nm and 123 nm (red arrows).




Figure 3-4 TEM images of 50 nm (A) and 100 nm (B) C-PB. The arrows on picture B point to the smaller particles sizes detected also by DLS. TEM measurements report a size of around 20 nm for the second population of nanoparticles (about 5% of the total population of cells). Scale bar for 50 nm C-PB: 200nm; Scale bar for 100 nm C-PB: 500 nm.

Polysciences described the C-PB as 100 nm \pm 10% coefficient of variance. DLS data (Figure 3-1B) reported a mean of 108 nm and coefficient of variance of 45% for the intensity values, a mean of 71 nm and \pm 93% variance for the mass and a mean of 67 nm and \pm 80% variance for the number distributions. Furthermore, the analysis of the DLS intensity values revealed a double Gaussian distribution with mean diameter values at 75 and 123 nm (Figure 3-3). TEM data (Figure 3-2B) reported a mean value of 83 nm and a coefficient of variance of \pm 39% for the main peak of nanoparticles. The size range 90-110 nm accounts for 195 events with 11 off peak events in total for nanoparticles size of 80-89 nm and 111-140 nm. However, a second peak of materials was detected around 20 nm. The size distribution of this peak ranged between 10 and 40 nm for a total of 51 events (5% of the total) and was also confirmed in TEM data where two size populations were visible at 20 and 100 nm diameters. Picture 3-4B shows the smaller population of nanoparticles (arrows). Z potential measurements revealed a charge of -34.2 mV.

3.3.3 Cell viability studies of C-PB, CPZ and MBCD

3.3.3.1 Cell viability assays titration curves and statistical analysis

Titration curves obtained with MTT and Cell Titer Glo at 4.5h are shown in Figure 3-5, titration curves with MTT at 24 and 48 h are shown in Figure 3-6. The titration curves show that the density used in toxicity assays of 31200 cells/cm² is within the linear correlation range between number of cells and detection signal. To further confirm these results, statistical measurements of the Z factor and Signal Window measured for negative and positive controls were also calculated for MTT, Apo I and Cell Titer Glo assays and are shown in Table 3-1. The statistical analysis confirms that the concentration of cells used for all endocytosis experiments was also suitable for toxicity studies. The Z factor and Signal Window calculated for the MTT tests at 24 and 48 h are reported in Table 3-2. The Z factor values range between 0.9 and 0.6, which correspond to excellent assays according to Zhang's classification while Signal Window values range between 1.4 and 34 corresponding to ideal and acceptable assays according to Iversen's classification (Table 3-1,3-2 and 3-3)^{25,26}




Figure 3-5 MTT and Cell Titer Glo titration curves for 3T3, HCT116 and MGLVA-1 cells showing a linear correlation between numbers of cells and signal from viable cells at the concentration used for toxicity tests and inhibition studies (red dotted lines). The readings were obtained at 4.5 h in HBSS/HEPES 20 mM for both MTT (left) and Cell Titer Glo (right). The upper density of cells for both assays was set to 312000 cells/cm² and was diluted 2-fold to achieve the minimum detection limit for the assay. Cell viability assays should be set within this linear detection region in order to obtain a linear correlation between signal and number of cells. Error bars represent the standard deviation of the mean (n=3).




Figure 3-6 MTT titration curves for 3T3, HCT116 and MGLVA-1 cells at 24 and 48 h showing a linear correlation between number of cells and signal from viable cells at the concentrations of cells used for toxicity and inhibition studies (dotted lines). Error bars represent the standard deviation of the mean (n=3).

	Toxicity assay							
		MTT	Ce	ell Titer Glo	Аро І			
Statistical analysis	Z factor*	Signal Window ^{**}	Z factor*	Signal Window**	Z factor *	Signal Window **		
3T3	0.8	8	0.7	9.9	0.7	26.5		
HCT116	0.6	1.9	0.6	16	0.7	8		
MGLVA-1	0.6	1.4	0.5	2.8	0.9	12		

Table 3-1 Statistical analysis to confirm that the cell density of 31200cells/cm² was suitable for cell viability studies. For MTT, Cell Titer Glo and Apo I toxicity assays, the Z factor and Signal Window in the 3 cell lines used was calculated against the positive and negative control signal values for each test according to equations described in the material and methods. (*²⁵; **²⁶).

		24h	48h		
Statistical analysis	Z factor*	Signal Window**	Z factor*	Signal Window ^{**}	
3T3	0.9	34	0.7	8	
HCT116	0.9	11	0.8	12	
MGLVA-1	0.9	28	0.6	5	

Table 3-2 Statistical analysis to confirm that the cell density used for MTT assays at 24 and 48 h was giving a good separation between negative and positive control according to $^{25}(*)$ and $(**)^{26}$.

Reference values *, **						
Z Fac	ctor*	Signal window**				
range comments		range	comments			
Z=1	Ideal*	SW>2	Recommended **			
1>Z≥0.5	Excellent *	1>SW>2	Acceptable**			

Table 3-3 Reference values for Z factor and Signal Window	provided according to ²	⁵ (*) and	²⁶ (**).
---	------------------------------------	----------------------	---------------------

3.3.4 C-PB cell viability studies

Cell viability studies at 4 h incubation were mainly in agreement for the effects of 100 nm C-PB and generally showed very little toxicity of the nanoparticles with broad IC_{50} values due to low toxicity.

In contrast, 50 nm C-PB were found to be more detrimental for cell viability in both tests, with the largest effects shown in the MTT assay. The IC₅₀ values of 50 nm C-PB were cell dependent and the IC₅₀ and 95% confidence interval at 4 h for 50 nm C-PB with an MTT and Cell Titer Glo tests are summarised in Table 3-4. No signs of cell toxicity were detected by the visual examination of cells treated with both 50 and 100 nm C-PB under a reverse microscope for concentrations up to 100 μ g/ml.




Figure 3-7 Biocompatibility studies of 50 and 100 nm C-PB at 4 h in 3T3, HCT116 and MGLVA-1 cells. Metabolic activity as a proxy for toxicity was detected with MTT (black lines and squares in the graphs) and Cell Titer Glo assays (red lines and circles in the graphs). Error bars represent the standard deviation of the mean (n=3).

As a consequence, a preliminary screening with an MTT of 50 nm C-PB was also run at 24 and 48 h (Figure 3-8 and Table 3-4). Results are based on one experiment only and show that the MTT assay does not report the same low viability for 50 nm C-PB. The IC₅₀ and 95% confidence intervals at 24 and 48 h incubation of 50 nm C-PB are summarised in Table 3-4. Z factor and Signal Windows for 3T3 cells at 24 h were equal to 0.8 and 12.2 respectively and 0.9 and 34 at 48 h corresponding to an excellent assay for the Z factor values and a recommended value for the Signal Window according to Zhang's and Iversen's classification. Z factor for HCT116 at 24 h was equal to 0.6 and a Signal Window of 5, Z factor of 0.8 and Signal Window of 11 at 48 h. In MGLVA-1 cells the Z factor at 24 h was equal to 0.7 and Signal Window of 8 and 0.9 and 28 for the Z factor and Signal Window at 48 h. the reported Z factor values correspond to an excellent assay, Signal Windows values correspond to a recommended assay. The IC_{50} results reported above refer to one single experiment replicate for 50 nm C-PB incubated at 24 and 48 h¹.

	50nm C-PB									
	4h				24h		48h			
	MTT		Cell Titer Glo		MTT		MTT			
	IC50	95% CI	IC50	95% CI	IC50	95% CI	IC50	95% CI		
3Т3	30	12-71	276	72-1056	309	213-450	312	213-450		
HCT116	27	8-81	135	70-261	271	196-373	341	251-463		
MGLVA-1	72	19-337	283	237-337	197	134-284	338	246-465		

Table 3-4 Summary of the IC₅₀ and 95% confidence intervals obtained with MTT and Cell Titer Glo triplicate experiments at 4 h incubation of 50 nm C-PB and preliminary results from one experiments only with an MTT assays at 24 and 48 h incubation. The values are expressed in μ g/ml of C-PB.




Figure 3-8 MTT toxicity assay of 50 nm C-PB at 24 and 48 h incubation in HBSS/HEPES 20 mM in 3T3 (black triangles and connecting line), HCT116 (white squares and black connecting line) and MGLVA-1 cells (grey circles and connecting lines). The results report the mean and standard deviation of a pilot study experiment obtained from triplicate wells. The experiments were not repeated due to lack of time. Error bars represent the standard deviation of the mean of triplicate wells (n=1).

3.3.5 Characterization of the viability of cells treated with MBCD

MBCD reduction of viability of cells was tested with both MTT and Cell Titer Glo toxicity studies of MBCD reported no toxicity for MBCD at concentrations up to 10 mM (Figure 3-9A, B and C). Although the toxicity of this drug was low, from the MTT inhibition curves it was possible to measure IC_{50} values. MBCD in 3T3 cells had an

¹ The experiments were not repeated because of lack of time.

 IC_{50} value of 140.8 mM; in HCT116 the IC_{50} was 15.5 mM while MGLVA-1 presented an IC_{50} of 10.6 mM. However, the IC_{50} 95% confidence intervals ($IC50_{95\%}$) were very broad limiting the reliability of such values. As both toxicity tests were in agreement no further tests on the effects of MBCD on cells were carried out.




Figure 3-9 MBCD (left) and CPZ (right) toxicity studies at 4.5 h with MTT (black lines and squares), Cell Titer Glo (red lines and circles) and Apo I caspase 3/7 (green lines and diamonds) in 3T3, HCT116 and MGLVA-1 cells. From graphs A, B and C it is possible to appreciate the low toxicity of MBCD at the concentration used in endocytosis inhibition studies of 1.25 mM (red dotted line in the graph) and the marked difference in cell viability of cells treated with CPZ reported in 3 different assays at 80 μ M (red dotted line in the graph). 80 μ M was the highest concentration used for endocytosis inhibition studies. Cells were seeded in triplicate wells and treated with different concentrations of inhibitors of endocytosis for 4.5 h. After the incubation time cells were processed as from standard protocol for each test and data recorded and normalised against the positive control assumed to be 100% viability or 0% caspase 3/7 expression. Error bars represent the standard deviation of the mean (n=3).

3.3.6 Characterization of the effects on cells of CPZ

The effects of CPZ (Figure 3-9, D, E and F, Table 3-5) was analysed by the 3 different viability tests: MTT Cell Titer Glo, and Apo I caspase 3/7, which quantifies

the presence of apoptotic caspase 3/7 enzyme activity. MTT, Cell Titer Glo and Caspase 3/7 $IC_{50} \pm Cl_{95\%}$ of CPZ are reported in Table 3-5. No visible signs of cell toxicity were detected after examination under a reverse microscope for concentrations of CPZ up to 80 μ M.

	CPZ 4.5h								
	MTT		Cell Tit	ter Glo	Аро I				
	IC50	95% CI	IC50	95% CI	IC50	95% CI			
3Т3	73	68-77	147	143-151	96	86-107			
HCT116	64	54-75	211	200-223	147	144-151			
MGLVA-1	112	102-123	197	187-209	93	64-134			

Table 3-5 IC₅₀ and 95% confidence intervals calculated with 3 different cell viability tests: MTT, Cell Titer Glo and Apo I caspase 3/7 activity at 4.5 h. Results are expressed in μ M.

3.3.7 Clathrin and caveolin immunocytochemistry studies

The qualitative and quantitative characterization of CHC α and cav-1 proteins in the cell lines intended for endocytosis inhibition studies was carried out by both confocal microscopy and flow cytometry. Flow cytometry (Figure 3-10) and fluorescence microscopy data (Figures 3-11 and 3-12) show that HCT116 cells expressed high levels of CHC α , while MGLVA-1 cells expressed high levels of cav-1. Furthermore, 3T3 murine fibroblastic cells presented a low fluorescence for CHC α and cav-1 and these results were reproducible over triplicate experiments. To confirm that the levels of immunostaining were comparable to the levels in human mesenchymal cells, expression of caveolin-1 was characterised by flow cytometry and confocal microscopy experiments using MRC-5 human fibroblasts (Figures 3-10, 3-12). The data report consistently similar levels of the immunostaining of the protein in the human and mouse cell lines.




Figure 3-10 CHC α and cav-1 flow cytometry immunofluorescence quantification. The plot shows a merge of 3 independent replicates of immunocytochemistry experiments. Here, the expression of CHC α and cav-1 were investigated in the 3 cell lines used for endocytosis studies (3T3, HCT116 and MGLVA-1). An additional human mesenchymal cell line was characterised and used to compare the expression of the 2 endocytic proteins in human and mouse fibroblasts. Error bars represent the standard deviation of the mean (n=3).

The same approach was undertaken to confirm the reliability of immunofluorescence experiments with CHC α in mouse 3T3 cells. However, immunocytochemistry experiments showed that human CHC α levels in MRC-5 were high and this contrasted with the level of CHC α found in 3T3 cells. To further probe that there were unlikely to be any differences in binding of anti-human antibody to human and murine cav-1, murine cav-1 was compared to the human sequence with ICOS protein 3D simulator software where a score ranging between 0 and 4 was given for the amino acids (aa) more or less interacting in the 3D structure of the protein and/or exposed to the external environment. The simulation reported a different score for murine and human antibody epitope regions of cav-1 both when analysing only the exposure to the solvent of the protein. This suggested that the murine protein rearranged in a 3D structure that did not resemble the human cav-1 in the epitope region and subsequently the mAb could potentially bind to the two regions with different strength and affinity (Appendices I and II)²⁹⁻³¹.

To verify that the binding affinity of the mAb was comparable between human and murine proteins, mouse CHC α protein 3D rearrangement was compared with the human sequences with ICOS protein 3D simulator software. The prediction suggested that the 2 point mutations were sufficient to modify the 3D structure and the exposure to the solvent of the epitope region recognised by the mAb. In other terms, the aa in the epitope region did not present the same 3D architecture and exposure to the solvent in human CHC α and murine CHC α according to the simulation (Appendices III and IV). From these data it is possible to suggest that the low expression of CHC α in 3T3 cells might not be genuinely due to the level expression of cav-1 and CHC α .

Finally, cav-1 levels in the epithelial cells tested were represented by a broad peak or dot plot suggesting that within the same cell line some cells might have expressed more cav-1 than others (Figure 3-13).




Figure 3-11 Qualitative immunocytochemistry confocal microscopy experiments for the detection of CHC α in 3T3, MRC-5, HCT116 and MGLVA-1. Here two negative controls were used: IgG1 and the secondary antibody. Blue fluorescence: nuclei (Dapi), Red fluorescence: CHC α , IgG1 or Secondary antibody (Sec. Ab.). Scale bars represent 10 μ m.





Figure 3-12 Immunocytochemistry confocal microscopy images of the staining of cav-1 in 3T3, MRC-5, HCT116 and MGLVA-1 cells. The above pictures show the blue fluorescence of the nuclei (Dapi) and the red fluorescence of cav-1 (first row of pictures), IgG1 and secondary antibody (Sec ab.) negative controls (second and third row of pictures). Scale bars represent 10 μm.



mAb fluorescence detection (FITC channel)

Figure 3-13 Histograms of the fluorescence intensity for Clathin mAb X22 / Caveolin-1 mAb clone 2297 immunolabelling (Green), IgG1 (Black) and AlexaFluor 488 secondary antibody (Grey) negative controls in 3T3 murine fibroblasts, MRC-5 human lung fibroblasts, HCT116 human colon carcinoma and MGLVA-1 human gastric cancer cells.

3.3.8 Wash efficiency studies of endocytosis markers

Experiments were designed to verify that the surface-bound ligands used as markers of endocytosis were efficiently removed to ensure that only the fluorescence of internalised markers was detected. Results of the wash efficiency studies are shown in Figure 3-14. These set of experiments show wash efficiency differences between Htf and LacCer. Here two different experimental setups were investigated: the washes were carried out both on cell suspensions in Eppendorf tubes on ice and were compared to the same buffer combination on 25 cm² flasks on ice and adherent cells. Results show that a more efficient removal of Htf was obtained when the washes occurred in Eppendorf tubes, on trypsinized cell suspensions. The opposite was true for LacCer where the most efficient removal of the surface-bound marker of endocytosis occurred in 25 cm² flasks on ice.




Figure 3-14 Flow cytometry results of 3 replicates experiments on the different efficiency of the removal of Htf and LacCer endocytic markers from the plasma membrane of cells. The washes were carried out on adherent cells (in 25 cm² flasks (T25)) or in cell suspensions (Eppendorf tubes washes (Epp wash)). The dotted line represents the fluorescence of the unwashed plasma membrane of cells calculated for positive controls and normalised to 100%. Error bars represent the standard deviation of the mean (n=3).

3.4 Discussion

C-PB of 50 and 100 nm diameter were characterized for effects on cell viability, size and charge; the concentration-dependent effects of endocytosis inhibitors were also evaluated and the presence of CHC isoform α and cav-1 in the cell lines designated

for endocytosis studies was determined by immunofluorescence. Finally, surface bound markers of endocytosis washing efficiency was also investigated with two different experimental procedures.

Size and charge characterization showed that C-PB of 50 nm displayed a broad size distribution with particle diameters ranging between 10 and 65 nm from TEM images and 28 and 97 nm from DLS measurements. The mean diameter was 30 nm from TEM and 57 nm from DLS studies. The fact that TEM results reported a smaller size than the one stated from the manufacturer is expected as TEM is a technique that measures the size of materials in dry conditions. Accordingly, the hydration diameter due to the solvent is not taken into consideration in TEM, although this is likely to be low for surface-carboxylated PS particles in aqueous media. However, DLS measurements reported a size of 57 nm which is closer to 50 nm of the manufacturer's report. The broad distribution of sizes, confirmed by both TEM and DLS, was an unexpected result and it is essential information to take into consideration when studying endocytosis as it has been extensively reported in literature that the size of the nanomaterials endocytosed can heavily affect the route of uptake³²⁻³⁴.

Characterization of 100 nm C-PB reported a double Gaussian distribution of sizes by both TEM and DLS studies. TEM data showed particles in two size ranges of 20 and 100 nm in diameter. The double Gaussian distribution in the DLS data did not allow distinction between the two populations of sizes, and the intensity measurements reported sizes ranging from 43 to 249 nm. DLS intensity data fitted a double Gaussian correlation as derived using GraphPad Prism with two major peaks apparent at 75 and 123 nm. The diameter of these materials as denoted in DLS was bigger than the TEM diameter for the two populations. This again might be due to the hydration diameter measured by DLS that is not measured in dry TEM conditions.

Another explanation might be that the two overlapping Gaussian distribution of sizes are too close for a precise discrimination of the size of the two populations of particles by DLS. TEM images of 50 and 100 nm C-PB show nanoparticles that are mainly separated and not aggregated on the grid which means that the sample preparation technique was appropriate for size characterization studies. The same images show that some nanoparticles are also less electron-dense with a lower extent of staining. This may have been due to heterogeneous composition of the material (for example as a result of uneven cross-linking during the polymer synthesis process) and suggests that these materials might not behave as one component during subsequent cell trafficking assays.

Zeta potential measurements of C-PB of 50 and 100 nm showed a negative charge that is slightly above the 30 mV threshold that is considered an approximate limit for colloidal stability³⁵. This meant that the nanoparticles used in this study were expected to be relatively stable to aggregation.

Preliminary studies using viability tests, statistical analysis and titration curves showed that it was possible to test for cell viability at the same cell numbers and concentrations consistent with endocytic pathway inhibition studies. Indeed, it has previously been reported that increasing the concentration of cells in toxicity tests changes the susceptibility of cells to toxic materials³⁶. The aim in these preliminary studies was to obtain accurate measures of any toxicity of materials under conditions analogous to those used in inhibition experiments.

C-PB viability studies were carried out with Cell Titer Glo and MTT assays. Both assays are routinely used to study the effects of nanoparticles on cell metabolic activity³⁷⁻⁴⁰. Both MTT and Cell Titer Glo are in agreement and report a low interference of such nanoparticles with the dehydrogenase activity of the MTT test and high levels of ATP in cells treated with 100 nm C-PB. These results suggest low

interference of these nanoparticles with the physiological functions of the tested cells. However, a big discrepancy between the results of the two tests was observed in regards to IC₅₀ of 50 nm C-PB in MTT and Cell Titer Glo experiments. For this reason, a preliminary screening of cell viability for cells treated with 50 nm C-PB at 24 and 48 h was attempted with an MTT assay in order to confirm the toxicity of the materials. Cell viability profiles of the same 50 nm C-PB incubated for longer times with the cells showed IC₅₀ values markedly higher that the ones reported for 4 h incubation. This result was not expected as toxicity is believed to be proportional to the extent of time that the toxic material is in contact to the cell line. Another group of researchers showed that MTT tests overestimate the toxicity of amine modified mesoporous silica nanoparticles (MSN). This effect is due to an increase of the exocytosis of the formazan crystals forming by the dehydrogenases of living cells, and that this is affected by the presence of MSN⁴¹. It is likely that this effect might not be only limited to positively charged MSN but also to other synthetic materials. Cell activity interference of 50 nm C-PB at 4, 24 and 48 h with an MTT test also accredit the hypothesis that MTT test should not be used with materials that interfere with endocytic processes as it is more extensively discussed below.

CPZ and MBCD were chosen as pharmacological inhibitors of endocytosis. As these materials have been repeatedly reported as toxic, the effects of CPZ and MBCD were characterised by two assays: MTT and Cell Titer Glo. An additional toxicity test was also used for CPZ and consisted of an Apo I caspase 3/7 assay^{13,42-44}.

MBCD toxicity was found to be low at the concentrations tested (up to 10 mM) in 3T3, HCT116 and MGLVA-1 cells. The Cell Titer Glo assay reported an increase of ATP content in 3T3 cells treated with increasingly high concentrations of MBCD when compared to ATP content of negative control cells. A possible explanation of this phenomenon might be that an increase in MBCD concentration might cause a

progressive increase in inhibition of endocytosis. It has been shown that endocytosis, which is a constant and energy demanding process, necessitates actin rearrangements, with energy required for cytoskeleton movements as well as for small GTPase intervention in the endocytic process (dynamin, Rab GTPases). As a consequence, inhibition of endocytic pathways might lead to a general increase of ATP and energy levels as ATP normally produced by cells for endocytic processes is not being used at the typical physiological rate ⁴⁵⁻⁴⁸. The above mentioned hypothesis might also explain why Cell Titer Glo usually underestimated toxicity profiles in CPZ studies (please see below).

CPZ has also been extensively reported as toxic in prior literature. The drug affects mitochondria at concentrations lower than 10 μ M causing rounding, swallowing and migration to the periphery of the nucleus of these organelles^{21,49}. At concentrations of 20-30 μ M it interferes with the cytoskeleton and blocks cell cycle in G2-M phase²⁰ while at concentrations of 50-100 μ M it binds to calmodulin. Calmodulin regulates the recruitment of myristoylated alanine rich C kinase substrates (MARCKS) that sequester phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2). Consequently, CPZ inhibits CME by stopping the interaction of the AP-2 adaptor complex with membrane bound PI(4,5)P2^{19,50}. For all these reasons, a full evaluation of its effects in the used cell lines was necessary.

It has been suggested that, since the MTT assay relies on endocytosis for the test compound to access healthy cells, and thus convert MTT to purple formazan, conducting an MTT assay in the presence of endocytosis inhibitors is inherently flawed⁵¹⁻⁵³. For all these reasons it was necessary to run further tests. Because of the high ATP levels in tested cells reported by Cell Titer Glo assay, it was hypothesized that if CPZ were to be toxic, the overall effect would lead to apoptosis. As a consequence, the presence of apoptotic cells was investigated through an Apo I

Caspase 3/7 kit. For 3T3 cells, IC₅₀ and confidence intervals of the three tests suggested that the real IC₅₀ values of CPZ ranged between 68 and 151 μ M for 3T3 and 64 and 209 µM for MGLVA-1 cells. For HCT116 cells the three toxicity assays gave broader IC_{50} values ranging from 54 to 223 μ M. The Cell Titer Glo assay reported the highest IC₅₀ values in the range, suggesting the effects of CPZ on ATP levels in all cell lines were lower than its effects on other metabolic pathways. MTT and Apo I assays were in partial agreement, suggesting that there was toxicity associated with the use of the drug at 4.5 h. However, the MTT test reported the highest effects on cell viability compared to Apo I and Cell Titer Glo. This might have been due to the effect of CPZ on mitochondria, where dehydrogenases that are partially involved in the conversion of the MTT to formazan reside. More specifically, CPZ has been reported to inhibit mitochondrial complex I activity that has been also reported to be involved in the reduction of the MTT to purple formazan in in vitro isolated mitochondria^{49,51}. If this hypothesis were to be true the MTT assay might be the most sensitive and reliable toxicity assay of the three reported in this chapter. However, even though reduction of activity of mitochondrial complex I is an excellent indication of cell viability given that the complex is involved in the oxidative phosphorylation and ATP production, CPZ is inhibiting a rather energy demanding process and for this reason ATP levels stay high. Hence, in these conditions, it is not clear if cells are really less viable or if there is a fine balance between the reduction of ATP production and ATP usage that enables cells to carry on with their physiological activities at low CPZ concentrations. Another point must be stressed: if the MTT assay relies also on an energy-dependent pathway for the MTT dye to enter cells rather than passive diffusion, a lack of purple formazan dye detected in the assay may have been due to lack of MTT uptake rather than loss of cell viability. These considerations might explain another anomaly: i.e. why did the Apo I caspase 3/7

assay do not indicate toxicity until CPZ concentrations reached higher levels than those in the MTT assay where viability decreased. Another possible way to explain such an anomaly might be that caspase 3/7 enzymes are produced at a rather late stage of the cell death process and thus would not have been activated at time points by which cell viability (as shown by MTT) had already decreased. However, evidence in the literature suggests that apoptosis is a rather rapid process that occurs within 5-15 minutes. In these papers, evidence of apoptosis activation was detected as a sharp increase of caspase 3 activity^{54,55}.

Immunofluorescence confocal and flow cytometry studies with anti human CHC isoform α clone X22 and cav-1 clone 2297 revealed that HCT116 cells expressed high levels of CHCα. MGLVA-1, on the other hand, presented high levels of cav-1 expression and this was an interesting result per se because the literature reports that *in vitro* cell lines often lack caveolae⁵⁶. Finally, cav-1 and CHCα expression was relatively low in 3T3 fibroblasts compared to the other cell lines. However, given that 3T3 fibroblasts were the only non human cell lines tested, a legitimate doubt was that the antibody used for immunofluorescence was less active against murine CHCa and cav-1. Cav-1 is a protein with 178aa and the mAb clone 2297 anti cav-1 recognises a region between aa 61 and 71⁵⁷. This region is conserved in both human and mouse according to FASTA database but murine and human cav-1 are not identical. They present 9 point mutations, two before the mAb target region (aa 36-37) and 7 after and corresponding to a 106-107, 154, 163, 170 and 173-174. CHC α (1675aa) of mouse and human are better conserved with respect of cav-1, and mouse CHCa presents 2 point mutations only at aa 1146 and 1406 respectively. These mutations are after the mAb clone X22 epitope region 1109-1128⁵⁸. To investigate whether the immunocytochemistry results in murine 3T3 cells could be correlated to those in human cells, an additional human fibroblastic cell line, MRC-5 lung derived, was also

used. Concentrations of cav-1 expression in MRC-5 was also found to be low. For CHC α levels, on the other hand, 3T3 immunofluorescence data was at variance with MRC-5 clathrin expression levels. These differences brought to the decision to investigate further the reliability of the immunofluorescence data with ICOS 3D prediction software. Results from the analysis of the 3D rearrangement of the proteins and their exposure to the solvent showed that both cav-1 and CHC α 3D architecture of the epitopes recognised by the two mAb were different. For these reasons it is not possible to conclude that CHC α and cav-1 quantification in 3T3 cells with immunofluorescence experiments can be compared to human expression of the same proteins as the mAb used are likely to have different levels of activity against human and mouse proteins.

The last experiments in this series were for the determination of the most efficient procedures for the removal of endocytic markers from the plasma membrane. Here two techniques were investigated:

- flask wash procedures using traditional buffers for the removal of endocytic markers from the plasma membrane of cells were applied on adherent cells before trypsinization, or
- cells were trypsinized and wash steps carried out on suspensions of cells.

When comparing washes in cell suspensions to washes on adherent cells of Htf it was evident that the best way to remove the Htf marker was with washes of suspensions of cells in Eppendorf tubes. The contrasting settings (in flasks) were better for the removal of LacCer from the plasma membrane. Three possible explanations can be hypothesised here for the more efficient removal of Htf in Eppendorf tubes. It is known in the literature that trypsin cleaves the membrane localised Htf receptor ⁵⁹. This is only a partial pool of the overall transferrin receptors

Results - Characterization of Materials and Cell lines

that are also present in the cytoplasm of cells, but the cleavage nevertheless neutralizes part of this pool and continuing these washes on ice might slow down and stop any further recycling on the plasma membrane. Trypsinization might have removed both the free receptor and the receptor bound to Htf. By doing so the application of trypsin might have aided the effects of the wash by contributing to the removal of membrane- and receptor-bound Htf. Trypsin cleavage of Htf receptor free from Htf might also have limited any unwanted interaction of the Htf that was being removed from the membrane and freed into solution with the Htf receptor. The detachment of the Htf from the receptor occurs during the last 2 steps of washes and after the acid wash. The acid wash (pH≤5) reduces and removes the iron from the holo-Htf producing an apo-Htf^{59,60}. Apo-Htf remains tightly bound to its receptor at acid pH (apparent dissociation constant, $K_d=13x10^{-9}M$,⁶¹). When the complex is then exposed again to neutral pH the apo-Htf is released. Apo-Htf has a binding affinity to the receptor at neutral pH that is 3 orders of magnitude lower than holo-Htf but still can bind the receptor, especially when the concentration of holo-Htf (K_d=7x10⁻⁹M) is low in solution and it is not competing for its binding. Also, the media used for washes has 0.1μ g/ml of ferric nitrate Fe(NO₃)₃·9H₂O which means that potentially the apo-Htf can bind to the iron in the media and produce a new holo-Htf for high affinity receptor binding. Finally, another practical consideration might contribute towards the efficiency of the washes in Eppendorf tubes. When Eppendorf tubes are on ice it is easier to control the temperature compared to the analogous experiments with larger 25cm² flasks on ice, as uneven distribution of the ice might create local gradients of temperatures making possible the internalization of Htf, which is a high speed process with recycling of the receptor back to the plasma membrane in as little as 4 minutes^{62,63}.

Results - Characterization of Materials and Cell lines

Removal of LacCer from the plasma membrane was more efficient in flasks than in Eppendorf tubes. A possible explanation is that the diffusion of the buffer components used for the washes was less efficient in Eppendorf tubes with respect to flask washes. Here, interaction of defatted albumin with the plasma membrane is essential for the displacement of LacCer from the membrane of cells and it is possible that a major exposure of the cells' surface to the buffer in adherent cells on flasks might aid the process. Also, defatted albumin buffers are usually applied for 10 minutes and it might happen that the natural sedimentation of suspensions of cells might interfere with the process. Finally, another hypothesis might explain why the surface of trypsinized cells is less accessible to the wash buffer and albumin. Cells presenting hydrophobic LacCer on their membrane might more promptly aggregate and consequently make the access of defatted albumin to the adherent portions of the two plasma membranes virtually impossible and by doing so reduce the overall efficiency of the wash processes.

3.5 Conclusions

In this set of experiments the conditions for the inhibition studies of endocytic pathways with pharmacological inhibitors were delineated. It was established that the C-PB chosen for the experiments were negatively charged as expected and that they were more colloidally stable than assumed. However, they also presented a broader range of size variation than expected, which was an unwanted characteristic for these materials in the intended experiments. Also, the bi-modal size distributions of 100 nm C-PB, although affecting only 5% of the population of such materials, was also an undesirable characteristic to take into consideration in inhibition studies. The effects of 50 nm C-PB on cell viability were shown to be low for Cell Titer Glo while a high toxicity profile was obtained for MTT in HCT116 and MGLVA-1 cells. These findings

Results - Characterization of Materials and Cell lines

suggested setting the concentration of nanoparticles for endocytosis inhibition to 100 μ g/ml and microscopy studies to 50 μ g/ml. The intended concentration of MBCD of 1.25 mM for inhibition studies was found to be appropriate as MBCD was virtually non toxic at this concentration in all cell lines. However, the intended concentration of CPZ for inhibition studies (80 μ M) was accompanied by some toxicity. Although a final IC₅₀ for the drug was not measured univocally by three separate tests, Apo I and MTT assays suggested that the dose of CPZ suitable for inhibition studies (80 μ M) might be close to a toxic level. For this reason, it was decided to carry out inhibition studies also with 40 and 60 μ M CPZ. Immunocytochemistry experiments delineated the experimental conditions in terms of quantity of endocytic proteins such as clathrin and caveolin in the cell lines used. The final experiments of this set on the efficiency of the removal of Htf and LacCer from the plasma membrane gave evidence that the best procedure for the washes utilized small scale Eppendorf tube washes and cells suspensions for Htf stripping from the membrane and on adherent cells and flasks for LacCer removal.

References

- 1 McMillan, J., Batrakova, E. & Gendelman, H. E. Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci **104**, 563-601 (2011).
- 2 Raemdonck, K., Martens, T. F., Braeckmans, K., Demeester, J. & De Smedt, S. C. Polysaccharide-based nucleic acid nanoformulations. Adv Drug Deliv Rev **65**, 1123-1147 (2013).
- 3 Champion, J. A., Katare, Y. K. & Mitragotri, S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release **121**, 3-9 (2007).
- 4 Saha, K. et al. Surface functionality of nanoparticles determines cellular uptake mechanisms in mammalian cells. Small **9**, 300-305, doi:10.1002/smll.201201129 (2013).
- 5 Elder, A., Vidyasagar, S. & DeLouise, L. Physicochemical factors that affect metal and metal oxide nanoparticle passage across epithelial barriers. Wiley Interdiscip Rev Nanomed Nanobiotechnol **1**, 434-450 (2009).
- 6 Dirisala, A. et al. Optimized rod length of polyplex micelles for maximizing transfection efficiency and their performance in systemic gene therapy against stroma-rich pancreatic tumors. Biomaterials **35**, 5359-5368 (2014).

- 7 Koch, S. & Nusrat, A. The life and death of epithelia during inflammation: lessons learned from the gut. Annu Rev Pathol **7**, 35-60 (2012).
- 8 Schlage, W. K. et al. In vitro systems toxicology approach to investigate the effects of repeated cigarette smoke exposure on human buccal and gingival organotypic epithelial tissue cultures. Toxicol Mech Methods, 1-37 (2014).
- 9 Frede, J., Adams, D. J. & Jones, P. H. Mutation, clonal fitness and field change in epithelial carcinogenesis. J Pathol (2014).
- 10 Kharaishvili, G. et al. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell International (2014).
- 11 Sotgia, F. et al. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research **13**, 213 (2011).
- 12 Sahay, G., Alakhova, D. Y. & Kabanov, A. V. Endocytosis of nanomedicines. Journal of Controlled Release **145**, 182-195 (2010).
- 13 Vercauteren, D. et al. The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls. Mol Ther **18**, 561-569 (2010).
- 14 Lamaze, C. & Schmid, S. L. The emergence of clathrin-independent pinocytic pathways. Current Opinion in Cell Biology **7**, 573-580 (1995).
- 15 Ivanov, A. I. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods in molecular biology **440**, 15-36 (2008).
- 16 Stuart, A. D. & Brown, T. D. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J Virol **80**, 7500-7509 (2006).
- Holmsen, H. & Rygh, T. Chlorpromazine makes the platelet plasma membrane permeable for low-molecular weight substances and reduces ATP production. Biochemical Pharmacology 40, 373-376 (1990).
- 18 Francesco, C. D. & Bickel, M. H. Membrane lipids as intracellular binders of chlorpromazine and related drugs. Chem Biol Interact **16**, 335-346 (1977).
- 19 Eisenberg, S., Giehl, K., Henis, Y. I. & Ehrlich, M. Differential Interference of Chlorpromazine with the Membrane Interactions of Oncogenic K-Ras and Its Effects on Cell Growth. Journal of Biological Chemistry **283**, 27279-27288 (2008).
- 20 Lee, M. S. et al. The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action. Cancer Research **67**, 11359-11367 (2007).
- 21 Dudani, A. K. & Gupta, R. S. Effect of chlorpromazine and trifluoperazine on cytoskeletal components and mitochondria in cultured mammalian cells. Tissue and Cell **19**, 183-196 (1987).
- 22 Maurer, I. & Möller, H.-J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem **174**, 255-259 (1997).
- 23 Ulloth, J. E. et al. Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death. Neurotoxicology **28**, 613-621, doi:D nlm: nihms25952
- 24 Ulloth, J. E. et al. Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death. Neurotoxicology **28**, 613-621 (2007).
- 25 Zhang, J. H., Chung, T. D. F. A. U. O. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of Biomolecular Screening 4, 67-73 (1999).

- 26 Iversen, P. W., B.J., E., Sittampalam, G. S. & Cox, K. L. A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. Journal of Biomolecular Screening 11, 247-252 (2006).
- 27 van Renswoude, J., Bridges, K. R., Harford, J. B. & Klausner, R. D. Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proceedings of the National Academy of Sciences **79**, 6186-6190 (1982).
- 28 Pagano, O. C. M. a. R. E. Internalization and sorting of a fluorescent analogue of glucosylceramide to the Golgi apparatus of human skin fibroblasts: utilization of endocytic and nonendocytic transport mechanisms. J Cell Biol **125**, 769-781 (1994).
- 29 Stout, M., Bacardit, J., Hirst, J., Smith, R. & Krasnogor, N. Prediction of topological contacts in proteins using learning classifier systems. Soft Computing **13**, 245-258 (2009).
- 30 Bacardit, J., Stout, M., Krasnogor, N., Hirst, J. D. & Blazewicz, J. in Proceedings of the 8th annual conference on Genetic and evolutionary computation 247-254 (ACM, Seattle, Washington, USA, 2006).
- 31 Stout, M., Bacardit, J., Hirst, J. D. & Krasnogor, N. Prediction of recursive convex hull class assignments for protein residues. Bioinformatics **24**, 916-923 (2008).
- 32 Frohlich, E. et al. Action of polystyrene nanoparticles of different sizes on lysosomal function and integrity. Particle and Fibre Toxicology **9**, 26 (2012).
- 33 Canton, I. & Battaglia, G. Endocytosis at the nanoscale. Chemical Society Reviews **41**, 2718-2739 (2012).
- 34 Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377, 159-169 (2004).
- 35 Xu, R. (Kluwer, Dordrecht, Netherland, 2001).
- 36 Freshney, R. I. (Alan R. Liss, Inc., New York, 1987).
- 37 Wang, F. et al. Time resolved study of cell death mechanisms induced by amine-modified polystyrene nanoparticles. Nanoscale (2013).
- 38 Lesniak, A. et al. Effects of the Presence or Absence of a Protein Corona on Silica Nanoparticle Uptake and Impact on Cells. ACS Nano 6, 5845-5857 (2012).
- 39 Vetten, M. et al. Label-free in vitro toxicity and uptake assessment of citrate stabilised gold nanoparticles in three cell lines. Particle and Fibre Toxicology **10**, 50 (2013).
- 40 Frohlich, E. et al. Action of polystyrene nanoparticles of different sizes on lysosomal function and integrity. Part Fibre Toxicol **9**, 26, doi:10.1186/1743-8977-9-26 (2012).
- 41 Fisichella, M. et al. Mesoporous silica nanoparticles enhance MTT formazan exocytosis in HeLa cells and astrocytes. Toxicology in Vitro **23**, 697-703 (2009).
- 42 Sun, X., Yau, V. K., Briggs, B. J. & Whittaker, G. R. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology **338**, 53-60 (2005).
- 43 Cantín, C., Holguera, J., Ferreira, L., Villar, E. & Muñoz-Barroso, I. Newcastle disease virus may enter cells by caveolae-mediated endocytosis. Journal of General Virology 88, 559-569 (2007).
- 44 Kiss, T. et al. Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur J Pharm Sci **40**, 376-380 (2010).
- 45 Schmid, S. L. & Carter, L. L. ATP is required for receptor-mediated endocytosis in intact cells. J Cell Biol **111**, 2307-2318 (1990).
- 46 Hutagalung, A. H. & Novick, P. J. Role of Rab GTPases in membrane traffic and cell physiology. Physiological Reviews **91**, 119-149 (2011).

- 47 Samuel C Silverstein, Ralph M Steinman & Cohn, Z. A. ENDOCYTOSIS. Ann Rev Biochem 46, 669-722 (1977).
- 48 Schmid, S., Carter, L. & Smythe, E. in Endocytosis Vol. 62 NATO ASI Series (ed PierreJ Courtoy) Ch. 13, 105-111 (Springer Berlin Heidelberg, 1992).
- 49 Hroudova, J. & Fisar, Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol Lett **213**, 345-352 (2012).
- 50 Levin, R. M. & Weiss, B. Mechanism by Which Psychotropic Drugs Inhibit Adenosine Cyclic 3',5'-Monophosphate Phosphodiesterase of Brain. Molecular Pharmacology **12**, 581-589 (1976).
- 51 Liu, Y., Peterson, D. A., Kimura, H. & Schubert, D. Mechanism of Cellular 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Reduction. Journal of Neurochemistry 69, 581-593 (1997).
- 52 Liu, Y. & Schubert, D. Cytotoxic Amyloid Peptides Inhibit Cellular 3-(4,5-Dimethylthiazol-2yl)-2,5-Diphenyltetrazolium Bromide (MTT) Reduction by Enhancing MTT Formazan Exocytosis. Journal of Neurochemistry **69**, 2285-2293 (1997).
- 53 Ahmad, S., Ahmad, A., Schneider, K. B. & White, C. W. Cholesterol interferes with the MTT assay in human epithelial-like (A549) and endothelial (HLMVE and HCAE) cells. Int J Toxicol 25, 17-23 (2006).
- 54 Tyas, L., Brophy, V. A., Pope, A., Rivett, A. J. & Tavare, J. M. Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep 1, 266-270 (2000).
- 55 Rehm, M. et al. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process. Role of caspase-3. J Biol Chem 277, 24506-24514 (2002).
- 56 D'Alessio, A., Al-Lamki, R. S., Bradley, J. R. & Pober, J. S. Caveolae Participate in Tumor Necrosis Factor Receptor 1 Signaling and Internalization in a Human Endothelial Cell Line. The American Journal of Pathology 166, 1273-1282 (2005).
- 57 Scherer, P. E. et al. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem **270**, 16395-16401 (1995).
- 58 Liu, S.-H., Wong, M. L., Craik, C. S. & Brodsky, F. M. Regulation of Clathrin Assembly and Trimerization Defined Using Recombinant Triskelion Hubs. Cell **83**, 257-267 (1995).
- 59 Dautry, A., Ciechanover, A., Lodish, C. & Lodish, F. H. Ph and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A **80**, 2258-2262 (1983).
- 60 Klauser, R. D., Ashwell, G., Van Renswoude, J., Harford, J. B. & Bridges, K. R. Binding of apotransferrin to K562 cells: Explanation of the transferrin cycle. Proc Natl Acad Sci USA **80**, 2263-2266 (1983).
- 61 Maxfield, F. R. & McGraw, T. E. Endocytic recycling. Nat Rev Mol Cell Biol 5, 121 132 (2004).
- 62 Presley, J. F., Mayor, S., McGraw, T. E., Dunn, K. W. & Maxfield, F. R. Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J Biol Chem **272**, 13929-13936 (1997).

4-Chapter 4

Inhibition of endocytosis and microscopy

studies

4.1 Introduction

Endocytosis is a highly regulated and efficient process that takes place in all cells. This process is used to introduce nutrients and growth factors by receptor-mediated pathways and the same route is also used for signalling^{1,2}. Furthermore, some pathogens such as viruses have evolved mechanisms to enter cells by endocytosis³⁻⁹. An increasingly high proportion of the literature reports that synthetic nanomaterials can access cells through endocytosis^{8,10-13}.

In this chapter are reported and discussed the results on the optimization of inhibition studies with both LacCer and Htf, markers of clathrin-dependent endocytosis (CME) and clathrin-independent endocytosis (CIE), and CPZ and MBCD, inhibitors of CMEphagocytosis/macropinocytosis and CIE. MBCD was tested at 1.25 mM and CPZ at 80 µM: these quantities were chosen from a preliminary screening as the lowest concentrations of inhibitors that efficiently inhibited CME and CIE. From viability results shown in chapter 3, MBCD did not produce any toxic effects at 1.25 mM, and for this reason this concentration only was tested in inhibition studies. However, as viability and a toxicity assay reported IC₅₀ values close to 80 µM for CPZ, experiments with 40 and 60 µM CPZ were also carried out. The results of the cell entry inhibition assays with low concentrations of CPZ were compared to the results obtained with 80 µM CPZ to detect any effects on endocytosis that the higher and supposedly toxic concentration was having on the uptake of Htf. To further probe that the effects obtained with 80 μ M CPZ were not due to general toxicity of the drug on cells, experiments in the absence of Ca²⁺ and Mg²⁺ were also performed. Finally, from the data obtained, the effect of the passage number of cells on inhibition studies was also investigated. CME inhibition was also studied with Pitstop 2, a relatively new molecule that binds the amino-terminal domain of CHC that is involved in the

interaction of clathrin with the adaptor proteins that help the formation of the clathrin lattice¹⁴. Finally, C-PB of 50 and 100 nm were chosen as a model of negatively charged nanocarriers of drugs and their route of uptake inhibited with CPZ 80 µM and MBCD 1.25 mM in 3T3, HCT116 and MGLVA-1 cells. Confocal microscopy was carried out on live cells treated with C-PB of 50 and 100 nm that were shown from inhibition studies to access cells through specific pathways. The aim of these experiments was to verify that the C-PB accessed cells and to characterize the specific route of uptake by any differences in compartmentalization.

4.2 Methods

4.2.1 Optimization of the inhibition of Htf uptake

4.2.1.1 Inhibition of Htf uptake with CPZ

For a more complete description of the methods used in these experiments please refer to §2.2.7 of the materials and methods. Here, cells were seeded at a density of 31200 cells/cm² and allowed to attach to the bottom of the 25 cm² flasks overnight. Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without 40-60 or 80 μ M CPZ and 1.25 mM MBCD for 30 minutes and then replaced with HBSS/HEPES 20 mM with or without Htf 0.81 μ M and 40-60 and 80 μ M CPZ or 1.25 mM MBCD. Upon completion of the incubation time, cells were washed, detached from flasks and then analysed with a BD LSR II flow cytometer. The acid wash was carried out on 25 cm² flasks on ice.

4.2.1.2 Inhibition of Htf uptake with Pitstop 2

HCT116 cells were seeded at a density of 31200 cells/cm² and allowed to attach to the bottom of 25 cm² flasks overnight (§2.2.8). Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without Pitstop 2 for 15 minutes and then replaced with HBSS/HEPES 20 mM with or without Htf 6.7 μ g/ml and

chemical inhibitor for 1 or 2 h. Pitstop working concentrations were selected as 12.5, 18.75 and 25 μ M. Upon completion of the incubation time, cells were washed, detached from flasks and then analysed with a BD LSR II flow cytometer. The results are shown as the mean of 2 independent experiments. Htf was removed by an acid wash as reported in the literature¹⁶ and in methods described above and §2.2.6.

4.2.2 Optimization of the inhibition of LacCer uptake with MBCD

Cells were seeded at a density of 31200 cells/cm² and allowed to attach to 25 cm² flasks overnight. Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without chemical inhibitors of endocytosis for 30 minutes and subsequently replaced with HBSS/HEPES 20 mM alone (negative control), LacCer 0.81 μM (positive controls) or with LacCer 0.81 μM in the presence of 80 μM CPZ or 1.25 mM MBCD. The incubation times were 1-2-3 and 4 h for all cell lines. Upon completion of the incubation time, cells were washed with the back exchange method and subsequently detached from flasks and then analysed with a BD LSR II flow cytometer and detected on a FITC channel, 530/30 optical bandpass filter¹⁷. The results were normalised against the positive and negative controls¹⁵. The LacCer washes were carried out in 25 cm² flasks on ice to inhibit endocytosis.

4.2.3 Inhibition of endocytosis of C-PB with CPZ and MBCD

Inhibition of endocytosis in the presence of 50 and 100 nm C-PB was carried out according to the protocols described in the materials and methods section §2.2.10. Cells were seeded at a density of 31200 cells/cm² and allowed to attach to 25cm^2 flasks overnight. Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES with or without 80 μ M CPZ and 1.25 mM MBCD for 30 minutes. The buffer was then replaced with HBSS/HEPES 20 mM alone (negative control), 50 nm or 100 nm C-PB 100 μ g/ml, (positive controls) or with 50 or 100 nm C-PB 100 μ g/ml in the presence of 80 μ M CPZ or 1.25 mM MBCD. C-PB and inhibitors were

further incubated for 1 and 2 h with 3T3 and HCT116 cells and for 2 and 4 h with MGLVA-1 cells. Subsequently, cells were washed twice with HBSS/HEPES 20 mM and EDTA, detached from flasks with trypsin/EDTA, centrifuged at 2000 g for 5 minutes and re-suspended in PFA 4% v/v in PBS. 10000 gated cells were then analysed with a BD LSR II flow cytometer and detected on a FITC channel, 530/30 optical bandpass filter. The results were normalised against the positive and negative controls¹⁵.

4.2.4 Confocal microscopy live imaging

Cells that showed sensitivity to CPZ and MBCD for the internalization of 50 and 100 nm C-PB were also investigated by live cell confocal microscopy studies. Endocytosis of 100 nm C-PB was investigated in 3T3 cells, endocytosis of 50 nm C-PB was studied in HCT116 cells and endocytosis of 50 and 100 nm C-PB were examined in MGLVA-1 cells. The confocal microscopy experiments were run on live cells for a period of 1 h. For a more detailed description of the materials and methods of this section please refer to 2.2.12. Briefly, cells were seeded in full media to a final density of 31200 cells/cm² in 6 well plates on sterile rounded 22x1.5 mm glass coverslips. Cells were left to attach to the glass coverslips overnight. The day after, cells were stained with Hoechst 33342 (1 µg/ml) and CellMask deep red cell membrane dye (1 µg/ml) for 30 minutes at 37 °C. The cells were then rinsed with HBSS/HEPES and the media replaced with HBSS/HEPES 20 mM for live imaging. Live images of 4 regions of interest were acquired at 4-10-20-30-40-50 and 60 minutes on a 40x water objective.

The measurements of the integrated fluorescence density of the C-PB for each cell and time point were processed with ImageJ software and subtracted from the integrated background from a region adjacent to each cell taken into the analysis as for the equation below:

154

 $(\int Fluor)_{Corr} = \int Fluor - (A_{cell} X M_{Fluor bkd})$

Where:

(JFluor)_{Corr} = Correct integrated fluorescence density

JFluor = Integrated fluorescence density of the cell of interest (IntDen in ImageJ)

 A_{cell} = area of the cell (Area in ImageJ)

M_{Fluor bkd} = mean fluorescence of the background (Mean in ImageJ)

Analysis of the integrated fluorescence density was derived from measuring a minimum of 30 cells for each time-point and plots showing the mean and the standard deviation.

Co-localization of the C-PB with Hoechst and CellMask was determined by calculation of the Pearson's correlation coefficient with a JACoP plugin of ImageJ. The Pearson's coefficient obtained for each picture and the time-point was averaged and the mean and the standard deviation are shown in the results. For each experiment, one z stack was also obtained to acquire a 3D image of the distribution of C-PB in cells.

4.3 Results

4.3.1 Optimization of the inhibition of Htf uptake

4.3.1.1 Optimization of the inhibition of Htf uptake with CPZ

In these experiments, CPZ at a concentration of 80 μ M was used to inhibit the uptake of Htf in 3T3, HCT116 and MGLVA-1 cells. Endocytosis was also inhibited with 40 μ M CPZ in 3T3 fibroblasts while additional inhibition studies in HCT116 cells were carried out with 40 and 60 μ M CPZ. For each experiment and time-point 1.25 mM MBCD was used as a control to evaluate if any interference on CME by MBCD occurred. All

these experiments were run for 1, 2, 3 or 4 h and results at each time-point compared. The experimental results shown below are the combination of 2 independent experiments for concentrations of CPZ of 40 and 60 μ M and up to 6 independent experiments for 80 μ M CPZ.

Inhibition of Htf uptake with CPZ was temporary and occurred over an incubation time that was cell-dependent (Figure 4-1 and 4-2, Table 4-1). The maximum inhibition of Htf uptake was obtained at 2 h for 3T3 fibroblasts, 1 h for HCT116 cells and 4 h for MGLVA-1. After that maximal inhibition, the uptake of Htf recovered to normal non-inhibited levels in 3T3 and HCT116 cells at 4 h. The extent of inhibition was affected by the concentration of CPZ used, with low inhibition of the uptake of Htf at lower concentrations of CPZ (Figure 4-3). However, the pattern of inhibition at different time points also remained unchanged at lower concentrations of CPZ and was time-dependent, with an optimal incubation time at 2 h for 3T3 and 1 h for HCT116. After maximal inhibition at that time-point, the uptake of Htf was restored in 3T3 and HCT116 cells. The extent of the recovery was dependent on the concentration of CPZ used with longer recovery times for higher concentrations of CPZ.




Figure 4-1 Flow cytometry results showing the time and cell dependence of the inhibition of the uptake of Htf with 80 μ M CPZ in 3T3, HCT116 and MGLVA-1 cells. Cells were preincubated with one inhibitor of endocytosis or HBSS/HEPES 20 mM for negative and positive control for 30 minutes. After that period of incubation the buffer was aspirated and replaced with HBSS/HEPES 20 mM for the negative control or Htf 0.81 μ M in HBSS/HEPES with or without inhibitors of endocytosis and further incubated for 1, 2, 3 or 4 h. The results are the combination of up to 6 independent experiments. They are shown as the mean and standard deviation of the fluorescence of 10000-20000 gated cells for each experiment and are normalised against the Htf treated positive control that was considered as 100% uptake. The dotted lines refer to 50 and 100% uptake of Htf.




Figure 4-2 Flow cytometry histograms on the inhibition of Htf uptake with 80 μ M CPZ at different time points and cell lines. The X axes show the fluorescence intensity of Htf, the Y axes show the number of cells. The dark shadows show Htf uptake at basal, uninhibited levels while the light shadows show Htf uptake in the presence of 80 μ M CPZ.

Statistical analysis of inhibition of Htf endocytosis with CPZ and MBCD			
Two-Way ANOVA	3Т3	Htf vs CPZ	Htf vs MBCD
3T3	1h	***	ns
	2h	***	ns
	3h	*	ns
	4h	ns	ns
HCT116	1h	***	ns
	2h	**	ns
	3h	ns	ns
	4h	ns	ns
MGLVA-1	1h	ns	ns
	2h	ns	ns
	3h	**	ns
	4h	* * *	ns

Table 4-1 Two-Way ANOVA and Bonferroni post-analysis test of the inhibition of Htf uptake in the presence of CPZ and MBCD. Htf uptake of untreated cells was compared with the uptake of Htf in the presence of CPZ and MBCD. The results above show that there is a significant inhibition in the uptake of Htf in the presence of CPZ and the significance is time dependent and depend on the cell line. MBCD inhibition of endocytosis of the uptake of Htf on the other hand, does not show statistical significance. (ns: non significant, P>0.05; *: P<0.05; **: P<0.01; ***: P<0.001).

Inhibition of CME was also obtained with 1.25 mM MBCD and the extent of inhibition was time-dependent, affecting up to 15% of Htf uptake in 3T3 cell lines at 1 h incubation, 10% of Htf uptake in HCT116 cells at 4 h, and 13% at 2 h with MGLVA-1 (Figure 4-1). However a two-way ANOVA statistical analysis showed that the inhibition of internalization of Htf by the action of MBCD was not statistically significant (Table 4-1).





Figure 4-3 Lower concentrations of CPZ reduce the extent of inhibition of Htf uptake in 3T3 and HCT116 cells. The flow cytometry results are normalised against the fluorescence of Htf positive control and expressed at the mean and standard deviation of a minimum of 10000 gated cells for each experiment (n=2). Cells were preincubated with HBSS/HEPES 20 mM with or without inhibitor for 30 minutes. Subsequently the pretreatment buffer was aspirated and 3T3 cells were treated with 40 and 80 μ M CPZ for up to 4 h and HCT116 with 40, 60 and 80 μ M of CPZ for up to 4 h. The dotted lines refer to 50 and 100% uptake of Htf.


In addition, to assess the consequences on cell viability induced by energy depletion resulting from endocytosis, CPZ stock solutions of 40 and 80 μ M were prepared with HBSS without Ca²⁺ and Mg²⁺ (instead of the standard HBSS with supplements of the two ions), complemented with HEPES 20 mM and applied on 3T3 and HCT116 cells as for standard protocol for a period of up to 4 h. The results are given by the combination of 2 independent experiments for 3T3 fibroblasts while only one experiment was attempted for HCT116 cells².

² The experiment was not repeated due to lack of time.

Inhibition studies with HBSS without Ca²⁺ and Mg²⁺ (Figure 4-4) in 3T3 cells showed that the effects on cell viability and induction of apoptosis by media depletion of essential ions was not sufficient to produce a recovery of the internalization of Htf. This suggested that the recovery of uptake of Htf is an energy dependent process that happens in viable cells but not in energy-depleted and stressed cells.



3T3 with HBSS no Ca²⁺ no Mg²⁺






Figure 4-4 Effects of the absence of Ca^{2+} and Mg^{2+} from the assay media on the inhibition and recovery of the uptake of Htf with CPZ. The results shown are represented as the mean and standard deviation of 2 independent experiments in 3T3 cells and only one pilot study experiment in HCT116 cells. The results are normalised against the Htf positive control and show the mean and the standard deviation of 10000 gated cells. Cells were preincubated with HBSS/HEPES 20 mM devoid of Ca^{2+} and Mg^{2+} with or without inhibitor for 30 minutes. Subsequently the pretreatment buffer was aspirated and replaced with fresh solutions of CPZ ranging from 40 to 80 μ M and MBCD 1.25 mM. The cells were further incubated for 1, 2, 3 or 4 h for 3T3 cells and 1, 2 and 3 h for HCT116 cells. The dotted lines refer to 50% and 100% uptake of Htf. Error bars represent the standard deviation of the mean of duplicate experiments, n=2 (3T3 cells).

Finally, the effect of passage number on the extent of the inhibition of endocytosis was investigated in 3T3 and HCT116 cells. Endocytosis was inhibited on 3T3 fibroblasts at passage number ranging between 28 and 53 and HCT116 at passage number 18-44. The experiments were run as from standard protocol for 1 h and 2 h. Each set of experiments was run in duplicates independent experiments and the results merged and averaged.

The inhibition of endocytosis with CPZ was affected by the passage number of the cells used for inhibition studies, with higher passage numbers being more resistant to the inhibition of Htf uptake (Figure 4-5 graph B for 3T3 cells and E for HCT116 cells). The maximal incubation time did not change at low passage numbers but was gradually lost in aged cells. When 3T3 fibroblasts at passage number 53 and 55 were inhibited with 80 μ M CPZ at 1 and 2 h, the inhibition was reduced and also the pattern of inhibition of endocytosis of Htf changed, as shown in graph C in Figure 4-5 with a comparable extent of inhibition at 1 and 2 h.




Figure 4-5 Passage number and ageing of cells affects the extent of inhibition of Htf uptake with CPZ. Cells at different passage numbers were incubated with Htf 6.7 μ g/ml and 80 μ M CPZ at 1 and 2 h in 3T3 and HCT116 cells. Graph A shows the inhibition obtained with 80 μ M CPZ in 3T3 cells at passage number 28 and 30, graphs B and C show the inhibition obtained by the same inhibitor and cell line at passage number 39-41 and 53-55 respectively. Graphs D and E show the extent of the inhibition obtained with 80 μ M CPZ in HCT116 cells at passage number 18-20 (graph D) and passage number 42-44 (graph E). Cells were treated as in previous experiments with 30 min preincubation of CPZ or HBSS/HEPES that was replaced by HBSS/HEPES 20 mM buffer supplemented of Htf for the positive control or 80 μ M CPZ and Htf, and further incubated for 1 or 2 h. The dotted lines refer to 50 and 100% uptake of Htf. The results show the mean and standard deviation of a minimum of 10000 gated cells for each experiment (n=2).

4.3.1.2 Optimization of the inhibition of Htf uptake with Pitstop 2

HCT116 cells incubated with Pitstop 2 12.25 μ M did not show any significant inhibition of endocytosis for a period of up to 2 h (Figure 4-6). When the concentration was raised to 18.75 and 25 μ M, Pitstop 2 reduced endocytosis to a consistent level and the extent of such inhibition was dependent on the concentration of the inhibitor. The recovery of the Htf uptake was not observed here at the incubation times and

concentrations used. Finally, indications of toxicity were detected at concentrations of Pitstop 2 of 18.75 and 25 μ M, with cells appearing rounded and unhealthy.




Figure 4-6 Effects of the inhibition of Htf endocytosis with Pitstop 2 at 12.5, 18.75 and 25 μ M in HCT116 cells. The results represent the combination of 2 independent experiments and show the mean fluorescence of Htf uptake of 20000 gated cells per experiment and the standard deviation of the mean of replicate experiments (n=2). The dotted lines refer to 50 and 100% uptake of Htf.

4.3.1.3 Optimization of the inhibition of LacCer uptake with MBCD

In these experiments, MBCD 1.25 mM was used as an inhibitor of CIE. The effect of the inhibitor on the uptake of LacCer, a marker of CIE, was studied at 1,2,3 and 4 h on 3T3, HCT116 and MGLVA-1 cells. As a further control, the specificity of CPZ on the inhibition of CME at each time point was also investigated with LacCer incubated in the presence of 80 μ M CPZ.

LacCer uptake inhibition with MBCD was easier to obtain, compared to the Htf inhibition with CPZ, as the inhibition was strong and steady for a period of up to 4 h (Figure 4-7). The effect of MBCD inhibition on LacCer uptake was less cell-dependent and a concentration 1.25 mM of MBCD produced a potent inhibition of endocytosis for all cell lines tested. A 1 h incubation period of the drug was sufficient to obtain maximal inhibition of endocytosis in 3T3 and HCT116, whereas 2 h were necessary for MGLVA-1 cells. Also, when CPZ was used as a control for specific clathrin-mediated endocytosis (CME), CPZ showed no ability to inhibit clathrin-

independent endocytosis (CIE). Instead, treatment with CPZ resulted in substantial increase of endocytosis of LacCer in all cells tested, enhancing the uptake of LacCer to 3 times higher levels than those observed in the positive control.




Figure 4-7 Effect of the inhibition of LacCer uptake with 1.25 mM MBCD. Cells were treated as described before. A preincubation step of 30 min was carried out in the presence and in the absence of endocytosis inhibitors. Upon completion of the preincubation time the media was aspirated and replaced with LacCer 0.81 μ M in the presence of in the absence of inhibitors of endocytosis. Cells were incubated for a maximum of 4 h and the results are the combination of 2 independent experiments (n=2), the error bars represent the standard deviation of the mean of a minimum of 20000 gated cells per experiment. The dotted lines refer to 50 and 100% uptake of LacCer.

4.3.2 Inhibition of the endocytosis of C-PB with CPZ and MBCD

The optimized protocol for the inhibition of Htf and LacCer uptake with CPZ and MBCD was applied for the inhibition of the endocytosis of 50 and 100 nm C-PB.


Results (Figure 4-8) show that the inhibition of 50 nm C-PB uptake was obtained with 80 μ M CPZ in both epithelial cells investigated, HCT116 and MGLVA-1. The reduction of the uptake of 50 nm C-PB in HCT116 cells was strong already at 1 h incubation of the inhibitor and the inhibition obtained was steady and uptake did not recover by 2 h. Reduction in the uptake of 50 nm C-PB with CPZ in MGLVA-1 cells was already evident at 2 h with approximately 35% reduction of endocytosis. However, the maximum effect of CPZ was obtained at 4 h with 60% inhibition of 50 nm C-PB uptake with respect to the positive control. The incubation of 50 nm C-PB with CPZ and MBCD in 3T3 fibroblasts produced an activation of the endocytosis of C-PB as for CPZ in LacCer inhibition studies. The same effect was observed in HCT116 and MGLVA-1 cells for 50 nm C-PB incubated with MBCD where an activation of endocytosis at 1-2 h in HCT116 and 2-4 h in MGLVA-1 cells were obtained. The activation was stronger in MGLVA-1 cells than HCT116 cells. No inhibition of endocytosis of 50 nm C-PB was obtained with CPZ and MBCD incubated for 1 and 2 h in 3T3 cells but the endocytosis was up-regulated by both inhibitors.


Endocytosis of 100 nm C-PB was sensitive to CPZ in 3T3 cells and sensitive to MBCD in MGLVA-1 cells. 100 nm C-PB nanoparticles were endocytosed by a non-CPZ non-MBCD sensitive pathway in HCT116 cells. Here, both CPZ and MBCD up-regulated the endocytosis of 100 nm C-PB.

Inhibition of 100 nm C-PB with CPZ in 3T3 cells was obtained at 1 h incubation and the endocytosis recovered almost completely at 2 h. The endocytosis of the same nanoparticles was only partially inhibited with MBCD at 2 h incubation in MGLVA-1

166

cells, and subsequently completely recovered, showing a modest up-regulation after 4 h.





4.3.3 Confocal microscopy live imaging studies

Cell lines that showed sensitivity to endocytic inhibitors in the presence of 50 or 100 nm C-PB were further investigated with confocal microscopy live imaging with the aim of confirming endocytosis and localization of the nanoparticles within the cell membrane boundaries. The internalization was not verified in flow cytometry experiments as the technique does not distinguish between membrane-bound and internalized signal from cells. As some cell lines incubated with C-PB showed

different susceptibility to inhibitors of endocytosis, live images of cells in the presence of C-PB were also carried out to study any pattern in compartmentalization of C-PB sensitive to different inhibitors of endocytosis.

Cells incubated with 50 and 100 nm C-PB showed a rapid uptake of nanoparticles. Endocytosis could already be detected at 4 minutes incubation in all cell lines studied (Figures 4-9, 4-14, 4-19 and 4-24). The Pearson's coefficient of co-localization for each time-point did not show any significant increase of co-localization of C-PB and Hoechst with time suggesting that the nanoparticles did not access nuclei under the experimental conditions used and time-points investigated (Figures 4-13, 4-18B, 4-23 and 4-28). Only a minor, non-statistically significant increase of colocalization of green fluorescence from the nanoparticles and blue fluorescence from the nuclei was detected in HCT116 that might be attributed to a possible effect of proximity with the nuclei of the nanoparticles localized to a perinuclear region resembling the endoplasmic reticulum (ER).




Figure 4-9 Confocal live imaging studies of 3T3 cells treated with 50 µg/ml 100 nm C-PB for a period of 60 min. Red fluorescence: CellMask deep membrane staining, Green: C-PB, Blue: Hoechst nuclei staining. Time 0 refers to cells before application of the C-PB. Pictures were then acquired at 4 and at 10, 20, 30, 40, 50 and 60 minutes from the application of the C-PB. The red intracellular structures stained by CellMask are believed to be the ER. Scale bars represent 50 µm.




Figure 4-10 Orthogonal projection of a 3D image of 3T3 cells treated with 50 µg/ml 100 nm C-PB showing internalised green nanoparticles (arrows) that can be seen inside the red membrane limit of the cells. Green: C-PB, Red: CellMask deep red membrane dye, Blue: Hoechst nuclei staining. The Cell Mask deep red membrane dye is staining a perinuclear intracellular compartment believed to be the ER. Scale bar represents 50 µm.




Figure 4-11 This picture shows the differences in the redistribution of CellMask red plasma membrane staining at 4 and 60 minutes in 3T3 fibroblasts treated with 100 nm C-PB. Less confluent cells appear to redistribute the dye more quickly to the plasma membrane of cells, while more confluent cells show the dye in the cytoplasmic region of cells also after 60 minutes incubation of cells in the presence of C-PB. The redistribution of C-PB from a perinuclear region to a cytoplasmic region is not evident from these pictures. Scale bar represents 50 µm. Green: 100 nm C-PB; Red: CellMask deep red membrane staining.




Figure 4-12 Zoom images of live experiments shown in Figure 4-9 – 4-11 of 3T3 cells treated with 100 nm C-PB 50 µg/ml for a period of 60 minutes. The arrows show aggregates of nanoparticles that detach from the membrane (details pictures). The arrow heads point to the membrane ruffling on the plasma membrane of 3T3 cells. Scale bars represent 10 µm. Green: C-PB; Red: CellMask membrane staining; Blue: Nuclei.




Figure 4-13 Analysis of the fluorescence of 3T3 cells treated with 50 µg/ml 100 nm C-PB for a period of 60 min. G: Green fluorescence of 100 nm C-PB; R: Red fluorescence of the CellMask deep red membrane staining; B: Hoechst nuclei staining. Here the green fluorescence normalised per area of cells and subtracted of the background of a region adjacent to the cells taken into the analysis is measured at different time points. From the graph it is possible to visualize an increase of the green fluorescence of the C-PB. The Pearson's coefficient analysis, obtained with a JACOP pluging of ImageJ, shows there is little co-localization of the nanoparticles with the nuclei and a partial co-localization of the CellMask deep red membrane staining and the C-PB. Error bars represent the standard deviation of the mean (n>20).

All cell lines showed some extent of internalization of the CellMask with a different degree of internalization depending on the cell line (Figures 4-11, 4-16, 4-21 and 4-26). The extent of internalization was higher in 3T3 and HCT116 cells with respect to MGLVA-1 cells.

CellMask stained the intracellular compartments of 3T3 cells more promptly than the plasma membrane where only weak staining was obtained (Figure 4-11), while a strong and stable staining of the cell membrane for up to 60 minutes was obtained with the dye in HCT116 cells (Figure 4-16). The same dye predominantly labeled the plasma membrane of MGLVA-1 cells, with moderate staining of intracellular compartments (Figure 4-21 and 4-26).

Furthermore, CellMask appeared to redistribute after application of the C-PB on cells with a stronger staining of the plasma membrane after application of 50 nm C-PB on HCT116 cells (Figures 4-14 and 4-16). A similar pattern was observed in 3T3 cells (Figures 4-9 and 4-11). However, here different confluence of cells also showed a different pattern of redistribution of CellMask where more confluent cells redistributed CellMask more slowly from the cytoplasm to the plasma membrane, while cells in less confluent regions looked more rounded and lost their elongated features (typical for this cell line) and presented a lower level of CellMask staining into the cytoplasm. The redistribution of CellMask in MGLVA-1 cells was less obvious after application of 50 and 100 nm C-PB (Figures 4-19, 4-21, 4-24 and 4-26). Uptake of C-PB was already evident at 4 minutes from their application in all cell lines.

Green fluorescence from C-PB in 3T3 cells (normalized per area of cells) increased immediately after application of 100 nm C-PB for up to 20 minutes, with a slight reduction of fluorescence at 10 minutes. However, after 20 minutes the green fluorescence due to the C-PB began to decrease with time. Here, the difference in the green fluorescence at different time points was not statistically significant with a t

test (Figure 4-13). Figure 4-12 at 20 and 30 minutes gives evidence of the presence of aggregates of nanoparticles adjacent to the plasma membrane at 20 minutes from the application of the 100 nm C-PB. These structures were also detected at other time-points (arrows) suggesting a rather active process taking place. Zoom images at 20 and 30 minutes in Figure 4-12 suggest that the process occurring might be exocytosis. Here, it is possible to see that 2 out of 3 C-PB aggregates present on the plasma membrane at 20 minutes (arrows) are detached and in the extracellular compartment at 30 minutes. The measured size of these aggregates was between 500-700 nm and lower than 1µm as measured by ImageJ. Also, at 30 minutes incubation (see expanded image) vesicle-like structures loaded with nanoparticles were detected in the extracellular compartment, with ImageJ measured size of about 1µm. The white arrowheads in the same set of pictures show ruffling of the plasma membrane that is symptomatic of exocytic, macropinocytic or phagocytic processes taking place. Co-localization studies of CellMask and C-PB show that 100 nm C-PB presented a partial degree of co-localization that was steady over time (Figure 4-13). Finally, the green fluorescence of the 100 nm C-PB in 3T3 cells did not appear to redistribute towards different regions of the cells over a 1 h period (Figure 4-11).

HCT116 cells incubated with 50 nm C-PB showed a rapid uptake of the nanoparticles at 4 minutes and localization of the nanoparticles in the cytoplasm of cells and adjacent to the peripheral region of nuclei (Figures 4-14, 4-16). The presence of the nanoparticles in this region was also suggested by a slight, albeit statistically non significant according to a t test, increase of the colocalization obtained by the green and blue channels of the C-PB and the nuclei at 4 and 10 minutes that was reduced upon translocation of the nanoparticles towards more peripheral regions of the cell (Figure 4-18B); this result is likely to be due to an effect of proximity of the nanoparticles with the nuclei. The analysis of fluorescence in cells showed that the

emission from 50 nm C-PB was steady and not increasing for up to 20 minutes (Figure 4-18B). Over time, the fluorescence of the cells increased slightly but in a non-statistically significant way. From 30 minutes, it was possible to appreciate the presence of C-PB on the cell membrane of HCT116 cells (Figure 4-14, 4-16 and 4-17). Nanoparticles appeared to redistribute from the perinuclear region towards the periphery of the cells and the membrane (Figure 4-16) where the cytoplasmic membrane, stained in red at 4 minutes, turned orange at 60 minutes incubation suggesting co-localization of green nanoparticles and red membrane staining. This effect was also suggested by a small increase of co-localization at 40, 50 and 60 minutes of incubation (Figure 4-18B). From the higher magnification images in Figure 4-17 the redistribution of the CellMask membrane dye from time 0 can be seen. Cells appeared more rounded and the membrane more clearly defined after application of the C-PB. Cells internalized quickly the C-PB in the cytoplasm of cells. However, cells gradually moved the C-PB towards the membrane (white arrows), where they became increasingly more concentrated on the edges of cells, immediately above the CellMask membrane staining towards the extracellular compartment at 50 and 60 minutes (yellow arrows and zoom at 60 minutes of the same Figure). Furthermore, aggregates of nanoparticles of about 500 nm in diameter were present in proximity of the plasma membrane from 30 minutes (zoom at 30 minutes on the same Figure). The intense activity of the membrane of cells was also demonstrated by the spindlelike structures (Figure 4-18A) that were already visible at 4 minutes incubation of the nanoparticles with cells and from membrane ruffling in Figure 4-17 as indicated by the arrowheads.




Figure 4-14 Merge of fluorescence live images for HCT116 cells incubated with 50 µg/ml of 50 nm C-PB for 60 minutes. Red: CellMask deep membrane staining, Green: C-PB, Blue: Hoechst nuclei staining. Scale bars represent 50 µm This set of pictures was obtained at time 0, before applying the solution of C-PB and at 4, 10, 20, 30 ,40 ,50 and 60 minutes after the application of the solution of C-PB. From the images it is possible to observe a quick uptake of the nanoparticles that were already internalised and localizing in a perinuclear region 4 minutes after their application on cells.




Figure 4-15 Orthogonal projection of a 3D image obtained with HCT116 incubated with 50 nm C-PB. This picture shows that the nanoparticles are localized inside cells (arrows). Scale bar represents 50 μ m. Green: C-PB; Red: Membrane staining; Blue: Nuclei.





Figure 4-16 Images of the redistribution of the red CellMask membrane staining at 4 and 60 minutes in HCT116 cells. Also the 50 nm C-PB redistribute from a perinuclear region towards the membrane of HCT116 cells at 60 minutes incubation. Scale bar represents 50 μ m. Red: Membrane staining; Green: C-PB.



10 µm

10 um

10 µm

10 µm

60 min

20 min

Results – Inhibition of Endocytosis and Microscopy Studies

Figure 4-17 Details of the live imaging pictures shown in Figure 4-14 – 4-16 with HCT116 cells incubated with 50 nm C-PB 50 μ g/ml for a period of 60 minutes. The white arrows point to aggregates of nanoparticles on the cell surface of HCT116 cells, the yellow arrows point to the layer of C-PB in the cell membrane at 60 minutes (the same aspect is also reproduced in detail in the adjacent magnification image). The arrowheads point to membrane ruffling. Scale bars represent 10 μ m. Green: C-PB; Red: Membrane staining; Blue: Nuclei.




Figure 4-18 A. Spindle-like structures of HCT116 membrane of cells incubated for 4 minutes with 50 nm C-PB, demonstrating an intense activity of the membrane. Blue: Nuclei; Green: C-PB; Red: Membrane staining. Scale bars represent 10 μ m. B. Analysis of the green fluorescence of HCT116 cells incubated with 50 nm C-PB (white squares and black connecting line) and of the Pearson's coefficient measuring the co-localization of the green fluorescence of the C-PB and the red membrane staining (light grey triangle and connecting line) and the green and the blue staining of the nuclei (dark grey diamonds and black connecting line). Error bars represent the standard deviation of the mean (n>20).

From confocal live cell imaging studies (Figures 4-19, 4-21, 4-24 and 4-26) on MGLVA-1 cells incubated with 50 µg/ml of 50 and 100 nm C-PB it was not possible to detect any distinct difference in the compartmentalization of the 2 nanoparticles (according to inhibition studies, the two nanoparticles were endocytosed by two discrete CPZ and MBCD sensitive pathways). The 50 and 100 nm C-PB nanoparticles showed little co-localization with CellMask, which mainly stained the plasma membrane of these cells (Figures 4-21 and 4-26). The normalized fluorescence per cell area was constant over the 60 minutes time-lapse of the experiment suggesting that the cells were balancing the ingress of nanoparticles with membrane localization or particle exocytosis. Evidence of accumulation of aggregates of nanoparticles on the plasma membrane is provided by images shown in Figure 4-22 for 50 nm C-PB and in Figure 4-27 for 100 nm C-PB (zoom at 10 and 20 minutes incubation for 50 nm C-PB and 20 and 30 minutes incubation for 100 nm C-PB). From zoom images at 10 and 20 minutes obtained for MGLVA-1 cells incubated with 50 nm C-PB (Figure 4-22) it is not possible to define any likely direction of the movement of the aggregates of nanoparticles and for this reason it is not possible to suggest any specific exocytic or endocytic process. For MGLVA-1 cells treated with 100 nm nanoparticles (Figure 4-27), zoom images at 20 and 30 minutes show a movement towards the plasma membrane of aggregates of nanoparticles of 700 nm according to ImageJ measurements suggesting an exocytic process taking place (arrows). Finally, evidence of membrane ruffling is shown by the arrow heads in both MGLVA-1 cells incubated with 50 nm (Figure 4-22) and 100 nm C-PB (Figure 4-27).




Figure 4-19 Confocal live studies of MGLVA-1 cells treated with 50 µg/ml 50 nm C-PB for a period of 60 minutes. Pictures were taken before applying the C-PB (time 0) and after 4, 10, 20, 30, 40, 50 and 60 minutes from the application of the C-PB. Green fluorescence: C-PB, Red: CellMask deep membrane staining and blue: Hoechst nuclei dye. Scale bars represent 50 µm.




Figure 4-20 Orthogonal projection of a 3D image taken from MGLVA-1 cells treated with 50 μg/ml 50 nm C-PB. The arrows show that the nanoparticles (green) are internalized by cells and are localized inside the membrane (red) periphery of cells. Blue: nuclei. Scale bar represents 50 μm.




Figure 4-21 MGLVA-1 cells treated with 50 μ g/ml 50 nm C-PB for 60 minutes. The images show the green channel of the C-PB at 4 and 60 minutes incubation with cells, the red channel for the CellMask deep membrane staining and a merge of the two. There is only little evidence of redistribution of the C-PB over time in different compartments of the cells as well as only little internalization of the CellMask over time. Scale bars represent 50 μ m.




Figure 4-22 Details of the live images studies shown in Figures 4-19 – 4-21 of MGLVA-1 cells treated with 50 μ g/ml 50 nm C-PB for a period of 60 minutes. The zoom at 10 and 20 minutes and the arrows give evidence for aggregates of nanoparticles trafficking the cytoplasmic membrane. The white arrow heads point to the membrane ruffles. Green: C-PB fluorescence, red: CellMask deep membrane staining and Blue: Hoechst dye are shown in these images. Scale bars represent 10 μ m.




Figure 4-23 Analysis of the fluorescence of MGLVA-1 cells treated with 50 nm C-PB for 60 minutes. Quantification of the green fluorescence of the C-PB normalised by cell area and background (white squares and black connecting line). Co-localization quantification given by the Pearson's coefficient measured at different time-points with a JACOP plugin from ImageJ. Co-localization for the green fluorescence of C-PB and the red CellMask membrane dye (dark grey diamonds and black connecting line); C-PB and the Hoechst blue fluorescence colocalization is shown by the light grey triangles and connecting line. Error bars represent the standard deviation of the mean (n>20).




Figure 4-24 MGLVA-1 gastric cancer cells treated with 100 nm C-PB for a period of 60 minutes. Time 0 refers to cells before the treatment with nanoparticles. Pictures were subsequently taken at 4, 10, 20, 30, 40, 50 and 60 minutes from the application of the C-PB. Green fluorescence from the 100 nm C-PB is present in the cytoplasm of MGLVA-1 at 4 minutes from the application of the C-PB. Red fluorescence: CellMask membrane staining, Blue fluorescence: Hoechst nuclei dye. Scale bars represent 50 µm.




Figure 4-25 Orthogonal projection of a 3D image obtained from MGLVA-1 cells treated with 100 nm C-PB. Blue: Hoechst, Green: C-PB, Red: CellMask membrane staining. The arrows point to the regions that show that the nanoparticles are internalized and localize in a region between the nuclei and the membrane. Scale bar represents 50 μm.





Figure 4-26 Redistribution of the C-PB (Green) and CellMask membrane staining (red) over time for MGLVA-1 cells treated with 50 μ g/ml of 50 nm C-PB (green). The Figures show 4 and 60 minutes images with single channels for C-PB and cell Mask and a merge of both. Scale bars represent 50 μ m.






Figure 4-27. A. Details of live images shown in Figure 4-24 - 4-26 of the endocytosis and trafficking of 100 nm C-PB in MGLVA-1 cells for a period of 60 minutes. B. Magnification of the regions enclosed in the squares of Figure 28A. From the enlarged images it is possible to verify some degree of rearrangement of the CellMask membrane dye on the plasma membrane from time 0 and 4 minutes were the dye concentrates in a more compact fashion of the plasma membrane of the cells after the application of C-PB. Also C-PB appear to redistribute, and from 30 minutes it is possible to see a more diffuse and less discrete cytoplasmic fluorescence. From the magnification detail in Figure 28B at 20 and 30 minutes incubation it is possible to detect a movement of aggregates of nanoparticles towards the plasma membrane of cells and the extracytoplasmic compartment. (arrows). The arrow heads point to the membrane ruffling present on the membrane of MGLVA-1 cells. Scale bars represent 10 μ m.




Figure 4-28 Analysis of the fluorescence of MGLVA-1 cells treated with 100 nm C-PB for 60 minutes. Quantification of the green fluorescence of 100 nm C-PB normalized by cells area and subtracted of the background fluorescence from regions adjacent the cells subtracted from the analysis (white squares and black connecting line). Pearson's coefficient quantification obtained with a JACOP plug-in of ImageJ of the co-localization of the C-PB with the red CellMask membrane staining (dark grey diamonds and black connecting line) and C-PB and Hoechst nuclei staining (light grey triangles and connecting line). Error bars represent the standard deviation of the mean (n>20).

4.4 Discussion

Initial experiments on the inhibition of clathrin-mediated endocytosis focused on the

use of the dopamine antagonist CPZ (Table 4-2).

Chemical nomenclature	Chemical structure	Molecular weight
3-(2-chloro-10H-phenothiazin-10- yl)-N,N-dimethyl-propan-1-amine		355.33

Table 4-2 CPZ chemical structure, chemical nomenclature and molecular weight.

CPZ is an amphiphilic molecule that intercalates in the inner leaflet of the membrane of cells¹⁸. Its cationic portion interacts with the negative charge of phospholipids and, in particular, phosphoinositides¹⁹. This binding alters the properties of the membrane, causing redistribution of phospholipids between the inner and outer leaflet and

clustering of membrane proteins^{19,20}. As a consequence it has been widely used as a CME inhibitor. However, its specificity has been often questioned in the literature. Its interference with other endocytic processes such as phagocytosis in neutrophils and macrophages has been repeatedly shown and it has been hypothesised that CPZ could interfere also with macropinocytosis in non specialised cells²¹. This conclusion has been justified by the similarity of the machinery of macropinocytosis and phagocytosis. However, recent findings suggest that clathrin might be also involved in phagocytosis processes partially restoring the credibility of the CPZ as a specific CME inhibitor^{22,23}.

Experiments described above showed that the inhibition of CME with CPZ was timeand cell-dependent and the duration of the incubation period of cells with specific pathway inhibitors was an important factor to take into consideration in these studies as effects were time-dependent.

As described in chapter 3, at the working concentrations used in the experiments reported in this chapter, CPZ inhibits endocytosis by binding to calmodulin, which regulates the recruitment of the myristoylated alanine-rich C-kinase substrate protein (MARCKS) that sequesters the phospholipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2). This phospholipid is essential for the interaction of AP-2 adaptor protein with the plasma membrane in CME^{24,25}. These data from the literature suggested a first hypothesis in order to explain the unusual pattern of Htf inhibition of uptake with CPZ: that with increased CME activity in the cell and consequent expression of clathrin, the longer is the time taken by CPZ to inhibit CME. However, conversely to the expectations, HCT116 cells, for which the highest expression of CHCα was found by immunocytochemistry experiments (please see chapter 3), were more quickly inhibited by the drug, while for MGLVA-1 cells, which expressed relatively low levels

of clathrin and higher levels of caveolin-1 compared to HCT116 and 3T3 cells, Htf uptake was less easily inhibited by CPZ.

Two other hypotheses were then formulated:

- A disparity of expression of MARCKS in different cell lines might be the cause for the difference in CPZ action where, an increase in MARCKS would be expected to decrease the time needed to inhibit the Htf uptake pathway, or
- Calmodulin expression might be different in different cell lines and thus the higher the level of cells with increased calmodulin, the longer the time taken for CPZ to inhibit Htf uptake.

There are prior reports of differences in expression of MARCKS in different cell lines^{26,27} but there is very little literature on the different levels of expression of calmodulin depending on the cell line. Furthermore, Bickeboller *et al* specifically characterized HCT116 cells for the expression of MARCKS by immunoblotting showing that the expression of the protein is low with respect to other colon cancer cell lines²⁷. This experimental observation alone is not sufficient to rule out the above-mentioned hypothesis as the expression of MARCKS should be evaluated in conjunction with time of inhibition of endocytosis. At the moment it is not possible to draw definitive conclusions from the data available. Further studies are necessary to better characterise any connections between the expression of calmodulin/MARCKS and the length of time needed to inhibit endocytosis with CPZ.

The finding that CPZ was inactive in the inhibition of Htf uptake after the maximal inhibition time-point of the endocytosis of Htf has not been reported in the literature previously. It was hypothesized that the recovery of the endocytosis of Htf was due to membrane toxicity of CPZ and the theory that increased Htf internalization after a maximal inhibition of CME was a consequence of such toxicity was evaluated.

The possibility of effects on cell activity by CPZ, additional to endocytic uptake inhibition, was investigated. CPZ has been also reported as a pore-forming molecule²⁸ and it is regularly used as a promoter of membrane fusion in experiments studying the dynamics of membrane reorganization in cells. However, this membrane-fusion property of CPZ is exerted only at concentrations that are near its critical micelle concentration (4 mM), i.e. well above the concentrations used in the pathway inhibition experiments of 80 µM²⁹. Nevertheless, concentrations of CPZ above 50 µM have been reported to produce leakage of low molecular weight cytoplasmic materials in platelets (< 2000 Da) suggesting that CPZ is indeed able to produce small pores in the membrane of cells²⁰. On the other hand, Htf is a large protein with a molecular weight of 80kDa and dimensions of 5 x 5 x 1.6 nm^{30} , suggesting that Htf is unlikely to enter cells as a consequence of CPZ-induced membrane pore formation. In addition, from the experiments using CPZ at 40 and 60 μ M, it was observed that the extent of the recovery of Htf uptake after inhibition was more significant at lower concentrations of CPZ, where any toxicity and pore-forming ability would be reduced. Further evidence that the recovery of the levels of Htf uptake was due to active transport of the protein inside cells was obtained from experiments in which media were used containing no Ca²⁺ and Mg²⁺. By depleting the levels of these two ions, the cells became energy-depleted too, and recovery of Htf uptake stopped with a steady reduction of the Htf internalization over a period of 4 h in 3T3 cells³¹. These data together suggest that inhibition of Htf uptake by CPZ and subsequent recovery of Htf endocytosis was not likely have occurred via a general toxicity effect of CPZ on cells, but instead was due to temporary interruption by CPZ of an active and energy-dependent transport of Htf into cells. Although this mechanism might be attributed to off target effects of a non-specific and complex

inhibitor of endocytosis such as CPZ, some speculations in other directions might also be worth some consideration.

The internalization of Htf by a non-transferrin receptor-mediated mechanism in hepatocytes was first reported in the 1980's³² with transferrin receptor 2 (TR2) being cloned some years later³³. The presence of TR2 in tissues other than the liver and erythroid precursor cells has been debated. However, some authors report the presence of TR2 in colon cancer and glioma cells and, more importantly, in HCT116 cells, which are part of the panel of cell lines used in these studies³⁴⁻³⁷.

TR2 is a type II transmembrane glycoprotein with at least two alternative splicing isoforms, TR2 α and β^{38} . TR2 α has a transmembrane and short cytoplasmic domain while TR2^β has only the extracellular portion of the protein and lacks the transmembrane and cytoplasmic domains. TR2 also binds iron, although at a lower affinity (K_d = 30x10⁻⁹M) with respect to transferrin receptor 1 (TR1, K_d =7x10⁻⁹M) also known as p90, CD71 and transferrin receptor³⁹. The endocytic process by which the transferrin is endocytosed together with TR2 is identical to the endocytosis of TR1. The complex is internalized, it is transported to an acidic compartment and then recycled back to the plasma membrane where the apo-transferrin is released³². TR2 presents a Yxx Φ motif that can bind an AP2 adaptor protein which suggests that it can be internalized by a clathrin receptor pathway. Chen and coworkers also showed that TR1 and TR2 can internalize through an AP2 pathway and compete for the pathway in the presence of holo-transferrin confirming support for a clathrin-mediated uptake pathway^{36,39}. Chen et al showed that the internalization of TR2 in the presence of holo-transferrin is directed towards a multivesicular body degradative pathway and this might explain the short half life of TR2 in the presence of holotransferrin when TR1 is active. The presence in the media of transferrin and binding of the transferrin to the TR2 can extend the half life of the receptor and direct it

towards a recycling pathway instead. The binding to the TR2 in physiological conditions has been reported to occur only when the TR1 was down-regulated in the liver which suggests that the receptor has a physiological role in the maintenance of the homeostasis of iron such as a sensor for transferrin levels in serum^{36,38,40}. From the data reported in this chapter and the literature it is possible to suggest that TR2 might be responsible for the uptake of Htf when TR1 is inhibited. There is prior evidence of the presence of the receptor at least for one cell line used in the experiments reported in this chapter (HCT116), and the mechanism by which the TR2 is activated and directed to a recycling pathway fits well with the results shown in this thesis^{34,35}. The mechanism hypothesized from these data is the following: when the TR1 is inhibited by CPZ, the TR2 starts binding Htf. This event triggers the switch from a degradative to a recycling pathway, which increases TR2 expression. The proposed increase in concentration of the receptor can be hypothesized in the experiments reported at 3 and 4 h in 3T3 cells and 2, 3 and 4 h in HCT116 cells. At 4 h the levels of endocytosis in these cell lines is comparable to the positive control, where the internalization of Htf occurs by a TR1-mediated route, which suggests that the TR2 can replace the activity of TR1 in the absence of functional TR1. However, there are a few points that still remain unclear.

Chen *et al* showed that both TR1 and 2 were active by clathrin-mediated endocytosis, but it is not clear why a TR2-mediated pathway would not be inhibited by the action of CPZ since the activity of CPZ is not due to specific TR1 or TR2 binding. A key question is whether the TR2 triggers a different endocytosis mechanism when it switches from a degradative to recycling pathway. It may be possible that TR2 induces clathrin-mediated endocytosis but employs a different connector protein (other than AP2) which does not rely on PI(4,5)P2 for anchoring the forming clathrin lattice to the plasma membrane. If this were to be the case, it must be a new and

uncharacterised protein given that all the known clathrin adaptor proteins rely on $PI(4,5)P2^{41}$ at the moment⁴² (the presence of new and uncharacterised adaptor proteins has been already suggested in the literature)⁴³. Chen et al also reported that, in the absence of holo-transferrin, TR2 can internalize through a different pathway and Calzolari and coworkers also came to this conclusion³⁴. The latter group of researchers showed that TR2 is associated with the detergent resistant insoluble fraction of cells in lipid rafts (colocalising to some extent with caveolae and caveolin-1 and in a different region with respect to TR1) and they also suggested a more signalling relevant role of the receptor in these conditions given that there was high colocalization with a CD81 membrane protein involved in exosome formation and signalling^{39,44,45}. However, these studies were not carried out on the panel of cell lines used in the experiments presented in this thesis. A caveolin-dependent endocytosis mechanism for internalization of Htf after the TR1 is inhibited is unlikely as Htf uptake is universally recognized as a CME marker⁴⁶. Clathrin has been recently found to be involved in phagocytosis as described more in detail in §1.3.4.7 of this thesis. However also phagocytosis is known to necessitate PI(4,5)P2 for its function (although through a slightly different process) and seems an improbable alternative internalization process candidate at the present⁴⁷. However, there may still be uncharacterized mechanisms by which proteins such as transferrin can enter cells when highly potent amphiphiles such as CPZ are present, and/or cells are stressed by being in the artificial cell culture environment rather than in a tissue.

Another feature of the inhibition of CME by CPZ might be explained by the data from different passage numbers of the cell lines used in inhibition studies. It was found that the higher the passage number or ageing of cells, the lower the levels of endocytosis inhibition by CPZ. This finding was partly expected, since dynamin expression, which is implicated in both clathrin and caveolin endocytosis, has been reported to be

susceptible to passage number and confluence of cells⁴⁸. Calmodulin expression has also been shown to change in relation to cell ageing and this might contribute to these results⁴⁹. As the density of cells in these experiments was deliberately kept constant to sub-confluent levels to control the expression of endocytic proteins, it seems likely that an important determinant factor in the variability of the inhibition of Htf uptake was the passage number and ageing of cells.

In order to investigate further the endocytic pathways involved in Htf uptake and therefore of relevance to nanoparticle and drug delivery system uptake, assays were carried out with the inhibitor Pitstop 2 (Table 4-3). Pitstop 2 is a small molecule that was originally selected from screening assays based on structure-activity relationship (SAR)^{14,50}.

Chemical nomenclature	Chemical structure	Molecular weight
N-[5-(4-Bromobenzylidene)-4- oxo-4,5-dihydro-1,3-thiazol-2- yl]naphthalene-1-sulfonamide		473.36

 Table 4-3 Pitstop 2 chemical structure, nomenclature and molecular weight.

Pitstop 2 is believed to bind specifically to the amino-terminal domain of clathrin which is essential for the interaction of the CHC with the endocytic machinery, which in turn assembles the clathrin lattice leading to vesicle formation. Pitstop 2 has been described as the first chemical inhibitor specific for CME, and is claimed to be non toxic in HeLa cells for up to 24 h. However, a number of papers have shown toxic effects of Pitstop 2, including reports of interactions with spindle formation in dividing HeLa cells, leading to cell death⁵¹. Also the specificity of Pitstop 2 has been

questioned, as it has effects on processes specific to other pathways of endocytosis^{52,53}. However, the differences in structure of Pitstop 2 and CPZ were sufficient that investigation of the effects of Pitstop 2 on Htf uptake were considered of interest in comparison to those of CPZ. Strong inhibition of Htf uptake was obtained at 1 and 2 h incubation with Pitstop 2 in HCT116 cells, in contrast to experiments involving CPZ, where a partials recovery of Htf uptake was observed at 2 h. However, toxicity of Pitstop 2 was observed during inhibition experiments and thus the incubation time of Pitstop 2 with cells was reduced to 2 h instead of 4 h incubation as used in experiments with CPZ. Toxicity, as suggested by the experiments using HBSS depleted of Ca^{2+} and Mg^{2+} , can generate a failure in the recovery of the Htf uptake after inhibition.

CPZ was also used in LacCer inhibiton studies as a further control of CPZ specificity towards CME. Here, CPZ did not show any inhibition of endocytosis of LacCer as expected and already reported in the literature^{15,21}. However, an increase of LacCer endocytosis was observed in the presence of the inhibitor and confirms results obtained by Vercauteren and coworkers¹⁵.

LacCer inhibition of endocytosis by MBCD was not complicated by the recovery of inhibition and cell passage number. Incubation times and cell line characteristics did not affect the ability of the inhibitor to function. The inhibition obtained was steady and maximal for a period of 4 h incubation and, as shown by viability studies in chapter 3 as well as experimental observations, it was not due to toxicity of the inhibitor on cells. Only a minimal dependence on cell lines was observed in MGLVA-1 cells. Here, although a good inhibition of LacCer uptake was obtained already at 1 h incubation of the inhibitor with cells, a maximal inhibition was obtained at 2 h. No dependence on passage number of cells was observed in these experiments and this gives evidence of the inherent non specificity of the drug towards a caveolin and

dynamin-mediated endocytosis where passage number of cells indeed affects the results of the inhibition. Furthermore, when MBCD was used as a control of its specificity towards CIE in Htf inhibition studies, the drug had a small but detectable inhibition of CME that was more evident at specific incubation times of the drug with cells. The latter result might be interpreted differently if the hypothesis that a caveolin-dependent pathway is involved in Htf uptake proves to be true.

Inhibition of C-PB uptake in the presence of CPZ and MBCD shows that the same material can be directed towards different endocytic machineries depending on the cell line tested and, significantly, without modification of the nanoparticles with specific targeting molecules. This result is not entirely unexpected as some other authors already showed different sensitivity to inhibitors of endocytosis depending on the cell line⁵⁴. 50 nm C-PB showed specificity towards CME, macropinocytosis or phagocytosis as demonstrated by the inhibition of their endocytosis in the presence of CPZ. Even if phagocytosis is considered not to be a highly represented process in non-specialized cells, it cannot be completely ruled out from these data. After inhibition of the uptake of 50 nm C-PB in HCT116 and MGLVA-1 cells with CPZ, no recovery of the uptake of 50 nm C-PB was observed. The nanoparticles that had not been targeted with any specific receptor binding molecules appeared to be selectively internalized by a CPZ-sensitive pathway. This might be due to the specificity of the uptake of these nanoparticles towards a CPZ-sensitive pathway. However, another possibility for these results might be due to a combination of CPZ and C-PB of 50 nm resulting in toxicity.

The same nanoparticles were endocytosed by 3T3 fibroblasts quite efficiently but the mechanism of internalization remains unknown. Both inhibitors used were ineffective in the inhibition of their endocytosis and suggests that 3T3 fibroblasts use non-CPZ non-MBCD sensitive machinery for the endocytosis of 50 nm C-PB. When cells

actively engaged in endocytosis were exposed to endocytic inhibitors that were not active on the pathway involved in the endocytosis of materials, the uptake of these materials was boosted and this mechanism has already been shown in the literature¹⁵. These results suggest a more dynamic way of thinking of endocytosis where pathways communicate with each other and 'sense' the level of activity of one pathway and compensate for its failure. This compensation can be quite substantial with up-regulation of the pathway up to 3 times the positive control in which the level of endocytosis is not perturbed by inhibitors of endocytosis. 100 nm C-PB on the other hand, internalized through a less specific mechanism of endocytosis and its endocytosis was only marginally inhibited before other pathways of internalization intervened and endocytosis recovered quickly to positive control levels.

Microscopy live studies gave evidence that the nanoparticles studied accessed 3T3, HCT116 and MGLVA-1 cells and they were endocytosed in less than 4 minutes. This data is in line with the literature that suggests a time of internalization as quick as 1 minute for some synthetic materials⁵⁶. Microscopy data did not rule out the possibility that the process taking place for the internalization of 50 nm C-PB in MGLVA-1 and HCT116 cells is due to phagocytosis or macropinocytosis. Microscopy pictures in fact intense membrane activity and ruffling compatible with exocytosis, show macropinocytosis and phagocytosis. 50 nm C-PB endocytosis was proven to be sensitive to CPZ in HCT116 and MGLVA-1 cells by inhibition studies and these data alone were also compatible with macropinocytic or phagocytic processes together with a CME uptake. CPZ inhibition of endocytosis, in fact, is not limited to CME only but also to phagocytosis and macropinocytosis. Although recent evidence suggests a clathrin involvement in phagocytosis which partially restores CPZ credibility as a CME inhibitor, from the data obtained it is not possible to assert with certainty what is the

endocytic process taking place for the uptake of 50 nm C-PB in HCT116 and MGLVA-1 cells.

As shown from analysis of C-PB treated cells over time, the level of fluorescence reaches a plateau which suggests that cells are able to counterbalance the presence of extracellular C-PB. From experimental evidence, it is possible to suggest, from 2 out of the 4 experiments described, that one of the ways used by cells to counterbalance the endocytosis of C-PB might be through active exocytosis of nanoparticles. The most evident drop of C-PB fluorescence after 20 minutes was observed in 3T3 cells with respect to the other cell lines tested as shown by analysis of the total cell fluorescence normalized by area of cell (Figure 4-13, 4-18B, 4-23 and 4-28). 3T3 cells showed an extracellular vesicle of about 1µm (zoom image at 30 minutes of Figure 4-12), loaded with C-PB as it is possible to extrapolate from the green fluorescence of the core of the vesicle, and it was enveloped by a membrane. However, even if the literature reports sizes of 0.1-1 µm for exocytic vesicles, the size of the vesicles detected in the extracellular compartment of 3T3 cells is close to those of apoptotic bodies. It has been shown that the size of apoptotic bodies is in the range of 1-5 µm, a factor which should be taken into account when suggesting exocytosis⁵⁷. In support of the hypothesis of exocytosis is the size of the aggregates of nanoparticles on the membrane of cells: these ranged between 0.5 and 0.8 µm and thus were of sizes that fit well with those of exocytic vesicles reported in the literature. Furthermore, from the magnification pictures shown of the 3T3 and MGLVA-1 cells, it is possible to suggest directionality towards the extracellular compartment of the cells for these aggregates of nanoparticles, again supporting the hypothesis. Aggregates of 50 nm C-PB were also observed on the plasma membrane of HCT116 and MGLVA-1 cells. However, a clear direction was not detected for the nanoparticles in these latter experiments. At least for HCT116 cells, a possibility is

that cells were not able to release the C-PB into the extracellular compartment because of the strong interactions of the nanoparticles with plasma membrane proteins. This process can be observed in the higher magnification image at 60 minutes in Figure 4-17 where a layer of green nanoparticles can be clearly distinguished over the CellMask membrane staining dye at 60 minutes. As C-PB are predominantly hydrophobic nanoparticles with a surface shell of negatively charged carboxyl groups, in serum-free media they may interact avidly with hydrophobic and/or positively charged proteins^{54,58}. It is possible to suggest that the event reported might be due to the interaction of C-PB negative charge and positive membrane proteins or positive domain of membrane proteins that are present on the plasma membrane of HCT116 cells. Exocytosis is known to be affected by the experimental use of buffers instead of full media. However, the effects described change depending on the material and cell line taken into consideration and some authors suggest that the presence of serum-free media boosts exocytosis while some others report an opposite effect^{54,56}.

4.5 Conclusions

From the experiments reported in this chapter some novel data have emerged in regard to the inhibition of endocytosis with CPZ. The time and cell specificity of the inhibitor of endocytosis and the subsequent recovery of the endocytosis of Htf have not been reported before and explains the difficulty reported by scientists working on inhibition of endocytosis in the use of CPZ as an inhibitor of this process. The effect on the passage number and ageing of cells on the endocytosis process also is a significant piece of information that has not been reported in the literature before and that has been important in establishing appropriate conditions for effective use of the inhibitor in C-PB inhibition studies in the reported experiments. The effect of the

inhibitor on LacCer uptake was also another interesting result that has been reported only once in the literature. Both LacCer and C-PB endocytosis were boosted in the presence of inhibitors of endocytic pathways that were not actively involved in the pathway of internalization of the material investigated. This suggests that the inhibition of one pathway activates other pathways of internalization giving a more organic and interconnected picture of endocytosis. Finally, 50 nm C-PB appear to be endocytosed by a CPZ-sensitive pathway and their uptake does not recover over time. Although this effect could be due to the combined toxicity of C-PB and CPZ, another hypothesis might be that C-PB show some specificity towards a CPZsensitive pathway and further investigations are required in order to understand the mechanisms underlying such specificity. Microscopy studies confirm that the nanoparticles are internalized by cells and that the endocytic process is rapid and efficient with nanoparticles internalized by cells already after 4 minutes. A suggestion of exocytosis of 100 nm C-PB in 3T3 and MGLVA-1 is also provided by these studies together with evidence of a membrane specific binding ability of 50 nm C-PB in HCT116 cells but not on MGLVA-1 cells. This observation supports the idea that the same nanoparticles can interact with different cells in different ways.

References

- 1 Tian, T. et al. Exosome Uptake through Clathrin-mediated Endocytosis and Macropinocytosis and Mediating miR-21 Delivery. J Biol Chem (2014).
- 2 Schmid, E. M. & McMahon, H. T. Integrating molecular and network biology to decode endocytosis. Nature **448**, 883-888 (2007).
- 3 Kann, M., Schmitz, A. & Rabe, B. Intracellular transport of hepatitis B virus. World J Gastroenterol **13**, 39-47 (2007).
- 4 Moreno-Ruiz, E. et al. Candida albicans internalization by host cells is mediated by a clathrindependent mechanism. Cell Microbiol **11**, 1179-1189 (2009).
- 5 Mehrbod, P. et al. Simvastatin modulates cellular components in influenza A virus-infected cells. Int J Mol Med **34**, 61-73 (2014).

- 6 Tchoupa, A. K., Schuhmacher, T. & Hauck, C. R. Signaling by epithelial members of the CEACAM family mucosal docking sites for pathogenic bacteria. Cell Commun Signal **12**, 27 (2014).
- 7 Zhang, Y. & Whittaker, G. R. Influenza entry pathways in polarized MDCK cells. Biochem Biophys Res Commun (2014).
- 8 Alva-Murillo, N., Lopez-Meza, J. E. & Ochoa-Zarzosa, A. Nonprofessional phagocytic cell receptors involved in Staphylococcus aureus internalization. Biomed Res Int **2014**, 538546 (2014).
- 9 Minakshi, R. & Padhan, K. The YXXPhi motif within the severe acute respiratory syndrome coronavirus (SARS-CoV) 3a protein is crucial for its intracellular transport. Virol J **11**, 75 (2014).
- 10 Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J **377**, 159-169 (2004).
- 11 Li, T. & Takeoka, S. Enhanced cellular uptake of maleimide-modified liposomes via thiolmediated transport. Int J Nanomedicine **9**, 2849-2861 (2014).
- 12 Quader, S. et al. Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy. J Control Release **188C**, 67-77 (2014).
- 13 Solarska-Ściuk, K. et al. Intracellular transport of nanodiamond particles in human endothelial and epithelial cells. Chemico-Biological Interactions **219**, 90-100 (2014).
- 14 Robertson, M. J. et al. Synthesis of the Pitstop family of clathrin inhibitors. Nat. Protocols **9**, 1592-1606 (2014).
- 15 Vercauteren, D. et al. The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls. Mol Ther **18**, 561-569 (2010).
- 16 van Renswoude, J., Bridges, K. R., Harford, J. B. & Klausner, R. D. Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proceedings of the National Academy of Sciences **79**, 6186-6190 (1982).
- 17 Pagano, O. C. M. a. R. E. Internalization and sorting of a fluorescent analogue of glucosylceramide to the Golgi apparatus of human skin fibroblasts: utilization of endocytic and nonendocytic transport mechanisms. J Cell Biol **125**, 769-781 (1994).
- 18 Ferrell, J. E., Jr., K.T., M. & Huestis, W. H. Membrane bilayer balance and platelet shape: morphological and biochemical responses to amphipathic compounds. Biochim Biophys Acta **939**, 223-237 (1988).
- 19 Chen, J. Y. et al. Selective amphipathic nature of chlorpromazine binding to plasma membrane bilayers. Biochimica et Biophysica Acta (BBA) Biomembranes **1616**, 95-105 (2003).
- 20 Holmsen, H. & Rygh, T. Chlorpromazine makes the platelet plasma membrane permeable for low-molecular weight substances and reduces ATP production. Biochemical Pharmacology 40, 373-376 (1990).
- 21 Ivanov, A. I. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods in molecular biology **440**, 15-36 (2008).
- 22 Sullivan, C. S. et al. The adaptor protein GULP promotes Jedi-1-mediated phagocytosis through a clathrin-dependent mechanism. Molecular Biology of the Cell (2014).
- 23 Liu, C., Wang, J. & Zhang, X. The Involvement of MiR-1-Clathrin Pathway in the Regulation of Phagocytosis. Plos One **9**, e98747 (2014).

- 24 Eisenberg, S., Giehl, K., Henis, Y. I. & Ehrlich, M. Differential Interference of Chlorpromazine with the Membrane Interactions of Oncogenic K-Ras and Its Effects on Cell Growth. Journal of Biological Chemistry **283**, 27279-27288 (2008).
- 25 Levin, R. M. & Weiss, B. Mechanism by Which Psychotropic Drugs Inhibit Adenosine Cyclic 3',5'-Monophosphate Phosphodiesterase of Brain. Molecular Pharmacology **12**, 581-589 (1976).
- 26 Rosé, S. D., Cook, H. W., Palmer, F. B. S. C., Ridgway, N. D. & Byers, D. M. Differential Expression of MARCKS and Other Calmodulin-Binding Protein Kinase C Substrates in Cultured Neuroblastoma and Glioma Cells. Journal of Neurochemistry 63, 2314-2323 (1994).
- 27 Bickeboller, M. et al. Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival. Oncogene **0** (2014).
- 28 Kozlovsky, Y., Chernomordik, L. V. & Kozlov, M. M. Lipid Intermediates in Membrane Fusion: Formation, Structure, and Decay of Hemifusion Diaphragm. Biophysical Journal 83, 2634-2651 (2002).
- 29 Mondal Roy, S. & Sarkar, M. Membrane fusion induced by small molecules and ions. J Lipids 2011, 528784 (2011).
- 30 Kilar, F. & Simon, I. The effect of iron binding on the conformation of transferrin. A small angle x-ray scattering study. Biophysics Journal **48**, 799-802 (1985).
- 31 Tarasov, A. I., Griffiths, E. J. & Rutter, G. A. Regulation of ATP production by mitochondrial Ca(2+). Cell Calcium **52**, 28-35 (2012).
- 32 Graham, R. M., Chua, A. C., Herbison, C. E., Olynyk, J. K. & Trinder, D. Liver iron transport. World J Gastroenterol **13**, 4725-4736 (2007).
- 33 Kawabata, H. et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem **274**, 20826-20832 (1999).
- 34 Calzolari, A. et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells, Molecules, and Diseases **39**, 82-91 (2007).
- 35 Calzolari, A. et al. TfR2 expression in human colon carcinomas. Blood Cells, Molecules, and Diseases **43**, 243-249 (2009).
- 36 Chen, J., Wang, J., Meyers, K. R. & Enns, C. A. Transferrin-directed internalization and cycling of transferrin receptor 2. Traffic **10**, 1488-1501 (2009).
- 37 Calzolari, A. et al. Transferrin Receptor 2 Is Frequently and Highly Expressed in Glioblastomas. Translational Oncology **3**, 123-134 (2010).
- 38 Kawabata, H. et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood **105**, 376-381 (2005).
- 39 Silvestri, L., Nai, A., Pagani, A. & Camaschella, C. The extrahepatic role of TFR2 in iron homeostasis. Front Pharmacol **5**, 93 (2014).
- 40 Johnson, M. B., Chen, J., Murchison, N., Green, F. A. & Enns, C. A. Transferrin receptor 2: evidence for ligand-induced stabilization and redirection to a recycling pathway. Molecular Biology of the Cell **18**, 743-754 (2007).
- 41 Owen, D. J., Collins, B. M. & Evans, P. R. Adaptors for clathrin coats: structure and function. Annu Rev Cell Dev Biol **20**, 153-191 (2004).
- 42 Mishra, S. K. et al. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. The EMBO Journal **21**, 4915-4926, doi:10.1093/emboj/cdf487 (2002).
- 43 Traub, L. M. Sorting it out: AP-2 and alternate clathrin adaptors in endocytic cargo selection. J Cell Biol **163**, 203-208, doi:10.1083/jcb.200309175 (2003).
- 44 Calzolari, A. et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci **119**, 4486-4498 (2006).

- 45 Poli, M. et al. Transferrin receptor 2 and HFE regulate furin expression via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) signaling. Implications for transferrin-dependent hepcidin regulation. Haematologica **95**, 1832-1840 (2010).
- 46 Sahay, G., Alakhova, D. Y. & Kabanov, A. V. Endocytosis of nanomedicines. Journal of Controlled Release 145, 182-195 (2010).
- 47 Scott, C. C. et al. Phosphatidylinositol-4,5-bisphosphate hydrolysis directs actin remodeling during phagocytosis. J Cell Biol **169**, 139-149 (2005).
- 48 Damke, H., Baba, T., van der Bliek, A. M. & Schmid, S. L. Clathrin-independent pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of dynamin. The Journal of Cell Biology 131, 69-80 (1995).
- 49 Linskens, M. H. et al. Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucleic Acids Res 23, 3244-3251 (1995).
- 50 Donner, A. Signaling: Clathrin pitstops. Nat Chem Biol 7, 654-654 (2011).
- 51 Smith, C., Haucke, V., McCluskey, A., Robinson, P. & Chircop, M. Inhibition of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell death in dividing HeLa cancer cells. Molecular Cancer **12**, 4 (2013).
- 52 Dutta, D., Williamson, C. D., Cole, N. B. & Donaldson, J. G. Pitstop 2 Is a Potent Inhibitor of Clathrin-Independent Endocytosis. Plos One **7** (2012).
- 53 Willox, A. K., Sahraoui, Y. M. E. & Royle, S. J. Non-specificity of Pitstop 2 in clathrinmediated endocytosis. bioRxiv (2014).
- 54 Lesniak, A. et al. Effects of the Presence or Absence of a Protein Corona on Silica Nanoparticle Uptake and Impact on Cells. J Am Chem Soc **135**, 1438-1444 (2013).
- 55 Panyam, J. & Labhasetwar, V. Dynamics of endocytosis and exocytosis of poly(D,L-lactideco-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res **20**, 212-220 (2003).
- 56 Gyorgy, B. et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci **68**, 2667-2688 (2011).
- 57 Monopoli, M. P., Bombelli, F. B. & Dawson, K. A. Nanobiotechnology: Nanoparticle coronas take shape. Nature Nanotechnology **6**, 11-12 (2011).

5-Chapter 5

In vitro studies of thermoresponsive micelle-like

nanoparticles

5.1 Introduction

One of the major problems in the development of new drugs is producing molecules that are not only effective, with specificity at the target cell, but which also have the required physico-chemical properties to ensure they accumulate, after administration, at the intended tissue. In many cases it is not possible to combine these features in one molecule and thus carriers or delivery systems are needed in order to take a drug with sub-optimal solubility or stability to a target in the body. Delivery systems can facilitate administration and biodistribution and can reduce unwanted off target toxicity of the drug. A large variety of materials have been developed which can encapsulate delicate, potent and/or poorly soluble drugs during transit in the body and then release the drug at a distal site. The specificity of delivery at the target cell, tissue or organ can be affected by a variety of methods, many of which take advantage of the specific characteristics of the inflammation site that often develops as a consequence of the medical condition and/or of the cell biology in the pathological tissues. The changed physiology at a disease site can lead to hyperthermia, a modified oxidative or reductive environment, and/or a changed pH. As a consequence, drug delivery systems which change their properties with temperature, redox state and pH are potential means of delivering drugs specifically at disease sites. Polymeric micelle-like nanoparticles are an example of such delivery systems, as their self-assembly into supramolecular structures is reversible and can be triggered in the forward or reverse direction by a variety of stimuli. Polymer micelle-like nanoparticles for biomedical applications are easily formed by preparing a hydrophobic core polymer block, which can accommodate hydrophobic compounds

(e.g. anticancer drugs) and coupling this block to a hydrophilic shield polymer that bestows water solubility to the carrier system.

In this chapter the results on biocompatibility and cell penetration of thermoresponsive micelle-like nanoparticles are studied and reported. The thermoresponsiveness of the system was designed in the long term to target specifically inflamed tissue, as found in a variety of diseases. Pathological conditions can produce an inflammation that has been reported to raise the local temperature up to 42 °C in some cases (hyperthermia). Hyperthermia can also be administered by ultrasound probes and near infrared irradiation in conjunction with the treatment with thermoresponsive materials¹⁻⁴.

5.2 Materials used for the studies

The thermoresponsive materials studied were based on polymers synthesized previously in our group by Abulateefeh *et al* and subsequently synthesized by Lee Moir. They can be described by the following general formulas in Figure 5-1 and $5-2^5$:




Figure 5-1 Poly(lactide-*co***-glycolide)***-block***-poly(poly(ethylene glycol methyl ether methacrylate)***-co***-poly(propylene glycol methacrylate))** (PLGA-*b*-(PPGMA-*co*-PEGMA)) thermoresponsive polymers. The different regions (or blocks) that constitute the polymer are labelled for easy detection. Some of the characteristics of these structures are summarised in the description in the text. X, y, m and n numbers are different in each polymer.




Figure 5-2 Polylactide- *block-* **poly(poly(diethylene glycol methacrylate)**-*co*-**poly(oligoethylene glycol methacrylate)) (PLA-***b***-(DEGMA**-*co*-**OEGMA)) thermoresponsive polymers.** The blocks that form the polymer are labelled for an easy detection. Both the hydrophobic and hydrophilic regions of these polymers have been modified in these second set of polymers with respect to polymers in Figure 5-1 and ⁵. Some of the characteristics of these structures are summarised in the description in the text. X, y, m and n numbers are different for each polymer.

The structures of poly(lactide-co-glycolide)-block-poly(poly(ethylene glycol methyl ether methacrylate)-co-poly(propylene glycol methacrylate)), (PLGA-b-(PPGMA-co-PEGMA)) is given in Figure 5-1. The polymer shown in Figure 5-2, which is slightly different to those prepared by Abulateefeh et al⁵ is polylactide- blockpoly(poly(diethylene glycol methacrylate)-co-poly(oligoethylene glycol methacrylate)) (PLA-b-(DEGMA-co-OEGMA)). The PLGA/PLA region forms the hydrophobic, inner core of the micelle when these co-polymers are added to water. PLGA is a polyester block copolymer formed by poly-lactic acid (PLA) and poly-glycolic acid (PGA) (Figure 5-1). The PLA contains an asymmetric α carbon producing 2 enantiomeric structures referred as D and L or, R and S. The PLGA acronym refers to R and S poly lactic acids represented in equal ratio in the polymer⁶. PLGA is a biocompatible and biodegradable material that has been approved by the Food and Drug Administration (FDA)⁷. The susceptibility to degradation is affected by the molecular weight of the PLGA and by the ratio between PLA and PGA, where increasing the ratio of PLA reduces the rate of hydrolysis and acid-catalysed degradation⁸. The thermoresponsive properties of the polymer are given by PEGMA, PPGMA, DEGMA and OEGMA. These regions have the ability to change their structure from coil to globule with increasing temperature, changing their conformation from stretched and highly hydrated to collapsed and only partially hydrated⁹. This phenomenon occurs above a designed lower critical solution temperature (LCST) that in these polymers has been determined indirectly as the increase of turbidity of the polymer solution (cloud point) and it is referred to as the thermal transition temperature (TTT)¹⁰. The ratios between the PEGMA and PPGMA monomers in the chain can change the LCST of the polymer with higher quantities of PPGMA lowering the LCST of the individual polymer chains and the TTT of micelle-like nanoparticles and nanoparticles

formed from the co-polymers^{5,11}. Different ratios of PLA and PGA were used in these polymers to modify the size of the polymer and hence the size of the hydrophobic core of the micelle as well as different ratios of PEGMA (LCST \approx 90 °C), PPGMA, DEGMA (LCST \approx 26 °C) and OEGMA (LCST \approx 90 °C) to study how these modifications affected the LCST and TTT¹²⁻¹⁵. Micelle-like nanoparticles were formed by nanoprecipitation¹⁶, adding an acetone solution, containing the solubilised polymer, to water either dropwise or with the aid of a syringe pump. These nanoparticles were of the size range (50-150 nm) similar to that of common virus particles, and thus were considered of interest as drug delivery systems.

The specific aim of this part of study was to produce polymers and micelle-like structures that were stable in suspension at normal physiological temperatures and resistant to cell uptake, but which were able to internalise into cells when above their TTT. Prior data from Abulateefeh *et al*, as well as numerous studies from the Chilkoti group, had shown that thermoresponsive polymers, polypeptides and nanoparticles were selectively internalised into some specific cell lines only when above their TTT^{16,17}. This study aimed to investigate if this phenomenon was cell-dependent, and if the polymer thermal response could be used for target specificity against cancer cells, as a first step towards organ or diseased issue specificity. Furthermore, it was intended to study the routes of internalization used by the polymer micelle-like nanoparticles to access cells as well as to compare and contrast the intracellular trafficking pathways of thermoresponsive polymers with those of C-PB reported earlier.

In this chapter are shown the results of tests of cell activity of micelle-like nanoparticles following incubation with the thermoresponsive polymers (formulated as kinetically trapped micelle-like nanoparticles), and microscopy studies to assess

the ability of the micelle-like nanoparticles polymers to access cells. The characteristics of the original polymers and the micelle-like nanoparticles formed by the assembly of these polymers are summarised in Table 5-1 and 5-2. The ζ potential for the nanoparticles tested was negative and close to neutrality (values ranging between -0.5 and -4 mV). ζ potential measurements were run in HEPES buffer 1 mM, pH 7.4 at 20 °C.

Nanoparticle formulation number	Constituent polymers PLGA ratio PLA:PGA	Constituent polymers [PPGMA]: [PEGMA]	M _n (GPC)	M _w (GPC)	Ð (polydispersity)	π	Diameter of the micelles (nm)	Dye
1	65:35 (Mn~7000)	3:1	29333	36658	1.25	~40°C	53.6/ 210	Rhodamine B (non conjugated)
2	65:35 (Mn~7000)	1:1	24633	29352	1.19	~64°C	29.2/ 179.2	Rhodamine B (non conjugated)
3	75:25 (Mn 8260)	2:1	15118	17087	1.13	~50°C	31/ 198.6	Rhodamine B (non conjugated)
4	75:25 (Mn 8260)	3:2	14050	15736	1.12	~58°C	29.2/ 197.6	Rhodamine B (non conjugated)
5	65:35 (Mn 17708)	4:1	31143	41836	1.34	~41 °C	142.4	Fluorescein (conjugated to PEGMA)
6	75:25 (Mn 19586)	5:1	28329	50014	1.76	~24°C	118	Fluorescein (conjugated to PEGMA)
7	75:25 (Mn 19586)	5:1	28329	50014	1.76	~24°C	49/312	Fluorescein (conjugated to PEGMA)

Table 5-1 Summary of the characteristics of the PLGA-b-(PPGMA-co-PEGMA) thermoresponsive polymers and micelle-like nanoparticles used for the study. Molecular weights have been determined by Gel Permeation Chromatography (GPC). The diameter of the nanoparticles was measured by DLS and carried out at 20°C in HEPES 20 mM.

Nanoparticle formulation number	Constituent polymers PLGA ratio PLA:PGA	Constituent polymers [DEGMA]: [OEGMA]	Mn (GPC)	Mw (GPC)	Ð (polydispersity)	Π	Diameter of the micelle (nm)	Dye
8	100:0 (Mn 13000)	95:5	47289	63840	1.35	29	56.4	Rodamine B + Fluoresceine methacrylate*
9	100:0 (Mn 13000)	95:5	41948	60482	1.44	27	44.8	Rodamine B + Fluoresceine methacrylate*

Table 5-2 Summary of the characteristics of PLA-b-(DEGMA-co-OEGMA) thermoresponsive micellelike nanoparticles used in the study. Molecular weights have been determined by Gel Permeation Chromatography (GPC); the diameter of the micelles was measured by DLS at 20°C and HEPES 20 mM buffer. A double system of detection was used here consisting of Rhodamine and Fluorescein methacrylate covalently bound to the backbone of the polymer^{*}.

Rodamine B and Fluorescein methachrylate were inserted randomly in the backbone of the hydrophilic region of the polymer and constituted 5% w/w of the reagents of the polymerization.

Polymer formulation	Experiments carried out	Cell lines	Techniques	Aggregation of micelles upon storage	
1	Toxicity studies	3T3 HCT116 MGLVA-1	MTT	na	
2	Toxicity studies	3T3 HCT116 MGLVA-1	MTT	na	
3	Toxicity studies	3T3 HCT116 MGLVA-1	MTT	na	
4	Toxicity studies	3T3 HCT116 MGLVA-1	MTT	na	
5	Microscopy 37 - 42°C 8h	3T3 HCT116	Widefield microscopy	na	
	Toxicity studies	3T3 HCT116 MGLVA-1	MTT		
6	Microscopy live images studies of the kinetics of uptake at 37°C for up to 1h	3T3	Confocal	Detected after one month storage at - 20°C	
	Microscopy with preincubation of the polymer at 37°C for 30 minutes and incubation of the polymer with cells for 2 and 17h		microscopy		
7	Microscopy with preincubation of the polymer at 37°C for 30 minutes and incubation of the polymer with cells for 2h	3Т3	Confocal microscopy	Already present in the formulation	
	Microscopy at 37°C after24h incubation	3T3, HCT116, MGLVA-1	Widefield microscopy	Already present and increasing with time	
8	Microscopy at room temperature followed by overnight incubation at 37°C both with and without cells	HCT116	Widefield microscopy		
9	Microscopy with 1h preincubation at room temp., 1h preincubation at room temperature and overnight incubation at 37°C and 37°C overnight without preincubation step	3T3 HCT116	Confocal microscopy	Present only upon incubation with cells at room temperature	

Table 5-3 Summary of experiments carried out for each polymer formulation.

5.3 Methods

For a schematics of all the experiments carried out with polymers formulations 1-9, cell lines used, and aggregation state please refer to Table 5-3.

5.3.1 Cell viability studies

Cell viability of thermoresponsive nanoparticles 1, 2, 3, 4 and 6 was assessed with an MTT test at 4 h incubation. The incubation time of the nanoparticles with cells for cell viability studies was decided on the basis of the inhibition studies timescale. The aim was to evaluate the effects of the polymers on metabolic activity when used with cells for the time-length needed for the inhibition studies. These tests were intended to verify that the synthesis and formulation process (in which potentially cytotoxic solvents and catalysts were used) did not lead to contamination of the final polymer formulations with toxic components. It was also intended to verify that the polymer 5, 7, 8 and 9 were not assessed because of lack of time.

Cells were counted and seeded in full media at a density of 31200 cells/cm² in a clear 96 well plate and allowed to attach to the bottom of the wells overnight. The day after, the medium was aspirated off and replaced with HBSS/HEPES 20 mM for the negative control, with PEI 500 μ g/ml (positive control) and concentrations of polymer nanoparticles ranging from 31.25 to 1000 μ g/ml in triplicate wells. Subsequently MTT (50 μ l of 1 mg/ml solution) was applied. Upon completion of the MTT incubation time the absorbance readings were recorded at 550 nm and results were plotted in GraphPad Prism, subtracted of the reading of the blank measurements without cells and normalised against the untreated negative controls. As a further control of the Z factor

and Signal Window were measured according to equations in §2.2.5.4 of the general materials and methods section.

5.3.2 Cell uptake studies

Uptake of thermoresponsive polymers was assessed with two techniques: widefield and confocal microscopy. Widefield microscopy was used for a screening on the behavior of the polymer nanoparticles in the presence and in the absence of cells. However, for a thorough assessment of the uptake of the nanoparticles in cells, confocal microscopy was used as the latter technique is the most suitable for uptake studies given that the resolution allows for the distinction of the regions outside and inside cells¹⁸.

The micelle-like nanoparticles chosen for uptake studies were 5, 6, 7, 8 and 9. The reasons why polymer formulations 1-4 were excluded from uptake studies were many: they presented a Rhodamine dye that was only adsorbed to the micelle and was susceptible to leakage, the polymerization of polymer 3 and 4 was only partially successful producing rather small polymers that were not ideal for the formation of micelle-like nanoparticles. Also all these polymers, when formulated via the nanoprecipitation technique, presented a double distribution of sizes which was problematic for interpreting endocytosis inhibition studies. Finally, their transition temperature was rather high and ranging between 40 and $64 \,^{\circ}$ C and mostly not compatible with cell studies. As the polymer nanoparticles were predicted not to internalize when in a hydrated (and less protein interacting form) when below their TTT, the microscopy study of polymers 1-4 in cells was not taken further^{5,16}.




Figure 5-3 Manual method for the formation of micelle-like nanoparticles from amphiphilic polymers. This simple method consisted in dropwise addition of the acetone polymer-containing solution to an aqueous solution under constant stirring. The acetone/water solution obtained was left to evaporate overnight to remove the acetone from the solution. This method was used for the production of the polymer formulations 1-7.




Figure 5-4 Schematic representation of the mixing apparatus used for the production of polymer formulation 8 and 9. The apparatus consisted of two chambers, one for the polymer dissolved in acetone and another for the water. The mixing was occurring gradually, controlling the flux of the two solutions that were coming to contact at a T junction of the apparatus.

5.3.3 Assessment of the uptake of polymer micelle-like nanoparticles 5

3T3 and HCT116 cells were counted and seeded at a density of 31200 cells/cm² in 6 well plates in duplicate and in full media and incubated at 37 °C and 5% v/v CO₂ to allow cells to attach to the bottom of the plate overnight. The following day micelle 5 suspensions were thawed, vortexed and sonicated for 1 minute. Full media from cells was aspirated and replaced with 500 μ l solution of 500 μ g/ml of the micelle or HBSS/HEPES 20 mM for the negative control. Cells were incubated for further 8 h. Cells treated with the nanoparticles were incubated at 42 °C. Two negative controls were used, one untreated control was incubated at 37 °C and another incubated at 42 °C. Standard tissue culture incubators were used for these experiments with a controlled atmosphere of 95% v/v humidity and 5% v/v CO₂. Upon completion of the incubation time cells were viewed on a Nikon Eclipse Ti widefield microscope, Kingston Upon Thames, UK, to detect any signs of toxicity due to the micelle or the treatment at 42 °C as well as internalization of the nanoparticles in cells.

5.3.4 Assessment of the kinetics of endocytosis of formulation 6

3T3 cells were counted and seeded at a density of 31200 cells/cm² on round glass coverslips in 6 well plates and full media and incubated overnight to allow cells to attach to the glass coverslips. The following day, CellMask deep red plasma membrane staining 1 μ g/ml was applied and incubated for 30 minutes. The media was subsequently aspirated, the coverslip applied on a mounting chamber and cells treated with HBSS/HEPES 20 mM. Micelle formulation 6 was previously thawed, equilibrated to room temperature, vortexed and sonicated for 1 minute and subsequently added to the buffer at final working concentration of 500 μ g/ml. Live images were acquired on untreated cells in HBSS/HEPES 20 mM before the

application of the polymer nanoparticles and at 10, 20, 40, 50 and 60 minutes from their application on cells. Micelle-like nanoparticles 6 were labeled with a fluorescein methacrylate dye for confocal microscopy.

5.3.5 Uptake studies for nanoparticle formulations 6 and 7

3T3 cells were counted and seeded on glass coverslips as described above and allowed to attach to coverslips overnight. The following day, micelle 6 and 7 suspensions were thawed to room temperature, vortexed, sonicated for 1 minute and incubated at 37 °C for 30 minutes before diluting an aliquot of the stock in HBSS/HEPES 20 mM to 500 μ g/ml and applying them to cells. Cells were further incubated with nanoparticles 6 and 7 for 2 h while a further incubation time set at 17 h was attempted for micelle 6. Negative control cells and micelle-treated cells were imaged on a Zeiss 710 confocal microscope.

5.3.6 Uptake studies of the internalization of micelle 8

3T3 and HCT116 and MGLVA-1 cells were counted and seeded at a density of 31200 cells/cm² in clear 96 well plates in full media and allowed to attach to the bottom of the plate overnight. The following day, the micelle suspensions were thawed and left to equilibrate to room temperature, vortexed and sonicated for 1 minute. The media from cells was aspirated and different concentrations of the nanoparticles were applied to the wells in triplicates for concentrations ranging between 31.25 and 1000 μ g/ml in HBSS/HEPES 20 mM. The negative control consisted of cells treated with HBSS/HEPES 20 mM. Treated cells were incubated for further 24 h. Upon completion of the incubation time cells were viewed on a Nikon Eclipse Ti widefield microscope to detect and signs of toxicity and internalization of the nanoparticles in cells.

HCT116 cells were counted and seeded in full media at a density of 31200 cells/cm² in a 25 cm² flasks and allowed to adhere to the bottom of the flask overnight. The day after, the media was aspirated and cells treated with 250 μ g/ml of the nanoparticles in HBSS/HEPES 20 mM in which micelles had been previously thawed, vortexed and sonicated for 1 minute. Cells were incubated at room temperature for 1 h, viewed on a Nikon Eclipse Ti widefield microscope and subsequently incubated overnight at 37 °C. A 25 cm² flask without cells was rinsed with full media and used as a control, incubated with the same solution of the micelle that was applied on cells, at room temperature for 1 h and subsequently incubated overnight at 37 °C. Images were taken after 1 h incubation at room temperature in both cells treated with nanoparticles and flasks with nanoparticles but devoid of cells. Another set of images was taken after overnight incubation at 37 °C before and after rinsing the nanoparticles suspension.

5.3.7 Uptake studies of the internalization of micelle-like nanoparticles 9

HCT116 and 3T3 cells were seeded at a density of 31200 cells/cm² on rounded glass coverslips in 6 well plates and allowed to attach to the glass coverslip overnight. Subsequently, cells were incubated with 250 μ g/ml of polymer formulation 9 overnight with and without an additional incubation step carried out for 1 h at room temperature. Alternatively, cells were treated for 1 h at room temperature with 500 μ g/ml of micelles formulation 9 before confocal microscopy. Cells were stained with Hoechst 33342 1 μ g/ml and/or CellMask deep red plasma membrane staining 1 μ g/ml for 30 minutes and the staining solution removed prior to confocal microscopy on a Zeiss Confocal microscope 710.

5.4 Results

5.4.1 Acute cell viability studies

MTT studies on polymer nanoparticle formulations 1, 2, 3, 4, are shown in Figure 5-5, and MTT assays of polymer 6 are shown in Figure 5-6. The graphs in Figure 5-5 represent the mean and standard deviation of triplicate experiments. Graph in Figure 5-6 represent the mean and standard deviation of duplicate experiments. Graphs illustrate that the nanoparticles were generally well tolerated in the cell lines tested and at the chosen experimental settings.






Figure 5-5 Assessment of cell activity interference of micelle-like formulation 1 (A), 2 (B), 3 (C) 4 (D) following incubation in 3T3, HCT116 and MGLVA-1 cells with an MTT acute test at 4 h. Cells were seeded in a clear 96 well plate and different dilutions of micelle applied in triplicate wells. Absorbance readings were recorded at 550 nm. PEI 500 μ g/ml was used as a positive control. Results are normalised against the negative control and represent the mean and standard deviation of triplicate experiments (n=3).

For all the polymers tested there was little effect on cell metabolic activity and for this reason broad IC₅₀ values and 95% confidence intervals were calculated. The Signal Window between the negative and positive control was calculated to investigate that there was enough separation between the positive and negative control absorbance for the MTT test, as this is an indication of the reliability of the assay¹⁹. In 3T3 fibroblasts the Signal Window was 5 which corresponds to a recommended value, in HCT116 it was 1.6 that corresponds to an acceptable value and in MGLVA-1 cells it was 7 and a recommended value according to Iversen et al¹⁹. Z factor values were equal to 0.5 for 3T3 cells (excellent separation between positive and negative control according to Zhang *et al*⁶⁰), for HCT116 it was equal to 0.2 which corresponds to a small separation between the positive and negative control, and Z factor for MGLVA-1 cells was equal to 0.7 corresponding to an excellent separation between positive and negative control.





Cell activity tests for micelle-like nanoparticles 6 are shown in Figure 5-6. The graph represents the mean and standard deviation of duplicate experiments and suggests that the polymers were well tolerated in the chosen cell lines and experimental settings. IC₅₀ values for polymer formulation 6 in 3T3 cells were equal to 5 mg/ml at a 95% confidence interval of 3.4-8 mg/ml; the obtained IC₅₀ value and confidence interval were not reliable in HCT116 cells (low toxicity) while in MGLVA-1 cells the polymers were essentially inactive. The Z factor and Signal Window for 3T3 cells were 0.2 and 1.7 respectively corresponding to a low separation between positive and negative control calculated by Z factor and an acceptable Signal Window; HCT116 cells presented a Z factor and Signal Window of -0.46 and -1.5 that are unacceptable while Z factor and Signal Window for MGLVA-1 cells were equal to 0.2 and 1.3 that correspond to poor separation between positive and negative control according to Z factor statistics but an acceptable Signal Window. The rather poor Z factor and Signal Window results obtained for polymer 6 were likely due to the unexpectedly low toxicity of the PEI positive control used in these studies.

5.4.2 Internalization studies of micelle-like structures from polymer 5

Polymer 5, formulated into nanoparticles with a single population of micellar diameters, and containing a Fluorescein dye covalently bound to the polymer backbone, were the first to be analyzed for internalization. The aim was to test the internalization of micelle-like nanoparticles of the polymer in 3T3, HCT116 and MGLVA-1 cells. As the TTT for the polymer was 41 °C, the experiments were conducted at 37 °C and 42 °C (respectively below and above the TTT of the polymer). As the high transition temperature was a limiting step for confocal microscopy (which required special arrangements with the confocal microscopy unit), an initial screening

of the uptake of the micelle-like nanoparticles was carried out with a more accessible widefield microscope. As apparent from Figure 5-7, the micelle-like structures obtained from polymer 5 were not sufficiently fluorescent for further confocal microscopy. However, it was noted that the polymers appeared to have an unexpected protective action on cells undergoing treatment at 42 °C for 8 h. As it can be seen from the images in Figure 5-7, 3T3 control cells treated at 42 °C were rounded and unhealthy compared to the control cells treated at 37 °C. The same cells incubated at 42 °C in the presence of formulation 5 looked slightly more flattened and less rounded which suggested a higher resistance to the increase of temperature (arrows).

The density of HCT116 control cells treated at 42 °C was reduced with cells detaching from wells and floating in the media as a consequence of the heat. The same cells treated at the same temperature in the presence of suspensions of nanoparticle formulation 5 presented a cell density that was similar to the untreated control at 37 °C suggesting an acquired resistance to the increase of temperature. Although the HCT116 cell morphology is mainly rounded, some of the cells looked slightly elongated when in good health (see arrows in Figure 5-7 at 37 °C). This morphology is not detected in cells treated with the micelle at 42 °C and can be interpreted as an indicator of cell stress.




Figure 5-7 Micelle-like structures 5 incubated at 42°C (above TTT) for 8 h. The pictures shown above were taken on 3T3 and HCT116 cells incubated for 8 h in the presence and in the absence of the nanoparticles at 42°C. Another set of cells from the same experiments were incubated at 37°C and are inserted in the above picture as a further control. Pictures show a merge of the green channel and the brightfield. Arrows point at some of the features of the cells that suggest good health (see text for further information). Exposure time for the Green Fluorescent Protein (GFP) filter was set at 1 s. Scale bars represent 100 µm.

5.4.3 Micelle 6 and 7 live imaging studies

Micelle-like nanoparticle formulations 6 and 7 (produced from the same polymer in two different circumstances with the manual method illustrated in Figure 5-3), were the first polymers to be screened for internalization with confocal microscopy. The fluorescence of these materials in suspension was assessed by guickly exposing the Eppendorf tube containing the polymer to a GFP filter in a widefield microscope. As the suspension was strongly fluorescent, it was apparent that dye-labeling of the polymer had been successful. The polymer forming the micelle-like nanoparticles presented a TTT of 24°C, suggesting that, for internalization studies at 37°C, the polymers would present a hydrophobic surface. Prior DLS studies (Table 5-1), indicated that formulations 6 and 7, although made with the same technique (Figure 5-3) and from the same polymer, were not identical. Formulation 6 showed a low tendency towards aggregation, while micelle-like nanoparticles from the same polymer, but as formulation 7, were already aggregated before application on cells. Also the size distributions of the two micelle-like nanoparticles were different. Nanoparticles in formulation 6 were of 118 nm diameter while those in formulation 7 displayed two populations with diameters of the nanoparticles of 49 and 312 nm as measured by DLS (Table 5-1).

Formulation 6 - 3T3 fibroblasts

Results – In vitro *Studies of Thermoresponsive Polymers*

Time (min)

Figure 5-8 Confocal live studies of the kinetics of uptake of micelle-like formulation 6 on 3T3 cells. Images were acquired before applying the polymers (time 0) and after and at 10, 20, 40, 50 and 60 minutes from the application of the nanoparticles. The pictures above represent the merge of the green (micelles) and red (CellMask membrane staining) channels. Scale bars represent 50 μ m.

A first set of experiments (Figures 5-8 and 5-9) was carried out using formulation 6 to investigate the uptake and to verify the time length of the uptake in 3T3 cells. The presence of the membrane dye was also introduced to investigate that, if uptake was occurring, as expected, the polymer formulation was localizing inside the membrane boundaries and not on the membrane or outside cells.

A timepoint experiment was carried out to understand the kinetics of internalization of micelle-like nanoparticles 6 and pictures of the cells treated with the nanoparticles

were acquired at 10, 20, 40, 50 and 60 minutes. The pictures showed in Figures 5-8 and 5-9 illustrate that nanoparticles were not internalized by 60 minutes from their application on cells.






Figure 5-9 Comparison of the fluorescence intensity of 3T3 cells before and after 1 h treatment with micelle-like formulation 6. The pictures shown represent the single channels of emission for formulation 6 (Green channel) and CellMask deep red membrane staining (Red channel). Scale bars represent 50 μ m.

To further investigate the reasons underlying this lack of internalization of formulation 6, another set of experiments was carried out, which consisted of preincubation of the micelle-like nanoparticles at 37 °C before application on cells for increased times of incubation. These conditions were chosen taking into consideration the thermoresponsive properties of the polymer. For these polymers, formulated by nanoprecipitation into micelle-like nanoparticles, the surface in the hydrated state below the TTT (24 °C) was considered less likely to promote internalization. By contrast, the change in conformation at the exterior around the thermal transition temperature (TTT) would produce a less hydrophilic surface to the particles, predicted to enhance uptake across lipid cell membranes. The extended incubation time with polymers pre-transitioned across their TTT was thus expected to lead to greater particle internalization. However, increases in the incubation time from 1 to 2 h did not result in 3T3 cells with fluorescent interiors, despite evidence (Figure 5-10) that the nanoparticles were strongly fluorescent when external to the cells. The formulation of micelle-like nanoparticles from formulation 6 also appeared to be well dispersed and non-aggregating, suggesting no changes in size over the temperature ranges compared to similar polymers which had been internalized by MCF-7 cells in previous studies^{5,16}. A second batch of the same polymer, nanoparticle formulation 7 (Table 5-1) was used and experiments carried out as explained above and in the materials and methods section. These micelle-like nanoparticles were applied to 3T3 cells after pre-incubation for 30 minutes at 37 °C and were further incubated for 2 h on the cells. A higher tendency for aggregation was observed with this formulation, and large, self-associated structures were present as can be seen from Figures 5-11 and 5-12. The size of the aggregates ranged from a few microns to tens of microns making the internalization of such structures very unlikely. These data suggested

significant differences in the two formulations derived from the same precursor polymer. As polymer formulation 6 showed less tendency to aggregate, these nanoparticles were incubated with 3T3 cells for up to 17 h at 37 ℃, with a preincubation stage for the polymers of 30 minutes at 37 °C before application to cells and imaging. Results, shown in Figure 5-13, illustrate that the nanoparticles formulation 6 were internalized (arrows) in 3T3 cells at 17 h. Absolute comparison of internalization was problematic as the negative control cells were accidentally contaminated by sterilization product and exhibited toxicity-induced а autofluorescence^{21,22}. Quantification and analysis with a Mann-Whitney t test of the fluorescence of each cell (subtracted from the background value of a region adjacent to the cell) reported a significantly increased fluorescence of cells treated with micelle-like nanoparticles 6 for a P value = 0.0038 (Figure 5-14). Fluorescence in cells treated with the micelle-like nanoparticles was not attributable to poor health of cells as the brightfield images showed no evidence of cell damage. However, further studies of the uptake of these polymer formulations were interrupted as the longerterm stability of nanoparticles 6 against aggregation was insufficient after one month incubation of the nanoparticles at -20 °C. The study was suspended and the chemistry of the polymers as well as the method used for the constitution of the suspension of micelle-like nanoparticles rethought for further experiments.



Results - In vitro Studies of Thermoresponsive Polymers







Figure 5-11 3T3 cells treated with micelle-like nanoparticles 7 preincubated for 30 minutes at 37°C before application on cells for 2 h. Scale bars for the top row represent 50 μ m; Scale bars for the bottom row of Figures represent 20 μ m.



Results – In vitro Studies of Thermoresponsive Polymers

Figure 5-12 Micelle-like nanoparticles 7 preincubated at 37°C for 30 minutes prior to the application on 3T3 cells for 2 h. This set of images show the green channel, brightfiled and a merge of both. Scale bars for the top row of pictures represent 50 μm; bottom row scale bars represent 20 μm.




Figure 5-13 Micelle-like formulation 6 preincubated at 37°C for 30 minutes and subsequently applied to 3T3 cells for 17 h. This set of pictures shows the green channel, the brightfield and a merge of the two in 3T3 negative control (top row of pictures) and positive control of cells treated with nanoparticles 6 (bottom row of pictures). The negative control cells shown in this set of pictures look stressed, retracting their elongated features and rounding up. The reason for this behaviour is believed to be due to the accidental contamination of cells with the sterilising solution of the mounting chamber of the coverslips used for confocal microscopy. Arrows point to the green fluorescence of nanoparticles 6 internalised into 3T3 fibroblasts. Scale bars represent 50 μm.




Figure 5-14 Mann-Whitney t test of the fluorescence for the negative untreated cells and positive control cells treated with formulation 6. The fluorescence was measured with ImageJ for each cell for both the negative and the positive controls, subtracted of the background measured from a region adjacent to the cell before analysing the measurements with a t test. Statistical analysis show a significance of the increase of fluorescence in cells treated with the nanoparticles for a P value of 0.0038. Error bars represent the standard deviation of the mean (n>15).

5.4.4 Live cell imaging of nanoparticles 8

Nanoparticles derived from polymer 8 (TTT = 29 °C) were based on very similar chemistries with respect to polymers 1-7, but formulation was carried out in a slightly different way. The polymer used for formulation 8 contained a hydrophobic PLA core and a thermoresponsive polyDEGMA/OEGMA outer block. The nanoparticles were prepared using nanoprecipitation, as before, but with a syringe-injection pump system for a more reproducible mixing of the acetone-polymer solution with water. The controlled fluid flow from the pumps allowed for a constant and reproducible flux of the two solvents when contacted at the T junction of the apparatus (Figure 5-4). Although good quality nanoparticles from polymer 8 were produced with the above mentioned technique (radius < 60 nm, narrow population distribution), after storage at -20 °C and thawing, aggregated structures were present that required intense vortexing and sonication for dispersal. Experiments using widefield microscopy to assess uptake in 3T3, HCT116 and MGLVA-1 cells were carried out using nanoparticles 8 at a range of concentrations. The set of pictures in Figure 5-15, 5-16,

5-17, 5-18, 5-19 and 5-20 was also acquired to investigate that the two dyes used during the synthesis of the polymers and nanoparticles (Fluorescein methacrylate and Rhodamine B) were both visible. As apparent from Figures 5-15, 5-16, at the highest concentration of nanoparticles, (1000 μ g/ml) large aggregates formed which produced a thick layer of material on cells. Furthermore, although this concentration was the highest of the ones tested and the exposure of the green channel was tested up to 3 times higher than the one used for the red channel in 3T3, and 10 times higher with respect to the exposure time used with HCT116 and MGLVA-1 cells, no fluorescence was detectable for the Fluorescein dye that was inserted in the backbone of the hydrophilic portion of the nanoparticles. Reducing the concentration from 1000 to 500 μ g/ml did not reduce sufficiently the thick layer of the aggregated polymer on cells, thus it was not possible to determine if any particles were internalized. Concentration of 500 µg/ml of formulation 8 appeared to produce two different sorts of aggregations depending on the cell line tested (Figure 5-17). Wormlike' assemblies of nanoparticles 8 were found to be associated with 3T3 and HCT116 cells while MGLVA-1 cells were surrounded by shorter and thicker 'tubes' of associated particles together with sheet-layers of the polymer. At lower concentrations of nanoparticles (250 µg/ml) cells were more clearly discerned. HCT116 cell density was low enough to suggest that the polymer aggregates were preferentially interacting with cell surfaces rather than the underlying cellBIND coating of the 96 well plates substrate (Figure 5-18). The same association between nanoparticles and cell surfaces was also apparent, although less definitively, for 3T3 cells. The larger size of 3T3 cells makes them more confluent than HCT116 and thus the interactions between polymers and cells were less defined. Polymers incubated with MGLVA-1 cells did not appear to show a similar strong affinity for these cell

surfaces and aggregates of the polymers were distributed both on cells and on the bottom of the well. At polymer concentration of 31.25 µg/ml the association of the nanoparticles with 3T3 and HCT116 cells was evident (Figure 5-20). Polymer nanoparticles were preferentially found on the cells with respect to the cellBINDtreated plastic of the well. For all experiments, polymers were detected not only as associated nanoparticles but also as layers and sheets of agglomerated material. It was also notable that the polymers were associated with the 3 cell lines in different ways (Figure 5-19). For polymers attached to 3T3 cells, the nanoparticles were present in longer, thinner regions compared to those at HCT116 and MGLVA-1 cell surfaces. This suggested that the polymer nanoparticles were associated at the cell surface structures, which are known to differ for the 3 cell lines chosen, rather than being present in the cytosol in each case. It is known that 3T3 cells produce extracellular matrix components and it is possible that the nanoparticles were attached to these regions as well as to the rest of the 3T3 cell surface, accounting for the difference in the appearance of the nanoparticles aggregates on 3T3 cells compared to HCT116 and MGLVA-1 cells^{23,24}. Internalization of the polymer nanoparticles in the 3 cell lines was not clearly evident from the pictures at this magnification, suggesting either that no internalization had taken place or that any internalized nanoparticles were masked by the aggregated particles at the cell surfaces.




Figure 5-15 3T3, HCT116 and MGLVA-1 cells treated with different concentrations of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels, brightfield and a merge of all. Cells were seeded at 31200cells/cm² in a 96 well plate and treated with formulation 8 previously thawed, vortexed and sonicated before application on cells. Images were acquired with a Nikon Eclipse Ti widefield microscope. The exposure time for the ds red tomato filter is 300 ms for 3T3 cells and 100 ms for HCT116 and MGLVA-1 cells. The exposure time for the GFP filter is 1s for all cell lines. The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 µm.




Figure 5-16 3T3, HCT116 and MGLVA-1 cells treated with 1000 μg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels (bottom Figures), brightfield and a merge of all (top Figures). The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 μm.




Figure 5-17 3T3, HCT116 and MGLVA-1 cells treated with 500 μg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels (bottom Figures), brightfield and a merge of all (top Figures). The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 μm.




Figure 5-18 3T3, HCT116 and MGLVA-1 cells treated with 250 μg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels, brightfield and a merge of all. The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 μm.




Figure 5-19 3T3, HCT116 and MGLVA-1 cells treated with 62.5 µg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels, brightfield and a merge of all. The nanoparticles were expected to fluoresce in both the Green and the Red channels. Magnification images are provided at the bottom of the Figure and show some features of the aggregates. Scale bars represent 50 µm.




Figure 5-20 3T3, HCT116 and MGLVA-1 cells treated with 31.25 μg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels (bottom Figures), brightfield and a merge of all (top Figures). The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 μm.

As this polymer formulation was found to aggregate rapidly under the tested experimental conditions and did not appear to internalize, the polymers from this batch were not brought further to confocal microscopy studies.

However, from these initial results two hypotheses were formulated:

- 1. The aggregation was a consequence of the incubation of the micelle with cells; i.e. that components in the cell culture media were interacting with the nanoparticles causing aggregation and precipitation.
- 2. The aggregation was a consequence of the change of conformation of the thermoresponsive part of the micelle at 29 ℃ and inherent instability of the resultant hydrophobic micelle surfaces in the aqueous suspension.

Following these hypotheses a second set of widefiled microscopy experiments was run to enquire of the nature of the aggregates.

HCT116 cells were treated with the micelles at room temperature for 1 h (<21 °C and below the TTT of the micelle = 29 °C). In this conformation the micelles were predicted to stay in a more hydrated and less interacting and expectedly less aggregated conformation. This anticipated conformation was left to stabilize for 1 h before imaging. Cells treated at room temperature were then incubated at 37 °C overnight and imaged again before and after rinsing the micelles from the flasks. Furthermore, to investigate that the aggregation of the micelle was not due to the presence of cells, a control without cells was also introduced in the experimental design.

After the thawing, the micelles looked more aggregated than previously noticed (Figure 5-21A). However, after vortexing and sonicating the nanoparticles, the

aggregates disappeared and the experiment was carried out as scheduled. Results showed that the treatment at room temperature did not reduce the formation of the aggregates that were still present and forming sheets of micelles in the range of a few micrometers. The following incubation at 37 °C did not change the aggregation state of the micelles and pictures taken after the rinse of the micelles showed that some of the nanoparticles bound quite readily with the cellBIND treated polystyrene plastic of the flask. The presence of cells did not appear to change the aggregation state of the micelles. However, when comparing the conformation of the micelles from the images of the previous experiment where the micelles were incubated at 37 °C without additional incubation steps (Figures from 5-15 to 5-20), some differences could be noticed. The presence of aggregated micelles in pseudo-filamentous filamentous and fibrous structures in the previous experiments was not apparent in the second set of experiments (Figure 5-22). In contrast, in the second experiment, micelles of formulation 8 were observed in wide sheet-like layers. After removing the polymer solution from cells and rinsing once with PBS, the aggregates appeared to be retained more in the presence of cells (Figure 5-22). The micelles were thawed a second time to repeat the experiment reported above on 3T3 and MGLVA-1 cells. However, this time the nanoparticles appeared heavily aggregated (Figure 5-21B and C) and vortexing and intense sonication did not disperse the aggregates. The experiment was interrupted.




Figure 5-21 Evidence of aggregation over time of formulation 8 upon storage at -20°C. Figure A shows the aggregates of the micelles upon thawing after 2 weeks of storage of the micelle in a -20°C freezer. The aggregates, in that occasion were eliminated by the routine procedures of vortexing and sonication before the use of the micelles on cells. Figure B and C show two different Eppendorf tubes of the same micelles thawed after 4 weeks of storage of the nanoparticles in a -20°C freezer. The aggregates pictured in Figure B and C were only reduced upon vortexing and sonication and structures were prone to re-aggregation after a few minutes of settling of the polymer at the bottom of the Eppendorf tubes.




Figure 5-22 Flasks with or without HCT116 cells treated with formulation 8 at room temperature for 1 h, at 37°C overnight and before and after rinse. This set of pictures show the behaviour of formulation 8 (red channel) in the presence and in the absence of cells. Different settings were applied in these experiments. Flasks with or without cells were treated with micelle 8 for 1 h at room temperature^{**}. Flasks were then moved to an incubator overnight at 37°C. The following day images were acquired prior and after rinsing the micelle from the flasks. Pictures shown in this Figure are the merge of the ds Red channel and the brightfield. Scale bars represent 50 μ m.

^{**} The flask without cells was rinsed with full media before the experiment to better resemble the conditions of the flask with cells.

5.4.5 Micelles 9 live imaging

The last polymer studied for cell internalization was polymer formulation 9. The chemistry of the polymer was very similar to formulation 8. The molar mass of the polymer, the diameter of the nanoparticles formed and the TTT closely resembled polymer 8 (Table 5-2). Because of the complications caused by the aggregation of the nanoparticle formulations upon freezing, the polymer was synthesized two days before the confocal microscopy experiment and the micelles produced by the syringe pump method described in Figure 5-4. The polymer was tested fresh without any freezing steps in between the synthesis and the application on cells. The internalization in HCT116 cells, assessed by confocal microscopy, was tested at room temperature and also below the TTT of the polymer (27° C). The polymer was also tested at a lower concentration of 250 µg/ml and incubated overnight at 37 °C in HCT116 and 3T3 cells. As a further control of the aggregation stability, the polymer was also preincubated at room temperature for 1 h before the overnight incubation at 37 °C in HCT116 cells.

The pictures of cells incubated with and without the polymer are shown in Figure 5-23, 5-24 and 5-25. Upon incubation at room temperature for 1 h and 500 μ g/ml, some aggregation of the polymer in solution was visible. However, the aggregation was reduced when the polymer was used at 250 μ g/ml and after overnight incubation. All cells treated with the polymer showed some extent of internalization, although the fluorescence was low. Internalization was apparent also when the polymer was incubated at room temperature and below the TTT. This suggests that the rearrangement of the polymer corona upon hydrophilic chain collapse above the TTT observed in buffer solutions either did not take place in the same way in the presence of cells, or that a change from a hydrophilic corona to a hydrophobic outer surface did

not significantly alter the internalization into cells. The distribution of the fluorescence resulting from polymer nanoparticles internalization was also different from that observed in C-PB. The fluorescence was more uniformly distributed in the cytoplasm and nuclei of cells and did not show the usual punctate structures that were detected for both C-PB nanoparticles and formulation of polymer 6. It should also be noted that z stack images (Figure 5-25) showed a tendency for the dye to undergo photobleaching and the internal fluorescence of the micelle was reduced upon repeated exposure to the laser beam.




Figure 5-23 Formulation 9 incubated with HCT116 cells in different conditions. HCT116 cells were incubated with polymer formulation 9 for 1 h at room temperature, or overnight at 37°C, with or without a preincubation step of 1 h at room temperature. The concentration of formulation 9 is 500 μ g/ml in room temperature experiments and 250 μ g/ml in overnight experiments. Green: micelles; Blue: Hoechst staining of the nuclei; Red: CellMask deep red membrane staining. Polymers were labelled with Rhodamine B which is detected in a red channel. For an easy distinction of the micelles from the Deep Red CellMask dye, the micelles are shown in Green. The last row of images is given by a magnification of the most significant features of the internalization of formulation 9 in HCT116 cells. Scale bars for the first 4 rows represent 50 μ m. Scale bars for the bottom row represent 20 μ m.




Figure 5-24 Internalization of 250 μ g/ml of micelle suspension 9 after overnight incubation at 37°C. Images were acquired on a Zeiss 710 confocal microscope after staining the cells with Hoechst 33342 1 μ g/ml (Blue). Green: Formulation 9 stained with a red Rhodamine B dye. The magnification picture in this Figure has been modified enhancing the fluorescence signal from the micelles to help the reader to detect the key features of the internalization of formulation 9 in 3T3 cells. Scale bars represent 50 μ m for the full images and 10 μ m for the zoomed image.

Nuclei+ From. 9 + Brightfield

Nuclei + Form. 9 + Brightfield

Zoom Nuclei + From. 9




Figure 5-25 Orthogonal projection of a 3D image acquired on 3T3 (left) HCT116 cells (right) treated with 250 μ g/ml of micelle suspension 9 overnight at 37°C. The arrows point at the internalization of the nanoparticles (Green) where its fluorescence can be localised within the boundaries of the red membrane. Nuclei: Blue. Scale bars represent 50 μ m.

5.5 Discussion

Cell activity studies on micelles 1, 2, 3 and 4 showed that the materials were generally well tolerated in the tested cell lines. HCT116 cells were the most sensitive to polymer micelle-like nanoparticles 1-4 with a minimum cell activity observed at 250 μ g/ml polymer. The drop in viability reached a minimum of about 70% viable cells in HCT116 with micelle 1-4 which implied a good overall biocompatibility of the micelles. The U shaped viability profile might have been due to different aggregation states of the polymers with the higher concentrations producing aggregates that reduced association and internalization of the polymers with/in the cells and hence interfering less with the cells activity.

Cell activity was also not affected adversely by polymer formulation 6. 3T3 fibroblasts were the most sensitive cell line of the panel of cells used. However, the PEI positive control in these experiments did not sufficiently reduce the viability of cells. This unexpected result must be taken into consideration when extrapolating from this set of data that micelle formulation 6 was well tolerated from cells.

Widefield microscopy studies at 37 °C and 42 °C for micelles 5 produced some inconclusive results on the ability of the micelle-like structures to access cells, given that the polymer did not present any detectable fluorescence. The reason for this absence of fluorescence was due to the insufficient concentration of the Fluorescein methacrylate dye used for the labelling of the polymer. However, the pictures obtained at 42 °C showed that cells incubated with the micelles acquired some resistance to the increase of the temperature with respect to the negative control. This unexpected event has not been reported in the literature before and it should be further investigated in order to confirm that this phenomenon is consistently and

reproducibly happening as the data shown are based on one experiment only. One hypothesis can be attempted to justify this observation. Micelles 5 were brought from 37° C to 42° C upon initiation of the experiment. The solution that contained the polymer gradually increased its temperature from 37° C up to 42° C. While the temperature of the plates was increasing, at temperatures near 41° C that is the TTT of the polymer, the change in conformation of the nanoparticles started occurring, subtracting energy from the system, which in other terms means that, for some reasons the transition in conformation started happening in a endoergonic way while the ΔG of the transition was still positive, subtracting energy from the solution. This process might have slowed down the escalation of the temperature of the solution in contact with the cells delaying the increase of the temperature to up to 42° C for a time sufficient to produce this apparent protective effect of the nanoparticles on cells.

Confocal live imaging of polymer formulation 6 thawed and applied to 3T3 cells for 1 h at 37 °C did not show any internalization of the micelles. Nanoparticles from formulation 6, with a transition temperature of 24 °C, were anticipated to display a hydrophobic, more amphiphilic and more cell-interacting conformation upon incubation at 37 °C. Based on prior data with similar nanoparticles, the collapsed structure of the PLGA-*b*-(PEGMA-*co*-PPGMA) above its TTT was expected to have interacted more promptly with the phospholipids bilayer and membrane proteins at the cell surfaces and promote an internalization process for the material. The internalization process is believed to occur in two steps:

 The polymer chains at the nanoparticle surface interact with the cell and bind to its membrane/membrane bound proteins; 2. The nanoparticles are subsequently internalised via the triggering of a receptor-mediated process or through fluid phase endocytosis.

As no evidence of internalization was provided by confocal microscopy studies for micelle-like structures 6, it is possible to hypothesise that one of the two processes described above must have failed to occur. In other terms, the polymer might have failed the binding on the cell surface or the polymer was binding on the cell surface but was not internalised. However, if it was the internalization process to be failing, the membrane of cells might have been fluorescent because of the polymeraggregates binding to the cell membrane; experimental evidence does not support this hypothesis. As a consequence, it is possible to suggest that a low interaction with the membrane of cells of the micelles was reducing its internalization. The preincubation step at 37 °C and the extension of the incubation time to 2 hours did not produce any detectable internalization. This time-length of internalization was proven sufficient for the similar nanoparticles in other studies¹⁶. Nevertheless preincubation at 37 °C and extension of the incubation time to 2 h showed that the micelles were not prone to aggregation and stable in their conformation and size. The internalization of the micelle-like nanoparticles occurred only when the micelles were incubated with cells for 17 h and this timescale of internalization was not compatible with the intended endocytosis pathway studies. This brings into question as to why the internalization of this formulation of polymer 6 was so slow. It might be possible that polymer 6 formulation had high affinity towards only a few proteins on the plasma membrane and this reduced its interaction with the membrane and consequently its internalization. Another hypothesis is that the polymer did not have any affinity for the plasma membrane of 3T3 cells but the prolonged incubation with 3T3 cells allowed for the cells to secrete enough proteins to condition the media. It has been reported in

the literature that such processes can enhance binding of the secreted protein to the polymer and hence its affinity for the cells' membrane and internalization²⁵. It is also important to stress that the lack of fluorescence inside cells upon incubation of the micelle-like polymer 6 might be due to a lack of detection of the polymer inside cells. It is known in the literature that Fluorescein methacrylate is a pH sensitive dye. It bears a carboxylic group that is protonated and hence switches the chemistry of the dye towards a less fluorescent form upon acidification of the solution in which resides. As many intracellular compartments to which the micelles can be directed upon internalization are acidic and with pH ranging between 6.5 and 4.5, it might be possible that the micelles were not poorly internalised but were not detectable as a result to traffic to acidic compartments. A reasonable question at this point might be on why the micelles were detected upon incubation at 17 h. One possible explanation might be that the polymer had moved to a less acidic compartment during the extended incubation. However, if the lack of cellular fluorescence was due to a failed internalization instead of a lack of fluorescence another consideration might be due. Previous work on polymers of very similar constituents and formation parameters showed internalization on MCF-7 epithelial cancer cell lines. Hence, it is possible to consider factors which might account for differences in the present study compared to the prior work: the 3T3 cells used for the studies were fibroblastic cell lines from mouse embryos and were not originating from a cancer line, thus suggesting some specificity of the PLGA-b-(PEGMA-co-PPGMA) micelles towards epithelial cancer cell lines.

Confocal microscopy on micelle formulation 7 showed that the formulation of the micelles with a manual nanoprecipitation method was not giving reproducible sizes of the micelles and it was confirmed by DLS studies (Table 5-1). The polymer used for

the formulation of these nanoparticles was the same as for formulation 6. However, upon incubation with cells, it produced large aggregates of tens of microns in size. The evidence that formulation 7 was more aggregated than micelle-like structures 6, that were originated from the same polymer, was already provided by DLS studies carried out straight after the formulation of the micelles where DLS was showing a double peak at 49 and 312 nm. It might be possible that the presence of bigger aggregates already in the original formulation of the polymer might have speeded up the process of nucleation that is essential for the formation of larger aggregates. Although formulation 6 showed a much slower tendency to aggregation, upon prolonged storage at -20 °C (about one month) the polymer presented large aggregates that were not dissolving with intense vortexing or sonication. These results suggest a more general instability upon storage of PLGA-*b*-(PEGMA-*co*-PPGMA) nanoparticles produced by the manual nanoprecipitation route.

From the above evidence of colloidal instability of PLGA-*b*-(PEGMA-*co*-PPGMA) formulation 6 and 7, nanoparticles 8 and 9 were synthesised. They were constituted from subtly different co-monomers and were formulated into nanoparticles by an automated system in order to increase the reproducibility of the size and surface characteristics of the nanoparticles. Also, in the attempt to produce a more reliable probe to detect the polymer in any cell compartment, the materials were synthesised in the presence of 2 dyes: Rhodamine B for a clear detection of the polymer at acidic pH²⁶, and Fluorescein metachrylate for a convenient detection in non acidic compartments^{27,28}. However, when nanoparticles from formulation 8 were tested at different concentrations for 24 h at 37 °C, aggregates nevertheless formed. While self-association and colloidal instability at 37 °C might be expected for polymer nanoparticles with a TTT of 24 °C, it was not expected when initial incubations were

carried out at room temperature (< 21 ℃). Indeed, DLS measurements of the formulation 8 nanoparticles reported a size of 56.4 nm at 20 °C, clearly indicating an initial non-aggregated formulation of the nanoparticles in HEPES 20 mM. The micelles aggregated at 37 °C, which although not entirely unexpected owing to predicted loss of colloidal stability above the TTT, was problematic for cell assays as the self-association occurred rapidly. Literature reports of phase transitions of polymers have shown that aggregation depends on many variables: temperature, ionic strength of the solution, concentration of the polymer in solution, as well as geometry of the hydrophilic to hydrophobic block of the micelles. However, these considerations have been made on relatively small aggregates that are usually detected with TEM techniques. The aggregates reported in the experiments in this thesis were of several microns in size and this suggests that the rod-like structures and worms so easily detectable might be given by complex interactions of the micelles with each other producing layers and layers of particles tick enough to become detectable in a widefield microscope with a low power objective. The presence of such bulky aggregates suggests that the materials were exceptionally more stable when aggregating with respect to the single micelles in solution. Also, reducing the concentration to 31.25 µg/ml did not prevent aggregation suggesting that the polymer nanoparticles were not stable in solution above their TTT and that aggregation was not intrinsically a consequence of a too high concentration of micelles in solution. Polymer formulation 8 appeared to show affinity for 3T3 and HCT116 cell surfaces. It is not clear if the presence of aggregates associated with 3T3 and HCT116 cells was due to an entrapment in the extracellular matrix proteins produced by 3T3 cells or to a more general affinity to the membrane composition of the cells as suggested by HCT116-aggregates interactions.

Furthermore, given that the fluorescence of aggregates was quite strong and the magnification used for the experiments was quite low, it is not possible to rule out some extent of internalization in cells of the modest portion of the nanoparticles that were non-aggregating. If some internalization occurred, it is possible that the lack of Fluorescein signal might have been due to internalization in acidic compartments as Fluorescein is well known for its pH dependent loss of fluorescence. However, most of the polymer was present outside cells and Fluorescein remained undetected in the GFP channel. The loss of fluorescence emission of Fluorescein methacrylate was most likely due to poor incorporation of the Fluorescein-based monomer during synthesis, as Fluorescein was used in low monomer feed ratios.

This double system of detection based on two dyes consisting in Fluorescein metacrylate and Rhodamine B is not new in literature and is has been already reported²⁹. This probe-system was chosen to give extra information on the pH of the compartment that the material was accessing upon endocytosis and also probing that the lack of florescence obtained with previous fluorescein labelled polymers was not due to the acidic compartmentalization of the materials upon internalization. It was disappointing not to be able to observe the dual signal in these experiments.

A hypothesis to explain the reasons for the strong tendency to aggregation of polymer nanoparticles 8 is that it might have been due to the chemistry of the PLA-*b*-(DEGMA-*co*-OEGMA). The portion of the DEGMA block, in fact, is highly represented in these polymers and constitutes 95% of the hydrophilic portion of the block copolymer. Although this ratio of the DEGMA portion is justified to lower the TTT of the polymer from about 90 °C of the OEGMA to more physiologically relevant transition temperatures, literature reports that the more the thermoresponsive chains are short (and DEGMA is formed by only 2 repetitions of ethyl ether), the more the

adhesion properties of the micelles above the LCST. Hence the high proportions of the DEGMA were probably undermining the colloidal stability of the polymer when incubating at 37 °C^{9,30}. It is also possible to speculate that this effect might have been reduced if the distribution of the OEGMA chains could have been controlled during the synthesis of the block copolymer. However, the statistical method used to synthesise these polymers does not allow this control. Another phenomenon that promoted aggregation and interfered with the stability of polymer 8 was the tendency for aggregation upon storage. This may have been due to too high concentration of the stock suspension of polymer in storage (7.5 mg/ml) and possible phase segregation in the buffer (HEPES 20 mM) leading to polymer-rich regions in suspension, chain entanglement and kinetic trapping of aggregates.

As a recent publication from Albanese *et al* showed that cells secretions can alter the properties of nanoparticles in relation to their tendency to aggregate, the polymer formulation 8 was tested both in the presence and in absence of HCT116 cells³¹. To further investigate the nature of the aggregation, the nanoparticles were incubated at room temperature and below the TTT of nanoparticle formulation 8 ($29 \,^{\circ}$ C). Results showed that the filamentous network of aggregated particles in these settings did not occur, either in the presence or in the absence of cells. From these data it is not entirely possible to rule out the involvement of HCT116 cells surface proteins and secretions in the formation of polymer nanoparticle-complex filaments aggregates obtained at $37 \,^{\circ}$ C as it might be possible that cells at room temperature can expose different proteins on their surface, since the endocytosis is still active but the trans-Golgi network cargo sorting on the plasma membrane and exocytosis are inhibited and potentially changing the protein expression at the plasma membrane and secreted in the media³². However, the aggregation in fact happened in both cell and

cell-free conditions suggesting that cellular secretions alone were not responsible for the formation of the layers of aggregates of micelles in these settings. It is probable that the poly-DEGMA corona might be already sticky and prone to aggregation at room temperature and the pre-treatment at 20 °C after thawing the micelles was stabilising the aggregation. This pretreatment was giving time to the micelles to rearrange to a more complex and a reduced entropy sheet conformation. This conformation might have been occurring less at higher temperatures because of thermal agitation of the solution in which the micelles reside, or the presence of cells at 37 °C might have stabilised the formation of the worm-like aggregates instead. The evidence of aggregation below the TTT of the polymer suggests that the chemistry of these polymers was not optimised against the aggregation of the micelles upon storage. After rinsing, the majority of large aggregates were removed. However, small sheet-like structures were still present to the bottom of the plate after rinsing. This show that the nanoparticles had some moderate affinity for the cellBIND treated surface of the flask.

The last set of experiments was with polymer formulation 9 with a TTT of 27 °C and a monomer composition closely resembling formulation 8. As it was evident from previous experiments that the nanoparticles were not stable upon storage, they were synthesized and micelles produced immediately before confocal live experiments. In this way the freeze-thawing step was avoided and fresh nanoparticles, with a DLS reported size (at 20 °C) of about 45 nm applied on cells. The temperature was not altered and experiments with HCT116 at room temperature and uptake studies run after incubation of the polymer with cells for 1 h. Despite the numerous efforts to reduce the aggregation, the nanoparticles showed some extent of self association, although the aggregation state did not interfere with the internalization of the

nanoparticles. However, in these experiments the nanoparticles were internalising below the TTT in HCT116 cells. Experiments with polymer formulation 9 carried out overnight, with and without preincubation step of 1 h at room temperature showed internalization as well. As the concentration of polymer in the experiments at room temperature and the ones with the overnight incubation were different, it is not possible to verify if the extent of internalization differed with the two settings. One explanation can be attempted for the internalization of the micelle-like aggregates 9 irrespective of the TTT and consistent with the earlier data on polymer selfassociation below the TTT. It is known from the literature that PEG chains can interact to some level with proteins³³. Their antifouling characteristics are given by the length of the PEG chain and its ability to produce a thick layer of flexible brushes that reduces the interactions of the PEG chain with the proteins³⁴. PEG chains around 400 Da of Mw are believed to be the less protein-interacting³³. However, the OEGMA, with Mw of 375Da, is represented for only 5% in the PLA-b-(DEGMA-co-OEGMA) polymers. This might mean that the 'PEG component' was too small to effectively produce a brush to reduce the interaction with proteins. As a result, given that in the chosen experimental settings the media was formed by HBSS that contains only a few aminoacids, the bulk of the proteins exposed to the polymer were derived from the membranes of cells. This might explain why, although below the TTT, the polymer was sufficiently interacting with cell proteins to allow a rather fast internalization of the polymer that was observed within 1 h from the application of the polymer on cells. The signal obtained by the internalised micelles was weak both above and below the TTT. Upon overnight incubation, the presence of the aggregates in the media was less evident. However, also the concentration used for the overnight experiments was halved with respect to the experiments with cells run at room temperature which

might reduce aggregation. Consequently, it is not possible to determine the reasons for the loss of aggregates in the media of cells upon overnight incubation. Furthermore, as pointed out in the results section for polymer formulation 9, the fluorescence of the internalised nanoparticles was different with respect to formulation 6 and C-PB. The latter nanoparticles appeared as discrete dots of different sizes in the cytoplasm and perinuclear accumulation that were also evident in immunofluorescence staining of clathrin heavy chain α and caveolin-1. To some extent, for the overnight incubation of the micelles, some increase of polymer fluorescence in the perinuclear region was observed. However, it is important to point out that there is evidence that Hela cells lysosomes change their distribution towards a conformation resembling the diffused fluorescence observed in HCT116 and 3T3 cells when incubated with toxic drugs that induce apoptosis such as the anticancer etoposide³⁵. However, even though this specific polymer was not tested for toxicity, other polymers with similar characteristics did not interfere with cell activity according to an MTT assay. It is nevertheless true that one test alone does not give the full picture of the toxicity of novel materials. If toxicity was occurring, the cells might result fluorescent as a consequence of the toxicity instead of the uptake of the material if they produce ROS. ROS oxidise proteins making them fluorescent and emitting in the green and red channels (the same mechanism underlying the phototoxicity events in microscopy that cause auto-fluorescence as a consequence of a too long exposure to the high power laser beam). In this experiment, the Green channel did not show fluorescence. However, in is known that an oxidised form of riboflavin (vitamin B₂) produces autofluorescence, emitting around 550 nm which was the region of detection of the Rodamine B dye in the confocal settings for these experiments^{36,37}. If toxicity and consequent autofluorescence was occurring that might be the reason for

fluorescence detection both above and below the TTT. Literature reports that ROS production is increased as the surface area of the material increases³⁸. Although the morphology of the cells did not suggest toxicity, the CellMask dye also stained some extracellular membrane features. These features might be apoptotic bodies as there are no macrophages to scavenge for these products and remove from the environment (although also non-specialised cells can clear from apoptotic bodies), or necrotic remains of cells. The toxicity overnight might also have been triggered by the prolonged incubation of cells in HBSS/HEPES media, where the absence of FBS might cause the cells to undergo stress and death. The last result for this set of experiments suggest that the micelles were undergoing photo-bleaching as the fluorescence obtained in the equatorial region of 3D images present a lower fluorescence with respect to the single plane images. This effect is reported in the literature for Fluorescein but Rhodamine B is considered a rather resistant dye, and the reasons underlying this effect are not clear. The next steps are to design the synthesis of improved materials and consequent experiments to rule out as much as possible any misinterpretation of the experimental results.

5.1 Conclusions

These experiments have revealed an unexpected difficulty for these synthetic polymers to produce micelles with reproducible characteristics. Polymer presented a high tendency to aggregation and inherent instability and little tendency to access cells. Although some progress has been made in regards to the manufacture of micelles with an automated system that can produce micelles from the same polymer that have similar characteristics of size, some improvements must still be addressed. One of the main problems for these polymers was their strong tendency to produce

bulky aggregates. The aggregation tendency was variable in different polymers. Polymer 6 with a PLGA-*b*-(PEGMA-*co*-PPGMA) chemistry was the most resistant to aggregation and produced stable micelles sizes for a period of two weeks. However, upon longer periods of storage the polymer presented extensive aggregation that was not compatible with the intended *in vitro* studies. This tendency became even more evident in the last two PLA-*b*-(DEGMA-*co*-OEGMA) polymers. Another issue that makes the control of aggregation more challenging is the statistical method used to synthesise these polymers. This way of producing polymers does not allow for a control of the distribution of the OEGMA in the hydrophilic chain of the polymer rendering the polymer tendency to agglomerate difficult to manage especially for polymers at low percentages of OEGMA. If this problem is not resolved by an optimization of the OEGMA ratio that is also compatible with a physiologically relevant TTT, other methods that allow for a more controlled synthesis of polymers for physiological applications might be worth some consideration³⁹⁻⁴³.

References

- 1 Arthur, R. M., Straube, W. L., Trobaugh, J. W. & Moros, E. G. Non-invasive estimation of hyperthermia temperatures with ultrasound. Int J Hyperthermia **21**, 589-600 (2005).
- 2 Chatterjee, D. K., Diagaradjane, P. & Krishnan, S. Nanoparticle-mediated hyperthermia in cancer therapy. Ther Deliv **2**, 1001-1014 (2011).
- 3 Dickerson, E. B. et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Letters **269**, 57-66 (2008).
- 4 Svaasand, L. O., Boerslid, T. & Oeveraasen, M. Thermal and optical properties of living tissue: Application to laser-induced hyperthermia. Lasers in Surgery and Medicine **5**, 589-602, doi:10.1002/lsm.1900050607 (1985).
- 5 Abulateefeh, S. R. et al. Facile synthesis of responsive nanoparticles with reversible, tunable and rapid thermal transitions from biocompatible constituents. Chemical Communications, 6068-6070 (2009).
- 6 Makadia, H. K. & Siegel, S. J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) **3**, 1377-1397 (2011).
- 7 Lu, J. M. et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn **9**, 325-341 (2009).

- 8 Wu, X. S. & Wang, N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation. J Biomater Sci Polym Ed **12**, 21-34 (2001).
- 9 Vancoillie, G., Frank, D. & Hoogenboom, R. Thermoresponsive poly(oligo ethylene glycol acrylates). Progress in Polymer Science **39**, 1074-1095 (2014).
- 10 Boutris, C., Chatzi, E. G. & Kiparissides, C. Characterization of the LCST behaviour of aqueous poly(N-isopropylacrylamide) solutions by thermal and cloud point techniques. Polymer **38**, 2567-2570 (1997).
- 11 Anghelache, A., Teodorescu, M., Stănescu, P., Drăghici, C. & Vuluga, D. Novel crosslinked thermoresponsive hydrogels with controlled poly(ethylene glycol)—poly(propylene glycol) multiblock copolymer structure. Colloid Polym Sci **292**, 829-838 (2014).
- 12 Hu, Z., Cai, T. & Chi, C. Thermoresponsive oligo(ethylene glycol)-methacrylate- based polymers and microgels. Soft Matter **6**, 2115-2123 (2010).
- 13 Luzon, M. et al. Water-soluble, thermoresponsive, hyperbranched copolymers based on PEGmethacrylates: Synthesis, characterization, and LCST behavior. Journal of Polymer Science Part A: Polymer Chemistry **48**, 2783-2792 (2010).
- 14 Lutz, J.-F. & Hoth, A. Preparation of Ideal PEG Analogues with a Tunable Thermosensitivity by Controlled Radical Copolymerization of 2-(2-Methoxyethoxy)ethyl Methacrylate and Oligo(ethylene glycol) Methacrylate. Macromolecules **39**, 893-896 (2005).
- 15 Ramírez-Jiménez, A., Alvarez-Lorenzo, C., Concheiro, A. & Bucio, E. Temperatureresponsiveness and biocompatibility of DEGMA/OEGMA radiation-grafted onto PP and LDPE films. Radiation Physics and Chemistry **99**, 53-61 (2014).
- 16 Abulateefeh, S. R. et al. Enhanced uptake of nanoparticle drug carriers via a thermoresponsive shell enhances cytotoxicity in a cancer cell line. Biomaterials Science **1**, 434-442 (2013).
- 17 MacEwan, S. R. & Chilkoti, A. Controlled Apoptosis by a Thermally Toggled Nanoscale Amplifier of Cellular Uptake. Nano Letters **14**, 2058-2064 (2014).
- 18 Kirchhausen, T. Imaging endocytic clathrin structures in living cells. Trends Cell Biol **19**, 596-605 (2009).
- 19 Iversen, P. W., B.J., E., Sittampalam, G. S. & Cox, K. L. A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. Journal of Biomolecular Screening **11**, 247-252 (2006).
- 20 Zhang, J. H., Chung, T. D. F. A. U. O. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of Biomolecular Screening 4, 67-73 (1999).
- 21 Aubin, J. E. Autofluorescence of viable cultured mammalian cells. Journal of Histochemistry & Cytochemistry **27**, 36-43 (1979).
- 22 Goldman, R. D., Swedlow, J. R. & Spector, D. L. Vol. 1 (ed Cold Spring Harb Laboratory Press) (John Inglis, New York, USA, 2010).
- Fabbro, C. et al. Cell type-specific transcription of the alpha1(VI) collagen gene. Role of the AP1 binding site and of the core promoter. J Biol Chem **274**, 1759-1766 (1999).
- Goldberg, B. Collagen synthesis as a marker for cell type in mouse 3T3 lines. Cell **11**, 169-172 (1977).
- Albanese, A. et al. Secreted Biomolecules Alter the Biological Identity and Cellular Interactions of Nanoparticles. ACS Nano **8**, 5515-5526, doi:10.1021/nn4061012 (2014).

- 26 Ramette, R. W. & Sandell, E. B. Rhodamine B Equilibria. Journal of the American Chemical Society 78, 4872-4878 (1956).
- 27 Martin, M. M. & Lindqvist, L. The pH dependence of fluorescein fluorescence. Journal of Luminescence **10**, 381-390 (1975).
- 28 Geisow, M. J. Fluorescein conjugates as indicators of subcellular pH: A critical evaluation. Experimental Cell Research **150**, 29-35 (1984).
- 29 Hu, J. et al. Ultrasensitive ratiometric fluorescent pH and temperature probes constructed from dye-labeled thermoresponsive double hydrophilic block copolymers. Journal of Materials Chemistry **21**, 19030-19038 (2011).
- 30 Synytska, A. et al. Biocompatible polymeric materials with switchable adhesion properties. Soft Matter **6**, 5907-5914 (2010).
- 31 Albanese, A. & Chan, W. Effect of Gold Nanoparticle Aggregation on Cell Uptake and Toxicity. ACS Nano 5, 5478 5489 (2011).
- 32 Manolea, F. et al. Arf3 is activated uniquely at the trans-Golgi network by brefeldin Ainhibited guanine nucleotide exchange factors. Mol Biol Cell **21**, 1836-1849 (2010).
- 33 Wu, J. et al. Binding characteristics between polyethylene glycol (PEG) and proteins in aqueous solution. Journal of Materials Chemistry B **2**, 2983-2992 (2014).
- 34 Roosjen, A., van der Mei, H. C., Busscher, H. J. & Norde, W. Microbial Adhesion to Poly(ethylene oxide) Brushes: Influence of Polymer Chain Length and Temperature. Langmuir **20**, 10949-10955 (2004).
- 35 Bottone, M. G. et al. Morphological Features of Organelles during Apoptosis: An Overview. Cells **2**, 294-305 (2013).
- 36 Rost, F. W. D. Vol. II (Cambridge University press Cambridge, USA, 1995).
- 37 Pawley, J. (ed Springer) (New York, USA, 2010).
- 38 Brown, D. M., Wilson, M. R., MacNee, W., Stone, V. & Donaldson, K. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol **175**, 191-199 (2001).
- 39 Furgeson, D. Y., Dreher, M. R. & Chilkoti, A. Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. Journal of Controlled Release 110, 362-369 (2006).
- 40 Ghoorchian, A., Chilkoti, A. & López, G. P. Simple Assay for Proteases Based on Aggregation of Stimulus-Responsive Polypeptides. Analytical Chemistry **86**, 6103-6110 (2014).
- 41 Mastria, E. & Chilkoti, A. Genetically encoded "smart" peptide polymers for biomedicine. MRS Bulletin **39**, 35-43 (2014).
- 42 MacEwan, S. R. & Chilkoti, A. Applications of elastin-like polypeptides in drug delivery. Journal of Controlled Release **190**, 314-330 (2014).
- 43 Li, N. K., Garcia Quiroz, F., Hall, C. K., Chilkoti, A. & Yingling, Y. G. Molecular description of the LCST behavior of an elastin-like polypeptide. Biomacromolecules (2014).

6-Chapter 6

General discussion and future perspectives

Polymer-therapeutics are a stimulating field for the pharmaceutical industry. They have been intensely investigated for their new approach to treatments and for their clinical potential. Many polymer-drug conjugates have now reached the market and have succeeded in their promise to improve the array of choices for medicinal remedies, reducing toxicity, increasing specificity and consequently patients' overall quality of life¹. However, recent progress in polymer chemistry has fuelled the polymers therapeutics field with new and inspiring 'smart' materials that can respond to environmental changes providing potentially elegant and sophisticated ways to deliver drugs²⁻⁵. Evidence in the literature indicates that responsive materials can increase selectivity of drug targeting and reduce toxicity and in vivo studies are gradually changing the perception of the field^{6,7}. One of the most important possibilities for these (nano)materials is that they can enhance delivery of drugs at the cellular and subcellular level. However, the understanding of endocytic processes underlying the uptake of many nanomaterials is limited at the moment and approaches to direct the nanocarriers of drugs towards one specific endocytic pathway have not yet led to improved results in clinical trials. This has created a renewed interest in the understanding of the mechanisms that lead to endocytosis of nanocarriers. Deciphering these mechanisms would allow controlled intracellular delivery and could open new and unexplored perspectives for the pharmaceutical industry in areas such as gene delivery and, more importantly, provide a therapeutic approach for many untreatable diseases.

The aim of this thesis was to investigate the uptake of synthetic nanoparticles *in vitro* using inhibitors of endocytosis and to recognize any similarities in the uptake of carboxylated polystyrene bead nanoparticles (C-PB) and thermoresponsive block co-polymer core-shell nanoparticles. As the polymers used for the study presented a

PEGMA brush that reduced their interactions with proteins and hence with a surface chemistry that was only marginally affected by the presence of FBS, C-PB studies were carried out in a buffer in the absence of FBS to better mimic the surface chemistry of the thermoresponsive polymers. Although thermoresponsive core-shell micelle-like nanoparticles with a similar chemistry had already been synthesized in our group in the past and showed good internalization rates in a specific cancer cell line, the newly synthesized thermoresponsive nanoparticles demonstrated a high tendency to aggregate above their thermal transition temperature (TTT) and an overall colloidal instability that hampered further endocytosis studies^{8,9}. The colloidal instability of PLGA-b-(PEGMA-co-PPGMA) and PLA-b-(DEGMA-co-OEGMA) nanoparticles, while not unexpected over prolonged time periods above the TTT, had not been reported before upon storage well below the TTT of the nanoparticles. Some ways to address this issue have been suggested in chapter 5; however, if not resolved, the colloidal instability might undermine any possibility of clinical applications of these nanocarriers. For this reason the aim of the experiments reported here remains unmet overall. Nevertheless, the study gave some information on aspects of endocytosis and C-PB uptake.

The first finding regarding the choice of cell viability tests for materials that interfere with endocytosis and/or are endocytosed confirms results shown in the literature. The choice of cell activity tests should be tailored to the material used, as nanomaterials can interfere with the test adopted and alter the concentration of the dye used as indicator of the viability of cells making difficult the interpretation of the results¹⁰. Many assays for cell viability rely on the endocytosis and exocytosis of viability markers¹¹⁻¹³. Results in this thesis show that this sort of activity test might overestimate the toxicity of some materials and should be used in conjunction with

other tests that do not rely on endocytosis/exocytosis. Also, viability tests that rely on enzymes to report cell activity interference should be used with caution when testing nanoparticles as some of these materials may interact with proteins and hence the enzymes of the assay compromising their activity¹⁴⁻¹⁶.

Some ground rules were also established on the inhibition of endocytosis of Htf (a CME marker) with CPZ. CPZ inhibition of Htf endocytosis was revealed to be timedependent and its internalization was only transiently inhibited by CPZ. Furthermore, the inhibition reached a maximum that was cell- and time-dependent and after that timepoint the uptake of Htf recovered despite the presence of CPZ suggesting that Htf can internalize through an alternative way that is not CPZ sensitive. Also, the study revealed that the CPZ inhibition was dependent upon the passage number and ageing of cells. Many laboratories that work on endocytosis consider CPZ inhibition 'temperamental' and many cell lines 'resistant' to its inhibition. The results shown in this thesis attempt an interpretation of the reasons for the unpredictable ability of CPZ to inhibit internalization of Htf. This study reveals that two factors can affect the supposed 'resistance' to inhibition of Htf uptake with CPZ: the time of incubation, which should be tailored for the specific cell line, and the cell lines used for the study, which should be at low passage number in order to observe the inhibitory effect of CPZ. Previous literature has reported that dynamin expression is reduced in ageing cells and this could explain the reduced inhibitory action of CPZ in the same cell lines¹⁷.

Further steps on this first set of results would be to complement the flow cytometry experiments presented in this thesis with confocal microscopy studies to confirm the reduction in the internalization of the Htf and to add on any relevant information such as redistribution of the Htf-labeled endosomes in the presence of CPZ. Furthermore,

exploring the hypothesis of the involvement of TR2 in the recovery of the endocytosis of Htf in the presence of CPZ would aid the scientific relevance of these studies. Experiments should be done to evaluate the level of expression of TR2 in the cell lines used in this thesis to confirm the expression of the receptor as indirectly suggested by the current results and the literature. Easy methods to quantify the level of expression of the TR2 would be through Western blot and real time RT-PCR as these two methods allow for quantification of expression both at the protein and at the transcription level. These techniques could be complemented with immunofluorescence followed by flow cytometry and confocal microscopy for quantitative and qualitative evaluation of the expression of the two receptors¹⁸. To confirm that the recovery of inhibition of Htf is not an artifact produced by a nonspecific inhibitor of endocytosis such as CPZ, the inhibition of Htf uptake should be explored by other means and a good starting point would be by siRNA silencing of the AP2 gene^{19,20}. These investigations would confirm that the inhibition observed with CPZ is mediated by the AP2 protein as reported in the literature. If this is the case, as expected, the uptake of Htf should recover after a temporary inhibition while the AP2 protein expression is knocked-down by the siRNA. As siRNA is a temporary way of silencing the expression of proteins, a good way to avoid misinterpretation in these experiments would involve a timepoint quantification of the levels of AP-2 protein and mRNA during the knockdown in relation to the levels of TR1 and 2. Moreover, it would be interesting to investigate the involvement of the caveolin or other lipid raft pathways that might be involved in the internalization of TR2. A first screening could easily be done with siRNAs against caveolin-1 and dynamin and with pharmacological inhibition of dynamin by Dynasore or the recent and more powerful version: Dingo-4a^{20,21}. As flotillins have been suggested to provide an alternative

endocytosis machinery when clathrin-mediated endocytosis is inhibited and they also localize in lipid rafts (as shown by Calzolari and coworkers which detected the TR2 in lipid rafts²²), they could constitute an alternative candidate for the endocytosis of Htf when cells are treated with CPZ^{22,23}. Flotillin involvement could be investigated with a flotillin-1 and 2 dominant negative mutants, such as Y160F and Y163F that perturbs the endocytosis through this pathway²⁴. Less immediate but fascinating experiments would involve the expression of a fluorescent or luminescent reporter for transferrin receptor 1 and 2 to further study the dynamics of expression upon inhibition of the CME pathway.

Data in this thesis and the literature suggest that dynamin might have a role in the loss of inhibition of CME in ageing cells. Hence, the quantification of dynamin levels in cells at low and high passage numbers would give interesting data to compare to the results with CPZ inhibition studies²⁵. Finally, to attempt an explanation of the reasons underlying different sensitivity to CPZ in different cell lines, the level of expression of calmodulin and MARCKS might be quantified^{26,27}.

Results on C-PB studies revealed that 50 nm C-PB access epithelial colon HCT116 and gastric MGLVA-1 cancer cells through a CPZ sensitive pathway which suggests the involvement of a CME or a macrophagic/macropinocytic uptake. The inhibition of endocytosis with CPZ did not appear to recover over time for these nanoparticles at the time points investigated suggesting a specific interaction of 50 nm C-PB with some membrane components (i.e. receptors) that are internalized by a CME or macropinocytic/phagocytic pathway. This suggests that some non-functionalized nanoparticles with properties similar to the carboxylated polystyrene nanoparticles, can also be internalized by a specific pathway implying that it might be possible to direct endocytosis towards one specific pathway without the use of targeting ligands.

To add information on this observed effect, 50 nm negatively charged nanoparticles other than C-PB might be a useful comparison. In addition, expanding the panel of cells for the studies, introducing other colon and gastric cancer cells as well as other fibroblasts, would add information confirming and defining the specificity of endocytosis of 50 nm C-PB which are negatively-charged, but still slightly hydrophobic. Finally, comparing the susceptibility to CPZ of 50 nm C-PB in the presence and in the absence of FBS could give useful information on the translation of these results in a more *in vivo* relevant environment.

Results on 100 nm C-PB showed that they are internalized by a CPZ sensitive pathway in 3T3 cells and by a MBCD sensitive pathway in MGLVA-1 cells. However, the internalization of 100 nm C-PB was only transiently inhibited by these endocytosis inhibitors and the uptake recovered over time suggesting a non specific mechanism of internalization for 100 nm C-PB. Consistent with this hypothesis, it was observed that, when the inhibitor of endocytosis was not effective in inhibiting the internalization of C-PB, it often caused an increase in the endocytosis of the nanoparticles. This finding mirrored the effects of CPZ in LacCer (a CIE marker) inhibition studies. When CPZ was used to verify that the drug was not interfering with CIE, a strong increment of CIE was observed that was increasing the internalization of LacCer up to 3 times more than the positive control. All together, these findings suggest a more dynamic and interconnected way of looking at endocytosis with activity of certain pathways being intensified and providing alternative machinery for endocytosis in response to the failure of other endocytosis mechanisms. This result suggests an additional complexity relating to the endocytosis of nanoparticles for drug delivery. However, it is possible to speculate that not all the possible pathways for the endocytosis of nanomaterials are interchangeable and a thorough investigation aimed to dissect all

the possible molecular mechanisms involved in the internalization of these nanoparticles when other pathways of uptake are inhibited could give more definitive answers to that hypothesis.

Microscopy studies with 50 and 100 nm C-PB showed that the nanoparticles triggered a rapid and efficient endocytosis. Also, for 100 nm C-PB in 3T3 and MGLVA-1 cells, an exocytic process was suggested which might explain how the cells reached a plateau in their fluorescence as a result of a maximal internalization of fluorescent C-PB. Although the data described in this thesis such as the size of the vesicles and the directionality of the movement point in the direction of exocytosis, further experiments should be run to confirm that the compartment that is observed trafficking to the membrane of cells with confocal microscopy is an exocytic vesicle. Labeling of the extracellular compartment with an exocytic marker (e.g. desmoyokin-Ahnak, d/A) as well as the use of exocytic inhibitors such as Exo I and II could confirm the nature of the compartment²⁸. Furthermore, literature reports that 3T3 cells can trigger exocytosis by a Ca²⁺-mediated mechanism²⁹. Intercellular free Ca²⁺ is a known signalling pathway used by cells and it would be interesting to find out if the exocytic process triggered by 100 nm C-PB might be mediated by this way. Fluorescent indicators of free intracellular Ca²⁺ are available and a starting point might be monitoring their levels by flow cytometry or confocal microscopy²⁹. However, TEM studies, with a better resolution, would add information on the compartmentalization of the C-PB upon internalization as well as giving more details on the membrane trafficking observed in confocal microscopy.

Some considerations on the possibility for an *in vivo* translation of the results in this thesis are due at this point given that the aim of these studies was for a pharmaceutical application. The studies carried out in this thesis were intended as an

in vitro preliminary screening of the endocytosis of thermoresponsive nanomaterials. As such they were limited by the absence of FBS in the experimental settings, a 3D organization that is displayed in tissues, the cellular heterogeneity that is present in a whole organ, the absence of immune cells and blood stream. Furthermore, cells in an *in vivo* environment are 100% confluent and hence the expression of receptors and proteins on the plasma membrane may be very different to those in culture³⁰. Finally, the cells generally employed in *in vitro* studies are immortalized which means that they have undergone a spontaneous or induced process of genetic modification to survive in an artificial environment and that often makes them to behave in a less *in vivo* relevant way.

A first step to improve on these limitations could involve the investigation of endocytosis in primary cells. Furthermore, 3D studies might help to translate the present results towards an experimental setting more relevant to *in vivo* studies. Indeed, 3D culture might give some more information on how the tridimensional organization of cells affects endocytosis when cells are simultaneously involved in signalling processes, that share the same machinery of endocytic pathways, and if the signalling activity can cause switching of the internalization pathways of nanomaterials. Signalling in fact is believed to be reduced to a minimum in 2D monocultures where the architectural complexity of *in vivo* studies is less represented. A further advancement towards more *in vivo* relevant experiments might be through the use of co-cultures of epithelial and fibroblastic cells that *in vivo* cohabit and interact in the same tissue. Given that fibroblasts have already been investigated in the present studies, co-cultures of 3T3 and HCT116 or 3T3 and MGLVA-1 would represent an easy choice. However, it is important to stress that much of the research field of endocytosis in mammalian cells at the moment is limited to more or less

sophisticated 2D in vitro studies. The reason for such limitations is that 3D culture approaches are challenged by the level of perfusion of the more internal compartments of the 3D scaffolds. Another important limitation is provided by the level of detection of optical fluorescence techniques currently available and the level of penetration in thick specimens for the detection of fluorophores. Two-photon or multi-photon microscopy is one of the most promising approaches for in vivo endocytosis research available at the moment. However, studies of endocytosis in functioning organs with a spatial resolution at the cellular and subcellular level in mammalians, is limited by the level of perfusion of the organs intended for the study of endocytosis and kidney and liver, with a high perfusion rate and, hence, more exposed than other organs to blood loaded markers of endocytosis, are the target of choice of these investigation^{31,32}. The limit of detection and tissue penetration with fluorophores and microscopic techniques could be solved in the near future by the optimization of research materials tagged with detection labels other than organic fluorophores. Gold nanorods, for example, with a plasmon band resonance in the so called 'water window' (800-1200 nm) are being evaluated for biological purposes³³. Their absorption wavelength is useful as water and many other body components do not absorb at those wavelengths enhancing the potential of penetration of light. Imaging by these means is claimed to give a spatial resolution of 100 nm in two photon luminescence microscopy and might well constitute a first step forward to the identification of subcellular endocytic processes in a tridimensional organization of cells³⁴. However, their irradiation also produces heat and this might potentially alter the tissue physiology and a careful evaluation of the level of interference that this phenomenon might cause is also a key question to answer.

A last challenge can be recognized in the study of the internalization of nanomaterials and translation to an *in vivo* situation. Many pathologies are associated with an altered expression of endocytic proteins. Pathologic environments can produce hypoxic niches and oxidative stress that can trigger autophagy and alter transiently the expression of membrane receptors and endocytic proteins, changing the way cells respond to endocytosis of nanoparticles³⁵. Furthermore, these alterations have been detected as a permanent hallmark in many pathological conditions. It is known in the literature that caveolin-1 overexpression or knockdown is associated with different form of cancers and many drug-resistant pathologies rely on a compromised endocytosis. It was shown that EGF-mediated gefitinib resistance in cancer is mediated by a compromised CME of the EGF receptor upon internalization that fails to be directed to degradation in a lysosome compartment³⁶. Other examples of known pathologies with an altered expression of endocytic proteins and an altered endocytosis are diabetes, Alzheimer's disease and Down's syndrome³⁷. These aspects of endocytosis make the translation from *in vitro* studies to the clinic probably more challenging but also open to new perspectives and applications. It seems possible from results in this thesis and the literature that when one pathway is compromised other pathways can be activated and the exploitation of this effect in pathologic situations for drug delivery purposes could be worth some investigation.

References

¹ Yeo, Y. Nanoparticulate Drug Delivery : Systems Strategies, Technologies, and Applications. (John Wiley & Sons, 2013).

² Koyamatsu, Y. et al. pH-responsive release of proteins from biocompatible and biodegradable reverse polymer micelles. Journal of Controlled Release **173**, 89-95 (2014).

³ Kempe, K., Ng, S. L., Gunawan, S. T., Noi, K. F. & Caruso, F. Intracellularly Degradable Hydrogen-Bonded Polymer Capsules. Advanced Functional Materials, n/a-n/a (2014).

- 4 Sakai, N., Jin, M., Sato, S.-i., Satoh, T. & Kakuchi, T. Synthesis of water-soluble polyisocyanates with the oligo(ethylene glycol) side-chain as new thermoresponsive polymers. Polymer Chemistry **5**, 1057-1062 (2014).
- 5 Themistou, E., Battaglia, G. & Armes, S. P. Facile synthesis of thiol-functionalized amphiphilic polylactide-methacrylic diblock copolymers. Polymer Chemistry 5, 1405-1417 (2014).
- 6 Chan, N., An, S. Y., Yee, N. & Oh, J. K. Dual Redox and Thermoresponsive Double Hydrophilic Block Copolymers with Tunable Thermoresponsive Properties and Self-Assembly Behavior. Macromol. Rapid Commun. **35**, 752-757 (2014).
- 7 Khan, A. R. et al. Camptothecin prodrug block copolymer micelles with high drug loading and target specificity. Polymer Chemistry **5**, 5320-5329 (2014).
- 8 Abulateefeh, S. R. et al. Facile synthesis of responsive nanoparticles with reversible, tunable and rapid thermal transitions from biocompatible constituents. Chemical Communications, 6068-6070 (2009).
- 9 Abulateefeh, S. R. et al. Enhanced uptake of nanoparticle drug carriers via a thermoresponsive shell enhances cytotoxicity in a cancer cell line. Biomaterials Science **1**, 434-442 (2013).
- 10 Fisichella, M. et al. Mesoporous silica nanoparticles enhance MTT formazan exocytosis in HeLa cells and astrocytes. Toxicology in Vitro **23**, 697-703 (2009).
- 11 Vistica, D. T. et al. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res **51**, 2515-2520 (1991).
- 12 Liu, Y. & Schubert, D. Cytotoxic Amyloid Peptides Inhibit Cellular 3-(4,5-Dimethylthiazol-2yl)-2,5-Diphenyltetrazolium Bromide (MTT) Reduction by Enhancing MTT Formazan Exocytosis. Journal of Neurochemistry **69**, 2285-2293 (1997).
- 13 Abe, K. & Saito, H. Amyloid beta protein inhibits cellular MTT reduction not by suppression of mitochondrial succinate dehydrogenase but by acceleration of MTT formazan exocytosis in cultured rat cortical astrocytes. Neurosci Res **31**, 295-305 (1998).
- 14 Holder, A. L., Goth-Goldstein, R., Lucas, D. & Koshland, C. P. Particle-induced artifacts in the MTT and LDH viability assays. Chem Res Toxicol **25**, 1885-1892 (2012).
- 15 Monteiro-Riviere, N. A., Inman, A. O. & Zhang, L. W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol **234**, 222-235 (2009).
- 16 Saptarshi, S., Duschl, A. & Lopata, A. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. Journal of Nanobiotechnology **11**, 26 (2013).
- 17 Linskens, M. H. et al. Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucleic Acids Res 23, 3244-3251 (1995).
- 18 Calzolari, A. et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells, Molecules, and Diseases **39**, 82-91 (2007).
- 19 Motley, A., Bright, N. A., Seaman, M. N. & Robinson, M. S. Clathrin-mediated endocytosis in AP-2-depleted cells. Jornal of Cell Biology **162**, 909-918 (2003).
- 20 Al Soraj, M. et al. siRNA and pharmacological inhibition of endocytic pathways to characterize the differential role of macropinocytosis and the actin cytoskeleton on cellular uptake of dextran and cationic cell penetrating peptides octaarginine (R8) and HIV-Tat. Journal of Controlled Release **161**, 132-141 (2012).
- 21 McCluskey, A. et al. Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis. Traffic **14**, 1272-1289 (2013).

- 22 Calzolari, A. et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci **119**, 4486-4498 (2006).
- 23 Otto, G. P. & Nichols, B. J. The roles of flotillin microdomains--endocytosis and beyond. J Cell Sci 124, 3933-3940 (2011).
- 24 Riento, K., Frick, M., Schafer, I. & Nichols, B. J. Endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn kinase. Journal of Cell Science **122**, 912-918 (2009).
- 25 Hinshaw, J. in Annual Reviews Collection (Bethesda (MD), 2002).
- 26 Bickeboller, M. et al. Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival. Oncogene 0 (2014).
- 27 Damke, H., Baba, T., van der Bliek, A. M. & Schmid, S. L. Clathrin-independent pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of dynamin. The Journal of Cell Biology 131, 69-80 (1995).
- 28 Cocucci, E., Racchetti, G., Podini, P., Rupnik, M. & Meldolesi, J. Enlargeosome, an exocytic vesicle resistant to nonionic detergents, undergoes endocytosis via a nonacidic route. Mol Biol Cell 15, 5356-5368 (2004).
- 29 Olofsson, M. H., Havelka, A. M., Brnjic, S., Shoshan, M. C. & Linder, S. Charting calciumregulated apoptosis pathways using chemical biology: role of calmodulin kinase II. BMC Chem Biol **8**, 2 (2008).
- 30 Wang, J., Chen, G. & Pantopoulos, K. Inhibition of transferrin receptor 1 transcription by a cell density response element. Biochem J **392**, 383-388 (2005).
- 31 Sandoval, R. M. & Molitoris, B. A. Quantifying endocytosis in vivo using intravital twophoton microscopy. Methods Mol Biol **440**, 389-402 (2008).
- 32 Gopalakrishnan, S. & Harris, E. N. In vivo liver endocytosis followed by purification of liver cells by liver perfusion. J Vis Exp (2011).
- 33 Alkilany, A. M. & Murphy, C. J. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res **12**, 2313-2333 (2010).
- 34 Murphy, C. J. et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res **41**, 1721-1730 (2008).
- 35 Jasmin, J.-F., Frank, P. G. & Lisanti, M. P. in Advances in experimental medicine and biology (ed Landes Bioscience) (Springer, New York, USA, 2012).
- 36 Verrite, E. G. Cancer Etiology, Diagnosis and Treatments : Drug Resistant Neoplasms. (Nova Science Publishers, Inc., 2009).
- 37 Wu, F. & Yao, P. J. Clathrin-mediated endocytosis and Alzheimer's disease: An update. Ageing Research Reviews **8**, 147-149 (2009).

7-Appendix I

ICOS 3D prediction software results for *human* cav-1. The first table shows the 2D and 3D rearrangements of adjacent aa and their exposure to the solvent. The second table shows the analysis for their exposure to the solvent only. The regions highlighted in yellow refer to the epitope of the mAb clone 2297. The 'All.con' bottom row gives a final score for all the parameter taken into account by the analysis.

0 - 69	0	1	2	3	4	5	6	
seq	MSGGKYVDSE	GHLYTVE	PIREQGNIY	KPNNKAMA DE I	. <mark>SEKQVYD</mark> AH	TKEIDLVNRD	PKHLN <mark>DDVVK</mark>	IDFED
cCN.Q2	000000000	0111000	000000000	00000010000	000000000	0001010000	00010 <mark>001001001001001001001001001001000100010000</mark>	11111
cCN.Q3	000000000	0111110	1000001	00000010000	000010001	0001010011	10011 <mark>011112</mark>	<mark>21212</mark>
cCN.Q5	000000000	0322120	10000000	0000030000	000020001	0003020031	00030 <mark>013124</mark>	4343 <mark>4</mark>
cCN.con	000000000	0322010	000000000	0000030000	000010000	0003020010	00030 <mark>003014</mark>	4343 <mark>4</mark>
dCN.Q2	000000000	0100000	000000000	00000010000	000000000	0000000000	00010 <mark>0010010010010010010010010010010001000100010000</mark>	11111
dCN.Q3	000000000	0111010	1000001	00000010000	000010001	0001010011	00011 <mark>012112</mark>	21212
dCN.Q5	0000111010	1222111	21010011	11111121001	000121011	1112121111	11121 <mark>013114</mark>	<mark>43433</mark>
dCN.con	000000000	0211000	10000000	00000020000	000010000	0001010000	0020 <mark>003004</mark>	<mark>43433</mark>
DT.Q2	100000000	0000000	00000000	000000000000000000000000000000000000000	000000000	0000000000	20000 <mark>00000</mark> 2	10100
DT.Q3	1100011011	0111111	.11100011	00101110111	001010111	1111011111	11111 <mark>111111</mark>	11111
DT.Q5	400000000	0000000	00000000	000000000000000000000000000000000000000	000000000	0000000000	00000 <mark>00000000000000000000000000000000</mark>	30300
DT.con	300000000	0000000	00000000	000000000000000000000000000000000000000	000000000	0000000000	00000 <mark>000000</mark> 00000	3 <mark>0300</mark>
GG.Q2	000000000	0110000	00000000	00000010000	000000000	0001000000	00010 <mark>001001001</mark>	11101
GG.Q3	000000000	0111000	000000000	000000000000000000000000000000000000000	000000000	0000000000	00010 <mark>002002</mark>	2121 <mark>0</mark>
GG.Q5	000001100	0222111	11000000	00010011000	000011001	1101111111	11111 <mark>11211</mark> 4	4232 <mark>1</mark>
GG.con	000000000	0221000	000000000	00000010000	000000000	0001000000	00020 <mark>003004</mark>	<mark>42311</mark>
MST.Q2	0111111111	.1111111	.111111111	1111 <mark>0</mark> 111111	1111111111	1111111111	01111 <mark>11111</mark>	11111
MST.Q3	0111111111	.1111111	.111111111	1111 <mark>0</mark> 111111	110111111	1111111111	01111 <mark>11111</mark>	11111
MST.Q5	0112111111	.1111111	.111111111	11110111111	111111111	1111111111	01111 <mark>11111</mark> 1	11111
MST.con	0222222222	22222222	222222222	2222 <mark>0</mark> 222222	221222222	2222222222)2222 <mark>22222</mark>	22222
RCH.Q2	000000000	0000000	000000000	000000000000000000000000000000000000000	000000000	0000000000	20000 <mark>00000</mark> 2	10100
RCH.Q3	000000000	0100000	000000000	00000010000	000000000	0001000010	00010 <mark>00100</mark> 1	11111
RCH.Q5	0000001100	0221100	00000001	00000020000	000010001	0002010011	00021 <mark>01211</mark>	3 <mark>231</mark> 3
RCH.con	000000000	0100000	000000000	00000010000	000000000	0001000000	00010 <mark>001003</mark>	313 <mark>01</mark>
RNG.Q2	000000000	0110000	000000000	00000010000	000000000	0001000000	00010 <mark>00100</mark>	11111
RNG.Q3	000000000	0110000	000000000	00000010000	000000000	0001000000	00010 <mark>001002</mark>	21211
RNG.Q5	0000011100)1221110	011010011	01000020000	000010011	1102121111	01021 <mark>11211</mark>	3 <mark>2322</mark>
RNG.con	000000000	0220000	000000000	00000020000	000000000	0002000000	0020 <mark>002000</mark>	3 <mark>2322</mark>
SA.Q2	1111111111	1001111	.111111111	111111 <mark>0</mark> 1111	111111111	111 <mark>0</mark> 111111	11101 <mark>11011(</mark>	00010
SA.Q3	2222222222	2111212	222222221	222222 <mark>1</mark> 2222	222212222	2221212211	22212 <mark>21012(</mark>	01011
SA.Q5	4444444444	4233334	44444444	4444424444	44444444	4442434433	44423 <mark>44133</mark> 1	12031
SA.con	4444444444	4113334	4444443	44444414444	444434444	4441434433	44413 <mark>43033(</mark>	01030
All.con	000000000	0211000	000000000	00000020000	000000000	0001010010	00020 <mark>002000</mark>	3 <mark>2312</mark>
70 - 139	0	1	2	3	4	5	6	
seq	VIAEPEGTHS	FDGIWKA	SFTTFTVT	KYWFYRLL <mark>S</mark> AI	FGIPMALIW	GIYFAIL <mark>S</mark> FL	HIWAVVPCIK	SFLIE
cCN.Q2	<mark>1</mark> 11010000	01011111	.11111111	01111011111	111111111	1101111111	11111111111	11010
cCN.Q3	<mark>2</mark> 211100111	1012212	22122122	1122212222	2222222222	2222222221	222222222212	22121
cCN.Q5	<mark>4</mark> 432300313	33133434	133344334	23444233344	444444444	4333433333	4444444333	33232
cCN.con	<mark>4</mark> 431300101	3 <mark>0</mark> 33434	133344334	13444133344	44444444	4323433333	4444444333	33131

ICN.Q2	11010000010011111111111111111111111111
CN.03	
~ ~ ~ ~	221110011110122122212212212212222222222
ICN.Q5	$\frac{4}{3}1111121121234243334433413343133344444434333331343323344444444$
lCN.con	<mark>4</mark> 320200100201342433344334033430333444444343333303433333444444
DT.Q2	<mark>0</mark> 1000000000000101000110000011101101110111010
DT.Q3	<mark>1</mark> 111110110111111111111111111111111111
DT.Q5	<mark>0</mark> 300000000000303000330000033303303303330333033303303303333
T.con	<mark>0</mark> 300000000000303000330000033303303303330333033303303303333
G.Q2	1 100100000100111111111111111111111111
G.Q3	22000000000121211122122122222222222222
G.Q5	<mark>3</mark> 311101111101232332244233224442443444344434443444342424234344334433443343
G.con	<mark>3</mark> 3001000001002323322442331344434434434443444344434443
IST.Q2	<mark>1</mark> 11111111111111111111111111111111111
IST.Q3	<mark>1</mark> 1111111111111111111111111111112111111221112112221121111
IST.Q5	<mark>1</mark> 12111111111111111111111111111121111112211121123101211111111
IST.con	22222222222222222222222222222222222222
CH.Q2	10000000000001011001100111011111111111
CH.Q3	<mark>1</mark> 100100101100111111111111111111122222211112111111
CH.Q5	<mark>3</mark> 31120021220133233323333333333333333333
CH.con	<mark>3</mark> 30010010110013133113313311333133333333
NG.Q2	10010000010011111111111111111111111111
NG.Q3	2100100101100121211122122012221221222221222221112211222211211
NG.Q5	<mark>3</mark> 21120111220123233223323312333233233333332332323232
NG.con	<mark>3</mark> 2002000012002323322332330233323333333333
A.Q2	00100110100100010001001000000000000000
A.Q3	001212211212100100110011011000100000000
A.Q5	00333444342430130022003002100030000000000
A.con	00321441321410030012003002000030000000000
ll.con	<mark>3</mark> 31120010120123232223323312333133233333333
40 - 178	0 1 2 3
eq	IQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEI
CN.Q2	11110011011101110111011100111110000
CN.Q3	212211220222122212211221121212100
CN.Q5	32331233133313332443133313332434332111
CN.con	32330133033303331443033303311434331000
ICN.Q2	10110011011101110111011100111110000
ICN.Q3	2122012202221222022212211212121100
ICN.Q5	32331133133313331343133323311434331112
ICN.con	31330033033303330343033313300434330000
DT.Q2	10110011001000011001001010100001
DT.Q3	111111111111111111111111111111111111111
G. con IST.Q2 IST.Q3 IST.Q5 IST.Con IST.Con IST.Con IST.Con IST.Con IST.Con IST.CON	30010000010023233224423313444344344344344344344344344344344344

-	
DT.Q5	3033003303330030033300300330030030004
DT.con	30330033013300300133003003300303030003
GG.Q2	11111111111011101111111110111110000
GG.Q3	22221122122202220222122200212120000
GG.Q5	43442244244413432243244324311324231000
GG.con	43442244244403430343244324310324230000
MST.Q2	111111111111111111111111111111111111
MST.Q3	11111111111111111222111111111111
MST.Q5	111101111111111112231111111111111
MST.con	22222222222222222222333222222222222222
RCH.Q2	1011001101110111011101100101000000
RCH.Q3	111111101110111011111101110111110000
RCH.Q5	33332233133313331333233313311323331100
RCH.con	31331133033303310333133303300313110000
RNG.Q2	11111111110111011111111100111110000
RNG.Q3	21221122122201210122122112110212110000
RNG.Q5	3233223323312321233233323221323221100
RNG.con	3233223323302320233233323210323220000
SA.Q2	0000110010000000010001010101111
SA.Q3	0100110010001000100010012010112222
SA.Q5	01003301300030013000300020033030313444
SA.con	00003300300030001000300020013030303444
All.con	32331133133302321333133313310323220000
L	

0 - 69	0	1	2	3	4	5	6	
seq	MSGGKYVD	SEGHLYT	VPIR <mark>EQG</mark> NIY	KPNNKAMADE	L <mark>SEKQVYD</mark> AH	TKEIDLVNRD	PKHLN <mark>DDVVKII</mark>	DFED
SA.Q2	11111111	1110011	1111111111	<u>1111110111</u>	1111111111	111 <mark>0</mark> 111111	11101 <mark>1101100</mark>	010
SA.Q3	22222222	2221112	1222222221	222222 <mark>1</mark> 222	2222212222	2221212211	22212 <mark>210120</mark> 1	011
SA.Q5	4444444	4442333	3444444444	444442444	4444444444	4442434433	44423 <mark>4413312</mark>	2031
SA.con	4444444	4441133	3444444443	44444 <mark>1</mark> 444	4444434444	444 <mark>1</mark> 434433	44413 <mark>430330</mark> 1	030
All.con	00000000	0002210	1000000000	0000002000	000000000000000000000000000000000000000	0002010011	00020 <mark>0031032</mark>	<mark>2413</mark>
70 - 139	0	1	2	3	4	5	6	
seq	<mark>v</mark> iaepegt	HSFDGIW	KASFTTFTVT	KYWFYRLL <mark>S</mark> A	LFGIPMALIW	GIYFAIL <mark>S</mark> FL	HIWAVVPCIKS	FLIE
SA.Q2	<mark>0</mark> 0100110	1001000	1000100100	1000010000	00000000000	0000000000	000000000100	0000
SA.Q3	<mark>0</mark> 0121221	1212100	1001100110	1100010000	00000000000	0010000101	100000000100)101
SA.Q5	<mark>0</mark> 0333444	3424301	3002200300	2100030000	00000000000	0020000102	10100000300)202
SA.con	<mark>0</mark> 0321 4 41	3214100	3001200300	2000030000	00000000000	001000001	00000000300)101
All.con	<mark>4</mark> 4112002	1120243	1442144134	1344414444	4444444444	4424444342	343444444144	1242
140 - 178	0	1	2	3				
seq	IQCISRVY	SIYVHTV	CDPLFEAVGK	IF <mark>SNVRINLQ</mark>	KEI			
SA.Q2	00001100	1000100	0000010001	0001010101	111			
SA.Q3	01001100	1000100	0100010001	0012010112	222			
SA.Q5	01003301	3000300	1300030002	0033030313	444			
SA.con	00003300	3000300	0100030002	0013030303	444			
All.con	43441143	1444144	3244414441	4420414130	000			

8-Appendix II

ICOS 3D prediction software results for *murine* cav-1. The first table shows the analysis for the 2D and 3D rearrangements of adjacent aa and their exposure to the solvent. The second table takes into consideration their exposure to the solvent only. The regions highlighted in yellow refer to the epitope of the mAb clone 2297. The 'All.con' bottom row gives a final score for all the parameters taken into account by the analysis.

0 - 69	0	1	2	3	4	5	6
seq	MSGGKYVI	D <mark>SEGHLYT</mark> V	PIREQGNIN	YKPNNKAMADE	V TEKQVYD AH	TKEIDLVNRD	PKHLN <mark>DDVVKIDFE</mark>
cCN.Q2	00000100	000011111	.00000001	000000000000000000000000000000000000000	0000010000	0000010000	00010 <mark>001001010</mark>
cCN.Q3	00000110	00112221	.110001111	L010000000	0000011011	0001010011	10010 <mark>001111111</mark>
cCN.Q5	00000320	00134443	330000032	2030000000	0000030001	0002020000	30030 <mark>013213130</mark>
cCN.con	00000310	000034443	110000031	1010000000	0000030000	0001020000	10030 <mark>003103030</mark>
dCN.Q2	0000010	000011111	.00000000	000000000000000000000000000000000000000	00000000000	0000000000	00010 <mark>001001010</mark>
dCN.Q3	00000110	00122221	110001111	1010000000	0000010001	0001010010	10010 <mark>001101020</mark>
dCN.Q5	0001122	111134441	121111121	11111111100	1101121111	1112121111	11121 <mark>013112131</mark>
dCN.con	00000210	000034442	2010000010	000000000000000000000000000000000000000	0000010000	0001010000	00020 <mark>003002030</mark>
DT.Q2	1000000	00001100	000000000	000000000000000000000000000000000000000	00000000000	0000000000	00000 <mark>00000000000000000000000000000000</mark>
DT.Q3	1100111:	101011111	110110111	11110111011	0001111011	11111111111	11010 <mark>101111011</mark>
DT.Q5	4000000	0000 <mark>33</mark> 00	000000000	000000000000000000000000000000000000000	00000000000	0000000000	00000 <mark>00000000000000000000000000000000</mark>
DT.con	3000000	00003300	000000000	000000000000000000000000000000000000000	00000000000	0000000000	00000 <mark>00000000000000000000000000000000</mark>
GG.Q2	0000001	000011110	00000001	000000000000000000000000000000000000000	0000010000	0001010000	00010 <mark>001001010</mark>
GG.Q3	0000000	000012210	000000000	000000000000000000000000000000000000000	00000000000	0000010000	00000 <mark>001001010</mark>
GG.Q5	00011110	01012 <mark>33</mark> 21	111011111	11101011100	0001011111	0101111111	11111 <mark>012111121</mark>
GG.con	0000001	00023320	000000010	000000000000000000000000000000000000000	0000010000	0001020000	00010 <mark>002002020</mark>
MST.Q2	0111011:	11 <mark>0</mark> 111111	.111111111	11111111111	1111111111	1111111111	11111 <mark>111111111</mark>
MST.Q3	0111011:	11 <mark>0</mark> 121111	.111111111	11111111111	1111111111	1111111111	11111 <mark>111111111</mark>
MST.Q5	01110111	110221111	111111111	11111111111	1111111111	1111111111	11111 <mark>111111111</mark>
MST.con	02220222	22 <mark>023</mark> 2222	2222222222	222222222222	22222222222	22222222222	22222 <mark>22222222</mark>
RCH.Q2	0000000	00001100	000000000	000000000000000000000000000000000000000	00000000000	00000000000	00000 <mark>00000000000000000000000000000000</mark>
RCH.Q3	00000100	000011111	01000001	000000000000000000000000000000000000000	0000010000	0000010000	00010 <mark>001001010</mark>
RCH.Q5	00010220	000033331	121011121	10200001000	1000021001	0101010011	10021 <mark>002113020</mark>
RCH.con	00000100	00001 <mark>33</mark> 10	01000001	000000000000000000000000000000000000000	0000010000	0000000000	00010 <mark>001001010</mark>
RNG.Q2	00000110	000011111	.010001010	00100000000	0000010000	0000010000	00010 <mark>001001010</mark>
RNG.Q3	00000110	000012211	010001010	0010000000	0000010000	0000010000	00010 <mark>001101010</mark>
RNG.Q5	00011220	010123322	2121011121	11201011100	1001021011	1101121111	10121 <mark>002112121</mark>
RNG.con	00000220	00023322	2020002020	0200000000	0000020000	0000020000	00020 <mark>002002020</mark>
SA.Q2	1111100	111100000	101110101	11011111111	1111101111	1110101111	11101 <mark>110110101</mark>
SA.Q3	22222112	222210011	112222211	12122222222	2222212221	2221212211	12212 <mark>221121212</mark>
SA.Q5	4444334	434410133	4444444	34444444444	4444444444	4444424433	44423 <mark>441341314</mark>
SA.con	4444114	434400011	314442413	34144444444	444414443	4441414433	34413 <mark>440340304</mark>
All.con	00000110	00023321	010001010	0010000000	0000010000	0001010000	00020 <mark>002102020</mark>
70 - 139	0	1	2	3	4	5	6
seq	VIAEPEG	THSFDGIWK	(ASFTTFTV)	TKYWFYRLL <mark>S</mark> I	'IFGIPMALIW	GIYFAIL <mark>S</mark> FL	HIWAVVPCIKSFLI
cCN.Q2	<mark>1</mark> 100000	00101111	.111111111	11111111111	1111111111	1111111011	111111111111111
cCN.Q3	<mark>2</mark> 1001003	1111 <mark>0</mark> 1221	222122122	22222212222	22222222222	2222222122	222222222222222
cCN.Q5	<mark>3</mark> 3013102	223313443	433344344	13444434444	444444444	4434443344	4444444434434
cCN.con	<mark>3</mark> 3001003	111303443	433344344	43444434444	4444444444	4434443144	4444444434434

dCN.Q2	1 100000000101111111111111111111111111
dCN.Q3	100100111101221221221222222222222222222
dCN.Q5	3311111211213343433334334344443434343444333344333333
dCN.con	30000010020334343333434444343434344433333444333333
DT.Q2	000000000001101000011011011001101101101
DT.Q3	
DT.Q5	00000000003303000330300033303303300330033030
DT.con	
GG.Q2	
GG.Q3	2 20000000001221211122022122221222222222
GG.Q5	3111011112023324222342332334324434434434443444344
GG.con	330000000201332422234233233432443443443444344434443
MST.Q2	
MST.Q3	12111111111111111111111111111111111111
MST.05	12111111111111111111111111111111111111
MST.con	2232222222322222222222222222222222322232232232222
RCH.Q2	
RCH.03	1001001011011111111111111222112112112112
RCH.Q5	301200111202332333332233333333333333333
RCH.con	
RNG.Q2	110010010110111111111111111111111111111
RNG.Q3	10010010110122121112212212222122122121212211211
RNG.Q5	2 2112012112123323222332332333322332332323233333222322322323
RNG.con	2200200202202332322233233233333233233233
SA.Q2	001101101001100100010010010000000000000
SA.Q3	102212212212100100110010010000100000000
SA.Q5	01433444441420130023003003100030000000000
SA.con	0431441420420030013003003000030000000000
All.con	220010010120233232223323323333333333333
140 - 178	0 1 2 3
seq	IQCISRVYSIYVHTFCDPLFEAIGKIFSNIRISTQKEI
cCN.Q2	1011001101110111011101101111110000
cCN.Q3	2122112201220222122102221221121212101
cCN.Q5	423312331333133323331333133324343332211
cCN.con	413301330333033313330333124343331100
dCN.Q2	10110011011101110111011100111110000
dCN.Q3	212201220122122101221221121212101
dCN.Q5	31331133133313331333133323311434331112
dCN.con	30330033033303330333033313300434330001
DT.Q2	1011001100110011001001010100001
DT.Q3	111111111111111111111111111111111

-	
DT.Q5	303300330033033003300330030030030004
DT.con	3033003300330133003300330030303030003
GG.Q2	111111111111111111111111001111110000
GG.Q3	2122112212221222122212200212120000
GG.Q5	4244224424423442343234324311424231100
GG.con	4244224424423442343234324300424230000
MST.Q2	111111111111111111111111111111111111
MST.Q3	11111111111111111122111111111111
MST.Q5	11110111111011111102231111111111111
MST.con	222222222222222222223322222222222222
RCH.Q2	1011001100110111011101100101010000
RCH.Q3	1111111011112111110111011100111110000
RCH.Q5	313322332333333333333333333333333333333
RCH.con	3033113301331333133303300313130000
RNG.Q2	111111111111111111111111110111111000
RNG.Q3	2122112212221222122112110212111000
RNG.Q5	32332233233233233233223221323222110
RNG.con	32332233233233233233223220323222000
SA.Q2	010011001000000000000010011010101111
SA.Q3	0100110010001000200010021010101222
SA.Q5	0300320030003000300020133030203344
SA.con	03003200300030001000300020033030203344
All.con	3133113312331333133313311323231001
L	

0 - 69	0	1	2	3	4	5	6	
seq	MSGGKYVD	SEGHLYT	/PIR <mark>E</mark> QGNIY	KPNNKAMADE	V TEKQVYD AH	FKEIDLVNRD	PKHLN <mark>DDVVK I</mark>	DFED
SA.Q2	11111001	11100000	0101110101	1011111111	1111101111	1110101111	11101 <mark>110110</mark>)1011
SA.Q3	22222112	22210011	112222211	2 <mark>1</mark> 22222222	2222212221	2221212211	12212 <mark>22112</mark> 1	2122
SA.Q5	44444334	3 44101 33	344444443	4444444444	4444444444	4444424433	44423 <mark>44134</mark> 1	3144
SA.con	44444114	34400011	1314442413	414444444	44444 <mark>1</mark> 4443	44414144 33	34413 <mark>440340</mark>	3044
All.con	00000220	00034322	2020001021	0200000000	0000020000	0002020011	00020 <mark>003103</mark>	3 <mark>0300</mark>
70 - 139	0	1	2	3	4	5	6	
seq	<mark>v</mark> iaepegt	HSFDGIW	(ASFTTFTVT	KYWFYRLL <mark>ST</mark>	IFGIPMALIW	GIYFAIL <mark>S</mark> FL	HIWAVVPCIKS	FLIE
SA.Q2	<mark>0</mark> 0110110	10011001	1000100100	1000010000	00000000000	000000000000000	00000000010	0001
SA.Q3	<mark>1</mark> 0221221	22121001	001100100	1000010000	00000000000	0000000101	00000010010	0101
SA.Q5	<mark>0</mark> 1433444	44142013	8002300300	3100030000	00000000000	000000300	1000000030	0202
SA.con	<mark>0</mark> 0431441	42042003	8001300300	3000030000	000000000000000000000000000000000000000	0000000100	00000000030	0102
All.con	<mark>3</mark> 3002002	01301431	442144144	1344414444	4444444444	444444243	34444434414	4241
140 - 178	0	1	2	3				
seq	IQCISRVY	SIYVHTFO	DPLFEAIGK	IF <mark>SNIRIST</mark> Q	KEI			
SA.Q2	01001100	10001000	000010001	0011010101	111			
SA.Q3	01001100	10001000	0100020001	0021010101	222			
SA.Q5	03003200	30003000	300030002	0133030203	344			
SA.con	03003200	30003000	0100030002	0033030203	344			
All.con	41441144	14441444	1244404441	4301414141	000			

9-Appendix III

ICOS 3D prediction software results for *human* CHC α . The region highlighted in yellow refers to the epitope of the mAb clone X22. The 'All.con' bottom row gives a final score for all the parameters taken into account by the analysis. The first table gives the results for the rearrangements of the aa in 2D and 3D, their point of contact and their exposure to the solvent. The second table gives the score for their exposure to the solvent.

0 - 69	0	1	2	3	4	5	6
seq	AQILPIRFQ	EHLQLQNI	LGINPANIG <mark>FS</mark>	TLTMESDKFI	CIREKVGE	QAQVVIIDMN	DPSNPIRRPISADSA
cCN.Q2	000111111	11101001	10100011010	<u>1111110111</u>	11110000	0111111110	000011110101111
cCN.Q3	001222121	22212111	1200012121	1222121122	22221100	1112222221	011121111212222
cCN.Q5	113344343	43423113	31311134143	3444343344	44341200	1334444441	113133333314444
cCN.con	001344343	43413003	80300034041	3444341344	44340100	0334444440	001033331304444
dCN.Q2	001111111	11101001	10100011010	0111110111	11110000	0111111110	000010110101111
dCN.Q3	001222121	22212112	21201012121	1212121122	22221100	1112222221	011121121212222
dCN.Q5	111344343	44413113	31311113131	1434111344	44431111	1334444441	111132131314444
dCN.con	002344343	44403003	30300023030	0434230344	44430000	0334444440	000031230304444
DT.Q2	111111111	1111111	01011111111	11111 <mark>0</mark> 1111	11110001	0001111111	111111111110111
DT.Q3	111111111	11111111	1111111111	1111111111	11111112	1111111111	11111111111111111
DT.Q5	433333333	3333333	3043433334	3333334333	33330004	00333333333	033333333340433
DT.con	333333333	3333333	3033333333	3333313333	33330004	0013333333	233333333330333
GG.Q2	000111011	11101001	10100011010	1111110011	11110000	0011111110	000010000101011
GG.Q3	000222121	02202001	0200002010	0212000122	22200000	001222220	000000010201012
GG.Q5	001334242	13313112	20311013121	1324111234	34321100	1124444341	101111121 <mark>313</mark> 123
GG.con	000334142	13303002	20300013020	1324110134	34320000	0024444340	000010010303023
MST.Q2	011111111	11111111	1101111111	1111111111	111111111	1111111111	11111111111111111
MST.Q3	011111111	11111111	.11 <mark>0</mark> 1111111	1111111111	21111111	1111111111	111111111112112
MST.Q5	011111111	11111111	1201111111	1111111111	21111111	1111111111	111111111112112
MST.con	022222222	22222222	22202222222	22222222222	32222222	2222222222	22222222222 <mark>3</mark> 22 <mark>3</mark>
RCH.Q2	000111110	11101001	10100011010	1111100111	11100000	0011111110	000011110101111
RCH.Q3	000222221	22212221	0101012122	2222222222	22210100	0112222220	011122212202222
RCH.Q5	001444443	44443443	34300033144	4444444444	44431300	0333444430	<mark>0</mark> 333333334 044 44
RCH.con	000444441	44413223	31300033042	444422444	44410100	0133444430	011133332404444
RNG.Q2	000111111	11101001	10100001010	0111110011	11110000	0011111110	000010000101011
RNG.Q3	000122121	11101001	0100011010	0212110022	22210000	0012222110	000010000101012
RNG.Q5	001233232	22212112	20201022121	2323221133	33321100	1223333221	111121111212123
RNG.con	000233232	22202002	20200012020	0323220033	33320000	0023333220	000020000202023
SA.Q2	111000101	00010110	01011100101	0000101100	00001111	1110000001	111101111010000
SA.Q3	222000101	10020221	2022210202	1010122100	00112122	2110000002	11 <mark>22</mark> 11111020110
SA.Q5	444101303	11130341	4134431314	3030344310	00123344	4230000103	3443333231313 <mark>0</mark> 0
SA.con	444000303	00030340	04034410304	1010324300	00013344	4230000003	3343 <mark>1</mark> 3323 <mark>0</mark> 30100
All.con	001333232	33313112	2120102 <mark>313</mark> 1	2333221233	33320100	0123333331	011121221 <mark>313</mark> 233
70 - 139	0	1	2	3	4	5	6
seq	IMNPASKVI	AL <mark>K</mark> AGKTI	QIFNIEMKSK	MKAHTMTDDV	TFWKWISL	NTVALVTDNA	VYHWSMEGESQPVKM
cCN.Q2	111100111	11110111	1111100001	1111010011	11111100	0111111111	111111000001111
cCN.Q3	222211122	22211112	22221201101	2112121112	22222211	1222222112	222212100112122
cCN.Q5	444421344	44331324	13443311112	3334231324	4444432	2344444334	444434100013334
cCN.con	444410344	44330324	13443300002	3334130124	4444411	1344444334	44443400003334

	I
dCN.Q2	11110011111100011111110000111111010001111
dCN.Q3	22221122222211122221201101211212111222222
dCN.Q5	4443113444431122434413111113334131114444343111344444114443423111113334
dCN.con	4443003444430012434423000023334030004444343000344444024443423000003334
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	33333333333333333333333333333333334443333
DT.con	333333333333333333333333333333333333333
GG.Q2	1111000111110000111111010001001010001111
GG.Q3	2211001222210001212202010002012020002222122000122222001222212000002112
GG.Q5	4332112443421112424314121113213131114343234101243443112443423100012224
GG.con	4332001443420001424314020003003030004343234000243443012443413000003224
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111111111211111111111111111111111111111
MST.Q5	111111111211111111111111111111111111111
MST.con	222222223222222222222222222222222222222
RCH.Q2	1111001111100001111111000011011010001111
RCH.Q3	2222222222210112222220110122122221222222
RCH.Q5	444444444444444444444444444444444444444
RCH.con	444422444442101334444301103323324212444444101344444224444423000103334
RNG.Q2	1111000111110001111101010001011010001111
RNG.Q3	221100022221100121220101000101201000212212
RNG.Q5	3322111333321112323312121112123220113233232101233333123332322110113223
RNG.con	332200033332000232330202000202302000323323
SA.Q2	0000111000011111000000111110110101110000
SA.Q3	00002210000112110100102112101102022100001001
SA.Q5	0011433000033433030131333421331314330100210343200000430002131444431320
SA.con	0000433000033433010010333420330304330000200343100000430001030444430320
All.con	3333112333321112333323011013123131113333233111333333123333323100013223
140 - 209	0 1 2 3 4 5 6
seq	FDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNAE
cCN.Q2	101000101111111110001111111110000111111
cCN.Q3	212111212222222211011222222211001121222222
cCN.Q5	433203333434444343113344444433001243434344431112434444444444
cCN.con	41310131343444434300134444443300014343434444300024144144444444341300000
dCN.Q2	1010001011111111000011111111100000111111
dCN.Q3	212111211222222210011222222211001121222222
dCN.Q5	41311141143444433111134444443111114343434343311133144144
dCN.con	4030004024344443300003444444430000043434343
DT.Q2	111111101111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111

Dit_Con Display Displa	DT 05	333333333333333333344303333333034403330333333
GG.Q2 1010001001111110000011111111000001011111	DT.Q5	
GG.Q3 201000200212222121000022222200000021212122110000012012		
GG.Q5 312111311324433232001344433410011323242432211111231222133142300101 GG.Q5 3020003003144332310000344433410000031324243220001102302232133041300000 MST.Q2 111111111111111111111111111111111111		
GG.con 30200303144332310000344433410000031324243220001102302232133041300000 MST.Q2 111111111111111111111111111111111111		
MST.02 111111111111111111111111111111111111		
MST.03 111111111111111111111111111111111111		
MST.05 111111111111111111111111111111111111	MST.Q2	
MST.con 222222222222222222222222222222222222	MST.Q3	111111111111111111111111111111111111111
RCH.Q2 1011101001111111000001111111100000111111	MST.Q5	111111111111111111111111111111111111111
RCH.03 222222122222222001122222221000022222222	MST.con	22222222222222222222222222222222222222
RCH.05 4333343444444433003344444433000133444443301033344444444	RCH.Q2	1011101001111111100000111111110000011111
RCH.con 423323124444443100114444443100003344444433000132442444444423230000 RN0.Q2 10100010111111100001111111110000011101111	RCH.Q3	2222222122222221001122222221100002222222
NIG. Q2 101001001111111100001111111110000101101	RCH.Q5	433334344444444330033444444330001334444443301033344444444
N.G. Q. 20100010021222212100002222222100000212121221100011011	RCH.con	4233323124444444310011444444310000334444433000132442444444232300000
RNG.Q 31211121122332322200113333333210011323233322011121221222223323220100 RNG.con 3020002003233323200003333332000032323232323220000202202	RNG.Q2	1010001001111111100001111111100000111111
RNG.con 302000203233322000033333320000032323232	RNG.Q3	20100010021222212100002222222100000212121221100011011
SA.Q2 01011101000000011100000001110000000110010000	RNG.Q5	31211121122332322200113333333210011323232332201112122222223232201101
SA.Q3 021112021010000101221100000012222201010101122210210	RNG.con	302000200323333232000033333332000003232323322000020222222
SA.QS 13334413413000021244331000003444430302020112444313113010100303144443 SA.con 0313340330300010144330000001444430301010001444103003000000303044443 All.con 313111313233333200133333321001323333332000231331333333231300000 210 - 279 0 1 2 3 4 5 6 seq ESTLFCFAVRGQAGGKLHTIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY cCN.Q2 011111111000111111111000000101011111111	SA.Q2	01011101101000000011110000000011111010000
SA. con 031334033030000101443300000014444303010100014441030030000030303044443 All.con 3131113113233333320011333333210001323333332000231331333333321300000 210 - 279 0 1 2 3 4 5 6 seq ESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY cCN.Q2 0111111100011111111000000101101111111001001111	SA.Q3	02111202101000010122110000000122222010101001122210210
All.con 313111311323333332001133333321000132333333200231331333333231300000 210 - 279 0 1 2 3 4 5 6 seq ESTLFCFAVRGQAGGKLHI IEVGTPPTGNQFFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY cCN.Q2 011111110001111111110000001011011111111	SA.Q5	1333441341300002124433100000034444303020201124443131130101000303144443
210 - 279 0 1 2 3 4 5 6 seq ESTLFCFAVRGQAGKLHI IEVGTPPTGNQPFPKKAVDVFFPPEAQNDFFVAMQI SEKHDVVFLITKYGY cCN.Q2 011111111000111111111000000101101111111	SA.con	03133403303000010144330000001444430301010001444103003000000303044443
seq ESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY cCN.Q2 01111111110001111111110000011101111111001001111	All.con	31311131132333333200113333332100013233333320002313313333333231300000
cCN.Q2 011111111000111111110000001011011111111	210 - 279	0 1 2 3 4 5 6
ccn.q3 1222222221112212222221000001112111222222	seq	ESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY
cCN.Q5 14444444333334344444110000133333344444433033344444443124444444444	cCN.Q2	011111111100011111111100000010110111111
CCN.con 044444443111343444442000000313313444444310311444444443024444444444	cCN.Q3	1222222221112212222221000001112111222222
dCN.Q2011111111000111111110000000101001111111	cCN.Q5	144444443333343444444110000133333344444433033344444444
dCN.Q3 1222222221112212222221000000112112222222	cCN.con	0444444431113434444442000000313313444444310311444444443024444444444
dCN.Q5 133444443311134244441411111113213344434311114444443411144444444	dCN.Q2	0111111111000111111111000000010100111111
dCN.con 03344444330003424444340000002031033444343002004444444444	dCN.Q3	1222222221112212222221000000112112222222
DT.Q2 1011111101100111111110011111111100111111	dCN.Q5	13344444331113424444141111111132133444343111114444443411144444444
DT.Q3 111111111111111111111111111111111111	dCN.con	0334444433000342444434000000203103344434300200444444340004444444444
DT.Q5 4033333303300333333044340433330344333440333333	DT.Q2	101111111011001111111111001111111111111
DT.con 303333330330033333323333013333333333333	DT.Q3	111111111111111111111111111111111111111
DT.con 303333330330033333323333013333333333333	DT.Q5	40333333303300333333304434043333303343333440333333
GG.Q3 02122222110000012222020000001020000222110001000222221200011222222		30333333303300333333323330133333233333333
GG.Q3 02122222110000012222020000001020000222110001000222221200011222222	GG . 02	
GG.Q5 1324444322100122434413000100011311123232210011113343424101224444432233	<u>z</u> -	0111111111000010111101000000000000010000
- 22, 22 · 1 · 1 · 2 · 2 · 1 · 1 · 2 · 2 · 1 · 2 · 2	GG.Q3	02122222110000012222020000001020000222110001000222221200011222222

HST.03 1111112111121111211111211111111111111		
NRT_05 IIIIII21IIII11111111111111111111111111	MST.Q2	111111111111111111111111111111111111111
MST. con 2222223222223222223222222222222222222	MST.Q3	111111112111112111111121111111111111111
RcH. Q2 0111111110001111111000000001111111111	MST.Q5	111111121111121111111111111111111111111
RcH. 03 0122222212112222222210000001122122222222	MST.con	222222322222322222232222222222222222222
RCH.Q5 13344444433344444443300000033333344444440333444444	RCH.Q2	011111111100011111110100000001111111111
CRL con 0334444432114444442310000033333344444440323444444320134444444444	RCH.Q3	012222221211222222210000001122122222221221
NNS.Q2 0111111110000111111000000000000000001001111	RCH.Q5	13344444433334444444330000003333334444444
N. G. O 0112222210000112122010000000000120110001001	RCH.con	0334444443211444444231000000333333444444403234444444320134444444444
NR. Q. 02233332211112232332211000111211212121002111223332320122333322223 NRG. con 022333322000022323302000000000000000230220002002	RNG.Q2	0111111111000011111101000000000100011011100010001111
RNG.con 0223333220000223230200000000002002302200020002333230001100000001100000001000 SR.q2 101000001111001000001111111101100000001100110000	RNG.Q3	01122222110000112122010000000010001201110001000112221210011222221112
sA.q2 101000001111001000000111111110010000110010000	RNG.Q5	0223333322111122323322110001111211123121210021112233323201223333322223
Number Number SA.Q3 2010000011221010101012122221201211010111121211000000	RNG.con	02233333220000223233020000000000200023022200020002233323200213333331223
And Sec. 412000022344103010031343444433133311111244333310002034313000003101 SA. con 4020000123440030000103434444330330020002341331000001143010000003000 All.con 1223333332112323333210000021311223233321021233333310123333332333 280 - 349 0 1 2 3 4 5 6 seq IHLYDLETGTCTYMNRISGETTFVTAPHEATAGIIGVNRKGQVLSVCVEEENITFYTTNULQNPDLALRM ccn.q2 111111111111100111111000111111100011011	SA.Q2	101000000111100100000011111111011100100
SA.con 4020000123440030001034344443303330020023413310000114301000003000 SA.con 4020000123440030001034344443303330020002341331000001143010000003000 SA.con 122333332111232333321102233332102112333333101223333332333 Seq 111201123333331012233333310122333333101223333332333 Seq 1HLYDLETGTTYMNRISETIFVTAPHEATAGIIGVNRKGQVLSVCVEENIIFYTTNUQNPDLALRM CCN.Q2 111111111111111001111110000111111110001111	SA.Q3	201000001112210101001012122221201211010111121211000001012111000000
All.con 122333332111232333321000000213112232333210211233333331013233333333	SA.Q5	412000002234410301003134344443313331111112443333100002034313000003101
280 - 349 0 1 2 3 4 5 6 seq IHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALRM cCN.Q2 11111111111111111111000011111111000011011100110000	SA.con	402000001234400300001034344443303330020002341331000001014301000003000
Seq IHYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALMM ccN.Q2 111111111111111110011111100011111110001111	All.con	12233333211123233332310000002131122323332102112333333310132333332333
GCN.Q2 11111111111111100111111000011111110000110110010000	280 - 349	0 1 2 3 4 5 6
CN.Q3 22222222222222222222212211222222110011222222	seq	IHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALRM
cCn.Q5 444444444444444331344444110034444441133444442101331331023011033113 ccn.con 444444444444443313444444000033444444003344444411000330330023000033003 dcn.q2 1111111111111110011111100000111111100000	cCN.Q2	11111111111111111100111111000011111111001111
CCN.con 444444444444444330144444400003344444400334444441000330330023000033003 dCN.q2 11111111111111111001111110000011111110000	cCN.Q3	222222222222222222222222112222222110011222222
dCN.Q211111111111111110011111110000011111110000	cCN.Q5	444444444444444444444444444444444444444
dcn.q3 222222222222222222222222222222222222	cCN.con	444444444444444444444444444444444444444
dcn.q5 4444444444333431144444411111144444311324444331111331331113111	dCN.Q2	111111111111111111001111110000011111111
dCN.con 44444444443334301444440000244444300324444330000330330000033003 dCN.con 4444444444433343014444440000244444300324444330000330330000033003 DT.Q2 111111111111111111111111111111111111	dCN.Q3	22222222222222222222222222222200011222222
DT.Q2 111111111111111111111111111111111111	dCN.Q5	444444444444333431144444411111144444311324444331111331331113111
DT.Q3 111111111111111111111111111111111111	dCN.con	444444444444333430144444400000244444300324444330000330330003000
DT.Q5 3333333333333333334443333334444303333333	DT.Q2	111111111111111111111111111111111111111
DT.con 3333333233333333333333333333333333333	DT.Q3	111111111111111111111111111111111111111
GG.Q2 111111111111111001111110000000111110000110111010	DT.Q5	333333303333330443333334444303333334333333
GG.Q3 222212002122210121001222220000000222210010222212000022022	DT.con	333333323333333333333333333333333333333
GG.Q5 4344231132343212321124443311001124434211214434231011431342122111143324 GG.con 434423113234321232002444330000004434200104434230000430342022000043324 MST.Q2 111111111111111111111111111111111111	GG.Q2	1111111111111111111001111110000000111111
GG.con 434423113234321232002444330000004434200104434230000430342022000043324 MST.Q2 111111111111111111111111111111111111	GG.Q3	222212002122210121001222220000000222210010222212000022022
MST.Q2 111111111111111111111111111111111111	GG.Q5	4344231132343212321124443311001124434211214434231011431342122111143324
MST.Q3 1111111211111111111111111111111111111	GG.con	434423113234321232002444330000004434200104434230000430342022000043324
MST.Q5 111111111111111111111111111111111111	MST.Q2	111111111111111111111111111111111111111
MST.con 222222232222222222222223022223222322232	MST.Q3	1111111121111111111111120111112112111111
RCH.Q2 111111111111111111001111110000011111110001111	MST.Q5	1111111121111111111111120111112112111111
	MST.con	2222222322222222222222302222322232222222
RCH.Q3 222222222222222222222222220000122222200222222	RCH.Q2	11111111111111111100111111000001111111001111
	RCH.03	2222222222222222222222222222000012222222

RCH.Q5	44444444444444444444444444443030033444444
RCH.con	444444444444444444444444444444444444444
RNG.Q2	1111111111111111111001111111000000111111
RNG.Q3	2222111111111111110012221100000122221001122121100001101211110000121111
RNG.Q5	333322122223222221123332201001123333211223323221101221222222110133222
RNG.con	33332222223222220023332200000233332002232322000022022
SA.Q2	000000000000000000000000000000000000000
	000000110100011100211000002122211000012211001011222200210121121
SA.Q3 SA.Q5	0000103301100113114310000133443320000133130020213443013103431433300230
	0000011000000100430000033442110000033010010103443003001430433300230
SA.con	
All.con 350 - 419	3333332333333232113333301001133333311323333331100331332122000033213 0 1 2 3 4 5 6
seq	AVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGIL
cCN.Q2	
cCN.Q3	01110201210121112102201101002212221200012111022012101001111122221221
cCN.Q5	1222030231033312311331111311341343131103311213312310211313133444333333
cCN.con	0111030130033301300330000300340343030003320103301300200103033444333133
dCN.Q2	
dCN.Q3	00110201200121112102201101002212221101012111021011101001121112221221
dCN.Q5	1111131131123211311330111311331343131112311103311310211111121444233133
dCN.con	000003003001320030033000030030343030002320003300300200003010444233033
DT.Q2	111111111111111111111111111111111111111
DT.Q3	
DT.Q5	333333333333333333333333333333333333333
DT.con	333333333333333333333333333333333333333
GG.Q2	11000101111111111111100001001111110100011000110111010
GG.Q3	101002112212221121122000020122122201000120000221221
GG.Q5	2121032242234323422441111312442443121112321113423421201110111344344234
GG.con	211003124323432342244000030144244302000230000341342020000000344344234
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111111012111111111111111012211211111111
MST.Q5	111111111111111111111111111111111111111
MST.con	222222123222222222222222222222222222222
RCH.Q2	000001011101111110011000010011011101000110000
RCH.Q3	0121020222222222112211101012212221201022110022112011001111222222
RCH.Q5	$1 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 3$
RCH.con	0121030343234433411331110300341444130103311003313300100111144444444
RNG.Q2	11010101111111111111000010111111101000110000
RNG.Q3	1110010121112111211220000101221221010001100002211100100
RNG.Q5	222112123222322322331111212332332120112211112322211201111111233233223
RNG.con	221102023222322322330000202332332020002200003322200200

SA.Q2 11101000010001000100111011001000111000101	100
Z 343331330331023303303333143003000414343123340033034244344433000210 SA.QS 3331303101300131013003333043003000404341013340033034144341433000100 All.con 111103123212332231331110301331333120102311103312310200111011333333 420 - 489 0 1 2 3 4 5 6 seq LDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKV cCN.Q2 100001001111110011000001100110011011011	
SA.con 333130310130013101300333304300300404341013340033034144341433000100 All.con 1111031232123322321331110301331333120102311103312310200111011333333 420 - 489 0 1 2 3 4 5 6 seq LDCGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKV2 CCN.Q2 10000100111111001100110011001100110011	.10
All.con 1111031232123322321331110301331333120102311103312310200111011333333 420 - 489 0 1 2 3 4 5 6 seq LDgGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKV cCN.Q2 10000100111111101100000011001100110011	
420 - 489 0 1 2 3 4 5 6 seq LD2GQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKV cCN.Q2 100001001111111011000000110011001101101	.00
seq LDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKV cCN.Q2 100001001111111001100000110011001101101	:23
cCN.Q2 100001001111111011000000110011001001011011011011011011011011011 cCN.Q3 1000120012221221221001102201210001102201210200122122	
cCN.Q3 10001200122212212210011022012100011022012102200122122	QC
ccN.q5 3010131133343443443201120331233001131331133033103441443334213133134 ccN.con 30000300333434414431000103301330000303300330	.01
cCN.con 30000300333434414431000103301330000303300330	212
dCN.Q2 100001001111011011000000110011001011001101100101	34
dCN.Q3 1000020011221221221221000102201210001202210210	314
dCN.Q5 3011131122331441333111121331133001131331132133112131444133113121114 dCN.con 300003002233044033300001033003300030330032030020304440330030230043 DT.Q2 1110000111111111111111111111111111111	.01
dCN.con 30000300223304403330000103300330030330032033002030444033003023004 DT.Q2 1110000111111111111111111111111111111	212
DT.Q2 1110000111111111111111111111111111111	314
DT.Q3 111111111111111111111111111111111111	304
DT.Q5 3330033333333333333333333333333333333	.11
DT.con 33300113333333333333333333333333333333	.11
GG.Q2 1000010011111111000010111110000101000101	33
GG.Q3 200001001222222222000010221122000020110022022	33
GG.Q5 31111311233434433341111214422441111313211431431121314443443130121244 GG.con 30000300233434433340000204422440000303100430430010304443443030100244	.11
GG.con 30000300233434433340000204422440000303100430430010304443443030100244	212
	124
MST.Q2 111111111111111111111111111111111111	124
	.11
MST.Q3 111111111111111111111111111111111111	.11
MST.Q5 111111111111111111111111111111111111	.11
MST.con 222222222222222222222222222222222222	222
RCH.Q2 100001001111111111000000110111000011110011011001111	.11
RCH.Q3 20001111222222222211011022112100111022002102200222222	222
RCH.Q5 30131301344444444333033034333300133333333	44
RCH.con 30000300344444444431101103413330001323300330330034344444444130130344	44
RNG.Q2 1000010001111111110000011111100001010001111	.11
RNG.Q3 10000100011212211211000002211220000101100221210000102221221	212
RNG.Q5 2111121122232332232210111332233111121211132232111121333233213121123	323
RNG.con 20000200022323322322000003322330000202000332320000203332332	323
SA.Q2 01101011100000010000111110011001100110)10
SA.Q3 0222201211001001100122112001100222211011200200)10
SA.Q5 14333133210030020003442230033104443131133013103423130002002314223300)30
SA.con 04323033200010020001442230033004443030033003003411030001001304113300)30
All.con 30000201233323323331101103312330011313201320	323
490 - 559 0 1 2 3 4 5 6	

seq	FAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQQ
cCN.Q2	110100100110110000100111011001101110011011011011011011011011011011010
cCN.Q3	2211102002102200102122221221122112201210221221
cCN.Q5	4312013013313301113244432332233131301331342233000033414113313330201212
cCN.con	430200300330330000312443133113303330033034133300003340430330330200202
dCN.Q2	1100001001101100001001110110011011100110110110000
dCN.Q3	2201101002102101102122221221122112201210221121000021212012202210101101
dCN.Q5	431111311321331111311133133113313311321341133000132413313313321211211
dCN.con	430000300320330000301333033003303300320340233000031403203303320100202
DT.Q2	11100011011111111111111111111111111001111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333330333333333333334433333333333333340333333
DT.con	3331103313333333332333333333333333332113333333
GG.Q2	1100001001111100001001111111110101011111
GG.Q3	221101201221220000100022122112212120122122
GG.Q5	4412124124324411112111332442244122312432443343100011314124424431212312
GG.con	4401014014324400002001332442244031302432443343000000304024414430302302
MST.Q2	110111101110110111111111111111111111111
MST.Q3	1101111111011011111111111101111110121012111111
MST.Q5	1111111111011011111111111101111110121112111111
MST.con	220222202202202222222222222222222222222
RCH.Q2	110100100110110000100111111111111001101101111
RCH.Q3	222111200210210110122222222222222201210222221000011222222
RCH.Q5	444431301331331330334444444344443430333144443300003344444444
RCH.con	442310300330330110322444444344443434301330444433000033424424424432301314
RNG.Q2	1111001011111110001000111111111010101111
RNG.Q3	22010010121122100010001112211210101012112211210000101010122122
RNG.Q5	33 1211212 3 22 3 321102111222 3 322 3 2122212 3 22 3 32232100021212123322 3 21202212
RNG.con	3312002023223320002000222332232020202322332232000020202023223320202202
SA.Q2	00111101100100111101100000010001000110010011001111
SA.Q3	00211102101200211211210110011001110210120011012222110101100100
SA.Q5	0033331430131043341343113003300311143013002101444443130330031014242233
SA.con	0033330430030043340341001003100300043003002200444411030130030004141131
All.con	3312103013213301102112332332233132301321332232000021313223313331202212
560 - 629	0 1 2 3 4 5 6
seq	CTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHFT
cCN.Q2	110111011000000000111011011000001101110001111
cCN.Q3	220221012000000012221221221010002101220101222101102201200102101210110
cCN.Q5	331333133111100101333333333111013313431113443313113312310203302320330
cCN.con	330333033000000003331331333000003303430003443303003301300103301310330
dCN.Q2	1101110110000000001110110110000011011100011011010

dCN.Q3	21022101100000000222122122101000220122010122110110
dCN.Q5	3313331331111001113331331331111133123311124122131133113
dCN.con	33033303300000000333033033000003302330002412203003300300003200300330
DT.Q2	111111111111011101111111111100101111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	3333333333404440333333333330433330333333
DT.con	333333333333303330333333333331031333233333333
GG.Q2	111111111000000000111111111000001111110001111
GG.Q3	2212221220000000022212212220000022122200012010020122122
GG.Q5	4324432441101000124333442433111114323441112311213224423421224323321320
GG.con	432443244000000004333442433000004323440002312003014413420104303330320
MST.Q2	110111111111111111111111111111111111111
MST.Q3	211111111110112111111111111111111111111
MST.Q5	211111111111111111111111111111111111111
MST.con	320222222222222222222222222222222222222
RCH.Q2	110111011000000000111111111000001101110001111
RCH.Q3	2212222200000010122222222010002222222112222202101201110102101210110
RCH.Q5	4444443310000001334444444313100344444343434443133133033303
RCH.con	44144423300000001344444443010003424442113444303103301310103303310330
RNG.Q2	111111111000000000111111111000001111110001111
RNG.Q3	221221112000000001111221211000002112210001111001012211210101111210110
RNG.Q5	322332233110100111222233232111113222321102212112123322321212222321220
RNG.con	33233223300000000222233232000003223320002222002023322320102222320220
SA.Q2	0010001001111111110001000000111110010001110000
SA.Q3	00200020022122222100010010011111200210021210111111
SA.Q5	0030013104433444330003003101333430131013342133231330032034331132034114
SA.con	0030003004433444330003001000333330030003341011130330032034330032034004
All.con	331333133000000013332332333110003313331112322213113312310103212320220
630 - 699	0 1 2 3 4 5 6
seq	DLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIEL
cCN.Q2	0100111111010010001100110010000110110010000
cCN.Q3	020121122212112010221012001010111022101201111122122
cCN.Q5	1311323343231231113320331130201231331033123212331343133213201333113303
cCN.con	0300323343130130003310330030100230330033011101330343033103200333003303
dCN.Q2	0100101111010010001110110010000110110010000
dCN.Q3	0101212222121120102210120010101110221012011101220122122
dCN.Q5	1311311443131131113321331130101231331023111111331343133113301313113303
dCN.con	0300303443030030003320330030002303300230000033034303300330
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	4333333333333334333333333333333403333333

RCH.Q2 01001111111101000111001000010110011001		
GG. 3 0100222222010020022202001000122122112112	DT.con	3333333333333333333333333323323323331333333
GG.Q5 12114334421213113431341312123323423421323244244243334511313124424 GG.Q6 0200433443020030034303400300233134213412322442444424334500330314414 MST.Q2 111111111111111111111111111111111111	GG.Q2	010011111101001000111011001000111011101101111
GG. con 02004334430200300343034003002331342134122322442444243334300300344144 MST.Q2 111111111111111111111111111111111111	GG.Q3	010022222201002000222022001000122122112211211
MST.Q2 111111111111111111111111111111111111	GG.Q5	12114334421211311134313411312123323422342
MST. 03 111111111111111111111111111111111111	GG.con	0200433443020030003430340030002331342134122322442444243334300303014414
MST.Q5 111111111111111111111111111111111111	MST.Q2	111111111111111111111111111111111111111
MRT.com 222222222222222222222222222222222222	MST.Q3	111111111111111111111111111111111111111
RCH.Q2 01001111111110100011101100100010110011000100101	MST.Q5	111111111111111111111111111111111111111
RCH.03 0101212222222220002221210101012102122211211	MST.con	22222222222222222222222222222222222222
RCH.05 03033444444433130443443030303331343343133334434433443	RCH.Q2	010011111111010001110110010000110110011000101
R.C. 03013344444423000443143103010133034124301131344144314411330033301303 RNG.Q2 0101111110100100111111001000111112111111	RCH.Q3	0101212222222200022212210101012102212221112112
RNG.Q2 01011111101001000111111001000111111111	RCH.Q5	0303344444443313044344330303033313433431333334434433443
RNG.Q3 0100211211010010001211100100011112211211	RCH.con	030133444444230004431431030101330341243011313441443144113300333013303
RNG.Q 1211322322121120113222211211122223322322222232233232231222122212323 RNG.con 02013223220000032222000002223322322322322322	RNG.Q2	010111111010010001111110010001111111111
RNG.con 02013223220020003322220020002223322322222233233	RNG.Q3	0100211211010010001211110010001111221112111112211211
SA.Q2 1011010000101101110010010011011001000100010001001100011000110001 SA.Q2 1011010000101101100010011011001001000100010001000100010001000100010001 SA.Q3 21110110001011021200120121212100001102111100110020011002001001	RNG.Q5	1211322322121120113322221121112222332223222
SA.Q3 2111011000101102120012121211020011102111110011002001002201010020 SA.Q5 4133032001314313340013103413343213103300333233103000300231143121330131 SA.con 40330310003033033400030034033431030033003	RNG.con	0201322322020020003322220020002222332223222
SA.Q5 4133032001314313340013103413343213103300333233103000300231143121330131 SA.con 4033031000303303400030034033431030033003	SA.Q2	101101000010110111000100110111100100100
SA. con 4033031000303303400030034033431030033003	SA.Q3	2111011000101102120012001212121102001110211111001100200110022010110020
All.con 02013233331311301033213310201012313311331	SA.Q5	4133032001314313340013103413343213103300333233103000300231143121330131
700 - 769 0 1 2 3 4 5 6 seq FESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQ cCN.Q2 10010110111110011011000011101101101000011010	SA.con	40330310003033033400030034033431030033003
seq FESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQ cCN.Q2 10010110011111001011000011101101101000010010000	All.con	02013233331311301033213310201012313311331
ccN.q2 100101100111110011011010001110110110110	700 - 769	0 1 2 3 4 5 6
cCN.Q32001021012212210210100110122122122121010010	seq	FESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQ
cCN.Q5 310313313323331331301110333244234312013023313310013313013212310113113 cCN.con 3003033013223310330310000333144134302003013103300003303003102300003003 dCN.Q2 10010110011111001101100001110110110000100100100010001000100110000	cCN.Q2	10010110011111001101100001110110110100100100100110000
cCN.con 3003033013323310330310000333144134302003013103300003303003102300003003 dCN.Q2 100101100111110011011000011101110000100110000	cCN.Q3	20010210122122102101001101221221221010010
dCN.Q21001011001111100110110100011101101100001001001000100110000	cCN.Q5	310313313323331331301110333244234312013023313310013313013212310113113
dCN.Q3 20010210122112102101000101211221222010010	cCN.con	3003033013323310330310000333144134302003013103300003303003102300003003
dCN.Q5 3113133113322311331231111333143134311112113113311113311013113310113113 dCN.con 3003033003322300330220000333043034300002003003300003300003003002 DT.Q2 111011111111111010110111111110101111111	dCN.Q2	1001011001111100110110000111011010001001001001000100010010001001
dCN.con 30030330033223003302200003330430343000020030033000030033000030030020 DT.Q2 1110111111111110101101111111101111011	dCN.Q3	20010210122112102101000101211221222010010
DT.Q2 1110111111111010110111111110111101111	dCN.Q5	311313311332231133123111133314313431111211311331111331101311331011311
DT.Q3 1111111211111111111111111111111111111	dCN.con	3003033003322300330220000333043034300002003003300003300003003002
DT.Q5 33303334333333030340333333333333333333	DT.Q2	11101111111111101011011111111011110101111
DT.con 33303334333333303033033333333333333333	DT.Q3	111111121111111111111111111111111111111
GG.Q2 11010110111111011000000011111111111100010011011010	DT.Q5	33303334333333330303403333333333333300333333
GG.Q3 200101101222221021010000022212212201002012112210002101012112220001000 GG.Q5 4112122023333421321210121343244234312113124224321113212114223431112011 GG.con 4102022023333420320100000343244234302003014224310003202004213430002000	DT.con	333033343333333303033033333333333333333
GG.Q5 4112122023333421321210121343244234312113124224321113212114223431112011 GG.con 4102022023333420320100000343244234302003014224310003202004213430002000	GG.Q2	110101101111111010000000111111111010010
GG.con 4102022023333420320100000343244234302003014224310003202004213430002000	GG.Q3	20010110122222102101000002221221222010020121122100021010121122200001000
	GG.05	
MST.Q2 111111111111111111111111111111111111	~ ~ ~	

MST.Q3 1111110211111111111111111022101100210111111	[
NFT.con 22222213222222222222222222222222222222	MST.Q3	111111102111111111111111111102211111111
RCH.Q2 100101111111110101000001111111110000100110000	MST.Q5	1111111021111111111111111111022101111111
RCH.Q3 210102222222222222110000022222222201011122122	MST.con	222222213222222222222222222222222222222
RCH.05 33030444444444430330133344444443030130333333000330301333333010304 RCH.050 310304444444444303100034444444301003013213320003301003113333001004 RNG.02 11010110111110100000001111111100010101111	RCH.Q2	1001011111111101101000001111111110000100100110000
RCH.con 310304444444444230310003444444430100301321332000330100311333001004 RNG.Q2 110101101111101000000111111100100111111	RCH.Q3	210102222222222221110000222222222011011122122
RNS.02 1101011011111010000000111111100010011111	RCH.Q5	3303044444444444443033013334444444303013033333330003303013333330103004
RNS.Q3 21010100111121010000000111122122101001100012112210001100 RNS.Q3 21212202222221211101112222323312112123223211122112322321102011 RNG.Q6 3202022022222302200000002223333000002000232233200002000232233200002000 SA.Q2 011010100000110111100010000011110110010211120100122101120012220112 SA.Q3 0221211110110121121121121010100002121121	RCH.con	31030444444444444444430310000344444444301003013213320003301003113330001004
RNG.05 321212202222221211101122223323312112123232111221123223321102011 RNG.05 3202022022222202000000022233233000020000023223300002000232233000020000 SA.02 011010010000011011110001000001111010010	RNG.Q2	11010110111111101100000001111111110100101
RNS.con 32020202222302200000002222332330200202000232233200002000 SA.Q2 0110101000001101111000100000111101100101	RNG.Q3	21010100111112101100000001111221221010010
SA.Q2 011010010000011011110001000000111101100101	RNG.Q5	3212122022222221221110111222233233312112123223211112211123223321102011
SA.Q3 02212111101101211211211210100100202121121	RNG.con	320202202222320220000000222233233020020232232
SA. Q5 0341412300121033124344333101300300042431330330034441231430331034341333 SA. con 03404013000100330143143330030010004243033013003444133440331034340331 All. con 31020321233232132011001033323323323302002013213310003202013113320002012 770 - 839 0 1 2 3 4 5 6 seq LPLIIVCDRPDFVHDLVLYLYRNNLGKYIEIYVCKVNPSRLFVVIGGLbVDCSEDVTKNLLILVVRGPS ccn. 02 011111100110011011010110110110110110110	SA.Q2	011010010000001100110111100010000001111011001001111
SA. con 034040130001003301431433330030100042430330130034440130430330034340331 All. con 3102032123323213201100103332332332330202013213310003202013113320002012 770 - 839 0 1 2 3 4 5 6 seq LPLIIVCDRFDFVHDUVLYLYRNNL0KYIEIYV0KVNPSRLPVVIGGLDVDCSEDVTKNLILVVRQFS CON Q2 011111100101001101100101101101101101101	SA.Q3	022121111011101211211211201010010002121121
All.con 310203212332321320110010333233233020020131331000320201311332002012 All.con 31020321233232132011001033323323302002012131331000320201311332002012 770 - 839 0 1 2 3 4 5 6 seq LPLIVCDRFDFVHDLVLYLYRNNL0KYIEIYVCKVNPSRLFVVIGGLDVDCSEDVIKNLILVVRQFS CCN.q2 011111100110011011001101110110110110110	SA.Q5	0341412300121033124344333101300300042431330330034441231430331034341333
770 - 839 0 1 2 3 4 5 6 seq LPLIIVCDRFDFVHDUVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLDVDCSEDVIKNLILVVRQFS cCN.Q2 011111101011001101100011011001011011011	SA.con	0340401300010033014314333000300100042430330130034440130430330034340331
seq LPLIIVCDRFDFVHDLVLVLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRQFS cCN.Q2 011111101011001101110001101101101101101	All.con	3102032123323321320110010333223323302002013213310003202013113320002012
cCN.Q2011111101011001101101101101101101101101	770 - 839	0 1 2 3 4 5 6
cCN.Q3 1222222110220122122000211221122112112112	seq	LPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQFS
cCN.q5 344443431331132233311132133333113343343444444141310133213333310231 cCN.q5 3444434303033003313430003203313330031431441444444040300033103333300230 dcN.q2 0111110010110011011011000110110110010001101111	cCN.Q2	01111111010110011011100011011011100101101101111
ccN.con 144443430303300331343000320331333003143144144444400300033103333300230 dcN.Q2 011111001011001101100011011011001001101111	cCN.Q3	1222222211022012212220002112211221112112
dcN.Q2 01111110010110011011100011011011001000110110110000	cCN.Q5	344443431313311332343111321333333113343344344444141310133213333310231
dcN.q3 122222211102200221222000211221222001221122122	cCN.con	14444343030330033134300032033133300314314414444440403000331033333300230
dCN.Q5 23443441131331133133113113213313331131311431444444131311133113412311131 dCN.con 13443440030330033003300320330330001300430444444030300033003402300030 DT.Q2 111111111111111111111111111111111111	dCN.Q2	01111110010110011011100011011011100101001101111
dCN.con 1344344003033003303300320330330031300430444444030300033003402300030 DT.Q2 111111111111111111111111111111111111	dCN.Q3	122222211102200221222000211221222001221122122
DT.Q2 111111111111111111111111111111111111	dCN.Q5	2344344113133113313331113213313331131311431444444131311133113412311131
DT.Q3 111111111111111111111111111111111111	dCN.con	13443440030330033033003203303330031300430444444030300033003402300030
DT.Q5 333333333333333333333333333333333333	DT.Q2	111111110111111111111111111011110111101111
DT.con 333333333333333333333333333333333333	DT.Q3	111111111111111111111111111111111111111
GG.Q2011111101011001111110001101101100011011	DT.Q5	333333333433333333333333333303333333333
GG.Q3 12222220010220122222200022122122210200001102220220	DT.con	333333331333333333333333333333333333333
GG.Q5 2344343112134124423441113324423442131111221343233121211134224433421131 GG.con 1344343102034014433440003314423441031000220343033020200034224433420030 MST.Q2 111111111111111111111111111111111111	GG.Q2	0111111101011001111111000110111110011000110111011010
GG.con 1344343102034014433440003314423441031000220343033020200034224433420030 MST.Q2 111111111111111111111111111111111111	GG.Q3	12222220010220122222200022122122210200001102220220
MST.Q2 111111111111111111111111111111111111	GG.Q5	2344343112134124423441113324423442131111221343233121211134224433421131
MST.Q3 11111121111101111110111111111111111111	GG.con	1344343102034014433440003314423441031000220343033020200034224433420030
MST.Q5 11111121111101111110111111111111111111	MST.Q2	111111111111111111111111111111111111111
MST.con 22222232222202222222222222222222222222	MST.Q3	111111211111011111101111111111111111111
RCH.Q2 01111111011001111110001111111011111101111	MST.Q5	111111211111011111101111111111111111111
RCH.Q3 22222222022022222221022222222222222222	MST.con	222222322222022222122222222222222222222
	RCH.Q2	011111111011001111110001111111110111111
RCH.Q5 444444444444444444444444444444444444	RCH.Q3	222222222022022222221022222222222222222
	RCH.Q5	444444444443303443443430434444444444444

RCH.con	2444444440330244344321043444444431444444242444444242300033324444412330
RNG.Q2	0111111101011011111111000111111111001010
	1122122101011012212210001112211220011100110121111010100012112211210010
RNG.Q3	1233233212022123323321102223322332122211221221221221221221221221
RNG.Q5	
RNG.con	0233232020220233232000222332233002120022023222202000232233223
SA.Q2	
SA.Q3	1000100121200110010002110110010001211112101000100211012210110011012101
SA.Q5	2000100231410330021014330231031003312143113001201433134310230032034313
SA.con	200000130400330010004330130010003301013003000200413034300230031034303
All.con	1333333212033013323331103223322331122221331333233131310033123323311131
840 - 909	0 1 2 3 4 5 6
seq	TDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCEK
cCN.Q2	
cCN.Q3	200210120010121221022101100010111121122122
cCN.Q5	3113302310212313331331022001101333332343333110113113311313313233213311
cCN.con	3003301300102303331330012001000313311341333000003003300303301133203300
dCN.Q2	1001100100000101110110001000001011001101110000
dCN.Q3	200210120010121221022001100010011221122
dCN.Q5	3113301310111313321331112001111113311431333111113113311313311223113311
dCN.con	300330030000303320330002000002033004303330000030033003
DT.Q2	111111011111111111111111110011111111111
DT.Q3	
DT.Q5	333333033333333333333333340033333333333
DT.con	333333033333333333333333333333333333333
GG.Q2	100110111000111111111111000000011111111
GG.Q3	2002211210102212221221112000001022212212
GG.Q5	4114422421212424432342233112111213332442434110113124421202311124313311
GG.con	400441242010342443234223300000113332442434000003024410302300034303300
MST.Q2	101110111111111111111111111111111111111
MST.Q3	101110111111111110111111111111111111111
MST.Q5	101110111111111111111111111111111111111
MST.con	20222022222222222222222222222222222222
RCH.Q2	1001100100001101111110001000001111101111
RCH.Q3	200110121011121222222111100010122222222
RCH.Q5	3013303330333444444343330003033344444444
RCH.con	3003301310113314444431113000101334442444443101003013300303442134313311
RNG.Q2	101111111000111111111111000000001111111
RNG.Q3	101221121010121121122111100000002211221211000001011210101100011001100
RNG.Q5	21233223211123223223322221111111123223323221101121233212022111221122
RNG.con	2023322320002322322332222000000033223323220000020233102022000220022
SA.Q2	0110011011110010001001001111111000110010001111

SA.Q3	022002101212101001100221022112111001100
SA.Q5	1330133033332030023103321444343330023003010334431331034142133310131143
SA.con	033003303331030013002310443343310023003000333430330034041033300230043
All.con	3013301310112313331331122000101223322332
910 - 979	0 1 2 3 4 5 6
seq	RDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALSE
cCN.Q2	01111111110010100011011101111001101110000
cCN.Q3	112222222201101011120222121221122112101101
cCN.Q5	234444443113131113313333443321331233011131331233000013311331343233301
cCN.con	1344444443003030003303331433310330233000010330133000003300330343133300
dCN.Q2	11111111110000100011010101111001101110000
dCN.Q3	112222222200101000120212122221122112101101
dCN.Q5	11114444431211311133131313131331333011121331133001113211331343133311
dCN.con	2233444443000030003303030333300330333000010330033000003200330343033300
DT.Q2	1011111111101111111111111111111111001111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333333333304333333333333333333333333333
DT.con	313333333333333333333333333333333333333
GG.Q2	010011111110001000110101011111111110000101
GG.Q3	0000222222010010002200010222211222222000010221122000001100221222122200
GG.Q5	1111433443121121113412121334422443344111121442344100102211442344233311
GG.con	010043344311002000340202033442244334400002044234400000220044234423
MST.Q2	111111111011111111111111111111111111111
MST.Q3	111111112111111011111111121111101111011101110111111
MST.Q5	1111111121011111101111111211111211110111111
MST.con	22222223202222122222223222322202222122022222222
RCH.Q2	11111111110000100011011101111101111110000
RCH.Q3	22222222222101211220222222222222220110102211220001012012
RCH.Q5	3444444444330311333144444444444443430331303333330003030330344444444
RCH.con	34444444442210310133044424444444443443011010331133000103301441444244420
RNG.Q2	0000111111100010001101010111111111110000
RNG.Q3	0000111221100010001101010111211121121000000
RNG.Q5	111122223321112111221212122232232232111111
RNG.con	0000222333200020002202022232232232000000
SA.Q2	10000000001111011100101010000110000001111
SA.Q3	1111000000211211121021111010011001000211112001100222121121
SA.Q5	3343001001333413331031313100133102101433323003201344332243003100310134
SA.con	3111000000333403330030303000033001000433313003200344131143003000300034
All.con	1222333333111021113303131333322332333011010331233000102201331333233310
980 - 1049	0 1 2 3 4 5 6
seq	TQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNYD

cCN.Q2	10000011011011010100110110011000001001111
cCN.Q3	1000002112211210102101220220021101012001112112
cCN.Q5	3010013313332331213212331331133201013103333333444343111202321331231131
cCN.con	3000003303312330203201330330033100003003333133444343000101310330230030
dCN.Q2	10000010111011100010001101100110000010000
dCN.Q3	1000002112211210101101220220021101002001112112
dCN.Q5	111101311331232111311133133113320111311113113343333111201311331231131
dCN.con	200000302330232000300033033003310000300003003343333000100300330130030
DT.Q2	010111111101111011111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	03044333333033334333333333333343333340333333
DT.con	030333333330333331333333333333333333333
GG.Q2	000000111111110101001110111111100001001
GG.Q3	0000002222212220001000221221122000001000112112
GG.Q5	2111114334423431203111442442243210112111224224444434211312432441231131
GG.con	0000004334423430203001441442243200002001124224444434120202431440130030
MST.Q2	111111111111111111101110111011111111111
MST.Q3	111101111111111111111110110111111111111
MST.Q5	111101111101111111011101101111111111111
MST.con	22221222222222222202202202222222222222
RCH.Q2	000000110110110101001110110011000001001
RCH.Q3	10000022222222010220222022112210000100111222222
RCH.Q5	30100033444433443033034413431333030130033344444444
RCH.con	1000003324423341303203440341033100003003314244444443111303430330330130
RNG.Q2	100000111111111010100111111111100001001
RNG.Q3	1000002112212210101001221221121100001001
RNG.Q5	2111113223323321202112332332232211112111122223322233121112322331120121
RNG.con	2000003223323320202002332332232200002002
SA.Q2	011111000001000101011000100110001111011010
SA.Q3	1221210110011012120121002002101121221221
SA.Q5	3433430030031014341333013003301344431443230320000001333242023103214413
SA.con	1433430010030004140331003003300143430441210110000000333242013003204403
All.con	1000003223322331202102331331133201013002123223333333111102321330130130
1050 - 1119	0 1 2 3 4 5 6
seq	APDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVW <mark>SQLAKAQLQKG V</mark>
cCN.Q2	100110110000110011011001000001101110010010010010010000
cCN.Q3	100220121010120122122001011102202220111010121012001000022 <mark>1122111100012</mark>
cCN.Q5	301330332010331333233113012113313331231130132033113111134 <mark>3233133301013</mark>
cCN.con	3003303310003301331330030010033033301300300
dCN.Q2	100110110000110011011001000001101110010010010010010000
dCN.Q3	100220121010110122122001011102201220111010121012001000022 <mark>1122111100001</mark>

dCN.Q5	3113313310102311331331130111133133311211301311330131111341133133311013
dCN.con	30033033000023003303300300000330333002003003
DT.Q2	01010111110111111111101011111111111001111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	03031333340403333333330403333331333330033333333
DT.con	0303033333032333333333303033333323333003333133333333
GG.Q2	1001101110001101111110010000011111100100101
GG.Q3	1012212220001201221220010000022122211211
GG.Q5	212432443111231243244112011113424442232241243244113011144 <mark>3243233311113</mark>
GG.con	201431443000230243244002000003424441131140243144003000044 <mark>3243233300003</mark>
MST.Q2	10111011111111111111111111111111111111
MST.Q3	2011201211111012111101111111121011111111
MST.Q5	1011201211111012111101111111121011111111
MST.con	302230232222212322220222222320222022220232223022222222
RCH.Q2	1001101100001101111110010000011011100100100110110010000
RCH.Q3	10022012101012222222001011102212221121010121022001000022 <mark>2222122200001</mark>
RCH.Q5	301330333010334444343113033303333433331030333133013000044 <mark>4344443300013</mark>
RCH.con	$300330331000332444343003011103313431130030133033003000044 \\ 4344143300003 \\ 3000030133033003000044 \\ 4344143300003 \\ 3000030133033003000044 \\ 43441433000003 \\ 30000301300300000000000000000$
RNG.Q2	1011111110001101111111010000011111110100101
RNG.Q3	101221221000110121122101000002212221110010121122101000022 <mark>1122121100001</mark>
RNG.Q5	212332332110221233233212011113323332221121232233212010133 <mark>2233222211012</mark>
RNG.con	202332332000220233233202000003323332120020232233202000033 <mark>2233232200002</mark>
SA.Q2	0110010001110010001001101111100100011011011001001101111
SA.Q3	12100210121210210010022121112002000211110210120022022
SA.Q5	143003102434114301311331433330031003313314302310331433301 <mark>2200311144431</mark>
SA.con	043003001434004100300330433330030003303304301300330433300 <mark>1200300044430</mark>
All.con	201330332000231233233002011103313331131030132133003000033 <mark>2233133300003</mark>
1120 - 1189	0 1 2 3 4 5 6
seq	KEAIDSYIKADDPSSYMEVVQAANTSGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFIN
cCN.Q2	0011011101001001001101100000100110110010000
cCN.Q3	0022022 21201101210220120010010021022011000100112221222222
cCN.Q5	114313431313013213302310201311331331231011013133334444442301311311331
cCN.con	0043034303003003103302300100300330330130000003033314444441300300300330
dCN.Q2	<mark>0011011</mark> 1010010010011011000001001101100100
dCN.Q3	00220222222222222222222222222222222222
dCN.Q5	<mark>1143134</mark> 313113113113302310101311331331131011011133314444441301301311331
dCN.con	0043034 <mark>3030030030033023000003003303300300000003330444444030030</mark>
DT.Q2	1111101 1101011111111101110101101111110110
DT.Q3	<mark>1111111</mark> 11111111111111111111111111111
DT.Q5	<mark>3313313</mark> 333403303333303340403303333333333
DT.con	<mark>3323303</mark> 3313033233333033303303303303333333333

GG.Q2	0011111	101001001	0011011000	001001111	111100000	01011111111	111110010	0110110
GG.Q3	<mark>0122122</mark>	201001002	1122122000	0020122122	2122101000	0021212222	222120020	1211220
GG.Q5	1244234	42201211 <mark>3</mark>	2144234111	0131244244	12 <mark>34</mark> 212111	1142324434	443231131:	2422441
GG.con	0144234	402002003	1044134000	0030144244	12 <mark>34</mark> 201000	1042324434	443230030	1421440
MST.Q2	0111011	111111111	1111011011	1110111011	L <mark>0</mark> 11111111	.1111111111	111111110	1110111
MST.Q3	0121011	112111111	1111012011	111011101	1111111111	.1111111111	21211111 <mark>0</mark>	1111111
MST.Q5	0121011	112111111	1111012011	1110111011	011111111	.1111111111	212111110	1111111
MST.con	0232022	22 <mark>3</mark> 222222	2222 <mark>0230</mark> 22	22220222022	2022222222	22222222222	323222220	2220222
RCH.Q2	0011011	101001001	0011011000	001001101	L00100000	1111111111	111110010	0100110
RCH.Q3	0122122	222002002	1021011001	0010121022	2111101100	2122222222	222220010	0110110
RCH.Q5	0333444	433033013	31331331 <mark>0</mark> 3	3 <mark>013033313</mark> 3	3333 <mark>0</mark> 3301	3344444444	444430130	1331330
RCH.con	<mark>0133144</mark>	423003003	1033033001	0030133033	311 <mark>3</mark> 101100	334444444	44430030	0310330
RNG.Q2	0111111	101001001	111111110	001011111	111111100	0011111111	111010010	111111 <mark>0</mark>
RNG.Q3	0122112	101001001	0122122100	0000122122	2112111100	0011112212	222010010	121121 <mark>0</mark>
RNG.Q5	1233233	212012112	1233233212	20111233233	322 <mark>3</mark> 222211	112222 <mark>33</mark> 23	33312 0 121:	2322321
RNG.con	<mark>0233233</mark>	202002002	1233233200	0010233233	322 <mark>3</mark> 222200	0022223323	3330200202	2322320
SA.Q2	1100100	010110110	0100100111	1101100100	0100111111	.010000000	00101101	1001001
SA.Q3	<mark>2100200</mark>	020211210	1200210221	2112100200)210121122	110101000	000202102	1022002
SA.Q5	<mark>33003</mark> 11	031431431	33 <mark>00</mark> 320343	3 4 3133 0 131()33 <mark>0</mark> 343343	330103000	010314313	3033014
0.7	3300300	020420420	1200210242		210242245	130001000	000304303	3023004
SA.con	0000000	030430430	1300310343	34303300300	0310343343	1000010000		5025001
All.con				1002013313				
	0133133							
All.con	<mark>0133133</mark> 0	313002003 1	11 <mark>33</mark> 023001 2	1002013313	<mark>3123111100</mark> 4)2133323333 5	3331300303 6	1311330
All.con 1190 - 1259	0133133 0 GPNNAHI	313002003 1 2000 C Y D 2000 C Y D	1133023003 2 EKMYDAAKLI	3	3123111100 4 LASTLVHLGE	0213332333 5 2YQAAVDGARI	3331300303 6 XANSTRTWKI	1311330 EVCFACV
All.con 1190 - 1259 seq	0133133 0 GPNNAHI 0011101	313002003 1 2QVGDRCYD 001100110	1133023001 2 EKMYDAAKLI 0001011111	3 JUNNVSNFGRI	3123111100 4 LASTLVHLGE	0213332333 5 CYQAAVDGARI 01001101100	333130030 6 KANSTRTWKI 010010110	1311330 EVCFACV 0110111
All.con 1190 - 1259 seq cCN.Q2	0133133 0 GPNNAHI 0011101 1122201	313002003 1 20VGDRCYD 001100110 002101210	1133023001 2 EKMYDAAKLI 0001011111 0011022122	.002013313 3 .YNNVSNFGRJ .1001001011	4 A LASTLVHLGE	22133323333 5 CYQAAVDGARI 01001101100 0200210221	6 KANSTRTWKJ 0100101100	1311330 EVCFACV 0110111 1221121
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3	0133133 0 GPNNAHI0 0011101 1122201 1343313	313002003 1 22VGDRCYD 001100110 002101210 113201320	1133023003 2 EKMYDAAKLI 0001011113 0011022123 0013144234	3 3 22112002113	4 LASTLVHLGE 101110100 2212221200	2213332333 5 SYQAAVDGARI 01001101100 0200210221 311431431	6 KANSTRTWKJ 0100101100 1101102213	1311330 EVCFACV 0110111 1221121 1332233
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5	0133133 0 GPNNAHI 1122201 1343313 0143303	313002003 1 20VGDRCYD 001100110 002101210 113201320 003200320	1133023001 2 EKMYDAAKLI 0001011111 0011022122 0013144234 0003044234	3 3 2211200213313 3 22112002112 13123013114	4 LASTLVHLGE 101110100 2212221200 1434432301	2213332333 5 CYQAAVDGARH 01001101100 02002102211 .311431431 03004304300	6 KANSTRTWKJ 0100101100 1101102211 130131332 0300303310	EVCFACV 0110111 1221121 1332233 0331233
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con	013313 0 GPNNAHI 1122201 1343313 0143303 0111101	313002003 1 22VGDRCYD 001100110 002101210 113201320 003200320 001000100	2 EKMYDAAKLI 0001011112 0011022122 0013144234 0003044234	3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4 LASTLVHLGE 101110100 2212221200 4434432301 4414431300	5 5 213332333 5 2YQAAVDGARH 01001101100 0200210221 311431431 3004304300 01001101100	6 KANSTRTWKJ 0100101100 110110221 130131332 0300303310 0100101100	EVCFACV 0110111 1221121 1332233 0331233 0110111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2	013313 0 GPNNAHI 1122201 1343313 0143303 0111101 0121201	313002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210	2 EKMYDAAKLI 0001011111 0011022122 0013144234 0003044234 0001011111	3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4 LASTLVHLGF 101110100 2212221200 1434432301 1414431300 101110100 2212221200	5 CYQAAVDGARI 01001101100 02002102213 .311431431 03004304300 01001101100 02002102203	6 KANSTRTWKJ 0100101100 1101102213 1301313323 0300303310 0100101100 1101202210	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3	013313 0 GPNNAHI 1122201 1343313 0143303 0111101 0121201 1113313	313002003 1 2QVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320	1133023003 2 EKMYDAAKLI 0001011113 0011022123 0013144234 0003044234 0001011113 0012022112 1113133323	3 3 3 3 3 3 3 3 3 1001001012 22112002112 13123013114 13013003024 1001001002 22111002112	4 LASTLVHLGE 101110100 2212221200 4434432301 4414431300 2212221200 4414431311	5 SYQAAVDGARH 01001101100 02002102211 3114314313 03004304304 01001101100 02002102201 3113313313	6 KANSTRTWKJ 0100101100 110110221 130131332 0300303310 0100101100 1101202210 131131331	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3	013313 0 GPNNAHI 0011101 1122201 1343313 0143303 0143303 0111101 0121201 1113313 0233303	313002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310	113302300 2 EKMYDAAKLI 000101111 0011022122 0013144234 0003044234 000101111 0012022112 1113133323 0003033323	3 <u>JYNNVSNFGRJ</u> <u>100100101</u> <u>22112002112</u> <u>312301311</u> <u>4301300302</u> <u>1001001001</u> <u>22111002112</u> <u>3311311311</u>	A A A A A A A A A A A A A A A A A A A	5 CYQAAVDGARI 01001101100 02002102213 3114314313 03004304304300 01001101100 02002102203 3113313313 03003303300	333130030 6 XANSTRTWKJ 0100101100 1101102213 1301313323 0300303310 0100101100 1101202210 1311313313 0300303300	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 0111101 0121201 1113313 0233303 0111111	313002003 1 2QVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101011111	2 EKMYDAAKLI 0001011111 0011022122 0013144234 0003044234 0001011111 0012022112 1113133323 0003033323	3 2002013313 3 2YNNVSNFGRI 100100101 22112002112 13123013114 13013003024 100100100 22111002112 33113113114	4 LASTLVHLGE 101110100 2212221200 4434432301 4414431300 2212221200 4414431311 4404430300	5 SYQAAVDGARI 01001101100 0200210221 .311431431 03004304304 01001101100 0200210220 .311331331 03003303300 .110111111	6 KANSTRTWKI 0100101100 110110221 130131332 030030331 0100101100 110120221 131131331 030030330 111011111	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q5 dCN.con DT.Q2	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 0111101 0121201 1113313 0233303 0111111 111111	313002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101011111 11111111	1133023003 2 EKMYDAAKLI 0001011113 0011022122 0013144234 0003044234 0001011113 0012022112 1113133323 0003033233 100111113 111111113	3 3 2 2 2 2 2 2 2 2 2 2 2 2 2	3123111100 4 ASTLVHLGE 1101110100 2212221200 1434432301 1414431300 1212221200 1414431301 1414431311 1404430300 11111111 111111111	5 SYQAAVDGARI 01001101100 02002102211 3114314311 03004304304 01001101100 02002102203 3113313313 03003303303 110111111 11111111	333130030 6 XANSTRTWKJ 0100101100 1101102213 1301313323 0300303310 0100101100 1101202211 1311313313 0300303300 110111113 1110111113	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 0111101 0121201 1113313 0233303 0111111 111111	313002003 1 QQVGDRCYD 001100110 002101210 113201320 001000100 002101210 113202320 003101310 101011111 111111111 303033334	1133023003 2 EKMYDAAKLI 0001011113 0011022122 0013144234 0003044234 0001011113 0012022112 1113133323 1001111113 111111113	3 .VNNVSNFGRI .100100101 .22112002112 .13123013114 .1001001001 .22111002112 .33113113114 .3003003004 .11111111	4 LASTLVHLGE 101110100 2212221200 434432301 4414431300 2212221200 4414431311 4404430300 111111111 111111111	5 SYQAAVDGARI 01001101100 0200210221 311431431 03004304304 01001101100 0200210220 311331331 0300330330 110111111 11111111 3330333033	333130030 6 KANSTRTWKI 0100101100 110110221 130131332 0300303310 0100101100 1101202210 131131331 0300303300 11101111 131333333	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111 3333333
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5	013313 0 GPNNAHI 0011101 1122201 1343313 0143303 0143303 0111101 0121201 1113313 0233303 0111111 1111111 0333303	313002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101011111 11111111 303033334 303033333	1133023003 2 EKMYDAAKLI 0001011113 0011022122 0013144234 0003044234 0001011113 0012022112 1113133323 000303323 100111113 111111113 4033333333 3013333333	3 <u>JYNNVSNFGRJ</u> <u>100100101</u> 22112002112 <u>1312301311</u> <u>1301300302</u> <u>1001001003</u> <u>22111002112</u> <u>3311311311</u> <u>33003003004</u> <u>111111113</u> <u>33333343333</u>	4 ASTLVHLGE 101110100 2212221200 4434432301 4414431300 101110100 2212221200 4414431311 4404430300 111111111 111111111 3333333333 33333333	5 SYQAAVDGARI 01001101100 0200210221 311431431 03004304304 01001101100 02002102203 311331331 03003303303 110111111 11111111 3330333033 3330333233	333130030 6 XANSTRTWKJ 0100101100 1101102213 1301313323 0300303310 0100101100 1101202210 1311313313 0300303300 1110111113 1110111113 13340333333 3330333333	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111 1111111 1333333 3333333
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 0111101 0121201 1113313 0233303 0111111 111111 0333303 0333323 0010101	313002003 1 QQVGDRCYD 001100110 002101210 113201320 001000100 002101210 113202320 003101310 101011111 111111111 303033334 3001101110	1133023003 2 EKMYDAAKLI 0001011113 0011022122 0013144234 0001011113 0012022112 1113133323 1001111113 4033333333 3013333333 00010111113	3 .YNNVSNFGRJ .100100101 .22112002112 .13123013114 .13013003024 .100100100 .22111002112 .33113113114 .3003003004 .111111111 .11111111 .3333334333 .33333333333	4 LASTLVHLGE LIOIIII0100 2212221200 4434432301 4414431300 2212221200 4414431311 4404430300 111111111 333333333 333333333 11111111	5 SYQAAVDGARI 01001101100 02002102213 3114314313 03004304304 01001101100 02002102203 3113313313 03003303303 1101111113 0330330330 033033233 033033233 0111101110	333130030 6 XANSTRTWKI 0100101100 110110221 130131332 0300303310 0100101100 1101202210 131131331 0300303300 111011111 334033333 03003033333 0100101111	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111 3333333 3333333 1111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 011101 0121201 1113313 0233303 0111111 1111111 0333303 0333323 0333323	313002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101011111 111111111 303033334 303033333 001101110 012212220	1133023003 2 EKMYDAAKLI 0001011113 0011022122 0013144234 0003044234 0001011113 0012022112 1113133323 0003033323 100111113 111111113 4033333333 3013333333 0001011111 0002022222	3 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2	3123111100 4 ASTLVHLGE 1101110100 2212221200 1434432301 1414431300 1212221200 1414431301 1414431311 1404430300 111111111 111111111 3333333333 33333333333 111111111 2212221211	5 SYQAAVDGARI 01001101100 02002102211 .3114314311 03004304300 01001101100 02002102203 .3113313313 .3113313313 .3110111111 .111111111 .3330330333 .3330332333 .1111101110	333130030 6 XANSTRTWKJ 0100101100 110110221 130131332 0300303310 0100101100 110120221 131131331 0300303300 111011111 111111111 1334033333 333033333 010010111 020010221	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111 1333333 3333333 1111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2 GG.Q3	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 0143303 0111101 0121201 1113313 0233303 0111111 111111 0333303 0333323 0010101 0000102 1111213	313002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101011111 111111111 303033334 3001101110 012212220 124323421	1133023003 2 EKMYDAAKLI 0001011113 0011022122 0013144234 0001011113 0001011113 0012022112 1113133323 1001111113 4033333333 00010111113 0001011113 00010111113 1001111113 1001111113 0002022222 0113133344	3 3 3 3 3 3 3 3 3 3 3 3 3 3	4 LASTLVHLGE LIOIIII0100 2212221200 434432301 414431300 2212221200 4144431311 4404430300 111111111 333333333 333333333 11111111	2213332333 5 SYQAAVDGARI 01001101100 02002102213 3114314313 03004304304300 01001101100 02002102203 3113313313 03003303300 1101111113 030033033033 11011111113 0330332333 1111101110 2112212210 24224423423	333130030 6 XANSTRTWKI 0100101100 110110221 130131332 0300303310 0100101100 1101202210 131131331 0300303300 111011111 03003033333 03003033333 0100101111 0340333333 0100101113 0200102213 1311213423	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111 3333333 1111111 1221222 2432333
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2 GG.Q3 GG.Q5	013313 0 GPNNAHI 1122201 1343313 0143303 0143303 011101 0121201 1113313 0233303 0111111 1111111 0333303 0333323 0333323 0010101 0000102 1111213	313002003 1 QVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101011111 111111111 303033334 303033334 303033334 001101110 012212220 124323421 014313430	2 EKMYDAAKLI 0001011111 0011022122 0013144234 0003044234 0003044234 0001011111 0012022112 1113133323 0003033333 0001011111 111111111 0002022222 0113133344 0003033344	3 3 3 22112002112 22112002112 22112002112 33123013114 3013003024 1001001001 22111002112 33113113114 33003003004 111111111 3333334333 3333334333 10010010112 22012002012 44223113124	3123111100 4 ASTLVHLGE 1101110100 2212221200 1434432301 1414431300 101110100 2212221200 1414431301 1414431311 1404430300 111111111 111111111 111111111 111111111 111111111 1111111111 1111111111 1111111111 1111111111 1111111111 1111111111 11111111111 11111111111 111111111111 111111111111 11111111111111 111111111111111111111111111111111111	2213332333 5 CYQAAVDGARI 21001101101 22002102211 3114314311 23004304304300 201001101100 2002102203 3113313313 230033033033 33033033033 330332333 330332333 31111101110 2212212210 24224423423	333130030 6 XANSTRTWKI 0100101100 110110221 130131332 0300303310 0100101100 110120221 131131331 0300303300 111011111 111011111 131131333 0300303303 0300303303 010010111 020010221 131121342 030020342	EVCFACV 0110111 1221121 1332233 0331233 0110111 0221121 1331232 0330232 1111111 1111111 1111111 1221222 2432333 2432333

MST.Q5	111121101221011111111111111111111111111
MST.con	22223220233202222222322222222222222222
RCH.Q2	000110100100010000010111110110010111111
RCH.Q3	1211202001101210001102222222120022222222
RCH.Q5	344333301330333000331444444333004434444433313314414433303303333444333
RCH.con	121330300310131000130444444233004234444433103104414411301303311443333
RNG.Q2	001010101111110000101111111010010111111
RNG.Q3	0010101012111210000101211221010010122122
RNG.Q5	1122212123222321111212322332121121233233
RNG.con	0020202023222320000202322332020020233233
SA.Q2	1100010110011001111010010001101101100000
SA.Q3	1111110220021012221020011002102201100100
SA.Q5	3343131330033024443131021003314313200300030330330130033143131133003101
SA.con	3311030330033014443030020003304303200100030330330030033043030033001000
All.con	0122303013211320001303323331130031233233323
1260 - 1329	0 1 2 3 4 5 6
seq	DGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQK
cCN.Q2	000010110111011001001001101100001100110110011010
cCN.Q3	0100201211221122112012002201100101201220220
cCN.Q5	010131333334313321411311331220121331233133123303000133444444443131201
cCN.con	0000303313343033104003003302200103301330330133030000334444444443030100
dCN.Q2	000010110011101100100100110110000110011011011010
dCN.Q3	000021121122112211200200220110010120121022112101000111222222
dCN.Q5	0111312312332133113013113312211113311331
dCN.con	0000302301332033003003302200003300330330330030000203331444433030000
DT.Q2	101111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	403333333333333333333333333333333333333
DT.con	303333333333333333333333333333333333333
GG.Q2	0000111111110110010111011111000011011111
GG.Q3	000021221222101100201211221220000220122122
GG.Q5	1111324423432123113124224423311213312442442233120011114332433442121112
GG.con	0000324423432023003024214423300003302442442233020000104332433442020002
MST.Q2	111111101111111101101111111111101110110
MST.Q3	111111120122111112011011111111111011101
MST.Q5	1111111211221011112011111111111111101110110
MST.con	222222302 <mark>33</mark> 222223022022222222222202202321202222 <mark>3</mark> 2222232222222222
RCH.Q2	00001011111111100111100110110000110111011011010
DOLL 02	
RCH.Q3	000121222222222112012002212100102202221221
RCH.Q5	000121222222222112012002212100102202221221

RNG. Q2 0000111111111111100001011111111110000101		
RNG.Q5 11113223222212211312323323222101121222332322322101121222232323223200002 RNG.con 00003223222202000020101101101001001100000000	RNG.Q2	0000111111111011001011111111100011011111
RNG.con 0000322322220200302323322200022023323322302000020222233233	RNG.Q3	00001112111101100201211221111000110122122
sA. q2 11101000000100101101100100111100100010	RNG.Q5	11113223222212211312322332222111221233233
SA. Q3 212101001100120111012001122121021002001100212221110001000001212121 SA. Q5 43331310320024113313303300312333411330030031044444313000100000303343 SA. con 433303011001400330330330133340031003001444442300000000303343 All.con 0001313222321331130211331221110330231331233020012233233333120101 1330 - 1399 0 1 2 3 4 5 6 seq MREHELFWSRVNIPKVLRAAEQAHLMAELVPLYDKYEEVDNITTVMHPTDAMKEQFKDITTKVANV cCN.Q2 1001011010010010000110111101001001010010000	RNG.con	00003223222202200302322332222000220233233
SA.65 433313103200241133133030031233411330030031041444423000300010313443 SA.con 43330301101400303303303013340031030010404443130010000033443 All.con 0001313223213113023113312211103302313312330200012233333333	SA.Q2	111101000000010011011011001001111001000100100101
SA. con 433303001100140033033030031334003100300100444413000100000303443 A11. con 000131322321321331231130231133122111030231331233020001223332333	SA.Q3	2121010011001201110110120011122121021002001100212221110001000001212121
All.con 0001313223321331130231133122111033023313312302001223332333	SA.Q5	4333131032002411331330330031233341133003003301414444230003000010313343
1330 - 1399 0 1 2 3 4 5 6 seq MREHELELFWSRVNI PKVLRAAEQAHLWAELVFLYDKYEEYDNA LITMMN PTDAWKEGOFKDI ITKVANV cCN.02 110110110100100000110111111000100101010000	SA.con	4333030011001400330330330030133340031003003100404443130001000000303343
seq MREHLELFWSRVNT PKVLRAAEQAHLWAELVFLYDKYTEYDNAIT ITWYNNPPTDAWKEGQFKDT ITKVANV cN.q2 110110110100100100000110111111000001001	All.con	0001313322332133113023113312211103302331331233020001223332333
CN.Q2 110110110101001000100110111111000001001	1330 - 1399	0 1 2 3 4 5 6
ccN.q3 210120121012021110120011221222221110010122122	seq	MREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVANV
ccN.05 3203312320231311330231122332344432120131144134023013301023213431313 ccN.05 32033023202303033013001133134443202003004403430130033000132034303013 dcN.02 1000100100110010001100110010011011100000	cCN.Q2	11011011101001000110010000110111111010010011011100100110000
cr. con 32033023202303033013001133134443202003004403430130033000132034303013 dcN. q2 10001001001100110011001100110011001100	cCN.Q3	2101201210120211110120011221222221110010122122
dCN.Q2 10001001000110011000011001111000001100110110000	cCN.Q5	3203312320231311330231122332344443212013114413430230133010232134313133
dr. Q3 21011012101202112101100112201222211100100	cCN.con	3203302320230300330130011331344443202003004403430130033000132034303013
dCN.Q 320131232013131133013111133114344321301311441333111133110232134313112 dCN.con 310030131003030030000330043443103003004403330000033000131034303002 DT.Q2 111111111111111111111111111111111111	dCN.Q2	100010010001010011001000011001111100100
dCN.con 310030131003030030003300434431030030044033300003300131034303002 DT.Q2 111111111111111111111111111111111111	dCN.Q3	210110121012021121011001122012222211100100
DT.Q2 111111111111111111111111111111111111	dCN.Q5	3201312320131311330131111331143443213013114413331111133110232134313112
DT.Q3 111111111111111111111111111111111111	dCN.con	31003013100303003300330043443103003004403330000033000131034303002
DT.Q5 333333333333333333333333333333333333	DT.Q2	111111111111111111111111111111111111111
DT.con 333333333333333333333333333333333333	DT.Q3	111111111111111111111111111111111111111
GG.Q21101111110010100110111111111111111100000	DT.Q5	333333333333333333333333333333333333333
GG.Q3 22122122201202012212211112212222220100201222222	DT.con	333333333333333333333333333333333333333
GG.Q5 4323423431231412442242222442243444212113124423431110112111243244322112 GG.con 431342343013040144134222244234344430200302443343000002000243144312012 MST.Q2 111111111111111111111111111111111111	GG.Q2	11011111100101001101111111111111110100101
GG.con 43134234301304014413422224423434443020030244334300000020002	GG.Q3	22122122201202012212211112212222220100201222222
MST.Q2 111111111111111111111111111111111111	GG.Q5	4323423431231412442242222442243444212113124423431110112111243244322112
MST.Q3 111111111111111111111111111111111111	GG.con	43134234301304014413422224423434443020030244334300000020002
MST.Q5 11111011111101101211111101111111111111	MST.Q2	111111111111110111011111110111111111111
MST.con 222222222222222222222222222222222222	MST.Q3	111111111111101111012111110111111111111
RCH.Q2 110110110100110010011111111111100100100	MST.Q5	111110111111011101211111011111111111111
RCH.Q3 21022122112222222101111112222222222100101222222	MST.con	22222222222222222222222222222222222222
RCH.Q5 33443434304344433303333334444444443300333444444	RCH.Q2	110110111011010011001001111111110010010
RCH.con 331431343043242233013113344444444223003014444430130033000134244444444 RNG.Q2 1111111100101010111111111111111110000101	RCH.Q3	2102212211222222210111111222222222100101222222
RNG.Q2 111111110010101011111111111111111110000101	RCH.Q5	3344343430434443330333333444444444330033344444333330331103344444444
RNG.Q3 2111211110010101221121111221121100001012211210000011000121122101001 RNG.Q5 32223222211212123322322223322333211012123322321111122111232233212112 RNG.con 3222322200202023322322223322333200002023322320000022000232233202001 SA.Q2 0010010001100100100010000000101101100000	RCH.con	331431343043242233013113344444444223003014444430130033000134244444444
RNG.Q5 322232221121212332232223322333211012123322321111122111232233212112 RNG.con 3222322200202023322322322323320000202332232000002200023023	RNG.Q2	1111111110010101111111111111111110000101
RNG.con 322232220020202332232232333200002023322320000022000232233202001 SA.Q2 0010010011001001000100000001011011000000	RNG.Q3	2111211110010101221121111221121121100001012211210000011000121122101001
SA.Q2 0010010001101010010001000000010110100000	RNG.Q5	3222322221121212332232222332232333211012123322321111122111232233212112
	RNG.con	32223222002020233223222332232333200002023322320000022000232233202001
SA.Q3 01210210121010110021021110011000001112202100100	SA.Q2	001001000110101100100110000100000010110110000
	SA.Q3	01210210121010110021021110011000001112202100100

SA.Q5	0231032014313033003303323013300101232431430020014334411334202300131332
SA.con	0130031004303033003103311003100000131430430010004114400314101300030111
All.con	<u>3212312320131311330131122331233333212003013323330120022010232133313112</u>
1400 - 1469	0 1 2 3 4 5 6
seq	ELYYRAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNLF
cCN.Q2	011101101100010111011001011111011000001111
cCN.Q3	012202212220112012212210121222201200101222210220121012101210221022
cCN.Q5	0233133224302131333243133211314334302310202444421331132013202331343134
cCN.con	0233033134301030333143033100304334302300101444410330032003101310343034
dCN.Q2	01110110110000001101101100010111110110000
dCN.Q3	0121022112201110121122022101212222201200101222210220121012101210221022
dCN.Q5	1233133134311111233143133111313333313310211414311331133113211311343133
dCN.con	023303303430000013304303300030333330330010043430033003
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333333333333333333333333333333333333333
DT.con	333333333333333333333333333333333333333
GG.Q2	011111111100000111111111000101011110110
GG.Q3	02221221222000001221221220002021222122000002022102221221
GG.Q5	13432342344111112432442441113131344234111113133213422432243
GG.con	0343234234400000243244244000303034413400000303310343243124312431344244
MST.Q2	111101111101110111111011111111111111111
MST.Q3	011102111101111111101111111111111111111
MST.Q5	111102111111111111111111111111111111111
MST.con	122203222202220222202222222222222222222
RCH.Q2	1111011111100110111011001010111110110000
RCH.Q3	222202222201220222222210222222211200101222212221121012101222222
RCH.Q5	4443444443033303434444333034444443331030334444033333303330
RCH.con	444314444301330343244233102424444413300101344411331133013301442444244
RNG.Q2	011111111100000111111111000101011111110000
RNG.Q3	01221221122000001111221210001010121111000001011002211211
RNG.Q5	123223322331112122223323221121212332221120121221133223322
RNG.con	023323322330000022223323200020202332220000020220033223322322
SA.Q2	1000100000011101000100111010000010011011010
SA.Q3	1100200110021112100100100122010110021022122010012001100210121012000200
SA.Q5	4201300311043333201300300343131120031034343131033102300320133013000300
SA.con	3100300100043313100300300343030010030034143030033002300310031003000300
All.con	123313323330112023323313310131323331230010132331033113311
1470 - 1539	0 1 2 3 4 5 6
seq	ITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQYA
cCN.Q2	10000100100100100101101100100001101001111

cCN.Q3	11111101210120121121120220120010221211222222
cCN.Q5	3212230231033013213333133113101033132234434411201311331331021331243134
cCN.con	3101130130033003103133033003000033031134434400100300330330000330143034
dCN.Q2	10000100100100100101101100100001101001111
dCN.Q3	101111012101200211211102201100102212112221221
dCN.Q5	3111130131133013113113133113101133131134434311111311331331011331143134
dCN.con	300003003003003003023033003000033030034434300000300330330000330043034
DT.Q2	111111101110111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333313033303333333333333334043333333333
DT.con	3333323033303333333333333333043333333333
GG.Q2	1111110111011001001011011011000011011111
GG.Q3	2111121121122002001012022112000022122122
GG.Q5	4221232242234113113123144224111133243243334422111311442432111231244234
GG.con	4222231242134003003023044124000033143243334421000300442432000230244234
MST.Q2	111111011101111111111111011011011111111
MST.Q3	11111101110111111111111111201111110111111
MST.Q5	11111101111111111111111111101111111122111111
MST.con	2222202220222222222222302202202222223 <mark>3</mark> 222222202 <mark>3</mark> 20222222202 <mark>3</mark> 20222222202 <mark>3</mark> 20222222202 <mark>3</mark> 20222222202320232023202320232023202320
RCH.Q2	100001001001100111111101100100001101101
RCH.Q3	221111012102200222222112111001022222222
RCH.Q5	3333330333033003344443333133003033333444444433301303331333033330344344
RCH.con	3211130131033003344443133013001033233244444433100301330331021330144144
RNG.Q2	111111111111001001001111111100001111111
RNG.Q3	211112112112200100100112211200001112112221211010010
RNG.Q5	22222 <mark>3</mark> 2232233112112112233223111022232233323321211212332332111221233233
RNG.con	32222322322330020020223322300002223223332332
SA.Q2	0101001101100100100100110110100100100000
SA.Q3	011210210120022012011020021022120110110001001
SA.Q5	0333313303300431431321300330443301302300020133343133003103443113300310
SA.con	03131033033004303303103003304413003013000100331430330030034130033003
All.con	3121230131133003113123133113001033132233333321100301331331011230133133
1540 - 1609	0 1 2 3 4 5 6
seq	SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD
cCN.Q2	101000011001101110000001111111110110101111
cCN.Q3	11100101211220121010011222222222122121121
cCN.Q5	21310203321331343010124444444444442432433323333331334444443323320330230
cCN.con	20300103310330343000011444444444441431413321333330311444443323320330130
dCN.Q2	00000011001101110000001111111110110101110111010
dCN.Q3	111001012112201210000112222222221221212221122110211222222
dCN.Q5	11111113311331330111114444444444441431413331233231311444443313221331131

dCN.con	00000033003303300000044444444444444430403330233130300444443303320330030
DT.Q2	110001111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	330303333333333334433033333333333333333
DT.con	330103333333333333333323333333333333333
GG.Q2	1010000111111111000000111111111010101111
GG.Q3	201000022112212220000002222222122022020222122211020021222222
GG.Q5	3111111442244234311011133434432321331313442433221311332333433432432242
GG.con	3020000442244234300000033434432330330303442433220300333333433431431241
MST.Q2	111111011111011101110111111111111111111
MST.Q3	2121110221111011101111121121111011111111
MST.Q5	2111110121111011101111121121111211110111111
MST.con	3232220332222022202222322322232220222222
RCH.Q2	100000011001101110000011111111111011011
RCH.Q3	111001012112212210000122222222222222222
RCH.Q5	333013033333333301013344444444444444444
RCH.con	311001033113313330000134444444444444444
RNG.Q2	1010000111111111000000111111111010101111
RNG.Q3	2010000121122122100000011222211110110101211122110100111111
RNG.Q5	212111123223323321101112233332222122121232223322021122222232322232
RNG.con	30200002322332320000002233332222022020232223322000222222
SA.Q2	010111100010010011111000000000000000000
SA.Q3	1212112001100210021221200000010020010100011001120120
SA.Q5	132433410330031014343340000001101311313001300
SA.con	03143340013003000434332000000003003010001000104013000001030013003303
All.con	212001033213313330100113333333333331331333323332
1610 - 1674	0 1 2 3 4 5 6
seq	KLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM
cCN.Q2	010000000000000000011000111111111111111
cCN.Q3	010000000000000000221112222222222222222
cCN.Q5	131001000000000000333313444444444444444
cCN.con	030000000000000003311034444444444444444
dCN.Q2	010000000000000000011000011111111111111
dCN.Q3	010000000000000000121112222222222222222
dCN.Q5	1310010001000000010231111444444444444444
dCN.con	0300000000000000002300014444444444444444
DT.Q2	010100010000100111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	030300033000303444433333433333333333333
DT.con	030300031000301333333333333333333333333
GG.Q2	110001000100000000011000001111111111111

1211111110000000000000022220110111010111110111111
24222222221111110101210111333212212121111221212121
2 4 111211120000000001200000 <mark>3333</mark> 1221222120222221222222222002 <mark>3</mark> 0100
111111111111111111111111111111111111111
111111111111111111111111111112211111111
111111111111111111111111111111111111111
222222222222222222222222233222223232222323
010000000000000000011111111111111111111
011000000000000000222222222222222222222
131111011111000000033344444444444444444
030000000000000003344444444444444444444
111111111111100000001000011110101010101111
1211111111111000000010000111111011110101111
232222222222211100012111112222222222121222222
232222222222200000002000022221202212020222222
101111111111111111111111011110000000000
20222122222222222221112211000010000101011000000
303333343444444444433343431001100111111311101011110111131011144
303333343444444444443134331000000000000
131101011100100000023111223333233333323233333333

0 - 69	0	1	2	3	4	5	6
seq					ICIREKVGE		NDPSNPIRRPISADS
SA.Q2		<u> </u>				~ ~	111110111101000
SA.Q3							211221111102011
SA.Q5							334433332313131
SA.con							333431332303010
All.con							010002111130323
70 - 139	0	1	2	3	4	5	6
seq				-			AVYHWSMEGESOPVK
SA.Q2	00000111	000011111	00000011111	011010111	000010011	1000000110	00001011111011
SA.Q3							00101022222111
SA.Q5							00213144443132
SA.con							00103044443032
All.con	44433001	444411011	42432301101	1311303001	434413410	0244444014	44231300000311
140 - 209	0	1	2	3	4	5	6
seq	MFDRHSSL	AGCOIINYF	RTDAKOKWLLL		VGA <mark>MOLYS</mark> V		GHAA <mark>SFAOFKMEGN</mark> A
SA.Q2	00101110	 110100000	00111100000	000111110		1110010010	200000010101111
sa.g3	00211120	210100001	.01221100000	001222220	101010011	2221021020	010010010112222
SA.Q5	01333441	341300002	212443310000	003444430	302020112	444313113(010100030314444
SA.con	00313340	330300001	.01443300000	001444430	301010001	4441030030	00000030304444
All.con	43021003	003144442	232001134444	1442000004	142424332	0002303304	434334414130000
210 270	-						
210 - 279	0	1	2	3	4	5	6
210 - 279 seq				-			6 I <mark>SEKHD</mark> VVFLITKYG
	EESTLFCF.	AVRGQAGGF	_ KLHIIEVGTPP1	GNQPFPKKA	VDVFFPPEA	QNDFPVAMQ	
seq	EESTLFCF.	AVRGQAGGF 001111001	 .00000011111	CGNQPFPKKA	VDVFFPPEA 010001110	QNDFPVAMQ	ISEKHDVVFLITKYG
seq SA.Q2	EESTLFCF. 11010000 22010000	AVRGQAGGF 001111001 011122101	LHIIEVGTPP 00000011111 01001012122	CGNQPFPKKA L111101110 2221201211	VDVFFPPEA 010001110 010111121	QNDFPVAMQ 1100000000 1110000010	ISEKHDVVFLITKYG
seq SA.Q2 SA.Q3	EESTLFCF. 11010000 22010000 34120000	AVRGQAGGF 001111001 011122101 022344103	CLHIIEVGTPP1	CGNQPFPKKA 1111101110 2221201211 1443313331	VDVFFPPEA 010001110 010111121 121113443	QNDFPVAMQ1 1100000000 1110000010 3311000020	ISEKHDVVFLITKYG 001100000000100 012111000000110
seq SA.Q2 SA.Q3 SA.Q5	EESTLFCF, 11010000 22010000 34120000 34020000	AVRGQAGGF 001111001 011122101 022344103 012344003	CLHIIEVGTPP 00000011111 01001012122 01003134344 000001034344	CGNQPFPKKA 11111011100 22212012110 1443313331 14433033300	VDVFFPPEA 010001110 010111121 121113443 020003341	QNDFPVAMQ 1100000000 1110000010 3311000020 3300000010	ISEKHDVVFLITKYG 001100000000100 012111000000110 034313000000310
seq SA.Q2 SA.Q3 SA.Q5 SA.con	EESTLFCF, 11010000 22010000 34120000 34020000	AVRGQAGGF 001111001 011122101 022344103 012344003	CLHIIEVGTPP 00000011111 01001012122 01003134344 000001034344	CGNQPFPKKA 11111011100 22212012110 1443313331 14433033300	VDVFFPPEA 010001110 010111121 121113443 020003341	QNDFPVAMQ 1100000000 1110000010 3311000020 3300000010	ISEKHDVVFLITKYG 001100000000100 012111000000110 034313000000310 014301000000300
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con	EESTLFCF, 11010000 22010000 34120000 34020000 00314444 0	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1	CLHIIEVGTPP: .00000011111 .01001012122 .01003134344 .00001034344 .43442310100 .2	CGNQPFPKKA 11111011100 22212012110 1443313331 1443303330 0001031013 3	VDVFFPPEA 010001110 010111121 121113443 020003341 313331002 4	QNDFPVAMQ1 1100000000 3311000020 3300000010 1133444424 5	ISEKHDVVFLITKYG 001100000000100 012111000000110 03431300000310 014301000000300 420132444444134
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349	EESTLFCF, 11010000 22010000 34120000 34020000 00314444 0 YIHLYDLE	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF	LHIIEVGTPP .00000011111 .01001012122 .01003134344 .000001034344 .43442310100 .2 	rGNQPFPKKA 1111101110 2221201211 4443313331 4443303330 0001031013 3 20001031013 3	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS	QNDFPVAMQ 110000000 3311000020 3300000010 1133444424 5 VCVEEENII	ISEKHDVVFLITKYG 001100000000100 012111000000110 034313000000310 014301000000300 42013244444134 6
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq	EESTLFCF. 11010000 22010000 34120000 00314444 0 YIHLYDLE 00000000	AVRGQAGGF 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000	<pre>(LHIIEVGTPP) .00000011111 .01001012122 301003134344 300001034344 .43442310100 2 XISGETIFVTAH 000110000001</pre>	CGNQPFPKKA 1111101110 2221201211 1443313331 1443303330 0001031013 3 2 2001031013 3	VDVFFPPEA 010001110 010111121 121113443 020003341 313331002 4 VNRKGQVLS 001100000	QNDFPVAMQ 110000000 111000001 331100002 330000001 1133444424 5 VCVEEENIII 000111100	ISEKHDVVFLITKYG 00110000000100 012111000000100 034313000000310 014301000000300 42013244444134 6 PYITNVLQNPDLALR
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2	EESTLFCF, 11010000 22010000 34120000 00314444 0 YIHLYDLE 00000000	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111	LHIIEVGTPP .00000011111 .01001012122 .0000013134344 .00001034344 .43442310100 2 .002110000001 .00211000002	rGNQPFPKKA 111101110 2221201211 4443313331 4443303330 0001031013 3 PHEATAGIIG 111000000 2122211000	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS D01100000 D12211001	QNDFPVAMQ 110000000 3311000020 3300000010 1133444424 5 VCVEEENIII 000111100 0112222002	ISEKHDVVFLITKYG 001100000000100 012111000000110 034313000000310 014301000000300 42013244444134 6 PYITNVLQNPDLALR 100111011110011
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3	EESTLFCF. 11010000 22010000 34120000 34020000 00314444 0 YIHLYDLE 00000000 00000001 10000103	AVRGQAGGY 001111001 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113	LHIIEVGTPP .00000011111 .01001012122 .01003134344 .00001034344 .43442310100 .00211000000 .00211000002 .00211000002	CGNQPFPKKAV 11111011100 22212012110 1443313331 14433033300 2001031013 3 2001031013 3 201031013 1110000000 21222110000 23443320000	VDVFFPPEA 010001110 010111121 121113443 020003341 31331002 4 VNRKGQVLS 001100000 012211001 013313002	QNDFPVAMQ 110000000 111000001 331100002 330000001 113344442 5 VCVEEENII 000111100 0112222002 021344301	ISEKHDVVFLITKYG 00110000000100 012111000000100 014301000000310 014301000000300 42013244444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q5	EESTLFCF, 11010000 22010000 34120000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113	<pre>SLHIIEVGTPP: .00000011111 .01001012122 301003134344 .00001034344 .43442310100 2 SISGETIFVTAN 000110000001 .00211000002 .00211000002 .00430000003</pre>	rGNQPFPKKA 111101110 2221201211 4443313331 4443303330 0001031013 3 PHEATAGIIG 111000000 2122211000 3344332000 3344211000	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS D01100000 D12211001 D13313002 D03301001	QNDFPVAMQ 110000000 3311000020 3300000010 1133444424 5 VCVEEENIII 000111100 0112222002 0213443013 0103443003	ISEKHDVVFLITKYG 00110000000100 012111000000100 03431300000310 01430100000300 420132444444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con	EESTLFCF, 11010000 22010000 34120000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113	<pre>SLHIIEVGTPP: .00000011111 .01001012122 301003134344 .00001034344 .43442310100 2 SISGETIFVTAN 000110000001 .00211000002 .00211000002 .00430000003</pre>	rGNQPFPKKA 111101110 2221201211 4443313331 4443303330 0001031013 3 PHEATAGIIG 111000000 2122211000 3344332000 3344211000	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS D01100000 D12211001 D13313002 D03301001	QNDFPVAMQ 110000000 3311000020 3300000010 1133444424 5 VCVEEENIII 000111100 0112222002 0213443013 0103443003	ISEKHDVVFLITKYG 00110000000100 012111000000100 01430100000310 014301000000300 42013244444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023 300343043340023
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q3 SA.Q5 SA.con All.con	EESTLFCF, 11010000 22010000 34120000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001 34444342 0	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113 100000001 243344332 1	SLHIIEVGTPP .00000011111 .01001012122 .0000013134344 .00001034344 .43442310100 2 SISGETIFVTAN .00110000001 .00211000002 .00430000003 .33013444430 2	rGNQPFPKKAV 1111101110 2221201211 4443313331 4443303330 0001031013 3 PHEATAGIIGY 111000000 2122211000 3344332000 3344211000 0100122444 3	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS D01100000 D12211001 D13313002 D03301001 430032442 4	QNDFPVAMQ 110000000 3311000020 3300000010 1133444424 5 VCVEEENIII 000111100 0112222002 021344301 0103443003 4230000430 5	ISEKHDVVFLITKYG 00110000000100 012111000000100 03431300000310 01430100000300 420132444444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023 300343043340023 034101301103410
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419	EESTLFCF, 11010000 22010000 34120000 34020000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001 34444342 0 MAVRNNLA	AVRGQAGGY 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113 100000001 243344332 1 GAEELFARF	CLHIIEVGTPP CLHIEVGTPP CO0000011111 CO1001012122 CO00103134344 CO001034344 CO001034344 CO001034344 CO00100000 CO011000000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO01000000 CO01000000 CO01000000 CO01000000 CO0100000 CO01000000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO0100000 CO01000000 CO01000000 CO0100000 CO0100000 CO0100000 CO010000000 CO0000000 CO00000000 CO00000000 CO00000000 CO0000000000	CGNQPFPKKAV 1111101110 2221201211 1443313331 1443303330 0001031013 3 PHEATAGIIG 111000000 334432000 334432000 3344211000 0100122444 3 SEAAKVAANA	VDVFFPPEA 010001110 010111121 121113443 020003341 313331002 4 VNRKGQVLS 001100000 012211001 013313002 003301001 430032442 4 PKGILRTPD	QNDFPVAMQ 110000000 111000000 331100002 330000001 113344422 5 VCVEEENII 000111100 0112222002 0213443013 0103443003 4230000430 5 TIRRFQSVP2	ISEKHDVVFLITKYG 00110000000100 012111000000100 01430100000310 014301000000300 42013244444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023 300343043340023 034101301103410 6
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq	EESTLFCF, 11010000 22010000 34120000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001 34444342 0 MAVRNNLA 01110101	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113 100000001 243344332 1 GAEELFARF 000100010	SLHIIEVGTPP .00000011111 .01001012122 .0000013134344 .00001034344 .43442310100 2 .00211000002 .00211000002 .00430000003 .00430000003 .33013444430 2 .57NALFAQGNYS .00100111101	rGNQPFPKKAV 2212012110 22212012110 22212012110 22212012110 22212012110 20001031013 3 20001031013 3 20001031013 3 20001031013 3 20001031013 3 21222110000 21222110000 21222110000 21222110000 21222110000 21222110000 21222110000 21222100000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 2122210000 210000000 2122210000 210000000 210000000 210000000 2100000000 210000000 2100000000 2100000000 210000000 2100000000 2100000000 2100000000 2100000000 2100000000 2100000000 2100000000 2100000000 2100000000 21000000000 21000000000 210000000000	VDVFFPPEA 010001110 010111121 121113443 020003341 313331002 4 VNRKGQVLS 001100000 012211001 013313002 003301001 430032442 4 PKGILRTPD 111000111	QNDFPVAMQ 110000000 111000000 3311000020 3300000010 1133444424 5 VCVEEENIII 000111100 0112222002 021344300 0103443003 4230000430 5 TIRRFQSVP2 0011011013	ISEKHDVVFLITKYG 00110000000100 012111000000100 03431300000310 01430100000310 01430100000310 142013244444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023 300343043340023 034101301103410 6 AQPGQTSPLLQYFGI
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq SA.Q2	EESTLFCF, 11010000 22010000 34120000 34020000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001 34444342 0 MAVRNNLA 01110101 02111101	AVRGQAGGY 001111001 01122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113 100000001 243344332 1 GAEELFARF 000100010 101110111	CLHIIEVGTPP CLHIEVGTPP CO0000011111 CO1001012122 CO00103134344 CO00103134344 CO001034344 CO001034344 CO001000000 CO01000000 CO01000000 CO01000000 CO010010000 CO1000001 CO1200211102 CO120021102 CO120021102 CO120021102 CO120021102 CO120021102 CO120021102 CO120021102 CO120021102 CO1200212 CO1200212 CO1200212 CO1200212 CO1200212 CO1200212 CO1200212 CO1200212 CO120022 CO120022 CO120022 CO12002	CGNQPFPKKAV 22212012110 22212012110 22212012110 22212012110 2221201210 2001031013 3 2001031013 3 2122211000 2122211000 2100100010 2100100020 2100100020	VDVFFPPEA D10001110 D10111121 121113443 D20003341 31331002 4 VNRKGQVLS D01100000 D12211001 D13313002 D03301001 430032442 4 PKGILRTPD 111000111 212101112	QNDFPVAMQ 110000000 111000000 331100002 330000001 113344424 5 VCVEEENIII 000111100 0112222002 0213443013 0103443003 4230000430 5 TIRRFQSVP2 001101101 0021012122	ISEKHDVVFLITKYG 00110000000100 012111000000100 01430100000310 01430100000300 42013244444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023 300343043340023 034101301103410 6 AQPGQTSPLLQYFGI 11101110000000
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq SA.Q2 SA.Q3	EESTLFCF, 11010000 22010000 34120000 00314444 0 YIHLYDLF 00000000 00000001 10000103 00000001 34444342 0 MAVRNNLA 01110101 02111101 03433313	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113 100000001 243344332 1 GAEELFARF 000100010 101110111 303310233	SLHIIEVGTPP .00000011111 .01001012122 .0000013134344 .00001034344 .43442310100 2 SISGETIFVTAH .00110000001 .00211000002 .00430000003 .0043000003 .00430000003 .00430000003 .00430000003 .00430000003 .00430000003 .00430000003 .00430000000000000000000000000000000000	rGNQPFPKKAV 1111101110 2221201211 4443313331 4443303330 0001031013 3 PHEATAGIIG 111000000 2122211000 3344211000 0100122444 3 SEAAKVAANA 100100010 2100100020 4300300041	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS D01100000 D12211001 D13313002 D03301001 D13313002 4 4 PKGILRTPD 111000111 212101112 434312334	QNDFPVAMQ 110000000 111000000 331100002 330000001 113344442 5 VCVEEENII 000111100 0112222002 021344301 0103443003 4230000430 5 TIRRFQSVP2 001101101 0021012122 0033034244	ISEKHDVVFLITKYG 00110000000100 012111000000100 013431300000310 01430100000310 01430100000300 420132444444134 6 PYITNVLQNPDLALR 10011101110011 210121121120012 310343143341023 034101301103410 6 AQPGQTSPLLQYFGI 1101110000000 212121100010011
seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq SA.Q2 SA.Q3 SA.Q3 SA.Q3 SA.Q3 SA.Q5	EESTLFCF, 11010000 22010000 34120000 34020000 00314444 0 YIHLYDLE 00000000 00000001 10000103 00000001 34444342 0 MAVRNNLA 01110101 02111101 0343313 03331303	AVRGQAGGP 001111001 011122101 022344103 012344003 421100341 1 TGTCIYMNF 000000000 101000111 301100113 100000001 243344332 1 GAEELFARF 000100010 101110111 303310233 101300131	SLHIIEVGTPP .00000011111 .01001012122 .01001012122 .01003134344 .000001034344 .4344231010 .2 RISGETIFVTAH .000110000001 .00211000002 .01430000003 .01301344443 .01200211102 .0030133314 .0130033304	CSNQPFPKKAV 22212012110 22212012110 22212012110 22212012110 22212012110 2221201210 222120103 2001031013 3 21021031013 2100100000 2100100020 210010000040 2100100020 2100100020 2100100020 2100100020 2100100020 21001000000 21001000000 21001000000 21001000000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 21001000000 2100100000 2100100000 21001000000 2100100000 2100100000 21001000000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 21001000000 2100100000 21001000000 21001000000 2100100000 2100100000 2100100000 2100100000 2100100000 2100100000 210000000 210000000 210000000 210000000 210000000 210000000 2100000000 2100000000 2100000000 210000000000	VDVFFPPEA D10001110 D10111121 121113443 D20003341 313331002 4 VNRKGQVLS D01100000 D12211001 D13313002 003301001 430032442 4 PKGILRTPD 111000111 212101112 434312334 434101334	QNDFPVAMQ 110000000 111000000 331100002 330000001 1133444424 5 VCVEEENIII 000111100 0112222002 021344301 010344300 4230000430 5 TIRRFQSVP2 001101101 0021012122 0033034144	ISEKHDVVFLITKYG 00110000000100 012111000000100 01430100000310 01430100000300 42013244444134 6 PYITNVLQNPDLALR 100111011110011 210121121120012 310343143341023 300343043340023 034101301103410 6 AQPGQTSPLLQYFGI 11101110000000 212121100010011 434443300021031

seq	LLDQGQL	NKYESLELC	RPVLQQGRKQ	LLEKWLKED	KLECSEELGD	LV <mark>KS</mark> VDPTLA	L <mark>S</mark> VYLRANVPNKVIQ
SA.Q2	0011010	111000000	1000011111	001100111	1010011001	0011000100	000001010011001
SA.Q3	0022220	121100100	1100122112	001100222	2110112002	0012110100	010012021121001
SA.Q5	0143331	332100300	2000344223	003310444	31 4 1133 0 13	1034231300	020023142233003
SA.con	0043230	332000100	2000144223	003300444	3030033003	0034110300	010013041133003
All.con	4300103	101344244	1344200110	441134000	0303310430	3410223144	424420302201441
490 - 559	0	1	2	3	4	5	6
seq	CFAETGQ	VQKIVLYAK	KVGYTPDWIF	LLRNVMRIS	PDQGQQFAQM	LVQDEEPLAD:	ITQIVDVFMEYNLIQ
SA.Q2	0001111	011001001	1110110000	001000100	0110010011	0011110101	001001000101001
SA.Q3	0002111	021012002	1121121011	001100111	0210120011	0122221101	011001001212111
SA.Q5	0003333	133013104	3341343113	003300321	1430130021	1144444313	033003101424223
SA.con	0003333	033003004	3340341001	003100310	0430030022	0044441303	013003000414113
All.con	4440111	301430340	1103102332	441244123	3014304411	3300002131	421441343020221
560 - 629	0	1	2	3	4	5	6
seq	QCTAFLL	DALKNNRPS	EGPLQTRLLE	MNLMHAPQV.	A <mark>D</mark> AIL <mark>GNQMF</mark>	THYDRAHIAQ	LCEKAGLLQRALEHF
SA.Q2	0001000	100111111	1110001000	000111110	0100011100	0001011001	101111001101100
SA.Q3	1002000	200221222	2210001001	001111120	0210021210	1111112002	102212012101200
SA.Q5	3003001	310433344	4330013003	001333430	1310133421	3323133003	203433113203411
SA.con	1003000	300433344	4330003001	000333330	0300033410	1113033003	203433003203400
All.con	2440443	034001000	0014431442	443111004	3034301023	2221310440	140010330141033
630 - 699	0	1	2	3	4	5	6
seq	TDLYDIK	RAVVHTHLL	NPEWLVNYFG	SLSVEDSLE	CLRAMLSANI	RQNLQICVQV	ASKYHEQLSTQSLIE
SA.Q2	1101101	000010110	1110001001	101111001	0011001000	0100100010	001001100011001
SA.Q3	2211101	100010110	2120012001	212121102	0011102111	1100110020	011002201011002
SA.Q5	4413303	200031431	3340013103	413343213	1033003331	3300300030	023114313133003
SA.con	4403303	100030330	3340003003	403343103	0033003110	1300300030	013004301033003
All.con	0031141	244413013	0104430341	030101230	3411340223	2144134404	421330032311440
700 - 769	0	1	2	3	4	5	6
seq	LFESFKS	FEGLFYFLG	SIVNFSQDPD	VHFKYIQAA	CKTGQIKEVE	RICRESNCYD	PERVKNFLKEAKLTD
SA.Q2							011011001111011
SA.Q3	1022121	120001001	1012112112	010100100	0212112101	1001222011	121012001222121
SA.Q5	1034141	230012103	3124244333	001300300	0424313303	3003444123	143033103434133
SA.con	0034040	130001003	3 014134 333	000300300	0424303301	3003444013	043033003434033
All.con	3400303	204432341	1320200110	433144144	4010130142	1441000321:	301410341000301
770 - 839	0	1	2	3	4	5	6
seq	QLPLIIV	CDRFDFVHD	LVLYLYRNNL		KVNPSRLPVV		EDVIKNLILVVRGQF
SA.Q2	~			~ ~			110011001001110
SA.Q3							221011001101210
SA.Q5							431023003203431
SA.con							430023003103430
All.con							003411441241013

840 - 909	0	1	2	3	4	5	6
seq	STDELVA	EVEKRNR	LKLLLPWL <mark>E</mark> AR	IHEGCEEPAT	'HNALAKIYII	SNNNPERFLF	ENPYYDSRVVGKYCE
SA.Q2	1011001	1011110	01000100010	0111111100	0110010001	1111011001	101001110011001
SA.Q3	1022002	1012121	01001100221	0221121110	0110010002	21122021002	212101111012002
SA.Q5	3133 <mark>0</mark> 13	3033332	03002310332:	1444343330	0230030103	33443133103	414213331013114
SA.con	3033003	3033331	03001300231	0443343310	0230030003	3343033003	404103330023004
All.con	1300430	1410102	41442134102	3000101124	4114414340	01000301340	030231113410330
910 - 979	0	1	2	3	4	5	6
seq	KRDPHLA	CVAYERG	QCDLELINVCN	ENSLFKSLSF	YLVRRKDPEI	WGSVLL <mark>ESN</mark> F	YRRPLIDQVVQTALS
SA.Q2	1100000	0000111	10111001010	1000011000	0001111010	0110011101	.001100100010001
SA.Q3	2111100	0000211:	21122102111	1110011001	0002111120	0110022212	112100200010002
SA.Q5	3334300	1001333	413332 <mark>0</mark> 3131:	3101133102	101433323C	0330134433	123300310031003
SA.con	3311100	0000333	403331030303	3000033001	0004333130	0330034413	013300300030003
All.con	0122244	3443011	03100240313	1333311342	3430111204	4114300020	320144034413440
980 - 1049	0	1	2	3	4	5	6
seq	ETQDPEE	V <mark>SVTVK</mark> AI	FMTADLPNELI	ELLEKIVLDN	I <mark>SVFSEHRNL</mark> Ç	ONLLIL <mark>T</mark> AIKA	DRTRVMEYINRLDNY
SA.Q2	1111111	0010010	00101011000	1001100011	1101101100	0000000011	111100100110110
SA.Q3	2121121	0110011	01212012100	2002101121	2212211101	1000001021	112101200210220
SA.Q5	4343243	0130031	014341333013	3003301343	4314422303	33000000133	3243 <mark>0</mark> 2310331441
SA.con	4343243	0030030	00414033100	3003300143	4304412301	100000033	324301300330440
All.con	0101101	4314413	43020310243	0440143201	0030021142	2444443301	110142034013003
1050 - 1119	0	1	2	3	4	5	6
seq	DAPDIAN	IAI <mark>SNE</mark> L	FEEAFAIFRKFI	DVNTSAVQVI	IEHIGNLDRA	YEFAERCNE	AVW <mark>SQLAKAQLQKG</mark>
SA.Q2	1011001	0001110	01000100110	1111100100	0110110100	0100110111	100 <mark>010010001111</mark>
SA.Q3	1121002	0012121	02100100221:	2111200200	0211110210	01200210211	200 <mark>11001010222</mark> 1
SA.Q5	3143003	1014341	14301301331	4333300310	1331331420	02310331433	300 <mark>32003111444</mark> 3
SA.con	3043003	0004340	041003003304	4333300300	0330330410	01300330433	300 <mark>120030004443</mark>
All.con	1301440	3430103	30243143003	0111044034	3013113024	2034013011	.044 <mark>21441333000</mark> 1
1120 - 1189	0	1	2	3	4	5	6
seq	VKEAIDS	Y <mark>IKADD</mark> P:	SSYMEVVQAAN'	TSGNWEE LVK	YLQ <mark>M</mark> ARKKAF	RESYVETELIE	ALA <mark>KTNRLAELEEF</mark> I
SA.Q2	0110010	0010110	11011001001	1111011001	0010011111	1010001000	000101101100100
SA.Q3	0210020	021211	21012002102:	2121121002	0011022122	2110101000	000102102102200
SA.Q5	0330031	0031432	43133013203	4343133 <mark>00</mark> 3	0033034334	3130103000	000314313303301
SA.con	0330030	030431	43033003103	4343033003	0031034334	13030003000	000304303302300
All.con	401440 3	<mark>4</mark> 403012	01310430240	0101301440	4412400100	0314341444	444130130141043
1190 - 1259	0	1	2	3	4	5	6
seq	NGPNNAH	IQQVGDR	CYDEKMYDAAK	LLYNNVSNFG	RLASTLVHLO	GEYQAAVDGAF	KANSTRTWKEVCFAC
SA.Q2	1110001	0110011	00111101001	0001101101	1000000001	1011001001	101101001100000
SA.Q3	2111111	0220021	01222102001	1002102201	1001000102	21012002001	112102001100110
SA.Q5	4334313	1330033	024443131023	1003314413	3003000303	3033013003	314313003300310
SA.con	4331103	0330033	01444303002	0003304403	3001000103	3033003003	304303003300100

All.con	011223130044014200013034134401300311442444240141043044113013044	1144234
1260 - 1329	0 1 2 3 4 5 6	
seq	VDGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAIL	Y <mark>S</mark> KFKPQ
SA.Q2	011110100000010011011011001001111001000100100100101	0010111
SA.Q3	021210100110002001101101200111221110210020011002122211100010000	0021212
SA.Q5	143331310320014113313303300312333411330030033014244442300030000	1031324
SA.con	04333030011000400330330330030133330031003003100414443110001000	0030324
All.con	301013134224430331131141044132001033024404412430200002244424444	3403010
1330 - 1399	0 1 2 3 4 5 6	
seq	KMREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKD	II <mark>TKV</mark> AN
SA.Q2	100100110011010100100110000100000110110	0001000
SA.Q3	101210210021010210021011110021000001112202100100	000 <mark>2</mark> 011
SA.Q5	302310320143131330032033230133001013324314300210143344124342023	0013133
SA.con	301300320043030330031033110031000003314304300200041144014141013	0003011
All.con	142034014301313014402411224302443431120030144134302200320202420	4430322
1400 - 1469	0 1 2 3 4 5 6	
seq	VELYYRAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSV	NESLNNL
SA.Q2	010001000000111010001001001101000001001	0100010
SA.Q3	111002001000211121001001001220111100210221220100120011002101210	1200020
SA.Q5	232013003110433131013003003431311200320343431310331023003201330	1300030
SA.con	131003001000433030003003003430300100310341430300330023003100310	0300030
All.con	212430442334011303431441441003133244024002003134103411440243024	3044404
1470 - 1539	0 1 2 3 4 5 6	
seq	FITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSL	YKDAMQY
SA.Q2	0010100110110011011010010011011010010000	0110010
SA.Q3	0011210210120022012011020021022120110110	0210020
SA.Q5	003333133033004314313213003304433013023000201333431330031034431	1330031
SA.con	003131033033004303303103003304413003013000100331430330030034130	0330030
All.con	441202301410440030031230440140020431421444243112013014403410203	3014403
1540 - 1609	0 1 2 3 4 5 6	
seq	ASESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVM	KEYLTKV
SA.Q2	001011110001001001111100000000000000000	0100110
SA.Q3	01212112001100210021221200000010020010100011001120120	1200210
SA.Q5	0132433410330031014343341000001101311313001300	2311330
SA.con	0031433400130030004343320000000030030100010001040130000010300	1300330
All.con	430201103421440343010011344444334303313244323442303203434424133	2033014
1610 - 1675	0 1 2 3 4 5 6	
seq	DKLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGY	SM
SA.Q2	110111111111111111111111011110000000000	11
SA.Q3	2202221212222222222111221100001000101011000000	22
SA.Q5	33033333343444444444433343431001100111111311101011111111	44

SA.con	330333334344444444443134331000000000000
All.con	0040001010000000000012100023443344333333323334343333333333

10-Appendix IV

ICOS 3D prediction software results for *murine* CHCα. The first table shows the analysis of the 2D and 3D rearrangements, point of contact of adjacent aa and their exposure to the solvent. In the second analysis, only the exposure to the solvent is taken into account. The region highlighted in yellow refers to the epitope of the mAb clone X22. The 'All.con' bottom row gives a final score for all the parameters taken into account by the analysis.

0 - 69	0	1	2	3	4	5	6
seq	AQILPIRFQ	EHLQLQNI	GINPANIGES	TLTMESDKFI	CIREKVGE	QAQVVIIDMN	DPSNPIRRPISADSA
cCN.Q2	000111111	11101001	.0100011010	<u>1111110111</u>	11110000	0111111110	000011110101111
cCN.Q3	001222121	22212111	1200012121	1222121122	22221100	1122222221	011121111212122
cCN.Q5	113344343	43423113	1311134143	3444343344	44341200	1334444441	113133333314444
cCN.con	001344343	43413003	0300034041	3444341344	44340100	0334444440	001033331304344
dCN.Q2	001111111	11101001	.0100011010	0111110111	11110000	0111111110	000010110101011
dCN.Q3	001222121	22212112	1201012121	1212121122	22221100	1112222221	011121121212222
dCN.Q5	111344343	44413113	1311113131	1434111344	44431111	1334444441	111132131314144
dCN.con	002344343	44403003	0300023030	0434230344	44430000	0334444440	000031230304144
DT.Q2	111111111	11111110	1011111111	11111 <mark>0</mark> 1111	11110001	0011111111	111111111110111
DT.Q3	111111111	11111111	.1111111111	1111111111	11111112	1111111111	11111111111111111
DT.Q5	433333333	33333330	3043433334	3333334333	33330004	00333333333	033333333340433
DT.con	333333333	33333330	3033333333	3333313333	33330004	00333333333	233333333330330
GG.Q2	000111011	11101001	.0100011010	1111110011	11110000	0011111110	000010000101011
GG.Q3	000222121	02202001	.0200002010	0212000122	22200000	001222220	000000010201012
GG.Q5	001334242	13313112	0 <mark>311013</mark> 121	1324111234	34321100	1124444341	101111121 <mark>313</mark> 123
GG.con	000334142	13303002	0300013020	1324110134	34320000	0024444340	000010010 <mark>303</mark> 023
MST.Q2	011111111	11111111	1101111111	1111111111	111111111	1111111111	11111111111111111
MST.Q3	011111111	11111111	1101111111	1111111111	21111111	1111111111	111111111112112
MST.Q5	011111111	11111111	1201111111	1111111111	21111111	1111111111	111111111112112
MST.con	022222222	22222222	2202222222	22222222222	32222222	2222222222	222222222222 <mark>3</mark> 22 <mark>3</mark>
RCH.Q2	000111110	11101001	.0100011010	1111100111	11100000	0011111110	000011110101111
RCH.Q3	000222221	22212221	0101012122	22222222222	22210100	0112222220	011122212202222
RCH.Q5	00144443	44443443	4300033144	4444444444	44431300	0333444430	<mark>0</mark> 333333334 0 4444
RCH.con	000444441	44413223	1300033042	4444422444	44410100	0133444430	011133332404444
RNG.Q2	000111111	11101001	.0100001010	0111110011	11110000	0011111110	000010000101011
RNG.Q3	000122121	11101001	0100011010	0212110022	22210000	0012222110	000010000101012
RNG.Q5	001233232	22212112	0201022121	2323221133	33321100	1223333221	11112111121212 <mark>3</mark>
RNG.con	000233232	22202002	0200012020	0323220033	33320000	0023333220	000020000202023
SA.Q2	111000101	00010110	1011100101	0000101100	00001111	1110000001	111101111010000
SA.Q3	222000101	10020221	2022210202	10101 <mark>22</mark> 100	00112122	2110000002	11 <mark>22</mark> 11111020110
SA.Q5	444101303	11130341	4134431314	3030344310	00123344	4220000103	344333323131310
SA.con	444000303	00030340	4034410304	1010324300	00013344	4220000003	3343 <mark>1</mark> 3323 <mark>030100</mark>
All.con	001333232	33313112	21201023131	2333221233	33320100	0123333331	<mark>011121221313233</mark>
70 - 139	0	1	2	3	4	5	6
seq	IMNPASKVI	AL <mark>K</mark> AG <mark>KT</mark> I	QIFNIEMKSK	MKAHTMTDDV	TFWKWISL	NTVALVTDNA	VYHW <mark>SMEGESQ</mark> PVKM
cCN.Q2	111100111	11110111	1111100001	1111010011	11111100	0111111111	111111000001111
cCN.Q3	222211122	22211112	2221201101	2112121112	22222211	1222222112	222212100112122
cCN.Q5	444421344	44331324	3443311112	3334231324	4444432	2344444334	444434100013334
cCN.con	444410344	44330324	3443300002	3334130124	4444411	1344444334	44443400003334

	I
dCN.Q2	11110011111100011111110000111111010001111
dCN.Q3	222211222222111122221201101211212111222222
dCN.Q5	44431134444311224344131111333413111444434311134444411444342311113334
dCN.con	4443003444430012434423000023334030004444343000344444024443423000003334
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	33333333333333333333333333333333334443333
DT.con	333333333333333333333333333333333333333
GG.Q2	1111000111110000111111010001010100011111
GG.Q3	2211001222210001212202010002012020002222122000122222001222212000002112
GG.Q5	4332112443421112424314121113213131114343234101243443112443423100012224
GG.con	4332001443420001424314020003003030004343234000243443012443413000003224
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111111111211111111111111111111111111111
MST.Q5	111111111211111111111111111111111111111
MST.con	222222223222222222222222222222222222222
RCH.Q2	1111001111100001111111000011011010001111
RCH.Q3	2222222222210112222220110122122221222222
RCH.Q5	44444444444433033344443033133343444344444444
RCH.con	444422444442101334444301103323324212444444101344444224444423000103334
RNG.Q2	1111000111110001111101010001011010001111
RNG.Q3	221100022221100121220101000101201000212212
RNG.Q5	3322111333321112323312121112123220113233232101233333123332322110113223
RNG.con	332200033332000232330202000202302000323323
SA.Q2	000011100001111100000011111010101100001001110000
SA.Q3	00002210000112110100102112101102022100001001
SA.Q5	0011433000033433030131333421331314330100210343200000430002131444431320
SA.con	0000433000033433010010333420330304330000200343100000430001030444430320
All.con	3333112333321112333323011013123131113333233111333333123333323100013223
140 - 209	0 1 2 3 4 5 6
seq	FDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNAE
cCN.Q2	101000101111111110001111111110000111111
cCN.Q3	212111212222222211011222222211001121222222
cCN.Q5	433203333434444343113344444433001243434344431112434444444444
cCN.con	41310131343444434300134444443300014343434444300024144144444444341300000
dCN.Q2	1010001011111111000011111111100000111111
dCN.Q3	212111211222222210011222222211001121222222
dCN.Q5	41311141143444433111134444443111114343434343311133144144
dCN.con	4030004024344443300003444444430000043434343
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111

[
DT.Q5	33333333333333333344303333333034403330333333
DT.con	333333333233333333333333333333333333333
GG.Q2	10100010010111111000001111111100000101111
GG.Q3	201000200212222121000022222220000002121212211000000
GG.Q5	3121113113244332320011344433411001132324243221111112312222133142300101
GG.con	3020003003144332310000344433410000031324243220001102302232133041300000
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111111111111111111111111111111111111111
MST.Q5	111111111111111111111111111111111111111
MST.con	22222222222222222222222222222222222222
RCH.Q2	1011101001111111100000111111110000011111
RCH.Q3	2222221222222210011222222211000022222222
RCH.Q5	4333343444444444330033444444330001334444443301033344444444
RCH.con	4233323124444444310011444444310000334444433000132442444444232300000
RNG.Q2	1010001001111111110000111111110000011111
RNG.Q3	20100010021222212100002222222100000212121221100011011
RNG.Q5	31211121122332322200113333333210011323232333220111212212222223232201101
RNG.con	302000200323333232000033333320000032323233322000020222222
SA.Q2	01011101101000000011110000000011111010000
SA.Q3	02111202101000010122110000000122222010101001122210210
SA.Q5	1333441341300002124433100000034444303020201124443131130101000303144443
SA.con	031334033030000101443300000001444430301010001444103003000000303044443
All.con	313111311323333332001133333321000132333333320002313313333333231300000
210 - 279	0 1 2 3 4 5 6
seq	ESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY
cCN.Q2	011111111000111111111000000101101111111
cCN.Q3	1222222221112212222221000001112111222222
cCN.Q5	144444443333343444444110000133333344444433133344444443124444444444
cCN.con	044444443111343444444200000031331344444432031144444443024444444444
dCN.Q2	011111111000111111110000000101001111111
dCN.Q3	122222222111221222221000000112212222222110111222222
dCN.Q5	13344444331113424444141111111132133444341111114444443411144444444
dCN.con	03344444330003424444340000000203103344434000200444444340004444444444
DT.Q2	101111111011001111111111001111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	40333333303300333333044340433333034333344333333
DT.Q5 DT.con	40333333303300333333044340433333034333344333333
DT.con	30333333303300333333233330133333233333333
DT.con GG.Q2	30333333330033003333333233330133333233333333

MST.Q2 111111111111111111111111111111111111		
MST. Q5 1111112111121111211111111111111111111	MST.Q2	111111111111111111111111111111111111111
MST.con 2222223222223222223222222222222222222	MST.Q3	111111112111112111111121111111111111111
RCH.Q2 01111111100011111110000000101111111111	MST.Q5	111111121111121111111111111111111111111
RCH.03 012222221211222222221000000102122222222	MST.con	222222322222322222232222222222222222222
RCH.Q5 1334444443334444443300000333334444444444	RCH.Q2	011111111100011111110100000001011111111
RCH.con 0334444443211444442310000003333444444441323444444420134444444444	RCH.Q3	0122222221211222222221000000102212222222
RK 0.2 0111111110000111111000000000000000000	RCH.Q5	13344444433334444444330000003333334444444
RNG.03 0112222211000011212201000000001001201110001001	RCH.con	0334444443211444444231000000303334444444413234444444320134444444444
NR.0 O2233332211112232332211000111121112312121002111223332320122333322223 RNG.con 02233333200002232330200000000002000230202000200123333322021333331223 SA.02 101000001110010000001111111101100000110110000	RNG.Q2	0111111111000011111101000000000100011010
RN.c.on 0223333220000233330200000000200023020200020122333230200133333123 SA.Q2 10100000111001000001111111011000000000	RNG.Q3	01122222110000112122010000000010001201110001000112221210011222222
SA.Q2 101000001111010000001111111100100011011	RNG.Q5	0223333322111122323322110001111211123121210021112233323201223333322223
Comparison Comparison SA.Q3 201000001122101010010121222212012110111112111000000	RNG.con	0223333322000022323302000000000200023020200020012233323200213333331223
SA.Q5 41200002234411301003134344443313331121113443331100002034313000000300 SA.con 4020000123400300010343444433033002000334133000000114301000003000 All.con 1223333321112323332310000021311223232311121233333310132333332333 280 - 349 0 1 2 3 4 5 6 seq IHLYDETGCTYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIFYTTNULQNPDLALRM CCN.Q2 111111111111100111110001011111100001101100110000	SA.Q2	101000000111100100000011111111011100100
A. con 40200001234400300010343444433033002000334133000001014301000003000 All.con 12233333211222333323100000213112232323111211233333331013233333333	SA.Q3	201000001112210101001012122221201211010111121111000001012111000000
All.con 122333332112323333231000000213112232323111211233333331013233333333	SA.Q5	412000002234411301003134344443313331121113443331100002034313000003101
280 - 349 0 1 2 3 4 5 6 seq IHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIFYITNVLQNPDLALRM cCN.Q2 111111111111111111110011111100000111111	SA.con	402000001234400300001034344443303330020003341330000001014301000003000
seq THLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALMM cCN.Q2 1111111111111111111111001111110000111111	All.con	122333333211123233332310000002131122323231112112333333310132333333233
ccN.q2 111111111111111001111110000011111110000110110000	280 - 349	0 1 2 3 4 5 6
CN.Q3 2222222222222222222222222222221001222222	seq	IHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALRM
cCN.Q5 4444444444444444331344444110034444441133444442101331331023011033113 cCN.Q5 44444444444444443430144444400001344444400334444441000330330023000033003 dcN.Q2 111111111111111001111110000011111110000110110000	cCN.Q2	111111111111111111100111111000001111111
CCN.con 4444444444444433014444400001344444000334444441000330330023000033003 dcN.Q2 11111111111111100111111000001111110000011011000100011001 dcN.Q3 222222222222222222222222222222222222	cCN.Q3	22222222222222222222222222222110011222222
dCN.Q211111111111111111001111110000011111110000	cCN.Q5	444444444444444444343134444441100344444411334444442101331331023011033113
dcn.q3 222222222222222222222222222222222222	cCN.con	444444444444444444444444444444444444444
dCN.Q5 4444444444333431144444411111144444311324444331111331331112011033213 dCN.con 44444444443334301444440000024444430032444433000330330002000033103 DT.Q2 111111111111111111111111111111111111	dCN.Q2	111111111111111111001111110000011111111
dCN.con 4444444444333430144444400000244444300324444330000330330002000033103 DT.Q2 111111111111111111111111111111111111	dCN.Q3	222222222222222222222222222222222222222
DT.Q2111111111111111111111111111111111	dCN.Q5	444444444444333431144444411111144444311324444331111331331112011033213
DT.Q3 111111111111111111111111111111111111	dCN.con	4444444444444333430144444400000244444300324444330000330330002000033103
DT.Q5 333333333333333333333333333333333333	DT.Q2	111111111111111111111111111111111111111
DT.con 3333332333333333333333333333333333333	DT.Q3	111111111111111111111111111111111111111
GG.Q2 111111111111111001111110000000111110000110111010	DT.Q5	333333303333330443333334444303333334333333
GG.Q3 222212002122210121001222220000000222210010222212000022022	DT.con	333333323333333333333333333333333333333
GG.Q5 4344231132343212321124443311001124434211214434231011431342122111143323 GG.con 434423113234321232002444330000004434200104434230000430342022000043323 MST.Q2 111111111111111111111111111111111111	GG.Q2	1111111111111111111001111110000000111111
GG.con 434423113234321232002444330000004434200104434230000430342022000043323 MST.Q2 111111111111111111111111111111111111	GG.Q3	222212002122210121001222220000000222210010222212000022022
MST.Q2 111111111111111111111111111111111111	GG.Q5	4344231132343212321124443311001124434211214434231011431342122111143323
MST.Q3 1111111211111111111111111111111111111	GG.con	434423113234321232002444330000004434200104434230000430342022000043323
MST.Q5 111111111111111111111111111111111111	MST.Q2	111111111111111111111111111111111111111
MST.con 2222222322222222222222222222222222222	MST.Q3	111111112111111111111112011111211211121
RCH.Q2 1111111111111111001111110000011111110001111	MST.Q5	1111111121111111111111120111112112111111
	MST.con	2222222322222222222223022222322223222222
RCH.Q3 222222222222222222222222222222222222	RCH.Q2	11111111111111111100111111000001111111001111
	PCH 03	2222222222222222222222222222222200001222222

RCH.Q5	444444444444444444444444444444444444444
RCH.con	444444444444444444444444444444444444444
RNG.Q2	111111111111111111001111110000001111111
RNG.Q3	22221111111111110012221100000012222100112212110000110121111000012111
RNG.Q5	3333 221222232222112 33 3220100112 333 321122 33 232211012212222221101 33 222
RNG.con	3333 222222222222222222222222222222222
SA.Q2	00000000000000000011000000011100000000110000
SA.Q3	000000110100011100211000002122211000012211001011222200210121121
SA.Q5	0000103301100113114310000133443320000133130020213443013103431433410230
SA.con	0000001100000001004300000033442110000033010010103443003003430433400230
All.con	333333233333332321133333301001133333311323333331100331331122000033213
350 - 419	0 1 2 3 4 5 6
seq	AVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGIL
cCN.Q2	0000010010011100100110000100110111010001110001100100100100101
cCN.Q3	01110201210121112102201101002212221200012111022012101001111122221221
cCN.Q5	1121030231033312311331111311341343131103311213312310211313133444333333
cCN.con	0010030130033301300330000300340343030003320103301300200103033444333133
dCN.Q2	000001001000110010011000010011011101000111000110010010000
dCN.Q3	00110201200121112102201101002212221101012111021011101001121112221221
dCN.Q5	1111131131123211311330111311331343131112311103311310211111121444233133
dCN.con	0000030030013200300330000300330343030002320003300300200003010444233033
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333333333333333333333333333333333333333
DT.con	333333333333333333333333333333333333333
GG.Q2	0110010111111111111100001001111110100011000110111010
GG.Q3	101002112212221121122000020122122201000120000221221
GG.Q5	2122032242234323422441111312442443121112321113423421201110111344344234
GG.con	112003124323432342244000030144244302000230000341342020000000344344234
MST.Q2	111111111111111111111111111111111111111
MST.Q3	11111101211111111111111012211211111110111111
MST.Q5	111111111111111111111111111111111111111
MST.con	222222123222222222222222222222222222222
RCH.Q2	00000101110111110011000010011011101000110000
RCH.Q3	0111020222222222112211101012212221201022110022112011001111222222
RCH.Q5	1333031343434433433334330301343444430303333303333330301333344444444
RCH.con	0111030343234433411331110300341444130103311003313300100111144444444
RNG.Q2	111001011111111111111000010111111101000110000
RNG.Q3	1110010121112111211220000101221221010001100002211100100
RNG.Q5	222112123222322321111212332332120112211112322211201111111233233223
RNG.con	222002023222322322330000202332332020002200003322200200

a	
SA.Q2	
SA.Q3	211110110111011101200211102100100020212101112002101212212
SA.Q5	33331330331023303301333143003000414343123340033034244344433000210310
SA.con	<u>3333303101300131013003333043003000404341013340033034144341433000100100</u>
All.con	1111031232123322321331110301331333120102311103312310200111011333333223
420 - 489	0 1 2 3 4 5 6
seq	LDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKVIQC
cCN.Q2	1000010011111110111000000110011000010110011011011101111
cCN.Q3	10001200122212212210011022012100011022012102200122122
cCN.Q5	3010131133343443443201120331233001131331133033103441443334213133134334
cCN.con	30000300333434414431000103301330000303300330
dCN.Q2	100001001111011011100000011001100001011001101100101
dCN.Q3	1000020011221221221000102201210001202210210
dCN.Q5	3011131122331441333111121331133001131331132133112131444133113121114314
dCN.con	3000030022330440333000010330033000030330032033002030444033003023004304
DT.Q2	111001111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333003333333333333333333333333333333333
DT.con	333003333333333333333333333333333333333
GG.Q2	100001001111111110000101111110000101000110110000
GG.Q3	200001001222122222000010221122000020110022022
GG.Q5	3111131123343443334111121442244111131321143143112131444344313012124424
GG.con	3000030023343443334000020442244000030310043043001030444344303010024424
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111111111111111111111111111111111111111
MST.Q5	111111111111111111111111111111111111111
MST.con	222222222222222222222222222222222222222
RCH.Q2	100001001111111111000000110111000011110011011001111
RCH.Q3	200011112222222222211011022112100111022002102200222222
RCH.Q5	301313013444444444333033034333300133333333
RCH.con	30000300344444444431101103413330001323300330330034344444444413013034444
RNG.Q2	10000100011111111110000011111100001010001111
RNG.Q3	10000100011212211211000002211220000101100221210000102221221
RNG.Q5	2111121112232332232210111332233111121211132232111121333233213121123323
RNG.con	20000200022323322322000003322330000202000332320000203332332
SA.Q2	0110101110000001000011111001100111101001100100100010000
SA.Q3	0222201211001001100122112001100222211011200200
SA.Q5	1433313321003002000344223003310444313113301310342313000200231422330030
SA.con	0432303320001002000144223003300444303003300300341103000100130411330030
All.con	30000311233323323331101103311330011313201320

seq	FAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQQ
cCN.Q2	110000100110110000100111011001101110011011011011011011011011011010
cCN.Q3	2211102002102200102122221221122112201210221221
cCN.Q5	4312013013313301113244432332233131301331342233000033414113313330201212
cCN.con	4301003003303300003124431331133033300330341333000033404303303330200202
dCN.Q2	1100001001101100001001110110011011100110110110000
dCN.Q3	2201101002102101102122221221122112201210221121000021212012201210101101
dCN.Q5	431111311321331111311133133113313311321341133000132413313313321211211
dCN.con	430000300320330000301333033003303300320340233000031403203303320100202
DT.Q2	1110001101111111111111111111111111001111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333330333333333333333333333333333333333
DT.con	3331103313333333332333333333333333332113333333
GG.Q2	1100001001111100001001111111110101011111
GG.Q3	221101201221220000100022122112212120122122
GG.Q5	4412124124324411112111332442244122312432443343100011314124424431212312
GG.con	4401014014324400002001332442244031302432443343000000304024414430302302
MST.Q2	11011110111011011011111111111111111101111
MST.Q3	1101111111011011111111111101111110121012111111
MST.Q5	1111111111011011111111111101111110121112111111
MST.con	22022220220220222222222222222222222222
RCH.Q2	110100100110110000100111111111111001101111
RCH.Q3	222111200210210110122222222222222201210222221000011222222
RCH.Q5	444431301331331330334444443444343430333144443300003344444444
RCH.con	44231030033033011032244444344434443301330444433000033424424424432201314
RNG.Q2	1111001011111110001000111111111010101111
RNG.Q3	22010010121122100010001112211210101012112211110000101010122122
RNG.Q5	3312112123223321102111222332232122212322332222100021212123322321202212
RNG.con	33120020232233200020002223322320202023223322220000202020233233
SA.Q2	001111011001001111011000000100010001100100110011001111
SA.Q3	00211102101200211211210110011001110210120011012222110101100100
SA.Q5	0033331430131043341343113003300311143013002101444433130330031014242233
SA.con	0033330430030043340341001003100300043003002200444413030130030004141131
All.con	3311103013213301102112332332233132301321332232000021313223313331201212
560 - 629	0 1 2 3 4 5 6
seq	CTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHFT
cCN.Q2	110111011000000000111011011000001101110001111
cCN.Q3	22022101200000001222122121010002101220101222101102201200102101210110
cCN.Q5	331333133111100101333333333111013313431113443313113312310203302320330
cCN.con	330333033000000003331331333000003303430003443303003301300103301310330
dCN.Q2	1101110110000000001110110110000011011100011011010

dCN.Q3	22022101100000000222122122101000220122010122110110
dCN.Q5	3313331331111001113331331331111133123311124122131133113
dCN.con	33033303300000000333033000003302330002412203003300300003200300330
DT.Q2	111111111111011101111111111100101111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	3333333333404440333333333330433330333333
DT.con	333333333333303330333333333331031333233333333
GG.Q2	111111111000000000111111111000001111110001111
GG.Q3	2212221220000000022212212220000022122200012010020122122
GG.Q5	4324432441101000124333442433111114323441112311213224423421224323321320
GG.con	432443244000000004333442433000004323440002312003014413420104303330320
MST.Q2	110111111111111111111111111111111111111
MST.Q3	211111111110112111111111111111111111111
MST.Q5	211111111111111111111111111111111111111
MST.con	320222222222222222222222222222222222222
RCH.Q2	110111011000000000111111111000001101110001111
RCH.Q3	2212222200000010122222222010002222222112222202101201110102101210110
RCH.Q5	4444443310000001334444444313100344444343434443133133033303
RCH.con	44144423300000001344444443010003424442113444303103301310103303310330
RNG.Q2	111111111000000000111111111000001111110001111
RNG.Q3	221221112000000001111221211000002112210001111001012211210101111210110
RNG.Q5	322332233110100111222233232111113222321102212112123322321212222321220
RNG.con	33233223300000000222233232000003223320002222002023322320102222320220
SA.Q2	0010001001111111110001000000111110010001110000
SA.Q3	00200020022122222100010010011111200210021210111111
SA.Q5	0030013104433444330003003101333430131013342133231330032034331132034114
SA.con	0030003004433444330003001000333330030003341011130330032034330032034004
All.con	331333133000000013332332333110003313331112322213113312310103212320220
630 - 699	0 1 2 3 4 5 6
seq	DLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIEL
cCN.Q2	0100111111010010001100110010000110110010000
cCN.Q3	020121122212112010221012001010111022101201111122122
cCN.Q5	1311323343231231113320331130201321331033112212331343133213201333113303
cCN.con	0300323343130130003310330030100320330033001101330343033103200333003303
dCN.Q2	0100101111010010001110110010000110110010000
dCN.Q3	0101212222121120102210120010101110221012011111220122122
dCN.Q5	1311311443131131113321331131101220331023111111331343133113301313113303
dCN.con	0300303443030030003320330030002203300230000033034303300330
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	433333333333333433333330330343333333300033033

DT.con	333333333333333333333333332332332333333
GG.02	0100111111010010001110110010001110111011101111
GG.Q3	01002222220100200222022001000122122112211211
GG.Q5	12114334421211311134313411312123323422342
GG.con	020043344302003000343034003000233134213412232244244243334300303014414 1111111111111111111111
MST.Q2	
MST.Q3	111111111111111111111111111111111111111
MST.Q5	111111111111111111111111111111111111111
MST.con	222222222222222222222222222222222222222
RCH.Q2	010011111111101000111011001000011011001001001101100010000
RCH.Q3	0101212222222200022212210101022102212221112112
RCH.Q5	0303344444443313044344430303033313433331333334434433443
RCH.con	030133444444230004431441030102330341233011311441443144113300333013303
RNG.Q2	010111111101001000111111001000111111111
RNG.Q3	0100211211010010001211110010001111221112111112211211
RNG.Q5	1211322322121120113322221121112222332223222
RNG.con	0201322322020020003322220020002222332232222233223322322
SA.Q2	1011010000101101110001001101111001001100110000
SA.Q3	2111011000101102120012001212121102001110211111001100200110022010110020
SA.Q5	4133032001314313340013103413343213103300333233103000300231143121330131
SA.con	40330310003033033400030034033431030033003
All.con	02013233331311301033213310201022213311331
700 - 769	0 1 2 3 4 5 6
seq	FESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQ
cCN.Q2	10010110011111001101100001110110110100100100110000
cCN.Q3	20010210122122102101001101221221221010010
cCN.Q5	3103133133323331331301110333244234312013023313310013313013212310113113
cCN.con	3003033013323310330310000333144134302003013103300003303003102300003003
dCN.Q2	10010110011111001101100001110110110000100100100110000
dCN.Q3	20010210122112102101000101211221222010010
dCN.Q5	
	311313311332231133123111133314313431111211311331111331101311331011311
dCN.con	311313311332231133123111133143134311112113113311113311013113310113111 300303300332230033022000033304303430000200300330000330000300300030
dCN.con DT.Q2	
	300303300332230033022000033304303430000200300330000330000300300030
DT.Q2	300303300332230033022000033304303430000200300330000330000300300030
DT.Q2 DT.Q3	300303300332230033022000033304303430000200300330000330000300300030
DT.Q2 DT.Q3 DT.Q5	300303300332230033022000033304303430000200300330000330000300300030
DT.Q2 DT.Q3 DT.Q5 DT.con	3003033003322300330220000333043034300002003003300003300003003003002 11101111111111
DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2	300303300332230033022000033304303430000200300330000330000300300030
DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2 GG.Q3	300303300332230033022000033304303430000200300330000330000300300030

MST.Q3 11111021111111111111111111111111111111		
MST.con 22222213222222222222222222222222222222	MST.Q3	111111102111111111111111111102211111111
RCH.Q2 100101101111110100000011111111100001001	MST.Q5	1111111021111111111111111111022101111111
RCH.Q3 210102222222222222110000022222222222101011122122	MST.con	222222213222222222222222222222222222222
RCH.05 333304444444444303013334444444303013333333000330301333333010304 RCH.05 31030442444444443031000034444444301003013213320003301003113333001004 RNG.02 1101011011111010000000111121222201221010010	RCH.Q2	1001011011111101101000001111111110000100100110000
RCH.con 31330442444444230310003444444430100301321332000330100311333000104 RNG.Q2 110101101111101000000111111100101111110000	RCH.Q3	210102222222222221110000222222222011011122122
RNG.Q2 110101101111101000000011111110001001001	RCH.Q5	3303044444444444443033013334444444303013033333330003303013333330103004
RN Q 2101010011111210110000000111122122101001100012112210001000 RNG QS 3212022022222121110111222332331211212322321112111	RCH.con	3103044244444444444444444444444444444444
NG. 0 3212022022222212111011122223323312112123223211122112322321102011 RNG. 0 3202022022222202000000022223323300002002	RNG.Q2	11010110111111101100000001111111110100101
RNO.con 32020202222230220000000222233233020022000232232	RNG.Q3	21010100111112101100000001111221221010010
SA.Q2 01101001000001100110111000100000111101100101	RNG.Q5	3212022022222221221110111222233233312112123223211112211123223321102011
SA. Q3 02212111101110121121121121010010002121121	RNG.con	320202202222320220000000222233233020020232232
S. Q. 034141230012103312434433310130030004243133030034441231430331034341333 SA. con 0340401300010033014314333300300100042430330130034441304303300344401304 All.con 3102032123323321320110010333232323302002013213310002202013113320002012 770 - 839 0 1 2 3 4 5 seq LFLIIVCDRFDFVHDLVLYLYRNNL0KYIEIYVCKVNPSRLFVVIGGLDVDCSEDVIKNLLUVVROFS ccn.02 01111110011001101101101010101010101010	SA.Q2	011010010000001100110111100010000001111011001001111
SA. con 0340401300010033014314333000300100042430330130034440130430330034340331 All.con 31020321233233213201100103332332333302002013213310003202013113320002012 770 - 839 0 1 2 3 4 5 6 seq LPLIIVCDRPDFVHDLVLYLYRNNLCKYIETYVCKVNPSRLPVVIGGLDVDCSEDVTKNLILVVRG0FS 6 6 cCN.Q2 011111100101001101100101011011011011011	SA.Q3	022121111011101211211211201010010002121121
All.con 310203212332332132011001033323332302002013213310003202013113320002012 770 - 839 0 1 2 3 4 5 6 seq LPLIIVCDRFDFVHDLVLYLYNNLQKYIETVOKVNPSRLFVVIGGLDDVDCSEDVIKNLLVVRQFS cCN.q2 011111101011001101110011011111010011001101111	SA.Q5	0341412300121033124344333101300300042431330330034441231430331034341333
770 - 839 0 1 2 3 4 5 6 seq LPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLDDVDCSEDVIKNLILVVRQOFS cCN.Q2 0111111010110011011000110110111100101010	SA.con	0340401300010033014314333000300100042430330130034440130430330034340331
seq LPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRQOFS cCN.Q2 011111101011001101101010110110110110110	All.con	3102032123323321320110010333233233302002013213310003202013113320002012
ccN.q2 011111101011001101110010110110110010011001101100100110011001001 ccN.q2 011111101011001101110001001101101100000100110110000	770 - 839	0 1 2 3 4 5 6
CN.Q3 12222221102201221220002112211211121122122	seq	LPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQFS
CN.Q5 3444434313133113323431113213333311334334434444411310133213333310231 cCN.con 144443430303300331343000320331333003143144144444400300033103313300130 dCN.Q2 0111110010110011001101100110011011100011001101111	cCN.Q2	0111111101011001101110001101101101010101
cCN.con 14444343030330033134300032033133300314314414444400300033103313300130 dcN.Q2 01111100101100110110001001101101000100	cCN.Q3	1222222110220122122200021122112211121122122
dcN.Q2 0111111001011001101110001101101100100110110110000	cCN.Q5	344443431313311332343111321333333113343344344444141310133213333310231
dcN.Q3 122222211102200221222000211221222001221122122	cCN.con	1444434303033003313430003203313330031431441444444040300033103313300130
dCN.Q5 23443441131331133133311132133133311311431444444131311133113412311131 dCN.con 13443440030330033003300320330330001300430444444030300033003402300030 DT.Q2 111111111111111111111111111111111111	dCN.Q2	0111111001011001101110001101101100101001101111
dcN. 1344344003033003303300320330330031300430444444030300033003402300030 DT.Q2 111111111111111111111111111111111111	dCN.Q3	122222211102200221222000211221222001221122122
DT.Q21111111011111111111111111111111111111	dCN.Q5	2344344113133113313331113213313331131311431444444131311133113412311131
DT.Q3 111111111111111111111111111111111111	dCN.con	134434400303300330330003203303330031300430444444030300033003402300030
DT.Q5 333333333333333333333333333333333333	DT.Q2	111111110111111111111111111111001111111
DT.con 333333333333333333333333333333333333	DT.Q3	111111111111111111111111111111111111111
GG.Q2011111101011001111110001101101100011011	DT.Q5	333333333433333333333333333330333333333
GG.Q312222220010220122222200022122122210200001102220220	DT.con	333333331333333333333333333332333311333333
GG.Q5 2344343112134124423441113324423442131111221343233121211134224433421131 GG.con 1344343102034014433440003314423441031000220343033020200034224433420030 MST.Q2 111111111111111111111111111111111111	GG.Q2	011111110101100111111000110111110011000110111010
GG.con 1344343102034014433440003314423441031000220343033020200034224433420030 MST.Q2 111111111111111111111111111111111111	GG.Q3	1222222001022012222220002212212210200001102220220
MST.Q2 111111111111111111111111111111111111	GG.Q5	2344343112134124423441113324423442131111221343233121211134224433421131
MST.Q3 11111121111101111110111111111111111111	GG.con	1344343102034014433440003314423441031000220343033020200034224433420030
MST.Q5 11111121111101111110111111111111111111	MST.Q2	111111111111111111111111111111111111111
MST.con 22222322222022222222222222222222222222	MST.Q3	111111211111011111101111111111111111111
RCH.Q2 01111111011001111110001111111101111111010	MST.Q5	111111211111011111101111111111111111111
RCH.Q3 222222222222222222222222222222222222	MST.con	222222 <mark>3</mark> 22222202222221222222222222222222222222
	RCH.Q2	011111111011001111110001111111110111111
RCH.Q5 444444444444444444444444444444444444	RCH.Q3	222222222022022222221022222222222222222
	RCH.Q5	444444444444330344344343043444444444444

RCH.con	24444444403302443443210434444443144444424444444444
RNG.Q2	0111111101011011111111000111111110010100100101
RNG.Q3	1122122101011012212210001112211221011100100
RNG.Q5	12332332120221233233211022233223321222112212321221202111232233223
RNG.con	02332332020220233233200022233223310212002002322202000232233223
SA.Q2	1000000101001100000011100100000110000100100100100101
SA.Q3	1000100121200110010002110110010001211112101000100211012210110011012101
SA.Q5	2000100231410330021014330231031003312143113000201433134310230032034313
SA.con	200000130400330010004330130010003301013003000200413034300230031034303
All.con	133333212033013323331103223323331122221331333233131310033123323311131
840 - 909	0 1 2 3 4 5 6
seq	TDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCEK
cCN.Q2	100110010000110111111000100100111100110110000
cCN.Q3	200210120010121221022101100010112221122122
cCN.Q5	3113302310212313331331023011101333302343333110113113311313313233213311
cCN.con	30033013001023033313300130010003333013413330000030033003
dCN.Q2	1001100100000101110110001001001011001101110000
dCN.Q3	200210120010121221022001100010012221122122
dCN.Q5	3113301310111313321331113003111113311341333111113113311313311223113311
dCN.con	300330030000303320330003002000213300340333000003003300303310123003300
DT.Q2	111111011111111111111111001111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333330333333333333333334003333333333333
DT.con	333330333333333333333333003333333333333
GG.Q2	100110111000111111111111000000011111111
GG.Q3	2002211210102212221221112000000102221221
GG.Q5	4114422421212424432342233112111213332442434110113124421202311124313311
GG.con	4004412420103424432342233000000113332442434000003024410302300034303300
MST.Q2	101110111111111111111111111111111111111
MST.Q3	101110111111111111111111111111111111111
MST.Q5	101110111111111111111111111111111111111
MST.con	202220222222222222222222222222222222222
RCH.Q2	1001100100001101111110001000001111101111
RCH.Q3	200110121011121222222211100010122222222
RCH.Q5	30133033303334444443433300030334444443443100133333103033433343
RCH.con	3003301310113314444432113000101344442443444100003113300303342134313310
RNG.Q2	101111111000111111111110000000111111111
RNG.Q3	1012211210101211211221111000000012211221212000001011210101100011001100
RNG.Q5	2123322321112322322332222111111223223323231101121233212022111221122
RNG.con	202332232000232232233222000000023322332
SA.Q2	0110011011110010001000100111111000110010001111

SA.Q3	022002101212101001100221022112111001100
SA.Q5	1330133033332030023103321443343310123003010334431331034142133310131143
SA.con	033003303331030013002310443343300023003000333430330034041033300230043
All.con	3013301310112313331332123001101223322332
910 - 979	0 1 2 3 4 5 6
seq	RDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALSE
cCN.Q2	01111111110010100011011101111001101110000
cCN.Q3	112222222201101011120222121221122112101101
cCN.Q5	2343444443113131113313333443321331233011131331233000013311331343233301
cCN.con	134344444300303000330331433310330233000010330133000003300330343133300
dCN.Q2	11111111110000100011010101111001101110000
dCN.Q3	112222222200101000120212122221122112101101
dCN.Q5	11114444431221311133131313131331333011121331133001113211331343133311
dCN.con	223344444300103000330303033330033330000103300330
DT.Q2	1011111111011111111111111111111110011111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	303333333304333333333333333333333333333
DT.con	303333333333333333333333333333333333333
GG.Q2	0100111111100010001101010111111111110000
GG.Q3	0000222222010010002200010222211222222000010221122000001100221222122200
GG.Q5	1111433443121121113412121334422443344111121442344100102211442344233311
GG.con	010043344311002000340202033442244334400002044234400000220044234423
MST.Q2	1111111110111111111111111111111111101111
MST.Q3	111111112111110111111112111121111011101
MST.Q5	11111111210111110111111121111101111110111111
MST.con	2222222320222212222222322223222202222122022222222
RCH.Q2	11111111110000100011011101111101111110000
RCH.Q3	222222222221012112202222222222222220110102211220001012012
RCH.Q5	33444444443303113331444444444344344303313033333300030330344444444
RCH.con	334444444221031013304442444442443443011010331133000103301441444244420
RNG.Q2	0000111111100010001101010111111111110000
RNG.Q3	0000111221100010001101010111211121121000000
RNG.Q5	111122223321112111221212122232232232111111
RNG.con	00002223332000200022020202232232232000000
SA.Q2	1000000001111011100101010000110000001111
SA.Q3	1111000000211211121021111010011001000211112001100222121121
SA.Q5	3333001001333413331031313100133102100433323003201344332243003100310134
SA.con	3111000000333403330030303000033001000433313003200344131143003000300034
All.con	1222333333111021113303131333322332333011010331233000102201331333233310
980 - 1049	0 1 2 3 4 5 6
seq	TQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNYD

cCN.Q2	100000110110110110110011001100000100011101111
cCN.Q3	1000002112211210102101220220021101012001112112
cCN.Q5	301001331332331213312331331133201013003333334444343121202321331231131
cCN.con	3000003303312330203301330330033100003001333134444343010101310330230030
dCN.Q2	1000001011101110001000110110010000100000
dCN.Q3	1000002112211210101101210220021101002001112112
dCN.Q5	111101311331232111311133033113320111311113113443333111201311331231131
dCN.con	200000302330232000300033033003310000300003023443333000100300330130030
DT.Q2	010111111110111110111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	03044333333033334333333333333343333340333333
DT.con	030333333303333313333333333333333333333
GG.Q2	000000111111111000100011011101110000100101
GG.Q3	00000022222122200020002212211220000010001121222222
GG.Q5	2111114334423431103111442442243211112111224234444434211312432441231121
GG.con	0000004334423430003000441442143200002001124234444434120202431440130020
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111101111111111111111101101111111111111
MST.Q5	111101111101111111111101101111111111111
MST.con	22221222222222222222222222222222222222
RCH.Q2	0000001101101101010000110110011000001001111
RCH.Q3	1000002222222222102202211221010010011222222
RCH.Q5	30100033444433443033034413431333030130033344444444
RCH.con	1000003324423342303202440341033101003003334244444443111303430330330130
RNG.Q2	100000111111110101001111111111000010010
RNG.Q3	1000002112212210101001211221121100001001
RNG.Q5	21111132233233212021123323322322111121112
RNG.con	2000003223323320202002332332232200002002
SA.Q2	011111000001000101011000100110001111010000
SA.Q3	1221210110011012120121002002101122221221
SA.Q5	3433430030031014341233013003301344431443230310000001333242023103214413
SA.con	143343001003000414023100300330014443044121010000000313242013003204403
All.con	1000003223322331203101331331133201013001123233333333
1050 - 1119	0 1 2 3 4 5 6
seq	APDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVW <mark>SQLAKAQLQKG V</mark>
cCN.Q2	100110110000110011011001000011011100100
cCN.Q3	10022012101011012212200101110221221011101012101200200
cCN.Q5	301331332010331333233113012213313430231130132033113011134 <mark>2233123301013</mark>
cCN.con	300330331000330133133003001103303430130030031033003000034 <mark>1133023300003</mark>
dCN.Q2	100110110000110011011001000011011100100
dCN.Q3	100220121010110121122001011102201220111010121012001000022 <mark>1122011100002</mark>

dCN.Q5	311331332010331133133113011113313330121130131033113111134 <mark>1133133301013</mark>
dCN.con	30033033100033003303300300000330333002003003003300300
DT.Q2	0101011111011111111110111111111111001111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	040313333404033333333330403333333333333
DT.con	03030333330323333333333333333333333333
GG.Q2	100110111000110111111001000011111100100
GG.Q3	101221222000120122122001000002212220121120122122
GG.Q5	212432443111231243244112011113424442232241243244113111134 <mark>2243233311114</mark>
GG.con	201431443000230243244002000003424440131140243144003000034 <mark>2243233300004</mark>
MST.Q2	1011101111111011111011111111110111101111
MST.Q3	201120121111101211110111111121011101111101210120111111
MST.Q5	101120121111101211110111111121011101111101210120111111
MST.con	30223023222220232222022222232022220222
RCH.Q2	1001101100001100111110010000011011100100100110110010000
RCH.Q3	100220121010120222122001011102212221121010121022001000022 <mark>1122122100001</mark>
RCH.Q5	301330333010330444333113033303333433331030333133003000033 <mark>3344333300013</mark>
RCH.con	300330331000330244333003011103313431130030133033003000033 <mark>1144133300003</mark>
RNG.Q2	10111111100011011111110100000111111111
RNG.Q3	101221221000110121122101000002212221110010121122101000011 <mark>1122121100001</mark>
RNG.Q5	212332332110221233233212011113323332221121232233212110123 <mark>2233222211012</mark>
RNG.con	202332320002202332320200003323332220020232233202000023 <mark>2233232200002</mark>
SA.Q2	0110010001110010001001101111100100011011011001001101111
SA.Q3	12100210121210210010022121112001000211110210120022022
SA.Q5	143003101434114301311331433330031003313314302310331434300 <mark>3300311144430</mark>
SA.con	043003000434004100300330433330030003303304301300330434300 <mark>3300300044430</mark>
All.con	201331332000230233233002011103313331131030132133002000033 <mark>1133133300003</mark>
1120 - 1189	0 1 2 3 4 5 6
seq	KEAIDSYIKADDPSSYMEVVQAANASGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFIN
cCN.Q2	<mark>0011011</mark> 1010010010011011000001001101100100
cCN.Q3	0022022 20100101210220120010010021022011000100112221222222
cCN.Q5	0133134 313113013213302310201311331331231011013133334444442301311311331
cCN.con	0033034303003003103302300100300330330130000003033314444441300300300300300
dCN.Q2	<mark>0011011</mark> 1010010010011011000001001101100100
dCN.Q3	0021012201001002102101200100100210220110001001
dCN.Q5	1133113 313112113113302310101311331331131011011133314444441301301311331
dCN.con	<mark>0033023</mark> 3030020030033023000003003303300300000003330444444030030
DT.Q2	1101101101101101111101010110111111011111
DT.Q3	<mark>1111111</mark> 11111111111111111111111111111
DT.Q5	<mark>3303303</mark> 33040330333330334040330333333333
DT.con	<mark>3303303</mark> 3303033033333303330333033333333

GG.Q2	<mark>0011111</mark>	101000001	101101100	0001001111	1111100000	1011111111	.111100100	0110110
GG.Q3	<mark>0022122</mark> 2	201001002	112212200	0002012212	2122101000	0021212222	221200201	211220
GG.Q5	<mark>1134234</mark>	<mark>312012113</mark>	224423411	1013124424	<mark>4234</mark> 212111	1242424434	432311312	2422441
GG.con	0034234	302001003	214413400	0003014424	4234201000	1042424434	432300301	421440
MST.Q2	0111011	111111111	111101101	1111011101	1 <mark>0</mark> 11111111	1111111111	.111111101	110111
MST.Q3	<mark>0121011</mark>	112111111	111101201	1111011101	1111111111	1111111112	2121111101	101111
MST.Q5	0121011	112111111	111101201	1111011101	1011111111	1111111112	2121111101	111111
MST.con	0232022	22 <mark>3</mark> 222222	2222 <mark>0230</mark> 2	2222022202	2 <mark>0</mark> 22222222	2222222222	232222202	2210222
RCH.Q2	0011011	101001001	001101100	0001001101	100100000	1111111111	111100100	0100110
RCH.Q3	0122022	222001002	102101100	1001012102	2111101100	2122222222	222200100	0110110
RCH.Q5	<mark>0133144</mark>	403033013	313313310	3013033313	3333303301	3144444444	444301301	330330
RCH.con	0033044	413003003	103303300	1003013303	311 <mark>3</mark> 101100	3244444444	444300300	0310330
RNG.Q2	<mark>0111111</mark>	101001001	111111110	0001011111	1111111000	0011111111	110100101	111110
RNG.Q3	<mark>0122112</mark>	101001001	012212210	0000012212	2112111000	0011112212	220100101	211210
RNG.Q5	<mark>1233223</mark> 2	212012012	123323321	2 <mark>0</mark> 1112 <mark>33</mark> 23	322 <mark>3</mark> 222111	1122223323	331201212	2322321
RNG.con	<mark>0233223</mark> 2	202002002	123323320	0001023323	3223222000	0022223323	330200202	2322320
SA.Q2	1100100	010110110	010010011	1110110010	0100111111	010000000	001011011	001001
SA.Q3	2200200	021211210	120021022	1211210020	0210121222	1101010000	002021021	012002
SA.Q5	<mark>3300311</mark>	141431431	330032034	343133 <mark>0</mark> 131	<mark>)</mark> 33 <mark>0</mark> 343343	2301030000	0103143133	8033014
SA.con	3300300	040430430	120021024	2420220020	2210242242	1300010000	003043033	3013004
SA.COII		040450450	130031034	5450550050	JS10343343	1000010000		01001
All.con						2133323333		
	0133123							
All.con	<mark>0133123</mark> 0	312002003 1	21 <mark>33</mark> 02300 2	1 <u>00201<mark>33</mark>13</u> 3	<mark>3123111100</mark> 4	2133323333	3 <mark>331300301</mark> 6	311330
All.con 1190 - 1259	0133123 0 GPNNAHI	312002003 1 QQVGDRCYD	213302300 2 EKMYDAAKL	1002013313 3 LYNNVSNFGR	3123111100 4 LASTLVHLGE	2 <u>133323333</u> 5	3331300301 6 CANSTRTWKE	1311330 EVCFACV
All.con 1190 - 1259 seq	0133123 0 GPNNAHI0 00111010	312002003 1 QQVGDRCYD 001100110	213302300 2 EKMYDAAKL: 000101111	1002013313 3 LYNNVSNFGR 1100100101	3123111100 4 LASTLVHLGE	2133323333 5 SYQAAVDGARF	3331300301 6 CANSTRTWKE 0100101100	2311330 EVCFACV
All.con 1190 - 1259 seq cCN.Q2	0133123 0 GPNNAHI(0011101(1121201(312002003 1 QQVGDRCYD 001100110 002101210	213302300 2 EKMYDAAKL 000101111 001102212	1002013313 3 LYNNVSNFGR 1100100101 2211200211	4 LASTLVHLGE	2133323333 5 :YQAAVDGARK 1001101100	6 (ANSTRTWKE 0100101100 .101102211	2007 2007 2007 2007 2007 2007 2007 2007
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3	0133123 0 GPNNAHI 0011101 11212010 1343313	312002003 1 2QVGDRCYD 001100110 002101210 113201320	213302300 2 EKMYDAAKL 000101111 001102212 001314423	3 LYNNVSNFGR 1100100101 2211200211 4312301311	4 LASTLVHLGE 1101110100 2212221200 4434432301	2133323333 5 2YQAAVDGARK 11001101100 22002102211	6 (ANSTRTWKE 0100101100 .101102211 .301313321	.311330 EVCFACV 0110011 .221121 .332233
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5	0133123 0 GPNNAHI(0011101) 11212010 1343313 01433030	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423	1002013313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302	4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300	2133323333 5 SYQAAVDGARF 1001101100 2002102211 3114314311	6 CANSTRTWKE 0100101100 .101102211 .301313321 0300303310	2VCFACV 0110011 2221121 1332233 0331133
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con	0133123 0 GPNNAHIG 00111010 11212010 13433133 01433030 01101010	312002003 1 22VGDRCYD 001100110 002101210 113201320 003200320 001000100	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111	3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100	4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300	2133323333 5 SYQAAVDGARK 1001101100 2002102211 3114314311 3004304300	6 CANSTRTWKE 0100101100 101102211 .301313321 0300303310 0100101100	2011330 2000 20110011 221121 232233 2331133 2110011
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2	0133123 0 GPNNAHI(00111010 11212010 13433133 01433030 01101010 01212010	312002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210	213302300 2 EKMYDAAKL: 000101111 001102212: 001314423 000304423 000101111 001202211	1002013313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211	3123111100 4 LASTLVHLGF 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200	2133323333 5 3YQAAVDGARF 1001101100 2002102211 3114314311 3004304300 1001101100	6 CANSTRTWKE 0100101100 101102211 301313321 0300303310 0100101100 .101202210	2VCFACV 0110011 1221121 1332233 0331133 0110011 0221121
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3	0133123 0 GPNNAHIG 00111010 11212010 13433133 01433030 01101010 01212010 11113133	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 0012022113 111313332	1002013313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311	4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431311	2133323333 5 2YQAAVDGARK 11001101100 2002102211 3114314311 3004304300 1001101100 2002102201	6 CANSTRTWKE 0100101100 .101102211 .301313321 0300303310 0100101100 .101202210 .111313311	2011330 2000 20110011 221121 332233 331133 0110011 0221121 331232
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3	01.33123 0 GPNNAHI 0011101 1121201 13433133 01433030 0110101 0121201 11113133 02303030	312002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 11131332 000303332	1002013313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300	3123111100 4 LASTLVHLGF 1101110100 2212221200 4434432301 4414431300 2212221200 4414431311 4404430300	2133323333 5 3YQAAVDGARF 1001101100 2002102211 3114314311 3004304300 1001101100 2002102201 3113313311	6 CANSTRTWKE 0100101100 .101102211 .301313321 0300303310 .101202210 .101202210 .111313311 0200303300	2VCFACV 0110011 1221121 1332233 0331133 0110011 0221121 1331232 0330132
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con	0133123 0 GPNNAHI 11212010 1343313 01433030 01101010 01212010 1111313 02303030 01111113	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101111111	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 111313332 000303332 100111111	3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 111111111	4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431311 4404430300 111111111	2133323333 5 SYQAAVDGARK 10001101100 2002102211 3114314311 3004304304 10001101100 2002102201 3113313311 30003303300	6 CANSTRTWKE 0100101100 101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .010111111	2011330 2007FACV 20110011 2221121 2332233 20331133 20110011 2221121 2331232 2330132 111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q5 dCN.con DT.Q2	0133123 0 GPNNAHI 0011101 1121201 13433133 01433030 0110101 0121201 11113133 0230303 0111111 1111111	312002003 1 20VGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 10111111 11111111	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 11131332 000303332 100111111 11111111	1002013313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 111111111 111111111	3123111100 4 LASTLVHLGF 1101110100 2212221200 4414431300 1101110100 2212221200 4414431301 1414431311 4404430300 111111111 1111111111	2133323333 5 SYQAAVDGARF 1001101100 2002102211 3114314311 3004304300 1001101100 2002102201 3113313311 3003303300 110111111	3331300301 6 CANSTRTWKE 0100101100 .101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .01011111 .11111111	2VCFACV 0110011 1221121 1332233 0331133 0110011 0221121 1331232 0330132 111111 .111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3	0133123 0 GPNNAHI 11212010 1343313 01433030 01101010 01212010 1111313 02303030 0111111 1111111	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 10111111 11111111 303033334	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 111313332 000303332 100111111 11111111	3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 1111111111 111111111	4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431311 4404430300 1111111111 1111111111	2133323333 5 SYQAAVDGARK 11001101100 2002102211 3114314311 3004304304300 10001101100 2002102201 3113313311 3003303300 1101111111	6 CANSTRTWKE 0100101100 101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .010111111 .111111111 .3040333333	EVCFACV 0110011 221121 332233 0331133 0110011 0221121 331232 0330132 111111 111111 3333333
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5	0133123 0 GPNNAHI 0011101 1121201 13433133 01433030 0110101 0121201 11113133 02303033 0111111 1111111 03303033	312002003 1 2QVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 10111111 11111111 303033334 303233333	213302300 2 EKMYDAAKL: 000101111 001102212: 001314423 000304423 000304423 000101111 001202211 111313322 000303332 100111111 11111111 11111111 403333333 301333333	3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 1111111111 111111111 111111111	3123111100 4 LASTLVHLGE 1101110100 2212221200 4414431300 1101110100 2212221200 4414431311 4404430300 111111111 1111111111 333333333333333333333333333333333333	2133323333 5 3YQAAVDGARF 1001101100 2002102211 3114314311 3004304300 1001101100 2002102201 3113313311 3003303300 110111111 11111111	3331300301 6 (ANSTRTWKE 0100101100 .101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .010111111 .111313313 0200303300 .010111111 .010111111 .010333333 .030333333	2VCFACV 0110011 221121 132233 0331133 0110011 0221121 1331232 0330132 111111 111111 111111 333333 333333
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con	0133123 0 GPNNAHI 11212010 1343313 01433030 01101010 01212010 1111313 02303030 0111111 1111111 03303033 0332323 00101010	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101111111 111111111 303033334 303233333 001101110	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 111313332 000303332 100111111 111111111 403333333 301333333 000101111	3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 1111111111 111111111 3333334333 3333333333	4 LASTLVHLGF 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431311 4404430300 1111111111 3333333333	2133323333 5 SYQAAVDGARK 11001101100 2002102211 3114314311 3004304304 1001101100 2002102201 3113313311 3003303303 1101111111 11111111	6 CANSTRTWKE 0100101100 101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .010111111 .111111111 .3040333333 030333333 0100101111	EVCFACV 0110011 221121 332233 0331133 0110011 0221121 331232 0330132 111111 3333333 3333333 111111
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2	01.3123 0 GPNNAHI 0011101 1121201 13433133 0143303 0143303 0110101 0121201 11113133 0230303 0110101 0330303 03323233 00101010 00001020	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 10111111 111111111 111111111 303033334 303233333 001101110 012212220	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 111313322 000303332 100111111 111111111 111111111 11111111	1002013313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 111111111 111111111 333333333 333333333 1100100101 2201200201	3123111100 4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431301 1414431311 4404430300 111111111 111111111 13333333333 333333333333333333333333333333333333	2133323333 5 3YQAAVDGARF 1001101100 2002102211 3114314311 3004304300 1001101100 2002102201 3113313311 3003303300 110111111 11111111	3331300301 6 (ANSTRTWKE 0100101100 .101102211 .301313321 030030310 0100101100 .111313311 0200303300 .01011111 .111313313 0200303300 .010111111 .010111111 .010111111 .010111111 .0101011111 .0101011111 .000102211	2VCFACV 0110011 221121 132233 0331133 0110011 0221121 1331232 0330132 111111 111111 111111 111111 1221222
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2 GG.Q3	0133123 0 GPNNAHI 11212010 1343313 01433030 01101010 01212010 1111313 02303030 01111111 03303033 0332323 00101010 00001020 1111213	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 101111111 111111111 303033334 303233333 001101110 012212220 124323321	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 111313332 000303332 100111111 111111111 403333333 301333333 0001011111 0002022222 011313334	3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 3311311311 3300300300 1111111111 111111111 3333334333 3333333333	3123111100 4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431311 4404430300 1111111111 33333333333 33333333333 1111111110 2212221211 4424442422	2133323333 5 SYQAAVDGARK 11001101100 2002102211 3114314311 3004304304300 10001101100 2002102201 3113313311 30003303303 110111111 11111111	3331300301 6 CANSTRTWKE 0100101100 .101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .010111111 .3040333333 .030333333 .010101111 .0000102211 .101213422	2VCFACV 0110011 221121 332233 0331133 0110011 0221121 331232 0330132 111111 333333 333333 111111 221222 2432333
All.con 1190 - 1259 seq cCN.Q2 cCN.Q3 cCN.Q5 cCN.con dCN.Q2 dCN.Q3 dCN.Q5 dCN.Q3 dCN.Q5 dCN.con DT.Q2 DT.Q3 DT.Q5 DT.con GG.Q2 GG.Q3 GG.Q5	01.3123 0 GPNNAHI 0011101 1121201 13433133 0143303 0143303 0110101 0121201 11113133 02303033 03323233 03323233 0010101 00001020 11112133 00102030	312002003 1 QQVGDRCYD 001100110 002101210 113201320 003200320 001000100 002101210 113202320 003101310 10111111 111111111 111111111 1012212220 124323321 014313330	213302300 2 EKMYDAAKL 000101111 001102212 001314423 000304423 000101111 001202211 111313322 000303332 100111111 111111111 111111111 11111111	IOO2O13313 3 LYNNVSNFGR 1100100101 2211200211 4312301311 4301300302 1100100100 2211200211 33131311311 3300300300 111111111 111111111 1333333333 3333333333 1100100101 2201200201 4422311312 4401300302	3123111100 4 LASTLVHLGE 1101110100 2212221200 4434432301 4414431300 1101110100 2212221200 4414431301 1414431311 4404430300 111111111 111111111 13333333333 3333333333333 1111111110 2212221211 4424442422 4424442421	2133323333 5 3 3 3 3 3 3 1 3 1 4 3 1 3 1	3331300301 6 (ANSTRTWKE 0100101100 .101102211 .301313321 0300303310 0100101100 .101202210 .111313311 0200303300 .01011111 .11111111 .01011111 .010111111 .010111111 .0101011111 .0101011111 .0101011111 .0000102211 .101213422 .100203422	2VCFACV 0110011 221121 132233 0331133 0110011 0221121 1331232 0330132 111111 111111 111111 1221222 2432333 2432333

MST.Q5	111121101221011111111121111111111111111
MST.con	2222 <mark>3</mark> 2202 <mark>33</mark> 202222222 3 2222222222222222222222 3 22222022222 3 222222 3 22222222 3 22222222 3 22222222
RCH.Q2	0100101000000100000010111110110010111111
RCH.Q3	1221201001101110001102222222120022222222
RCH.Q5	34343330133033300033144444433004434444433313304414431303303333444333
RCH.con	142130300310131000130444444233004234444433103104414410101303311443333
RNG.Q2	0010101011111110000101111111010010111111
RNG.Q3	0000101012111210000101211221010010122122
RNG.Q5	1121212123222321111212322332121121233233
RNG.con	0020202023222320000202322332020020233233
SA.Q2	1100010110011001111010010001101101100000
SA.Q3	1111110220021012221020011002102201100100
SA.Q5	3343131330032024443131021003313313200300030330330131033343130133003201
SA.con	3311030330032014443030020003303303200100030330330030033143030033001100
All.con	0121303013211320001303323331130031233233323
1260 - 1329	0 1 2 3 4 5 6
seq	DGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQK
cCN.Q2	000010110111011001001001101100001100110110011010
cCN.Q3	0100201211221122112012002201100101201220220
cCN.Q5	0101313333343133214113113312201213312331331233030134444444444
cCN.con	00003033133430331040030033022001033013303301330300114444444444
dCN.Q2	0000101100111011001001001101100001100110110011010
dCN.Q3	0000211211221122112002002201100101201210221121010011222222
dCN.Q5	0111312312332133113013113312211113311331
dCN.con	00003023013320330030033022000033003303303300330
DT.Q2	101111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	403333333333333333333333333333333333333
DT.con	303333333333333333333333333333333333333
GG.Q2	0000111111110110010111011111000011011111
GG.Q3	000021221222101100201211221220000220122122
GG.Q5	111132442343212311312422442331121331244244223312111214333433442121112
GG.con	0000324423432023003024214423300003302442442233020001204333433442020002
MST.Q2	111111101111111101101111111111101110110
MST.Q3	111111120122111111201101111111111101110
MST.Q5	111111121122101111201111111111111101110
MST.con	2222223023322222302202222222222220220232122222322222222
RCH.Q2	00001011111111100111100110110000110111011011010
RCH.Q3	000121222222222112012002212100102202221221
RCH.Q5	010333344444444433403311333331330340343143333303003344444444
RCH.con	00013134444444441141330033133001034034304313330100124444444444

RNG.Q2 0000111111111100101111111111000110111111
RNG.Q5 11113223222221211312322332222111221233233
RNG.con 0000322322220200302322332220002202332332
SA.Q2 111101000000010011011011001001111001000100100101
SA.Q3 212101001100120111011012001112212102100200110021222111000000
SA.Q5 4333131032002411331330330031233341133003003301424443110001000010
SA.con 433303001100140033033033003013334003100300310041444100000000
All.con 000131332233213311302311331221110330233133123302001133333333
1330 - 1399 0 1 2 3 4 5 6
seq MREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVAN
cCN.Q2 11011011010010010000110111111010010011011001001100100110110000
cCN.Q3 2101201210121211110120011221222221110020122122
cCN.Q5 32033123312313113301311213333444442120131144144302301330103321343131
cCN.con 32033023302303003300300103313444420200300440443013003300013203430300
dCN.Q2 100010010001000100001100110010010010010
dCN.Q3 210120121012021011011001122012222111002002
dCN.Q5 320131232013131133013111331143443212013114413331111331112321331131
dCN.con 3100301310030300330033004344310200300440333000003300013203330300
DT.Q2 111111111111111111111111111111111111
DT.Q3 111111111111111111111111111111111111
DT.Q5 333333333333333333333333333333333333
DT.con 333333333333333333333333333333333333
GG.Q2 110111110010100110111111111111111010010
GG.Q3 22122122200202012211211122112222220100201222222
GG.Q5 4323423431131412442242232442243444212113124423431111121112
GG.con 43134234300304014412422324422434443020030244334300000020002
MST.Q2 1111111111101110111111111111111111111
MST.Q3 11111111111101110121111110111111111111
MST.Q5 11111111111101110121111110111111111111
MST.con 222222222222222222222222222222222222
RCH.Q2 110110110100100110010011111111001001001
RCH.Q3 2102212210222222101111112222222222100201222222
RCH.Q5 3344343330444443330331333444444443300333344444433303313033444440444
RCH.con 33143133304424223301301334444444422300301344444133003301033424442422
RNG.Q2 1111111100101011111111111111111110000101
RNG.Q3 211121111001010122112111122112112210000101221121000001100012112210100
RNG.Q5 322232222112121233223222332232333211012123322321111221112322332121
RNG.con 322232220020202332232233223332000020233223200000220002322332000
SA.Q2 0010010001100110110100000000101101100000
SA.Q3 01210210121010110021021110011000001112202100100

SA.Q5	0131032014313033003303323113300101232431430020004334411434202300131332
SA.con	0030031004301033003303313003100000131430430010004114400434101300030311
All.con	3212312320131311330131122331233333212003013323331110022010232133313112
1400 - 1469	0 1 2 3 4 5 6
seq	ELYYKAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNLF
cCN.Q2	011101101110000011101101100010111110110
cCN.Q3	0121022112101110122122022101212122201200101222210221121012101210221022
cCN.Q5	0232133124302131333243133212344444413311303444421331133013203331343133
cCN.con	02320330243010103331430331013143444033003014444103300330
dCN.Q2	001101101110000001101101100010111110110
dCN.Q3	0121022012101110121122022101212222201200101222210220021012101210221022
dCN.Q5	024313313330111123314313311141313441331111141431133113
dCN.con	014303303330000013304303300040333440330000043430033003
DT.Q2	111111111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	333333333333333333333333333333333333333
DT.con	333333333333333333333333333333333333333
GG.Q2	011111111100000111111111000101011110110
GG.Q3	02221221222000001221221220002000122012000002022102221221
GG.Q5	13432442344111112422442441113111234123111113133213422432243
GG.con	0343244234400000243244244000301023402300000303310343243124312431343244
MST.Q2	111111101110111111111111111111111111111
MST.Q3	011112101110111111111111111111111111111
MST.Q5	011102111111111111111111111111111111111
MST.con	122223202220222222222222222222222222222
RCH.Q2	111101101110011011101101100010111110110
RCH.Q3	222112212220122022222221012222222200102222210221121012101222222
RCH.Q5	444334443430333034344443330334444433300303444440333333
RCH.con	4443144134301330343244233101324444423300102444410331133013301442444244
RNG.Q2	01111111110000011111111100010101110110000
RNG.Q3	0122122112100000111122121000100012101100000101100121121
RNG.Q5	123223322321111122223323221121211231221110121221133223322
RNG.con	023323322320000022223323200020202330220000020220033223322322
SA.Q2	10001001000111010001001001110100001001111
SA.Q3	1100200100021122101100100121011110021022121010012001100210121012000200
SA.Q5	3201300311043343201300300343133320031134343131033102300320133013000300
SA.con	3100300300043323100300343031310030034343030033002300320031003000300
All.con	123313313330111023323313310131223331230010132331033113301320132
1470 - 1539	0 1 2 3 4 5 6
seq	ITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQYA
cCN.Q2	100001001001001001011011001000011011011

crn. 03 10011101220221221222222222222222222222		
ccN. con 30011301300303131333033000003303213443440010030033030000330143034 dCN. Q2 100001001001010101001001011010000011001001111	cCN.Q3	10011101210120121121120220120010221211222222
dCN.Q2 100001001001001010101001001101100000100110110000	cCN.Q5	3002230231033113233333133113101033132234434411201311331331021331243134
dcn. q3 100111012101200211211022011001022121122122	cCN.con	3001130130033003113133033003000033032134434400100300330330000330143034
dCN.05 31111301311330131131131311310113313131444343111131331310113313310113314314 dCN.05 30000300300300300300300300030003000300	dCN.Q2	100001001001100100101101100100001101001111
dCN.con 3000030030030030030030030030000300003	dCN.Q3	100111012101200211211102201100102212112221221
DT.Q2 1111010111011111111111111111111111111	dCN.Q5	3111130131133013113113133113101133131134434311111311331331011331143134
DT.Q3 111111111111111111111111111111111111	dCN.con	3000030030033003003023033003000033030034434300000300330330000330043034
DT.Q5 3333313033303333333333333333404333333333	DT.Q2	111110101110111111111111111111111111111
Dr. con 3333030333033333333333333333333333333	DT.Q3	111111111111111111111111111111111111111
GG.Q2 111110110100100101101101000011011111111	DT.Q5	3333313033303333333333333334043333333333
Gr. 03 2111121221220020010120221120000221221222222	DT.con	333330303330333333333333333330433333333
GG 42222322423411311312314422411113243243334422111311442432111231244243 GG, con 42223124313400300302304412400003143243334421000300442432000230244243 MST.02 1111101111111111111111111111111111111	GG.Q2	1111110111011001001011011011000011011111
GC 4222231243134003003023044124000033143243334421000300442432000230244234 MST.Q2 11111011101111111111101010101111111111	GG.Q3	2111121122122002001012022112000022122122
MST.Q2 11111011011111111111101010101111111111	GG.Q5	4222232242234113113123144224111133243243334422111311442432111231244234
MST.Q3 1111101110111111111111001111111122111111	GG.con	4222231243134003003023044124000033143243334421000300442432000230244234
MST. QS 1111110111111111111111110110111111122111111	MST.Q2	111111011101111111111111101101101111111
MST. con 2222202220222222222222203020222222233222222	MST.Q3	1111110111011111111111111201111110111111
RCH.Q2 100001001001100111111101001000011011011	MST.Q5	111111011111111111111111111101111111122111111
RCH.Q3 2211110121022102222222112111001022222222	MST.con	22222202220222222222223022022022222233222222
RCH.Q5 3333303300344444333133003033334444443301303331330033330344344 RCH.Q5 33333033003444443133013001033233244444433010301330331021330144144 RCH.con 321113013103003444443133013001033233244444433100301330331021330144144 RNG.Q2 11111111111001001011111110000111111111	RCH.Q2	100001001001100111111101100100001101101
RCH.con 3211130131033003444443133013001033233244444433100301330331021330144144 RNG.Q2 111111111110010010011111111000011111111	RCH.Q3	221111012102210222222112111001022222222
RNG.Q2 111111111100100100100111111100001111111	RCH.Q5	333333033303300344444333313300303333344444443330130333133303330
NRG.Q3 111112112111200100100112211200001112112221211010010	RCH.con	3211130131033003444443133013001033233244444433100301330331021330144144
NG.Q5 32222223231121121223322311022232233232321211212332332111221233233 RNG.con 322223223223002002002233223000022232233323200020233233	RNG.Q2	111111111111001001001111111100001111111
RNG.con 322223223233002002002233223000022232233323200020233233	RNG.Q3	111112112111200100100112211200001112112221211010010
SA.Q2 0111101101101101101001001101101001000000	RNG.Q5	322222232233112112112233223111022232233323321211212332332111221233233
SA.Q3 022110210120022012011020021022120110110001001	RNG.con	322223223223300200200223322300002223223332332
SA.Q5 1333313303310331431321300330443301302300020133343133003103443113300310 SA.con 0333303303303303303303103003304413003013000100331430330030034130033003	SA.Q2	0111101101100110110100100110110100100000
SA.con 0333303303303303303303103003304413003013000100331430330030034130033003	SA.Q3	022110210120022012011020021022120110110001001
All.con 311112013212300311312313311300103313223333321100301331331011230133133 1540 - 1609 0 1 2 3 4 5 6 seq SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD cCN.Q2 101000011001101110000001111111111101101	SA.Q5	1333313303310331431321300330443301302300020133343133003103443113300310
1540 - 1609 0 1 2 3 4 5 6 seq SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD cCN.Q2 101000011001101110000001111111111011011	SA.con	03333033033003303303103003304413003013000100331430330030034130033003
seq SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD cCN.Q2 101000011001101110000001111111110110101111	All.con	3111120132123003113123133113001033132233333321100301331331011230133133
ccN.Q2 1010000110011011100000011111111110101011101111	1540 - 1609	0 1 2 3 4 5 6
cCN.Q3 111001012112201210100112222222221211211122110211222222	seq	SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD
cCN.Q5 2131020332133134301012444444444444442432433323333331334444443323320330230 cCN.con 2030010331033034300001144444444444441431413321333330311444443323320330130 dCN.Q2 000000011001101110000001111111110110101111	cCN.Q2	101000011001101110000001111111110110101111
cCN.con 203001033103303430000114444444444441431413321333330311444443323320330130 dCN.Q2 00000001100110111000000111111110110101110111010	cCN.Q3	1110010121122012101001122222222222122121121
dCN.Q2 0000000110011011100000011111111011010101	cCN.Q5	213102033213313430101244444444444442432433323333331334444443323320330230
dCN.Q3 111001012112201210000112222222221221222110211222222	cCN.con	203001033103303430000114444444444441431413321333330311444443323320330130
	dCN.Q2	0000000110011011100000001111111110110101
dCN.Q5 1111111331133133301111144444444444441431413331233231311444443313221331131	dCN.Q3	1110010121122012100001122222222222122122
	dCN.Q5	1111111331133133301111144444444444441431413331233231311444443313221331131

	T
dCN.con	00000033003303300000044444444444444030403330233130300444443303320330030
DT.Q2	110101111111111111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	330303333333333334433033333333333333333
DT.con	330303333333333333333323333333333333333
GG.Q2	10100001111111110000000111111111010101111
GG.Q3	201000022112212220000002222222122022020222122211020021222222
GG.Q5	3111111442244234311011133434432321331313442433221311332333433432432242
GG.con	3020000442244234300000033434432330330303442433220300333333433431431241
MST.Q2	111111011111011101110111111111111111111
MST.Q3	2121110221111011101111121121111011111111
MST.Q5	2111110121111011101111121121111211110111111
MST.con	32322203322220222022223223222322220222222
RCH.Q2	1000000110011011100000111111111101101111
RCH.Q3	111001012112212210000122222222222222222
RCH.Q5	333013033333333301013344444444444444444
RCH.con	311001033113313330000134444444444444444
RNG.Q2	10100001111111110000000111111111010101111
RNG.Q3	2010000121122122100000011222211110110101211122110100111111
RNG.Q5	212111123223323321101112233332222122121232223322021122222232322232
RNG.con	30200002322332320000002233332222022020232223322000222222
SA.Q2	010111100010010001111100000000000000000
SA.Q3	1212112001100210021221200000010020010100011001120120
SA.Q5	132433410330031014343340000001101311313001300
SA.con	03143340013003000434332000000003003010001000104013000001030013003303
All.con	212001033213313330100113333333333331331333323332
1610 - 1674	0 1 2 3 4 5 6
seq	KLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM
cCN.Q2	010000000000000000011110111111111111111
cCN.Q3	010000000000000000000000000000000000000
cCN.Q5	131001000000000000333334444444444444444
cCN.con	030000000000000000333313444444444444444
dCN.Q2	010000000000000000111000111111111111111
dCN.Q3	010000000000000000111211222222222222222
dCN.Q5	1310010001000000011221111444444444444444
dCN.con	0300000000000000002221004444444444444444
DT.Q2	010000010000100111111111111111111111111
DT.Q3	111111111111111111111111111111111111111
DT.Q5	030300033000303444433333433333333333333
DT.con	030100031000301333333333333333333333333
GG.Q2	110011000100000000011000001111001111111

GG.Q3	12111111100000000000000022220111111010111111
GG.Q5	242222222211111100022200113332122221212122121212222212221
GG.con	24112211120000000022100003333012222212022222232222211230101
MST.Q2	111111111111111111111111111111111111111
MST.Q3	111111111111111111111111111111221111111
MST.Q5	111111111111111111111111111111111111111
MST.con	22222222222222222222222222223 <mark>3</mark> 22222222
RCH.Q2	010000000000000000011110111111111111111
RCH.Q3	011000000000000000222222222222222222222
RCH.Q5	131111011111000000033444444444444444444
RCH.con	030000000000000003444244444444444444444
RNG.Q2	1111111111111100000001000001111010110101
RNG.Q3	1211111111111000000010000111111011010101111
RNG.Q5	23222222222222111000121111122222222212121222222
RNG.con	232222222222200000002000022221202202020222222
SA.Q2	101111111111111111100011100000000000000
SA.Q3	2022212122222222222111121100001000010101101
SA.Q5	3033333343444444444433343431001010111111311101011111111
SA.con	303333334344444444441113331000000000000
All.con	131111011100100000022211123333233332323232

0 - 69	0	1	2	3	4	5	6
				-			NPIRRPISADS
seq		~ ~ ~ ~				~	.10111101010
SA.Q2 SA.Q3							21111102021
SA.Q5							31332313141
SA.QJ							30332303040
All.con							03111130303
70 - 139	0	1	2	3	4	5	6
							0 IWSMEGESOPVK
seq SA.Q2			~				000011111001
SA.Q3							.01022222111
SA.Q5							213144443133
SA.con							.01044443013
All.con							32300000321
140 - 209	0	1	2	3	4	5	6
seq							SFAOFKMEGNA
SA.Q2		~ ~	~	~~~	~ ~ ·	~ ~	000010101111
SA.Q3							10020212222
SA.Q5							00031314444
SA.con							00030304444
All.con							34403030000
210 - 279	0	1	2	3	4	5	6
seq	EESTLFCFA	AVRGOAGGKL		NOPFPKKAV	DUEEDDEAONI		
1			TITTTOVGTLLI		DVFFFFEAUNI		
SA.Q2	110100000)111111010				~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	.01000000100
SA.Q2 SA.Q3			0000011111	1111011100	0000001011(20000000011	
	221100000)111221010	0000011111	2 2 2 2 2 2 2 2 2 2 2 2 2 1 1	00000010110 10101121113	00000000011 00000010122	.01000000100
SA.Q3	221100000 341200000)111221010)323443030	0000011111 0001011122 1003134344	2 1111011100 2222022111 4434134311	00000010110 10101121111 31112343343	200000000011 10000010122 31000010343	.01000000100 211000000110
SA.Q3 SA.Q5	221100000 341200000 340200000)111221010)323443030)323443030	00000111111 0001011122 1003134344 0001033344	1111011100 2222022111 4434134311 4434034300	00000010110 10101121111 31112343343 10001141333	2000000000011 10000010122 31000010343	0100000100 211000000110 31300000320
SA.Q3 SA.Q5 SA.con	221100000 341200000 340200000)111221010)323443030)323443030	00000111111 0001011122 1003134344 0001033344	1111011100 2222022111 4434134311 4434034300	00000010110 10101121111 31112343343 10001141333	2000000000011 10000010122 31000010343	01000000100 11000000110 13000000320 03000000310
SA.Q3 SA.Q5 SA.con All.con	221100000 341200000 340200000 003144444 0)111221010)323443030)323443030)323443030 1111001414 1	0000011111 0001011122 1003134344 0001033344 3442310100 2	1111011100 2222022111 4434134311 4434034300 0000300133 3	00000010110 10101121111 31112343343 10001141333 23332202102 4	2 2000000000011 20000010122 31000010343 20000000143 23444434200 5	.01000000100 :11000000110 :13000000320 :03000000310 :3144444124
SA.Q3 SA.Q5 SA.con All.con 280 - 349	221100000 341200000 340200000 003144444 0 YIHLYDLET	0111221010 0323443030 0323443030 4111001414 1 TGTCIYMNRI	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV	00000010110 10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV	2 2000000000011 20000010122 31000010343 20000000143 23444434200 5 7 7 22 24 24 24 23 23 23 23 23 23 23 23 23 24 24 24 24 24 24 24 24 24 24 24 24 24	01000000100 11000000110 13000000320 03000000310 03144444124 6
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq	221100000 341200000 340200000 003144444 0 YIHLYDLET 000000000	0111221010 0323443030 0323443030 4111001414 1 CGTCIYMNRI 0000000010	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP 0110000001	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000	00000010110 10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000	2000000000011 10000010122 31000010343 10000000143 23444434200 5 VEEENIIPYIT 21111001000	01000000100 11000000110 13000000320 03000000310 03144444124 6 NVLQNPDLALR
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2	221100000 341200000 003144444 0 YIHLYDLET 000000000 00001012	0111221010 0323443030 0323443030 4111001414 1 TGTCIYMNRI 0000000010 2010001110	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP 0110000001 0221000001	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010	2 200000000011 2000010122 31000010343 2000000143 23444434200 5 VEEENIIPYIT 21111001000 22221002000	0100000100 1100000110 1300000320 03000000310 03144444124 6 NVLQNPDLALR 011011110011
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3	221100000 341200000 003144444 0 YIHLYDLET 000000000 00001012 101001033	0111221010 0323443030 0323443030 1111001414 1 CGTCIYMNRI 0000000010 2010001110 3030003131	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP 0110000001 0221000001 1432000014	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000 3444420100	00000010110 10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010	D00000000011 10000010122 31000010343 10000000143 23444434200 5 VEEENTIPYIT D1111001000 D2221002000 D3343003101	01000000100 1100000010 13000000320 03000000310 03144444124 6 10101110011 021121220012
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q5	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012	0111221010 0323443030 0323443030 0111001414 1 TGTCIYMNRI 0000000010 2010001110 8030003131 2010001030	0000011111 0001011122 1003134344 3442310100 2 SGETIFVTAP 011000001 022100001 143200014 0431000003	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000 3443410000	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010 13313001020 03303000010	2 2000000000011 200000010122 31000000143 23444434200 5 VEEENIIPYIT 21111001000 22221002000 03343003101 23343003000	0100000100 1100000110 1300000320 0300000310 03144444124 6 NVLQNPDLALR 011011110011 021121220012 43243430023
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012	0111221010 0323443030 0323443030 0111001414 1 TGTCIYMNRI 0000000010 2010001110 8030003131 2010001030	0000011111 0001011122 1003134344 3442310100 2 SGETIFVTAP 011000001 022100001 143200014 0431000003	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000 3443410000	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010 13313001020 03303000010	2 2000000000011 200000010122 31000000143 23444434200 5 VEEENIIPYIT 21111001000 22221002000 03343003101 23343003000	0100000100 1100000110 1300000320 03000000310 03144444124 6 NVLQNPDLALR 011011110011 021121220012 43243430023 043143430023
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012 343443421 0	0111221010 0323443030 0323443030 4111001414 1 TGTCIYMNRI 0000000010 2010001110 3030003131 2010001030 424442313 1	0000011111 0001011122 1003134344 3442310100 2 SGETIFVTAP 011000001 0221000001 143200014 043100003 3002444430 2	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000 3443410000 1000024344 3	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010 13313001020 03303000010 31031443424 4	200000000011 10000010122 31000010343 10000000143 23444434200 5 VEEENTIPYIT 01111001000 02221002000 03343003101 03343003000 40001440343 5	0100000100 1100000110 1300000320 0300000310 13144444124 6 NVLQNPDLALR 11011110011 121121220012 43243430023 43143430023 01201004410
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012 343443421 0 MAVRNNLAG	0111221010 0323443030 0323443030 0323443030 0111001414 1 CGTCIYMNRI 0000000010 201000110 3030003131 2010001030 1424442313 1 SAEELFARKF	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP 0110000001 0221000001 1432000014 0431000003 3002444430 2 NALFAQGNYS1	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 3444420100 3444420100 3443410000 1000024344 3 SAAKVAANAP	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010 13313001020 03303000010 31031443424 4 KGILRTPDTIM	200000000011 200000000011 200000001343 20000000143 23444434200 5 7 7 5 7 7 5 7 7 5 7 7 1111001000 02221002000 03343003101 03343003101 03343003000 40001440343 5 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8	01000000100 11000000100 13000000320 03000000310 03144444124 6 NVLQNPDLALR 011011110011 021121220012 43243430023 043143430023 01201004410 6
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012 343443421 0 MAVRNNLAG	0111221010 0323443030 0323443030 4111001414 1 TGTCIYMNRI 0000000010 201000110 3030003131 2010001030 424442313 1 GAEELFARKF 011000110	0000011111 0001011122 1003134344 3442310100 2 SGETIFVTAP 011000001 0221000001 143200014 043100003 3002444430 2 NALFAQGNYS 1100110101	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000 3443410000 3443410000 1000024344 3 EAAKVAANAP 1001000101	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001010 13313001020 03303000010 31031443424 4 KGILRTPDTIH 11000001003	2 200000000011 20000000011 2000000143 23444434200 5 VEEENIIPYIT 21111001000 2221002000 23343003101 23343003000 40001440343 5 RRFQSVPAQPG 11011011111	0100000100 1100000110 1300000320 0300000310 13144444124 6 NVLQNPDLALR 11011110011 121121220012 43243430023 143143430023 01201004410 6 0 CTSPLLQYFGI
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq SA.Q2	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012 343443421 0 MAVRNNLAC 001101011 102212122	0111221010 0323443030 0323443030 0111001414 1 CGTCIYMNRI 0000000010 201000110 3030003131 2010001030 424442313 1 SAEELFARKF 011000110 2011101210	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP 0110000001 0221000001 1432000014 0431000003 3002444430 2 NALFAQGNYS1 1100110101 1200221102	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 3444420100 3444420100 3443410000 1000024344 3 EAAKVAANAP 1001000101 1001000212	0000001011(10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001000 13313001020 03303000010 31031443424 4 KGILRTPDTIH 11000001003 21101012002	D00000000011 10000010122 31000010343 1000000143 23444434200 5 VEEENIIPYIT D1111001000 02221002000 03343003101 03343003101 03343003000 40001440343 5 RRFQSVPAQFG 11011011111 21022122122	01000000100 11000000100 13000000320 03000000310 03144444124 6 NVLQNPDLALR 011011110011 021121220012 43243430023 043143430023 01201004410 6 02TSPLLQYFGI 1100000000
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq SA.Q2 SA.Q3	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012 343443421 0 MAVRNNLAG 001101011 102212122 104334243	0111221010 0323443030 0323443030 4111001414 1 TGTCIYMNRI 0000000010 2010001100 3030003131 2010001030 424442313 1 SAEELFARKF 011000110 2011101210 3032102330	0000011111 0001011122 1003134344 3442310100 2 SGETIFVTAP 0110000001 0221000001 1432000014 0431000003 3002444430 2 NALFAQGNYS1 1100110101 1200221102 3311443313	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 1221210000 3443410000 1000024344 3 EAAKVAANAP 1001000101 1001000212 3003000424	0000001011(10101121111 31112343343 10001141331 23332202102 4 NRKGQVLSVCV 01101000000 11201001010 1331300102(03303000010 31031443424 4 KGILRTPDTI 11000001001 21101012002 33113124001	2 2000000000011 200000000011 20000000143 23444434200 5 VEEENIIPYIT 21111001000 2221002000 23343003101 23343003000 40001440343 5 RRFQSVPAQFG 11011011111 21022122122 33034244344	01000000100 11000000100 11000000320 03000000310 03144444124 6 NVLQNPDLALR 01011110011 021121220012 43243430023 043143430023 01201004410 6 02TSPLLQYFGI .1100000000 221100010010
SA.Q3 SA.Q5 SA.con All.con 280 - 349 seq SA.Q2 SA.Q2 SA.Q3 SA.Q5 SA.con All.con 350 - 419 seq SA.Q2 SA.Q2 SA.Q3 SA.Q2 SA.Q3 SA.Q2 SA.Q3 SA.Q2 SA.Q3 SA.Q5	221100000 341200000 003144444 0 YIHLYDLET 000000000 000001012 101001033 000000012 343443421 0 MAVRNNLAC 001101011 102212122 104334243 004314143	0111221010 0323443030 0323443030 0323443030 0111001414 1 CGTCIYMNRI 0000000010 201000110 201000110 2010001030 1424442313 1 SAEELFARKF 0011000110 2011101210 3032102330 3032001330	0000011111 0001011122 1003134344 0001033344 3442310100 2 SGETIFVTAP 0110000001 0221000001 1432000014 0431000003 3002444430 2 NALFAQGNYS1 1100110101 1200221102 3311443313 3300441303	1111011100 2222022111 4434134311 4434034300 0000300133 3 HEATAGIIGV 1111100000 3444420100 3444420100 3443410000 1000024344 3 SAAKVAANAP 1001000101 1001000212 3003000414	00000010110 10101121111 31112343343 10001141333 23332202102 4 NRKGQVLSVCV 01101000000 11201001000 13313001020 31031443424 4 KGILRTPDTIH 11000001003 21101012002 33113124003	200000000011 200000000011 2000000010122 31000000143 23444434200 5 7 7 22444434200 5 7 7 221002000 03343003101 03343003101 03343003101 03343003101 03343003000 40001440343 5 8 RRFQSVPAQFG 11011011111 21022122122 33034244344 33034144344	01000000100 11000000100 13000000320 03000000310 03144444124 6 NVLQNPDLALR 011011110011 021121220012 43243430023 043143430023 01201004410 6 0 0 0 11000000000 221100010010 43300020031

seq	LLDOGOL	IKVESLEL(PREVI.OOGRKO	TTERMIKED	(LECSEELCD		L <mark>SVYLRANVPNKVIO</mark>
SA.Q2							010001010011000
SA.Q3							010012020111001
SA.Q5							030123141133002
SA.con							030013040033001
							414320303311442
All.con 490 - 559			2.				
		1		3	4	5	
seq SA.Q2	Ĩ	~			~ ~~ ~	- Ĩ	ITQIVDVFMEYNLIQ
SA.Q3							011001001212102
SA.Q5							033003101323213
SA.con							013003000312103
All.con							421441343021230
560 - 629	0	1	2	3	4	5	6
seq	~		~	~	~~~	~	LCEKAGLLQRALEHF
SA.Q2							001100001000100
SA.Q3							002211001100200
SA.Q5							103313013201411
SA.con							003301003100400
All.con							340032431243033
630 - 699	0	1	2	3	4	5	6
seq						<u> </u>	ASKYHEQLSTQSLIE
SA.Q2	11010000				0011001000		001001100011001
		00120110					
SA.Q3					0011002101		
SA.Q5	43133022	200031331	13130013104	4133430130	033003201	33002000300	023004313133003
SA.Q5 SA.con	43133022 43031011	200031331	13130013104 03030003004	4133430130 4033430030	0033003201	33002000300 31001000100	023004313133003 013004301033003
SA.Q5 SA.con All.con	43133022 43031011 00312422	200031333 L00030330 244303113	13130013104 03030003004 30304430340	413343013(403343003(0311014304	0033003201 0033003100 1411440243	33002000300 31001000100 1244244424	023004313133003 013004301033003 420440032301440
SA.Q5 SA.con All.con 700 - 769	43133022 43031011 00312422 0	200031333 L00030330 244303113 1	13130013104 03030003004 30304430340 2	413343013(403343003(0311014304 3	0033003201 0033003100 4411440243 4	33002000300 31001000100 1244244424 5	023004313133003 013004301033003 420440032301440 6
SA.Q5 SA.con All.con 700 - 769 seq	43133022 43031011 00312422 0 LFESFKSF	200031333 1000303330 244303113 1 FEGLFYFLC	13130013104 03030003004 30304430340 2 GSIVNFSQDPD	413343013(403343003(0311014304 3 VHFKYIQAA(0033003201 0033003100 1411440243 4 CKTGQIKEVE	33002000300 31001000100 1244244424 5 RICRESNCYDI	023004313133003 013004301033003 420440032301440 6 PERVKNFLKEAKLTD
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2	43133022 43031011 00312422 0 LFESFKSF 00110100	200031333 100030333 244303113 1 FEGLFYFLC 010000003	13130013104 03030003004 30304430340 2 GSIVNFSQDPD 11001011111	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(0033003201 0033003100 4411440243 4 CKTGQIKEVE 0111101101	33002000300 31001000100 124424424 5 RICRESNCYDI 10011110010	D23004313133003 D13004301033003 420440032301440 6 PERVKNFLKEAKLTD D11001001101011
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3	43133022 43031011 00312422 0 LFESFKSE 00110100 00221211	200031333 100030333 244303113 1 FEGLFYFLC 01000000 22000100	13130013104 03030003004 30304430340 2 GSIVNFSQDPD 11001011111 11002112112	413343013(403343003(0311014304 3 VHFKYIQAAC 000100100(000100200(0033003201 0033003100 1411440243 4 CKTGQIKEVE 0111101101 0212102101	33002000300 31001000100 1244244244 5 RICRESNCYDD 10011110010 10022221110	023004313133003 013004301033003 420440032301440 6 PERVKNFLKEAKLTD 011001001101011 021012002212121
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q5	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411	200031333 200030333 244303113 1 FEGLFYFLC 010000003 20001003	13130013104 03030003004 30304430340 2 SSIVNFSQDPD 11001011111 11002112112 33113144333	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(001300300)	0033003201 0033003100 4411440243 4 CKTGQIKEVE 0111101101 0212102101 1434313303	33002000300 31001000100 124424424 5 RICRESNCYDI 10011110010 10022221110 3003344113	D23004313133003 D13004301033003 420440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q5 SA.con	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400	20003133 100030330 244303113 1 FEGLFYFLC 01000000 120001003 130001003 030000003	13130013104 03030003004 30304430340 2 SSIVNFSQDPD 11001011111 11002112112 33113144333 33003034333	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(001300300) 000300300(0033003201 0033003100 4411440243 4 CKTGQIKEVE 0111101101 0212102101 1434313303 0434303303	33002000300 31001000100 1244244244 5 RICRESNCYDD 10011110010 10022221110 3003344113 30033440030	D23004313133003 D13004301033003 420440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143 D43013003414043
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q3 SA.Q5 SA.con All.con	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400 43002033	20003133 200030333 244303113 1 FEGLFYFLC 010000003 20001003 30000003 30000003 304443443	13130013104 03030003004 30304430340 2 GSIVNFSQDPD 11001011111 11002112112 33113144333 33003034333 11330300110	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003 000300300(4431440443	0033003201 0033003100 4411440243 4 CKTGQIKEVE 0111101101 0212102101 1434313303 0434303303 8010130141	33002000300 31001000100 124424424 5 RICRESNCYDI 10011110010 1002221110 30033441133 30033440030 14400003313	D23004313133003 D13004301033003 420440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143 D43013003414043 301420340020301
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 770 - 839	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400 43002033 0	200031333 200030333 244303113 1 FEGLFYFLC 01000000 120001003 130001003 30000003 30000003 12001003 130001003 30444344 1	13130013104 03030003004 2 03014430340 2 03014430340 2 030101011111 11002112112 03113144333 0303034333 11330300110 2	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003) 000300300(4431440443 3	0033003201 0033003100 1411440243 4 CKTGQIKEVE 0111101101 0212102101 1434313303 0434303303 3010130141 4	33002000300 31001000100 1244244424 5 RICRESNCYDD 10011110010 10022221110 30033441133 30033440033 14400003313 5	223004313133003 213004301033003 420440032301440 6 PERVKNFLKEAKLTD 211001001101011 221012002212121 143033103434143 243013003414043 301420340020301 6
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q3 SA.Q5 SA.con All.con 770 - 839 seq	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400 43002033 0 QLPLIIVO	200031333 244303113 1 FEGLFYFLC 010000003 20001003 30001003 304443443 1 CDRFDFVHI	13130013104 03030003004 30304430340 2 GSIVNFSQDPD 11001011111 11002112112 33113144333 33003034333 11330300110 2 DLVLYLYRNNL	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003 000300300(4431440443 3 QKYIEIYVQE	0033003201 0033003100 4411440243 4 2KTGQIKEVE 0111101101 0212102101 434313303 0434303303 3010130141 4 KVNPSRLPVV	33002000300 31001000100 1244244244 5 RICRESNCYDD 10011110010 10022221110 30033441133 3003344003 14400003313 5 IGGLLDVDCSI	D23004313133003 D13004301033003 420440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143 043013003414043 301420340020301 6 EDVIKNLILVVRGQF
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 770 - 839 seq SA.Q2	43133022 43031011 00312422 0 LFESFKSE 00110100 00221211 01332411 00331400 43002033 0 QLPLIIV0 10000000	200031333 200030333 244303113 1 FEGLFYFLC 01000000 120001003 30001003 3004443443 1 CDRFDFVHI 000010013	13130013104 03030003004 30304430340 2 SSIVNFSQDPD 11001011111 11002112112 33113144333 33003034333 11330300110 2 DLVLYLYRNNL 10000001010	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003) 0003003004 4431440443 3 QKYIEIYVQP 0100100013	0033003201 0033003100 1411440243 4 0XTGQIKEVE 0111101101 0212102101 1434313303 0434303303 8010130141 4 KVNPSRLPVV 1010110010	33002000300 31001000100 1244244424 5 RICRESNCYDD 10011110010 10022221110 30033441133 30033440033 14400003313 5 IGGLLDVDCSI 00000001013	D23004313133003 D13004301033003 420440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143 D43013003414043 301420340020301 6 EDVIKNLILVVRGQF 110011000001110
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q3 SA.Q5 SA.con All.con 770 - 839 seq SA.Q2 SA.Q2 SA.Q3	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400 43002033 0 QLPLIIVO 10000000 11000000	200031333 200030333 244303113 1 FEGLFYFLC 010000003 20001003 30000003 304443443 1 CDRFDFVHI 000010013 011120023	13130013104 03030003004 30304430340 2 GSIVNFSQDPD 11001011111 11002112112 33113144333 33003034333 11330300110 2 DLVLYLYRNNL 10000001010 10010002120	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003 0003003000(4431440443 3 QKYIEIYVQH 0100100013 1100200022	0033003201 0033003100 4411440243 4 CKTGQIKEVE 0111101101 0212102101 434313303 0434303303 3010130141 4 KVNPSRLPVV 010110010 2111220110	33002000300 31001000100 124424424 5 RICRESNCYDI 10011110010 1002221110 3003344113 3003344003 14400003313 5 IGGLLDVDCSI 00000001013	D23004313133003 D13004301033003 d20440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143 043013003414043 301420340020301 6 EDVIKNLILVVRGQF 110011000001110 220011001002110
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q5 SA.con All.con 770 - 839 seq SA.Q2 SA.Q2 SA.Q3 SA.Q2 SA.Q3 SA.Q5	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400 43002033 0 QLPLIIV0 1000000 33000000	200031333 200030333 244303113 1 FEGLFYFLC 01000000 120001003 3004443443 1 CDRFDFVHI 000010013 033131133	13130013104 03030003004 30304430340 2 SSIVNFSQDPD 11001011111 11002112112 33113144333 3300304333 11330300110 2 DLVLYLYRNNL 10000001010 10010002120 30021013330	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003) 000300300(4431440443 3 QKYIEIYVQI 0100100013 1100200022 2300301033	0033003201 0033003100 1411440243 4 CKTGQIKEVE 0111101101 0212102101 1434313303 0434303303 3010130141 4 KVNPSRLPVV 1010110010 2111220110 3131431130	33002000300 31001000100 1244244424 5 RICRESNCYDD 10011110010 10022221110 30033440133 30033440030 14400003313 5 IGGLLDVDCSI 0000001012 00000102022 00001314133	223004313133003 213004301033003 420440032301440 6 PERVKNFLKEAKLTD 011001001101011 021012002212121 143033103434143 043013003414043 301420340020301 6 EDVIKNLILVVRQQF 110011000001110 220011001002110 441033003103431
SA.Q5 SA.con All.con 700 - 769 seq SA.Q2 SA.Q3 SA.Q3 SA.Q5 SA.con All.con 770 - 839 seq SA.Q2 SA.Q2 SA.Q3	43133022 43031011 00312422 0 LFESFKSF 00110100 00221211 01332411 00331400 43002033 0 QLPLIIV0 1000000 33000000	200031333 200030333 244303113 1 FEGLFYFLC 01000000 120001003 3004443443 1 CDRFDFVHI 000010013 033131133	13130013104 03030003004 30304430340 2 SSIVNFSQDPD 11001011111 11002112112 33113144333 3300304333 11330300110 2 DLVLYLYRNNL 10000001010 10010002120 30021013330	413343013(403343003(0311014304 3 VHFKYIQAA(000100100(000100200(0013003003) 000300300(4431440443 3 QKYIEIYVQI 0100100013 1100200022 2300301033	0033003201 0033003100 1411440243 4 CKTGQIKEVE 0111101101 0212102101 1434313303 0434303303 3010130141 4 KVNPSRLPVV 1010110010 2111220110 3131431130	33002000300 31001000100 1244244424 5 RICRESNCYDD 10011110010 10022221110 30033440133 30033440030 14400003313 5 IGGLLDVDCSI 0000001012 00000102022 00001314133	D23004313133003 D13004301033003 d20440032301440 6 PERVKNFLKEAKLTD D11001001101011 D21012002212121 143033103434143 043013003414043 301420340020301 6 EDVIKNLILVVRGQF 110011000001110 220011001002110

840 - 909	0	1	2	3	4	5	6	
seq							RENPYYDSRVVGKY	YCE
SA.Q2							1010001100010	
SA.Q3							22121111110020	
SA.Q5							34242133320031	
SA.con							34141013310030	
All.con							0202321124403	
910 - 979	0	1	2	3	4	5	6	
seq	-						YRRPLIDQVVQTA	ALS
SA.Q2							L0011001000000	
SA.Q3							21122001100100	
SA.Q5							12233003100310	
SA.con							1133003000100	
All.con							02200441344234	
980 - 1049	0	1	2	3	4	5	6	
seq							DRTRVMEYINRLI	DNY
SA.02		0000010	0011101110	0100110001	11101101100	~	00111001001101	110
SA.Q3	2121122	0111010	0022211210	0200110012	2221221110	11000000021	1121012002102	221
SA.Q5							13243023103304	
~ SA.con	4343243	80000030	0044403430	0300330014	4330441330:	11000000030	01243013003304	440
All.con	0001100	4333414	4300031014	3044114320	0003002114:	22444444403	32101420340140	003
1050 - 1119	0	1	2	3	4	5	6	
seq	DAPDIAN	IAISNEL	FEEAFAIFRK	FDVNTSAVQV	LIEHIGNLDRA	AYEFAERCNE	PAVW <mark>SQLAKAQLQ</mark> P	KGM
SA.Q2	1011001	.0001010	0100010011	0110110010	00110110110	00100110111	L100 <mark>0100100011</mark>	<mark>111</mark>
SA.Q3	1121002	0012120	0210010022	1211120020	0021121021	01200220221	L200 <mark>1100200022</mark>	<mark>211</mark>
SA.Q5	3143013	1024231	1330030133	1422230031	01332331420	02300331433	3300 <mark>320031114</mark> 3	<mark>342</mark>
SA.con	3043003	0014130	0310030033	0421230030	00331330420	01300330433	3300 <mark>120030004</mark> 3	<mark>332</mark>
All.con	1301430	3420203	3024414300	3012104403	43012013014	42044003001	L044 <mark>2144033300</mark>	<mark>001</mark>
1120 - 1189	0	1	2	3	4	5	6	
seq	VKEAIDS	YIKADDP	SSYMEVVQAA	NASGNWEELV	KYLQ <mark>M</mark> ARKKAI	RESYVETELII	FALAKTNRLAELEI	EFI
SA.Q2	0110010	010110	1101100110	1111101100	1001100111:	1101000000	00001011011001	100
SA.Q3			0101000010	2212112100	2001101212	0011010100	0002121021022	200
· · · ·	0210020	011211	2101200210	2212112100	2001101212.	22110101000		200
SA.Q5							0013133133033	
	0330031	. <mark>1</mark> 133433	4 3133 00 320	34343133 <mark>0</mark> 1	3103302433	43130303000		301
SA.Q5	0330031 0330030	.1133433 00031431	4313300320 4303300320	3434313301 3434303300	31033024334 30033014334	43130303000 43030101000	00013133133033	301 300
SA.Q5 SA.con	0330031 0330030 4014403	.1133433 00031431	4313300320 4303300320	3434313301 3434303300	31033024334 30033014334	43130303000 43030101000	00013133133033 00003033033023	301 300
SA.Q5 SA.con All.con	0330031 0330030 4014403 0	133433 00031431 3 <mark>3</mark> 312012 1	4313300320 4303300320 0131044014 2	3434313301 3434303300 0010130143 3	31033024334 30033014334 03411420100 4	43130303000 43030101000 00314242444 5	00013133133033 00003033033023 14430301301410	301 300 043
SA.Q5 SA.con All.con 1190 - 1259	0330031 0330030 4014403 0 NGPNNAH	133433 0031431 3312012 1 1100VGDR	4313300320 4303300320 0131044014 2 CYDEKMYDAA	3434313301 3434303300 0010130143 3 KLLYNNVSNF	3103302433 3003301433 03411420100 4 GRLASTLVHL	43130303000 43030101000 0031424244 5 GEYQAAVDGAH	00013133133033 00003033033023 14430301301410 6	301 300 043 FAC
SA.Q5 SA.con All.con 1190 - 1259 seq	0330031 0330030 4014403 0 NGPNNAH 1100101	133433 00031431 3312012 1 1100VGDR .0110011	4313300320 4303300320 0131044014 2 CYDEKMYDAA 0011100100	3434313301 3434303300 0010130143 3 KLLYNNVSNF4 1000010110	3103302433 3003301433 03411420100 4 GRLASTLVHL0 01000000103	43130303000 43030101000 00314242444 5 GEYQAAVDGAP 11011001003	00013133133033 00003033033023 14430301301410 6 RKANSTRTWKEVCI	301 300 043 FAC 000
SA.Q5 SA.con All.con 1190 - 1259 seq SA.Q2	0330031 0330030 4014403 0 NGPNNAH 1100101 2111111	133433 00031431 3312012 1 HIQQVGDR 0110011 0120021	4313300320 4303300320 0131044014 2 CYDEKMYDAA 0011100100 0122210210	3434313301 3434303300 0010130143 3 KLLYNNVSNFF 1000010110 1000210221	3103302433 3003301433 03411420100 4 GRLASTLVHL 0100000010 1100100010	43130303000 43030101000 00314242444 5 GEYQAAVDGAR 11011001001 21022002001	00013133133033 00003033033023 1443030130141(6 RKANSTRTWKEVCI 11011010011000	301 300 043 FAC 000 110

All.con	01221313	104401320	00230241344	1113003314	434341401	4004304411	.30030331144234
1260 - 1329	0	1	2	3	4	5	6
seq	VDGKEFRL	AQMCGLHIV	VHADELEELIN	1YYQDRGYFE	ELITMLEAA	LGL <mark>ER</mark> AHMGN	IFTELAILY <mark>S</mark> KFKPQ
SA.Q2	01111010	001010100	01011011001	1001111101	100100110	0101100000	00000000010111
SA.Q3	02121021	011010100	01121012002	2102212102	2100200210	0212211010	00100000021212
SA.Q5	13333130	032131300	13143033013	3104434213	300300330	1414443100	00300001041334
SA.con	03333030	012030300	03043033003	3 004 4342 0 3	300300330	0404411000	0010000040334
All.con	30101303	421313144	31301410430	0340010130	0144044014	3030022334	44244443403010
1330 - 1399	0	1	2	3	4	5	6
seq	KMREHLEL	FWSRVNIPK	VL <mark>R</mark> AA <mark>EQ</mark> AHLV	VAELVFLYDF	YEEYDNAII'	TMMNHPTDAW	IKEGQFKDIITKVAN
SA.Q2	10010011	001101011	00110110000	0100000011	011011001	0001111100	11100110001011
SA.Q3	10121021	012102012	00210111100	0110100011	122011001	0002122211	22210120012021
SA.Q5	30231032	014313033	1033 <mark>0</mark> 332201	1330010123	3143133 <mark>00</mark> 2	0014334411	33410230023143
SA.con	30130032	004303033	00330331100	0310000023	8043033002	0004334400	33400230013043
All.con	14203401	430130410	34 <mark>014</mark> 112243	3124334311	300311441	4430100033	800034104420301
1400 - 1469	0	1	2	3	4	5	6
seq	VELYYKAI	QFYL E FKPL	LLNDLLMVLSI	PRLDHTRAVN	IYF <mark>S</mark> KVKQLP	LVKPYLR <mark>S</mark> VÇ	ONHNNKSVNESLNNL
SA.Q2	01000100	100011111	00010000011	L100000001	001101101	0011001100	11001100100010
SA.Q3	12001100	1000 <mark>2</mark> 1111	10010010011	L <mark>201</mark> 111002	2101212102	001 <mark>2</mark> 001101	21012100200120
SA.Q5	14001300	311043223	10130020033	3313132003	3103434313	1033003303	33013301300231
SA.con	04000300	300043223	00030010033	301011003	8003414303	0033003301	33003300300130
All.con	30443144	133401111	34314424411	L032322440	341020130	3410441142	201430143044203
1470 - 1539	0	1	2	3	4	5	6
seq	FITEEDYQ	ALRTSIDAY	DNFDNISLAQ	RLEKHELIEE	RRIAAYLFK	GNNRWKQSVE	LCKKDSLYKDAMQY
SA.Q2	00111001	001100110	11010010011	1011010010	01000001	1011011001	.00111100100010
SA.Q3	00222102	101200220	22021020011	1022010110	0110001001	2121021002	200122210210020
SA.Q5	11333213	303300331	43133030033	3033130130	330002013	3343133003	310344311330031
SA.con	00333103	103300330	43031030033	3033030030	0130001003	3143033003	800344300310030
All.con	33000230	241044003	00302404411	1400314314	214442431	0201301440	34100033024403
1540 - 1609	0	1	2	3	4	5	6
seq	ASESKDTE	LA <mark>EE</mark> LLQWF	LQEEKRECFGA	ACLFTCYDLI	RPDVVLETA	WRHNIMDFAN	1PYFIQVMKEYLTKV
SA.Q2	00101111	001100100	01111110000	000000100	101000000	0001011000	00001000100110
SA.Q3	01212212	002100200	02122120000	000100200	0102000110	0112012101	00001001200210
SA.Q5							00003002311330
SA.con							00003001300330
All.con							344441442033014
1610 - 1675	0	1	2	3	4	5	6
seq	DKLDASES	LRKEEEQATI	ETQPIVYGQPG	QLMLTAGPSV	VAVPPQAPFG	YGYTAPPYGÇ	<u>PQPGFGYSM</u>
SA.Q2	11011111	1111111111	11111001111	L000000000	100000000	000000000000000000000000000000000000000	000000011
SA.Q3	22012212	2 <mark>1</mark> 2222222	22211112121	1010110011	201111101	0001000011	011000122
SA.Q5	33034334	334444444	44433334343	31000 <mark>3</mark> 1111	411131110	1011111143	8131111144

SA.con	33034334334444444444331143430000100004000100000000
All.con	004100100100000000011220101334323333333333